Metabolic dysfunction and impairments in the DNA Damage Response: dissecting a pathomechanistic link between

Microcephalic Primordial Dwarfisms and cancer cachexia by Macpherson, Annie
   
 
A University of Sussex PhD thesis 
Available online via Sussex Research Online: 
http://sro.sussex.ac.uk/   
This thesis is protected by copyright which belongs to the author.   
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author   
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author   
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
Please visit Sussex Research Online for more information and further details   
Metabolic dysfunction and impairments in 
the DNA Damage Response: dissecting a 
pathomechanistic link between 
Microcephalic Primordial Dwarfisms and 
cancer cachexia 
 
 
 
Annie Macpherson 
 
 
 
A thesis submitted to the University of Sussex for the degree of Doctor 
of Philosophy (DPhil) 
 
 
 
August 2017 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
DECLARATION  
 
 
I hereby declare that this thesis has not been and will not be submitted in 
whole or in part to another University for the award of any other degree.  
 
 
Signed …………………………………………………………………………………………………………. 
 
 
Annie Macpherson 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
Professor Mark O’Driscoll has been the driving force behind my academic development. 
I am filled with gratitude, for the time and energy he has invested is above and beyond 
what I could ever have expected from a supervisor. Thank you for your limitless support 
and enduring enthusiasm, for the development of both this project and myself. 
To be superfluous (as is convention in a thesis acknowledgements), I am in fact incredibly 
grateful to everyone, and everything, that has influenced my growth and development. 
To all, past and present, that have taught, guided, counselled and empowered me; to 
those that have embraced me and helped me choose the right path. I never could have 
made it this far without so much positive influence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis is dedicated to my Mum and my Dad, and to my partner through it all, Tom. 
iv 
 
University of Sussex 
Annie Macpherson 
DPhil Genome Stability 
Metabolic dysfunction and impairments in the DNA 
Damage Response: dissecting a pathomechanistic 
link between Microcephalic Primordial Dwarfisms 
and cancer cachexia 
 
SUMMARY 
ATR (ataxia telangiectasia and Rad3-related) encodes master regulator of the DNA damage 
response ATR. Hypomorphic mutations in ATR result in microcephalic primordial dwarfism 
disorder Seckel Syndrome (SS). ATR-SS also presents with an apparent lack of subcutaneous fat. 
This potentially suggests ATR deficiency impairs lipogenic function. This is concerning 
considering the proposed use of small molecule kinase inhibitors of ATR (ATRis) as cancer 
chemotherapeutics. ATRi is a highly selective anti-cancer agent due to synthetic lethality in ATM- 
or p53-deficient cells. An invariant feature of cancer is metabolic dysregulation, aggressive 
cancers can enforce systemic metabolic reprogramming resulting in drastic weight loss. Several 
screens have identified putative substrates for ATR in insulin signalling and metabolic pathways, 
indicating uncharacterised roles for ATR may exist here. Using several clinically relevant ATRis, I 
dissected the metabolic consequences of impaired ATR functionality on adipogenesis and 
lipogenic function of the 3T3-L1 cell line - widely utilised to investigate adipogenic 
differentiation. Acute ATRi treatment attenuated transcription of key adipogenic factors in 
differentiating preadipocytes, resulting in a failure to complete adipogenesis. I treated mature 
adipocytes chronically with ATRis, observing a striking transdifferentiation process known as 
browning – fat-storing white adipocytes underwent transcriptional reprogramming towards a 
thermogenic, brown adipocyte-like status. ATR deficiency generated this phenomenon by 
impinging on multiple pathways associated with metabolic regulation. I also observed striking 
cytoplasmic vacuolation and a disrupted autophagy response in every cell line treated with 
ATRis. I discovered ATR at the ER membrane, where ATRi-induced vacuolisation was derived 
from swollen endoplasmic reticulum (ER) concomitant with ER stress. I have characterised novel 
effects of ATR deficiency in adipocyte differentiation and metabolism, and ER and autophagic 
functionality. Autophagy and lipid metabolism are consistently deregulated in cancers, 
suggesting these results could lead to the generation of novel synthetic lethality approaches 
utilising ATRis and compounds targeting metabolic or autophagic pathways. 
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Introduction 
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1.1. The DNA Damage Response (DDR) 
Tissues are required to constantly replenish worn-out cells and remodel, to preserve 
optimum function and maintain homeostasis. Reliable and accurate replication of 
genomic DNA is essential for the production of functional cells to maintain tissue 
homeostasis. Yet, throughout existence, cells face incalculable encounters with both 
exogenous and endogenous DNA damage, which can result in compromised genomic 
integrity. Exposure to UV-B light results in the generation of cyclobutane pyrimidine 
dimers, bulky lesions which perturb normal replication, requiring nucleotide excision 
repair (NER) (Guintini et al., 2015). UV-A light exposure results in the generation of 
reactive oxygen species (ROS), which induces oxidative base damage (e.g. 8-oxo-
guanine), ribose-sugar modification, abasic sites and single and double stranded DNA 
breaks (SSBs; DSBs). ROS are also produced endogenously, as a by-product of oxidative 
phosphorylation (Rahman, 2007). Ionising radiation induces SSBs and DSBs (Vignard et 
al., 2013). To maintain genomic integrity, DNA damage must be detected, cell cycle 
checkpoints activated, and DNA repaired before continuation of the cell cycle. Where 
attempts to repair damaged DNA are unsuccessful, the fate of the cell can include  
apoptosis, cellular senescence or malignant transformation.  
Intricate and highly regulated signalling pathways are essential to ensure 
stringent cell cycle parameters and DNA synthesis, effective repair of damaged DNA, and 
the programmed senescence or death of deleterious cells. Collectively known as the 
DNA damage response (DDR), this signalling axis further functions to protect and 
maintain effective stem cell populations from DNA damage-induced senescence 
throughout early development and adulthood. Controlled cell division is intimately 
linked to the determination of cell fate and induction into various differentiative 
programmes, denoting functional significance to the DDR in tissue development and 
homeostasis (Errol et al., 2006). A functional DDR ensures genomic stability – when the 
DDR is compromised, cells can experience elevated levels of mutagenesis, uncontrolled 
replication and malignant transformation. 
Cells are equipped with multiple systems for the effective decision-making 
required to maintain genomic integrity - high levels of functional redundancy exist 
within the DDR to achieve this exceptional stability of genomic maintenance and repair 
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required to confront constant assault (Errol et al., 2006). The DDR is the coordinated 
cellular response that orchestrates appropriate DNA repair after genomic injury, 
principally regulated by the serine/threonine (S/T) protein kinases of the 
phosphatidylinositol 3-kinase (PI3K)-like kinase (PIKK) family.  
1.2. The PIKK family 
DDR-related PIKK family members include DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs), Ataxia Telangiectasia-Mutated (ATM), and ATM and Rad3-related 
(ATR) (Sirbu and Cortez, 2013). Members of the PIKK family also include: Mechanistic 
Target of Rapamycin (mTOR), a kinase activated by multiple metabolic cues to control 
global cell metabolism and growth, Suppressor of Morphogenesis in Genitalia 1 (SMG1), 
a critical component of the mRNA surveillance complex mediating nonsense-mediated 
RNA decay, and transcription factor co-activator TRRAP (transformation/transcription 
domain associated protein).  
PIKK family members are large proteins classified by the presence of a conserved 
protein S/T kinase domain (Lempiäinen and Halazonetis, 2009). Although PIKKs do not 
phosphorylate lipids, their kinase domains share significant sequence similarity to the 
PI3K family. PIKKs also contain large, highly conserved regions that generally lack 
sequence similarity between family members (Cimprich and Cortez, 2008). Considering 
the conservation, yet striking variability between each PIKK, these largely 
Figure 1.2.1. The PIKK family. HEAT - Huntingtin, elongation factor 3, subunit of protein phosphatase 
2A, PI3-kinase target of rapamycin 1; FAT - FRAP-ATM-TRRAP domain; FRB - FKBP−rapamycin-binding 
domain; PIKK – PI3K-like kinase domain; FATC - FAT-C-terminal domain. Taken from (Rivera-Calzada et 
al., 2015) 
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uncharacterised regions may provide future opportunity to investigate unique and non-
canonical activities of each kinase. 
PIKK family members share similar domain organisation – C-terminal kinase 
domains flanked by conserved FAT (FRAP-ATM-TRAP) and FAT C-terminus (FATC) 
domains, with vast N-terminal HEAT repeats expanding the majority of each protein (Fig 
1.2.1) (Perry and Kleckner, 2003). Many common themes appear in the regulation and 
activation of each member of the PIKK family – structural homology, recruitment to sites 
of activation via interacting partners, and unique secondary activator components that 
associate with conserved PIKK Regulatory Domains (PRDs) (Table 1.2.1) (Mordes and 
Cortez, 2008).  
Dependent on the availability of a sister chromatid for HR strand exchange, DSB 
repair consists of homologous recombination (HR) or the non-homologous end joining 
pathway (NHEJ), the latter instigated by DNA-PKcs (Kakarougkas and Jeggo, 2014; Krejci 
et al., 2012). Comparatively to ATR and ATM, DNA-PKcs regulates a small number of 
targets as the catalytic subunit of DNA-dependent S/T kinase DNA-PK. DNA-PKcs relies 
on heterodimeric KU70-KU80 to trigger its kinase activity and mediate localisation at 
DNA DSB ends (Walker et al., 2001). DNA-PKcs is also required for V(D)J recombination 
– the process utilising programmed NHEJ to promote immune system diversity – 
evidenced by the severe combined immunodeficiency (SCID) observed in DNA-PKcs 
knockout mice (Taccioli et al., 1998).  
The mTOR complexes (mTORC1/2) are key effectors and regulators of nutrient 
status within the cell. Incoming glucose, amino acids, growth factors and cytokines act 
as potent metabolic cues, where signals are transduced through multiple signalling 
cascades resulting in differential, threshold-based activation of the mTOR complexes. 
mTORC1/2 regulate autophagy, protein, lipid and nucleotide synthesis, as well as 
glycolysis and cytoskeletal reorganisation (Laplante and Sabatini, 2012). Generally, 
Table 1.2.1. PIKK family binding partners and activators. 
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mTORC1 promotes protein and lipid synthesis, fuelling proliferation when energy 
conditions are favourable and autophagy when they are not, and mTORC2 promotes cell 
survival by activating protein kinase B (AKT). Together, the vast signalling networks 
engaged in the activation and suppression of the mTORCs, and the multiple levels of 
cross talk between mTORC1 and 2 at differing nodes allows input from almost every 
effector of cellular metabolism, and tailored responses to small changes in nutrient 
status (Laplante and Sabatini, 2012).  
Briefly, following stimulation by insulin, a rapid signal transduction response 
cascades through the cell, via the mTOR signalling axes. Insulin Receptor (IR) is rapidly 
autophosphorylated on the cytoplasmic -subunit, resulting in multiple 
phosphorylations on IR adaptor protein insulin receptor substrate 1 (IRS1), including at 
Y989. P-IRS1 induces activation of PI3K, resulting in the generation of PI(3, 4, 5)P3, which 
recruits AKT to the plasma membrane where it becomes phosphorylated at S473 by 
multiple proteins, including the mTORC2 complex (Fig 1.2.2). AKT is also phosphorylated 
at the plasma membrane at T308 by PI3-dependent kinase PDK1 (Yu and Cui, 2016). 
Figure 1.2.2. Simplified schematic of mTOR signalling. Taken from (Yu and Cui, 2016) 
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Activated AKT inhibits Tuberous Sclerosis Complex 2 (TSC2) via phosphorylation, 
rendering it unable to bind to RAS homolog enriched in brain (RHEB), enabling activation 
of mTORC1.  
ATM shares multiple DDR-dependent substrates with ATR and appears to 
phosphorylate hundreds of proteins at Ser/Thr-Glu (S/TQ) motifs after DNA damage 
(Matsuoka et al., 2007). Together, ATR and ATM appear to be the master regulators of 
the DDR, transducing signals to a large network of cellular processes (Maréchal and Zou, 
2013). Whereas ATR is recruited to DNA-SSBs via Replication Protein A (RPA), ATM is 
recruited to DNA-DSBs via the MRE11-RAD50-NBS1 (MRN) complex, where it directly 
phosphorylates histone variant H2AX allowing adaptor proteins to bind and recruit 
effector proteins including checkpoint kinase 2 (CHK2) and p53 (Fig 1.2.3). This signal is 
Figure 1.2.3. DNA damage response signalling through PIKK family members ATM and ATR. 
Taken from (Sulli et al., 2012) 
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propagated across the flanking chromatin, increasing the recruitment of DDR proteins 
to the site of damage (Fernandez-Capetillo et al., 2004). ATM primarily acts upon sites 
of DSBs, whereas ATR is activated after a variety of insults that expose regions of single-
stranded DNA (ssDNA), frequently formed at replication forks, collectively termed 
‘replicative stress’ (Cimprich and Cortez, 2008). ATR exists within a stable heterodimer 
with ATR-interacting protein (ATRIP) (Cortez et al., 2001), whereas ATM exists as a 
homodimer, dissociating into monomers following activation and autophosphorylation 
at S1981 (Bakkenist and Kastan, 2003). 
1.3. DNA damage recognition and ATR activation 
The widely established method of ATR activation is via DNA damage that induces regions 
of single-stranded DNA (ssDNA). RPA heterotrimers bind to exposed regions of ssDNA 
with high affinity. A common intermediate DNA structure, RPA-coated ssDNA allows 
activation of ATR in response to a wide variety of cues, including end-resected DSBs at 
the S- and G2-M phase checkpoints, nucleotide excision repair (NER) intermediates, 
replication fork restart and telomere erosion. Most notable of these is the canonical 
activator of ATR at the intra-S-phase checkpoint – replication stress (Cimprich and 
Cortez, 2008). Replication stress induced by fork stalling throughout S-phase is 
perceived as the most common activator of ATR. Replication fork stalling can occur due 
to a number of reasons, amongst these; DNA polymerase encountering a DNA lesion or 
adduct; common fragile sites (CFS); and interstrand cross-links (ICLs). At the stalled fork, 
the uncoupled MCM2-7 (minichromosome maintenance complex) helicase continues, 
generating long stretches of ssDNA through its DNA unwinding activity, allowing RPA 
and other DNA damage sensors to bind, recruit and activate ATR (Fig 1.3.1) (Berti and 
Vindigni, 2016). Most notable is Topoisomerase II Binding Protein 1 (TOPBP1), which 
functions to hyperactivate the ATR-ATRIP complex (Kumagai et al., 2006). 
CFS are large, non-randomly distributed genomic regions that prove particularly 
difficult for replication machinery to copy. CFSs are exceptionally sensitive to genomic 
instability, where enhanced replicative stress results in gaps and breaks at CFS loci in 
metaphase chromosomes (Glover et al., 1984). Replication fork stalling at CFSs appears 
to be a common event throughout S-phase, hence accurate reproduction of these loci 
hinges on the ATR-dependent intra-S-phase checkpoint. ATR activity has been shown to 
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be vital for CFS maintenance - ATR deficiency results in high levels of fragile site breakage 
(Casper et al., 2002).  
Here I will summarise the key mediators required in the activation of ATR. 
1.3.1. ATRIP  
ATRIP is the obligate binding partner of ATR. Interacting via a region within the N-
terminal HEAT repeats of ATR, ATRIP is essential for the stability, and canonical 
localisation and activation of ATR at sites of DNA damage (Ball et al., 2005; Nam and 
Cortez, 2011). Small interfering RNA (siRNA) directed against ATRIP causes loss of ATR 
expression, demonstrating the stability of ATR is dependent on ATRIP (Cortez et al., 
2001). ATR is localised to regions of ssDNA via a direct interaction between ATRIP and 
stretches of RPA-coated ssDNA (coined RPA nucleofilaments) (Zou and Elledge, 2003). 
ATRIP also appears essential for the association and subsequent hyperactivation of ATR 
by TOPBP1 through a functionally conserved domain (Mordes et al., 2008).  
1.3.2. Replication protein A (RPA) 
RPA exists as a heterotrimeric protein complex, consisting of RPA70, RPA32 and RPA14 
(Zou et al., 2006). RPA binds to ssDNA with avidity, in a sequential manner in the 5’ to 3’ 
direction (de Laat et al., 1998). Whilst all RPA subunits contain DNA-binding domains 
Figure 1.3.1. RPA facilitates stalled fork stabilisation. RPA binds to ssDNA at stalled replication forks to 
recruit ATR. 
9 
 
 
 
(DBDs), binding and association with ssDNA appears to mostly occur within the tandem 
DBDs of RPA70, where cooperative binding of all four DBDs occludes roughly 30 
nucleotides of ssDNA (Zou et al., 2006). RPA32 contains an unstructured N-terminal 
phosphorylation domain, which is hyperphosphorylated by PIKK family members in an 
ssDNA- and replication-dependent manner following DNA damage. It has been 
suggested that hyperphosphorylation of RPA occurs following damage to limit the use 
of RPA in DNA replication, whilst shifting small fractions of nuclear RPA into DNA repair 
actions only (Patrick et al., 2005). Whilst RPA14 has no binding affinity for ssDNA, it is 
required for RPA heterotrimer formation and stability (Wold, 1997).  
RPA nucleofilaments are involved in almost all processes concerning DNA 
replication and repair, and are widely established as the common intermediate unifying 
the variety of disparate and genotoxic DNA structures that are capable of inducing ATR 
activation (Zou and Elledge, 2003). 
1.3.3. RAD9-HUS1-RAD1 complex 
The DNA damage-specific RAD9-RAD1-HUS1 (9-1-1) clamp complex preferentially binds 
to DNA substrates possessing 5’ recessed ends, and is loaded onto the ssDNA-dsDNA 
junction by the alternative clamp loader RAD17-RFC complex (RAD17 and replication 
factor C) (Ellison and Stillman, 2003). RPA nucleofilaments are an important 
intermediate structure here, recognised by the RAD17-RFC complex (Zou and Elledge, 
2003). RPA also interacts with the 9-1-1 complex via the RAD9 subunit (Maréchal and 
Zou, 2013). 
The 9-1-1 complex has similar structure and substrate specificities to the 
promiscuous, homotrimeric sliding clamp protein proliferating cell nuclear antigen 
(PCNA), asides from the presence of an unstructured, highly phosphorylated tail on the 
C-terminus of RAD9, which enables it to activate the essential ATR activator TOPBP1.  
1.3.4. TOPBP1  
TOPBP1 hyperactivates ATR through DNA-dependent and DNA-independent 
mechanisms (Kumagai et al., 2006). 9-1-1-dependent activation of TOPBP1 is required 
for ATR activation. TOPBP1 contains several BRCA1 C-terminus (BRCT) domains which 
can function as phospho-peptide binding sites, allowing interaction with the highly 
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phosphorylated C-terminus of RAD9, in a phosphorylation-dependent manner 
(Delacroix et al., 2007). Recently, human protein 9-1-1 interacting nuclear orphan 
(RHINO) has been identified as a novel factor capable of facilitating 9-1-1-TOPBP1 
complex formation in a phosphorylation-independent manner (Cotta-Ramusino et al., 
2011). Association with RAD9 tethers TOPBP1 at sites of DNA damage, allowing it to 
effectively stimulate ATR through association with the FATC domain whilst 
concomitantly acting as a scaffold that facilitates ATR kinase-substrate interactions. 
Activation-inducing trans-autophosphorylation of ATR at T1989 in the FAT domain 
appears to be independent of TOPBP1 activity (Ellison and Stillman, 2003; Nam et al., 
2011).  
RPA nucleofilaments appear to serve as the common intermediate structure 
required for the assembly and recruitment of the two independent checkpoint 
Figure 1.3.2 Canonical ATR activation. Taken from (Cimprich and Cortez, 2008) 
Slow origin 
firing 
Fork stability, 
Fork restart Cell-cycle  
arrest 
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complexes for ATR activation – the 9-1-1-TOBP1 complex and ATR-ATRIP. Furthermore, 
the specificity of the 9-1-1-clamp complex to ssDNA-dsDNA junctions, and this 
requirement of RPA-ssDNA for ATR activation, together may provide a mechanism to 
ensure ATR is only activated at sites of DNA damage, rather than regions of ssDNA 
alone.   
1.3.5. MRE11-RAD50-NBS1 (MRN) complex 
The Nijmegen breakage syndrome 1 (NBS1) subunit of the MRN complex also directly 
activates ATR independently of TOPBP1, via its N-terminal BRCT2 domain (Kobayashi et 
al., 2013). Cells deficient in NBS1 are unable to retain or activate ATR at RPA 
nucleofilaments (Stiff et al., 2005). The MRN complex also appears essential for 
appropriate recruitment, but not activation, of TOPBP1 to the ssDNA-dsDNA junction 
(Duursma et al., 2013). Both TOPBP1 and NBS1 appear essential for effective ATR 
activation. 
1.4. ATR downstream signalling 
Following DNA damage recognition and activation, ATR and ATM phosphorylate 
hundreds of substrates at S/TQ motifs, transducing the signal to downstream targets 
resulting in a multitude of cellular outcomes. Here I will give a brief overview of some of 
the key mediators of ATR-DDR signalling. 
1.4.1. CHK1 
CHK1 is activated by ATR via phosphorylation on S317 and S345 in response to DNA 
damage, as well as in undisturbed cell cycles. Unlike other DDR protein kinases, which 
act at the site of DNA damage, CHK1 propagates the DNA damage signal to the rest of 
the nucleoplasm - the association of CHK1 with sites of DNA damage appears to be 
transient (González Besteiro and Gottifredi, 2015). As a multifaceted and versatile 
signalling kinase, CHK1 mediates a vast array of ATR-specific signalling in response to 
DNA damage. Chromatin association and activation of CHK1 requires ATR-ATRIP-
dependent phosphorylation of RAD17 and BRCA1 (Bao et al., 2001). This also appears to 
be mediated by adaptor protein CLASPIN (Kumagai and Dunphy, 2000), which interacts 
with CHK1 in a damage-dependent manner. CLASPIN binds to the phosphorylated 9-1-1 
complex subunit RAD17 at the ssDNA-dsDNA junction – an interaction important for 
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sustaining CHK1 phosphorylation (Wang et al., 2006). CLASPIN-mediated CHK1 
activation is also mediated by the multifunctional TIMELESS protein and TIMELESS-
interacting protein TIPIN. TIMELESS exists in a tightly bound complex with TIPIN. 
Following UV irradiation or hydroxyurea (HU) treatment, TIMELESS-TIPIN binds to RPA 
nucleofilaments, stabilising CLASPIN and facilitating CHK1 phosphorylation by ATR at 
sites of DNA damage (Kemp et al., 2010).  
Following activation, CHK1 is released from the site of damage to localise to 
activate downstream targets within the nucleoplasm and at the centrosome (Niida et 
al., 2007). The most well characterised CHK1 substrate is the dual-specificity Cell division 
cycle 25  (CDC25) phosphatase (Furnari et al., 1997). ATR activation induces cell cycle 
arrest via CHK1-dependent phosphorylation of critical phosphatase CDC25A (T504). 
CDC25A-dependent dephosphorylation the cyclin-dependent kinase (CDK)-cyclin 
complexes is essential for their activity and cell cycle progression. Phosphorylation of 
CDC25A causes inhibition and degradation, preventing CDC25A-dependent 
dephosphorylation of CDK2-Cyclin A. Inhibition of CDK2-Cyclin A reduces association of 
CDC45 with replication origin complexes, resulting in a global inhibition of DNA synthesis 
due to decreased initiation of replication (Falck et al., 2001). CHK1 also phosphorylates 
DBF4, which may contribute to inhibition of origin firing via the regulation of CDC7 
(Heffernan et al., 2007).  
Much like the intra-S phase checkpoint, ATR acts upon the G2/M phase 
checkpoint through activation of CHK1 following ATM-dependent DNA DSB end 
resection, resulting degradation or cytoplasmic sequestration of the CDC25 
homologues. The resulting lack of phosphatase activity increases inhibition of the Cyclin 
B1-CDK1 complex by maintaining inhibitory phosphorylations on CDK1, conferring G2/M 
phase arrest (Furnari et al., 1997). 
1.4.2. MLL (Myeloid/Lymphoid Leukaemia 1) 
ATR-induced S-phase arrest is instigated via several further mechanisms resulting in the 
inactivity of the CDC25 phosphatase and CDC45. Specifically, ATR phosphorylates lysine 
methyltransferase MLL in response to DNA damage, preventing MLL degradation by the 
S-phase kinase-associated protein 2 (SKP2) complex (Liu et al., 2007). Increased MLL 
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expression results in increased histone H3 methylation at replication origins, resulting 
in reduced loading of replication initiation factor CDC45 – required for origin firing. 
CDC45 binds directly to H3, an interaction blocked by H3K4 methylation. Hence, in 
response to DNA damage in S-phase, ATR activity intercepts S-phase progression 
through the stabilisation of MLL and blocking of CDC45. CHK1 also phosphorylates 
TRESLIN, further inhibiting CDC45 loading at replication origins (Guo et al., 2015). 
1.4.3. MCM2 
MCM2 is a component of the MCM2-7 helicase that functions to unwind dsDNA during 
DNA synthesis. Following replicative stress, ATR phosphorylates MCM2 at S108 at the 
replication fork, creating a docking site for Polo-Like Kinase 1 (PLK1) (Trenz et al., 2008; 
Yoo et al., 2004). PLK1 is then capable of binding to chromatin, facilitating CDC45 loading 
onto local replication origins, in a manner that appears contradictory to the ATR-CHK1 
generated global repression of origin firing (Trenz et al., 2008). However, by promoting 
dormant origin firing within existing factories local to the stalled replication fork through 
MCM2-PLK1, whilst inhibiting the activation of new replication complexes via CHK1, ATR 
redirects origin firing away from unreplicated parts of the genome, minimising the 
damaging consequences of replication stress whilst promoting the completion of 
replication within problematic areas (Ge and Blow, 2010). 
1.4.4. dNTP synthesis 
Several mechanisms supporting a role for ATR-CHK1 in regulating deoxynucleotide 
triphosphate (dNTP) synthesis after damage have been characterised (Anacker et al., 
2016; Moss et al., 2010; Zhang et al., 2009). One established pathway describes the ATR- 
and CHK1-dependent downregulation of Cyclin F and CDK2 activity after DNA damage. 
Ribonucleotide Reductase (RNR) activity peaks in S-phase, when dNTP synthesis for DNA 
replication is most highly required. RNR subunit RRM2 (ribonucleotide reductase family 
member 2) is subject to targeted degradation in G2-M phase in a Cyclin F- and CDK2-
dependent manner, as cells prepare to enter mitosis. Following ATR activation, Cyclin F 
and CDK2 activity is decreased, alleviating the degradation of RRM2 allowing production 
of dNTPs to continue (D'Angiolella et al.). These mechanisms ensure adequate 
production in times of genotoxic stress, where dNTPs are required for DNA synthesis 
and repair. 
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1.5. Modulators of ATR activity 
Multiple proteins regulate ATR expression, signalling and activation. I will review some 
key modulators of ATR function in this section. 
1.5.1. TEL2 
PIKK family members are exceptionally large. During synthesis, these >250 kDa proteins 
require chaperone-assisted folding to acquire correct conformational maturation and 
protein stability. Telomere Length Regulation Protein 2 (TEL2) forms a chaperone 
complex with TELO2 interacting protein 1 (TTI1) and TTI2, coined the Triple T complex 
(TTT), which further contains the chaperone Heat Shock Protein 90 (HSP90), to promote 
the proper folding of the vast HEAT repeats contained in PIKK family members (Takai et 
al., 2007). The TTT/HSP90 complex acts as a PIKK-specific chaperone, interacting with 
the large -helical HEAT repeats of each protein and preferentially associating within 1 
hour of synthesis and not after (Hořejší et al., 2010; Hurov et al., 2010). When TEL2 is 
absent, ATR is not appropriately folded, resulting in checkpoint defects and reduced 
association with ATRIP (Hurov et al., 2010). 
1.5.2. Fanconi Anemia group M/FA-associated protein 24 (FANCM/FAAP24)  
Interstrand cross-links (ICLs) induce replication fork stalling. However, in the case of ICL-
induced fork stalling, the replication machinery remains coupled, due to the ICL acting 
as a physical obstruction to both helicase and polymerase. With no uncoupling of the 
replication machinery to generate the regions of RPA-ssDNA required for ATR activation, 
restructuring must occur before the lesion can be repaired. FAAP24 possesses the ability 
to associate with fork-structures and can form a complex with the highly conserved 
helicase FANCM, which possesses DNA translocase activity. As FANCM is required for 
effective checkpoint activation following ICLs, it is postulated that FANCM/FAAP24 is 
required to expose regions of ssDNA at ICLs to mediate ATR activation in response to 
these lesions (Huang et al., 2010). However, it appears FAAP24 is the only crucial 
mediator in the generation of ssDNA-RPA; hence, the level at which FANCM/FAAP24 
mediates ATR activation at ICLs remains unclear (Nam and Cortez, 2011). 
FANCM/FAAP24-mediated activation of ATR demonstrates one of many pathways that 
facilitate ATR activation in response to a wide variety of DNA structures. 
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1.5.3. ATM and TOPBP1 
Trans-autophosphorylation of ATR at T1989 generates a docking site for TOPBP1 via its 
BRCT domains. Phosphorylation of TOPBP1 on S1131 by ATM further promotes TOPBP1 
binding to and activation of ATR, in an RPA-independent manner, suggesting ATM 
facilitates ATR activation at DSBs via TOPBP1 (Yoo et al., 2007). TOPBP1 is also 
phosphorylated by ATR at S1131 following replication stress, suggesting a positive 
feedback mechanism in which ATR- or ATM- dependent TOPBP1 phosphorylation 
enhances ATR activity. TOPBP1 also interacts with ATRIP via its ATR-activation domain, 
hypothesised to generate conformational changes in ATR increasing kinase activity or 
substrate binding (Mordes et al., 2008). ATM-induced, RPA-independent ATR activation 
demonstrates one of multiple means of activating ATR without all of the established ATR 
signalling components. 
1.5.4. mTOR signalling axis  
Protein kinase A (PKA) and the IGF-1 signalling axis have recently been implicated as a 
regulator of ATR in response to UV-induced DNA damage (Jarrett et al., 2014; Jarrett et 
al., 2016; Kemp et al., 2017a). PKA is a cAMP-dependent kinase with roles in regulation 
of many different cellular metabolic and signalling processes (Del Gobbo et al., 2016). In 
2014, Jarrett et al. characterised a direct PKA-dependent phosphorylation on S435 of 
ATR, which enhanced recruitment of NER protein XPA following UV-induced DNA 
damage. They further characterised this event as mediated by A-kinase-anchoring 
protein 12 (AKAP12), which associates and is phosphorylated by ATR following damage 
(Jarrett et al., 2016). This work provides a mechanistic link between PKA-dependent 
transcription and activation of metabolic proteins, and ATR-dependent DNA repair 
pathways. Reduced or defective IGF-1 signalling, precursors to PKA activation, have also 
recently been implicated as a negative effector of ATR-CHK1 kinase signalling axis (Kemp 
et al., 2017b). 
Mechanisms placing mTOR effector AKT in checkpoint activation and DNA repair 
pathways have also been widely discussed, where increased AKT activity appears to 
suppress DNA damage-induced RPA foci formation and CHK1 activation. Inhibition of 
AKT restores DNA-damage induced recruitment and activation of these factors (Xu et 
al., 2010). AKT phosphorylates TOPBP1 at a conserved S1159 residue, inducing TOPBP1 
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oligomerisation, which may prevent association with ATR following damage (Liu et al., 
2006). 
1.6. ATR protein structure  
I will further discuss existing and postulated non-canonical roles of ATR in another 
section – prior to this, it is important to consider the protein structure of ATR.  
1.6.1. HEAT repeats 
A single HEAT repeat is a structural motif consisting of two alpha helices linked by a small 
loop (Yoshimura and Hirano, 2016). Over half of ATR’s protein structure consists of HEAT 
repeat units, the biological relevance of which is not fully understood (Perry and 
Kleckner, 2003). PIKK family members contain high levels of ‘-helicity’, which only 
appears to differ in the arrangement and number of specific HEAT repeat units. Of the 
45 HEAT repeats observed within ATR, 10 are unique and not observed in other PIKKs 
(Perry and Kleckner, 2003). ATM is known to interact with NBS1 via specific internal 
HEAT repeats (You et al., 2005), and ATRIP binds to ATR at within an N-terminal HEAT 
repeat domain, indicating functional relevance of the HEAT repeat domain. 
Research is emerging on this structural component of the PIKK family members, 
where the prospective role of HEAT repeats in non-canonical activation of ATR is 
considered. Interestingly, FLAG-ATR purified from mammalian cells has been reported 
to directly interact with DNA, preferentially following UV-damage (Ünsal-Kaçmaz et al., 
2002). Linearised DNA plasmids activate ATR in vitro in a TOPBP1-dependent manner, 
where stimulation of ATR again increases when the DNA is damaged by UV (Choi et al., 
2009). The binding of ATR to DNA appears to be independent of RPA-ssDNA complexes. 
To date, the DNA-binding activity of ATR has not been isolated to a specific region. This 
Figure 1.6. Primary ATR protein structure. ATRIP – ATRIP binding site; NLS – Nuclear localisation signal; 
FAT - FRAP-ATM-TRAP; PRD – PIKK regulatory domain; FATC – FAT C terminus domain. S428 – PIN1 
isomerisation site; S435 – PKA-dependent phospho-site. 
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information gains relevance when considering two further discoveries; 1) In 2010, 
Sibanda et al. utilised X-Ray crystallography to determine the 3D structure of DNA-PK, 
clearly demonstrating the -helical HEAT repeats generate a flexible cradle structure, 
which most likely binds to DNA (Sibanda et al., 2010); and 2) Rubinson et al. reported in 
2008 the bacterial DNA glycosylase AlkD utilises its HEAT-like repeats to bind to DNA, 
allowing the recognition of helical distortion induced by damage bases (Fig 1.6.1) 
(Rubinson et al., 2008). This data opens the possibility that ATR may bind to DNA via its 
HEAT repeats, providing explanation of how multiple types of DNA lesions are 
recognised by ATR (Nam and Cortez, 2011).  
Figure 1.6.1. HEAT repeats can bind DNA. A) Crystal structure of DNA-PKcs. Taken from (Sibanda et 
al., 2010) B) Theoretical Binding of AlkD to DNA. Taken from (Rubinson et al., 2008) 
A 
B 
18 
 
 
 
Further to this, In 2014, Kumar et al. characterised a role for ATR HEAT repeats 
as a sensor of mechanical stress at the nuclear envelope (Kumar et al., 2014). Following 
osmotic and mechanical stress, independently of RPA and the DDR, ATR localised to the 
inner and outer nuclear membranes, and appeared to modulate chromatin and nuclear 
envelope association. The authors comment on the properties of N-terminal HEAT 
repeats, suggesting they could behave as ‘elastic connectors’, allowing mechanical 
forces influence on ATR activity. 
Additionally, Mori et al. described cell death preluded by a cytoplasmic 
vacuolisation phenotype with moderate overexpression of ATR (Mori et al., 2013). 
Through expression analysis of variously sized tagged ATR-deletion constructs, they 
identified the N-terminus heat repeats as sufficient to induce vacuolisation, suggesting 
a role for ATR-HEAT repeats in cellular vacuolisation. 
1.6.2. FAT and FATC 
PIKKs exhibit strong sequence homology in the S/T kinase-flanking FAT and FATC regions 
(Mordes and Cortez, 2008). The FATC domain is required in all PIKKs for kinase activity 
and target protein recognition, and as FAT and FATC domains only exist together, this 
could be due to interaction between the two domains promoting proper folding of the 
kinase domain (Jiang et al., 2006). The ATR FAT domain is also the site of its activating 
trans-autophosphorylation on T1989. 
1.6.3. PRD (PIKK regulatory domain) and PI3K domain 
TOPBP1 activates ATR through binding to ATRIP and ATR’s PRD domain, located between 
the FATC and PI3K domains. Mutations in this domain result in loss of TOPBP1-induced 
ATR activation (Kumagai et al., 2006; Mordes and Cortez, 2008). Large variations in 
sequence within the PRDs of different PIKK family members may allow individual 
responses to different regulators – ATR, ATM and mTOR are all regulated by PRD 
interactants (Kumagai et al., 2006; Sekulić et al., 2000; Sun et al., 2007). The PRD of ATM 
is acetylated by TIP60 inducing activation, and mutations in the PRD of DNA-PKcs 
interfere with function (Mordes et al., 2008; Sun et al., 2007). The PI3K domain supplies 
ATR with its apical kinase activity – allowing the phosphorylation of substrates 
specifically at S/TQ motifs. 
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1.6.4. BH3-like domains 
Three ‘BH3-like’ (BCL-2 homology domain 3-like) domains have recently been discovered 
within ATR (Fig 1.6.4). Evidence has validated the functional significance of at least one 
of these domains - conferring cytoplasmic ATR the ability to interact with BCL-2 family 
members at the mitochondria in an anti-apoptotic manner (Hilton et al., 2015). The 
functional relevance of these novel, BH3-like domains in relation to ATR activity is yet to 
be fully acknowledged, however their recognition provides further opportunity for the 
characterisation of previously unconsidered, non-canonical ATR interactants. 
Interestingly, one BH3-like domain of ATR (462-474) appears proximal to a collection of 
N-terminal residues that are regulated by an array of cytoplasmic enzymes (Fig 1.6). ATR-
S428/P429 is a prolyl isomerase 1 (PIN1) isomerisation site (Hilton et al., 2015); ATR-
S435 confers a PKA-dependent phosphorylation (Jarrett et al., 2014); ATR-S438 has been 
identified as a putative AKT-dependent phospho-site following insulin treatment in 
adipocytes (Humphrey et al., 2013). The significance on ATR function of this ‘hub’ of 
cytoplasmic interactants is yet to be fully ascertained. 
1.7. Putative ATR/ATM substrate screens 
In the last decade, several publications utilising a variety of screening approaches have 
identified putative, novel ATM/ATR substrates. Investigating changes in proteomic S/TQ 
phospho-status following DNA damage generated excellent candidates for follow-up, 
hypothesis-driven studies to validate novel roles for ATR and ATM. Very few of these 
putative, novel ATR/ATM targets have been investigated further following publication. 
Figure 1.6.4. Alignment of BH3-like consensus sites within ATR with BCL2 family members. Taken 
from (Hilton et al., 2015) 
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Of those that have, the functional significance has been validated, as novel bona fide 
ATR/ATM substrates in vivo. 
1.7.1. Matsuoka et al. 
In 2007, Matsuoka et al. identified over 700 putative ATM/ATR substrates, using a stable 
isotope labelling with amino acids in cell culture (SILAC) mass spectrometry approach 
(Matsuoka et al., 2007). Heavy- and light-labelled samples were treated with or without 
IR and immunoprecipitated using a variety of phospho-SQ or phospho-TQ antibodies - 
bound peptides were then analysed by mass spectrometry. Peptides demonstrating a 
four-fold change in phospho-status after damage were considered putative substrates. 
Matsuoka et al. utilised this approach to acquire a dataset of unbiased, putative 
ATR/ATM substrates in vitro. The group validated a small subset of the putative targets 
Figure 1.7.1. Network of putative ATR/ATM substrates involved in cell metabolism identified by 
Matsuoka et al. Red shading indicates putative ATR/ATM substrates after ionising radiation. FOXO1 - 
forkhead box protein O1; 4E-BP1 - Eukaryotic translation initiation factor 4E-binding protein 1; p70S6K - 
Ribosomal protein S6 kinase beta-1; VAMP2 – vesicle associated membrane protein 2; PP2A – protein 
phosphatase 2A. Taken from (Matsuoka et al., 2007) 
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identified in their screen. The majority of the targets identified had roles in nucleotide 
metabolism and DNA repair/cell cycle checkpoints – pathways with which ATR is well 
established. Further from this, unexpectedly, many putative cytoplasmic targets were 
identified, particularly enriched in this subset were those with roles in vesicle and 
membrane transport, and insulin signalling and metabolism (Fig 1.7.1).  
1.7.2. Stokes et al. 
Stokes et al. also identified large numbers of novel ATR/ATM substrates in 2007, using 
immunoaffinity phosphopeptide isolation and mass spectrometry, but in this case, after 
UV damage (Stokes et al., 2007). Peptides with a 2-fold increase in intensity were 
considered putative ATM/ATR substrates - of 192 previously undescribed substrates 
recognised in this screen, roughly half were also found by Matsuoka et al.,. UV-induced 
DNA damage induces bulky lesions resulting primarily in ATR activation, suggesting the 
putative substrates Stokes et al. identified could have higher relevance within the ATR 
signalling axis over that of ATM. 
1.7.3. Cara et al. 
Established ATM and ATR substrates commonly contain clusters of highly conserved 
S/TQ motifs that constitute an SQ/TQ cluster domain (SCD) (Cara et al., 2016). Using a 
bioinformatics approach to identify SCD-containing proteins, Cara et al. identified over 
800 putative ATM/ATR targets conserved across differing vertebrae proteomes. 
Interestingly, they discovered significant enrichment of SCD-containing proteins in 
vesicle trafficking, neural development and metabolic pathways, hinting at broad, 
uncharacterised cytoplasmic roles for ATM and ATR. 
1.8. Established non-canonical activation of ATR 
The recognition of an influence of metabolic signalling on the ATR-CHK1 axis, and the 
volume of putative ATM/ATR substrates identified by Matsuoka et al. and Stokes et al. 
in their proteomics screens has encouraged a re-approach to how ATR signalling is 
considered. Cytoplasmic, non-DDR roles for ATR and ATM are gaining increased 
recognition (Li et al., 2009; Mori et al., 2013; Postigo et al., 2017). Whilst cytoplasmic 
localisation of these proteins has been established for some time (Cuadrado et al., 
2006), the implications of such have not been addressed, with the majority of ATR/ATM 
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research focused on DDR functions. Here I will provide a brief overview of several non-
canonical roles of ATR – demonstrating how current perspectives on a metabolic role 
for ATR are steadily developing. 
1.8.1. VAMP2 
In 2009, Li et al. validated two novel ATM/ATR targets – VAMP2 and synapsin-I. VAMP2 
(vesicle associated membrane protein 2) is a member of the synaptobrevin/VAMP family 
and is required for effective vesicle docking and membrane fusion of synaptic vesicles 
with the presynaptic membrane. Li et al. reported ATR and ATM within neuronal 
cytoplasm at levels comparable to that of the nucleus, where canonical ATM-activating 
DNA damage had no effect on activity of cytoplasmic ATM. They further noted defects 
in synaptic vesicle recycling in ATM-deficient brains. Utilising evidence from the 2007 
Matsuoka et al. substrate screen and a site-directed mutagenesis approach, Li et al. 
validated VAMP2 and synapsin-I as a novel ATR and ATM substrates, respectively (Li et 
al., 2009). 
Interestingly, in insulin-sensitive tissues VAMP2 is required for a similar 
membrane fusion process – the translocation of the vesicle-bound glucose transporter 
GLUT4 to the plasma membrane in response to insulin (Ramm et al., 2000). The 
functional relevance of impaired ATR activity on the requirement of VAMP2 in insulin-
sensitive glucose uptake is yet to be ascertained – although Li et al. did not observe 
cytoplasmic ATR in insulin-sensitive NIH3T3 cells. 
1.8.2. Cell metabolism - Mitochondria and Autophagy 
Hilton et al. recently characterised an anti-apoptotic role for ATR at the mitochondria 
(Hilton et al., 2015). They reported cis- and trans-isomers of cytoplasmic ATR, where 
basal levels of trans-ATR were maintained by prolyl isomerase PIN1, and cis-ATR had 
unique pro-survival activity at the mitochondria following UV damage. PIN1 isomerised 
ATR from cis- to trans- at the phosphorylated Ser428-Pro429 motif, downregulating ATR 
mitochondrial activity. UV damage induced inhibition of PIN1, allowing stabilisation and 
interaction of pro-survival, cis-ATR with pro-apoptotic truncated BH3 interacting-
domain (tBID) at the mitochondria, via a specific ATR BH3-like domain, exposed only in 
cis- formation. ATR-tBID binding blocked mitochondrial recruitment of pro-apoptotic 
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BCL2 associated X (BAX), required for initiation of apoptosis. The stabilisation of cis-ATR 
following UV appeared to be specific to cytoplasmic ATR, where nuclear trans-ATR 
remained unaffected following UV.  
The group further described the mitochondrial activity of ATR as independent of 
ATR-kinase activity and ATRIP, suggesting a novel, non-canonical activity of cytoplasmic 
ATR. It is notable that ATR also interacts with BID in a canonical manner following DNA 
damage. BID is directly phosphorylated by ATR following DNA damage, and is required 
for appropriate regulation of the intra-S-phase checkpoint (Zinkel et al., 2005). Helix-4 
of BID also interacts with the coiled-coil domain of ATRIP, facilitating chromatin 
localisation of ATR-ATRIP during replicative stress (Liu et al., 2011). Hence, it appears 
ATR can interact with BID in a highly context-specific manner, where immediate 
conditions induce differing consequences, dependent on the kinase activity and protein 
structure of ATR. 
Another group has characterised a role for ATR and the mitochondria in yeast. In 
2017, Yi et al. described a role for Mec1 (ATR) in the regulation of mitochondrial 
respiration following starvation-induced autophagy (Yi et al., 2017). They described Snf1 
(AMPK)-dependent phosphorylation events of Mec1 at the mitochondria following 
glucose deprivation, resulting in recruitment of Atg1 (ULK1). The formation of a Snf1-
Mec1-Atg1 complex appeared essential for the maintenance of mitochondrial 
respiration and subsequent autophagic induction throughout glucose starvation. Active 
mitochondrial respiration has recently been characterised as a prerequisite for glucose 
deprivation-induced autophagy (Okamoto, 2011), hence, a novel role for Mec1 in 
starvation-induced autophagy has been characterised here. 
Mori et al also documented that overexpression of ATR, but not ATM, mTOR or 
SMG-1 resulted in autophagic cell death, suggesting tight regulation of ATR expression 
is crucial for cell viability (Mori et al., 2013). Taken together, these papers suggest 
further characterisation is required to elucidate the full influence of ATR on autophagic 
processing, mitochondrial maintenance and cell metabolism.  
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1.8.3. Viral genome replication 
In 2017, Postigo et al. suggested that canonical ATR activation was possible within the 
cytoplasm, to promote replication of viral genomes (Postigo et al., 2017). In contrast to 
long-held beliefs (Moss, 2013), the group reported that smallpox virus family member 
Vaccinia recruited conserved DNA replication and repair components of the ATR 
signalling axis to facilitate amplification of its genome within the host cytoplasm. Using 
phospho-S/TQ specific antibodies and ATR/ATM inhibitors, the group noted CHK1- and 
ATR-dependent, cytoplasmic increases in pS/TQ status following viral infection. This 
increase was not due to nuclear DNA damage, as it only occurred within the cytoplasm. 
Although their specific conclusions are controversial in the recruitment of eukaryotic 
factors to the viral genome, their data further appears to reinforce the existence of 
multiple cytoplasmic substrates of ATR. Human Papilloma Virus 31 (HPV31) has also 
been reported to activate ATR-CHK1 signalling, to elevate RRM2 levels providing the 
dNTPs necessary for viral replication (Anacker et al., 2016). 
1.8.4. Primary cilia 
A functional genomic screen searching for proteins that interact with the coiled-coil 
domain of ATRIP identified CINP (CDK2 interacting protein) as a transient interactor, 
where CINP silencing induced modest defects in ATR-dependent CHK1 phosphorylation 
and HU sensitivity (Lovejoy et al., 2009). The function of CINP in ATR signalling remains 
unclear. Nam and Cortez [2011] postulated that the interaction of CINP with CEP152 
(centrosomal protein 152 kDa) provided some evidence for a role of ATR and CINP in 
centrosomal regulation, due to mutations in both ATR and CEP152 generating the 
microcephalic primordial dwarfism disorder Seckel Syndrome (SS) (Nam and Cortez, 
2011). Further to this, centriole appendage protein CEP164 has a role in ATR-dependent 
CHK1 phosphorylation following UV damage. CEP164 is also phosphorylated by and 
exists in complex with ATR and ATM in a DNA-damage-independent manner 
(Sivasubramaniam et al., 2008). 
ATR localisation to the primary cilia and cilia dysfunction with ATR deficiency has 
been reported (Valdés-Sánchez et al., 2013). Primary cilia are chemo- and mechano-
sensory organelles that transduce signals from the surrounding microenvironment into 
the cytoplasm (Satir et al., 2010). In 2016, Stiff et al. characterised a novel, TOPBP1-
25 
 
 
 
dependent role for ATR at the primary cilia (Stiff et al., 2016). ATR-inhibited and ATR-SS 
cells displayed dramatically impaired cilia-dependent signalling when treated with 
smoothened (SMO) agonist SAG, a phenotype rescued by ATR overexpression. Zebrafish 
embryos depleted of Atr displayed a SS-like morphology and developmental defects 
typically conferred by cilia dysfunction, suggesting the observed cellular defects in cilia 
signalling had developmental consequences. The group conclude that defective cilia 
signalling may contribute to the clinical manifestation of ATR-SS. 
1.8.5. ATM  
Cytoplasmic roles of ATM are more widely established than those of ATR (Yang et al., 
2011). Roles for ATM in mTORC1 suppression and pexophagy, insulin-dependent protein 
translation and GLUT4 translocation, endocytosis, synaptic vesicle transport and 
neurotransmitter release, and regulation of mitochondrial homeostasis have all been 
reported (Barlow et al., 2000; Halaby et al., 2008; Li et al., 2009; Lim et al., 1998; Vail et 
al., 2016; Yang and Kastan, 2000b; Zhang et al., 2015).  
The clinical significance of these functions of ATR and ATM are yet to be fully 
understood. Insight to the essential functions of ATR can be gained through examining 
the congenital disorder caused by hypomorphic mutations in ATR, ATR-SS. 
1.9. Disorders of ATM and ATR 
1.9.1. Ataxia Telangiectasia (AT) 
ATR shares a vast set of substrates with its homologue ATM (Matsuoka et al., 2007). 
However, ATM is non-essential  – Atm-/- mice are viable (Kuljis et al., 1997). Loss of 
function mutations in ATM generate the progressive neurodegenerative disorder Ataxia 
Telangiectasia (AT). AT is characterised by coordination and movement difficulties 
(ataxia), insulin resistance, telangiectasias (capillary dilation generating visible ‘spider-
like’ clusters), predisposition to leukaemia/lymphomas and radiosensitivity (Lavin and 
Shiloh, 1997). The neurological features of AT increase in severity throughout 
development, where complete immobilisation often occurs towards the end of the first 
decade of life (Boder and Sedgwick, 1987). Ataxia appears to manifest as the affected 
child becomes ambulatory, whereas telangiectasias have a slightly later onset (2-8 years) 
(Lavin, 2008). Degenerative changes can be observed throughout the CNS and 
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predominantly within the cerebellum – cerebellar Purkinje cell loss appears to underlie 
the progressive neurodegeneration observed in AT. Interestingly, neuronal cells have 
high levels of cytoplasmic ATM – where cytoplasmic roles for ATM in neurotransmitter 
release, pexophagy and lysosomal clearance have been characterised (Barlow et al., 
2000; Li et al., 2009; Lim et al., 1998; Yang et al., 2011). However, loss of these 
cytoplasmic functions of ATM does not appear to generate the Purkinje cell loss 
observed in AT. Hypomorphic mutations in the gene encoding MRN complex member 
MRE11 generates AT-Like disorder (ATLD) – characterised by similar neurodegeneration 
to AT (Taylor et al., 2004). MRE11 enables ATM activation at sites of DNA DSBs, 
indicating that deficits in ATM-dependent DSB repair are more likely to generate this 
aspect of the syndrome.  
 Furthermore, AT patients are immunocompromised. ATM appears to stabilise 
DNA-DSB complexes during V(D)J recombination, as well as having a role in 
immunoglobulin class switch recombination (Bredemeyer et al., 2006; Lumsden et al., 
2004). Loss of ATM here results in increased instability of these DSB-dependent 
processes, generating lymphopenia and increased oncogenic translocations at antigen 
receptor loci. Increased translocations at T-cell receptor (TCR) loci have the pathological 
consequence of lymphoma predisposition, also observed in AT. 
Figure 1.9.1. Loss of function mutations in ATM generate Ataxia Telangiectasia. Patients at 10 years 
(top left) and 22 years (top right). Bottom panel shows ocular telangiectasia observed in AT. Taken 
from (Taylor et al., 2015) 
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 Additionally, AT is characterised by insulin resistance and diabetes - ATM appears 
to have a role in insulin signalling – where insulin-induced ATM-dependent 
phosphorylation of eIF-4E-binding protein 1 (4EBP1) at S111 is required for insulin-
dependent initiation of translation (Yang and Kastan, 2000a). It is postulated that 
through this mechanism, ATM deficiency generates the metabolic aspects of AT. 
1.9.2. Seckel Syndrome  
Hypomorphic mutations in ATR cause the severe disorder ATR-Seckel Syndrome (ATR-
SS - OMIM 210600) (O'Driscoll et al., 2003). Seckel Syndrome (SS) describes many 
unspecified and diverse forms of microcephalic primordial dwarfism. Clinically and 
genetically heterogeneous, SS is characterised by intrauterine and postnatal growth 
retardation, atypical facial features, mental retardation and failure to thrive (Majewski 
et al., 1982). Among these striking clinical features, ATR-SS patients also display a 
marked reduction in subcutaneous fat (O’Driscoll et al., 2004), which is more often 
clinically associated with metabolic dysfunction (Fig 1.9.2).  
Figure 1.9.2. Seckel Syndrome generated by mutations in ATRIP and ATR. A) ATR-SS generated by 
compound heterozygous mutations in ATR. Patient shows lipodystrophy of the face and marked 
reduction in ATR expression from B-cell lymphoblastoid samples (LBLs). Taken from (Mokrani-Benhelli 
et al., 2013) B) SS generated through compound heterozygous mutations in ATRIP. Facial 
lipodystrophy is apparent, and reduced ATRIP and ATR are shown in patient LBLs. Modified from (Ogi 
et al., 2012) 
A 
B 
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A single 2101A-G transition in ATR represents the first mutation associated with 
ATR-SS. This mutation was shown to affect splicing efficiency, resulting in almost 
undetectable expression levels of ATR. However, this splicing defect appears ‘leaky’, 
where a fraction of ATR sufficient for viability is expressed (O'Driscoll et al., 2003). 
Additional compound heterozygous mutations in ATR have also been identified as 
underlying SS (Fig 1.9.2.A) (Mokrani-Benhelli et al., 2013; Ogi et al., 2012). Compound 
heterozygous mutations in ATRIP, generating a C-terminal truncation and splicing 
defects of ATRIP have also been identified in patients with SS, phenocopying ATR-SS, 
exhibiting reduced ATR expression and an impaired ATR-DDR signalling axis (Fig 1.9.2.B) 
(Ogi et al., 2012).  
To date, over 100 disease-causing mutations in ATR have been discovered (Table 
1.9.2). Interestingly, other SS-causing mutations have been characterised in several 
genes encoding proteins associated with mitotic spindle formation and centrosome and 
kinetochore function, including centromere protein J (CENPJ), centrosomal protein 152 
(CEP152), ninein, and CTBP-interacting protein (CtIP) (Alcantara and O'Driscoll, 2014). 
CENPJ has roles in centrosomal biogenesis, spindle assembly and disassembly, as well as 
controlling centriole length and duplication (Chen et al., 2006; Schmidt et al., 2009). 
CEP152 is a centrosomal scaffold protein, controlling centriole duplication via 
interaction with CENPJ (Guernsey et al., 2010). Ninein is essential for asymmetric 
division – required for centriole organisation and microtubule anchoring (Dauber et al., 
2012). CtIP has an essential role in homologous recombination DSB repair (HRR) – 
without functional CtIP, DSB end resection is impaired, preventing the generation of 
RPA-ssDNA, suppressing ATR activation (Qvist et al., 2011). Centrosome and spindle pole 
orientation have essential roles in asymmetrical cell division during brain development. 
A failure to maintain centrosome stability and function during development is ascribed 
as a potential contributor severe microcephaly observed in SS (Alderton et al., 2004). 
Interestingly, SS generated by mutations in genes encoding centrosomal proteins does 
not appear to have equivalent lipodystrophy to SS generated by hypomorphisms in 
ATR/ATRIP, although ciliopathies are commonly associated with metabolic syndrome 
(Waters and Beales, 2011). 
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Nuclear fragmentation, micronuclei formation, impaired phosphorylation of 
ATR-dependent substrates, increased centrosome number and defective G2/M arrest 
are common features of SS patient cell lines (Alderton et al., 2004). This indicates that 
as well as enhanced replicative stress, defective mitotic checkpoint function can 
underlie the clinical features associated with SS. More recently, ATR-SS has been 
Table 1.9.2. Documented ATR mutations that generate Seckel Syndrome. ‘=’ indicates no change. 
Sourced from https://www.ncbi.nlm.nih.gov/clinvar (August 2017) 
Location on ATR VariationID
 c.7875G>A (p.Gln2625=) 93669
 c.7725G>A (p.Ala2575=) 158004
 c.7667C>G (p.Thr2556Ser) 343581
 c.7471G>A (p.Val2491Ile) 343582
 c.7359_7361dupTAG (p.Ser2453_Arg2454insSer) 343583
 c.7300C>G (p.Pro2434Ala) 158003
 c.7274G>A (p.Arg2425Gln) 136470
 c.7041+4G>C 158002
 c.6961T>C (p.Phe2321Leu) 158001
 c.6960G>A (p.Lys2320=) 343584
 c.6897+464C>G 156537
 c.6896T>C (p.Met2299Thr) 343585
 c.6339A>G (p.Val2113=) 157999
 c.6259A>G (p.Met2087Val) 343586
 c.6226C>G (p.Leu2076Val) 343587
 c.6221+3G>A 343592
 c.6197G>A (p.Arg2066Gln) 343593
 c.6090G>A (p.Ala2030=) 343594
 c.6079-14G>A 343595
 c.6078+10T>C 343596
 c.5987T>C (p.Met1996Thr) 343597
 c.5899-8delT 343598
 c.5868C>T (p.Tyr1956=) 157996
 c.5739-14_5739-6delGTTACTTCCinsT 343599
 c.5739-14G>T 157995
 c.5732A>G (p.Asn1911Ser) 157994
 c.5635G>T (p.Asp1879Tyr) 41901
 c.5572T>C (p.Cys1858Arg) 343600
 c.5460T>C (p.Tyr1820=) 136471
 c.5349G>T (p.Gln1783His) 343601
 c.5208T>C (p.Tyr1736=) 157992
 c.5052T>C (p.His1684=) 343602
 c.4835A>G (p.Asn1612Ser) 157989
 c.4820G>A (p.Ser1607Asn) 343603
 c.4764C>T (p.Leu1588=) 210490
 c.4677C>T (p.Asp1559=) 210489
 c.4641+15C>T 157987
 c.4641+1G>T 210488
 c.4407C>T (p.Thr1469=) 343604
 c.4382+6T>C 343605
 c.4351C>T (p.Arg1451Trp) 157985
 c.4323A>G (p.Gln1441=) 343606
 c.4306A>G (p.Asn1436Asp) 157984
Location on ATR VariationID
 c.4218G>A (p.Ala1406=) 343607
 c.4002G>A (p.Gln1334=) 157981
 c.3945+2dupT 343608
 c.3799G>A (p.Val1267Ile) 157980
 c.3497A>C (p.His1166Pro) 343610
 c.3477G>T (p.Met1159Ile) 156536
 c.3424A>G (p.Ser1142Gly) 157977
 c.3120G>A (p.Leu1040=) 157975
 c.2875G>A (p.Val959Met) 157974
 c.2844A>C (p.Ala948=) 157973
 c.2776T>C (p.Phe926Leu) 343612
 c.2688G>A (p.Leu896=) 157972
 c.2653G>A (p.Val885Ile) 343613
 c.2532+4G>A 343614
 c.2503T>C (p.Leu835=) 343615
 c.2442A>G (p.Glu814=) 157971
 c.2226T>C (p.Cys742=) 343616
 c.2022A>G (p.Gly674=) 8307
 c.1950G>A (p.Glu650=) 157968
 c.1885+7G>A 343617
 c.1815T>C (p.Asp605=) 157966
 c.1784C>T (p.Ser595Leu) 343618
 c.1776T>A (p.Gly592=) 157965
 c.1350-3T>C 157964
 c.1326A>G (p.Lys442=) 157962
 c.1318C>T (p.Pro440Ser) 343619
 c.1006C>T (p.Arg336Trp) 343620
 c.946G>A (p.Val316Ile) 158006
 c.632T>C (p.Met211Thr) 93668
 c.489T>C (p.Asn163=) 343621
 c.483A>G (p.Arg161=) 157990
 c.436A>G (p.Thr146Ala) 343622
 c.431T>G (p.Val144Gly) 343623
 c.423T>C (p.Ile141=) 157983
 c.325C>T (p.Arg109Trp) 343624
 c.292+15T>G 343625
 c.268C>T (p.His90Tyr) 235760
 c.260G>T (p.Ser87Ile) 343626
 c.225C>T (p.Ile75=) 343627
 c.190A>G (p.Thr64Ala) 343628
 c.152-9T>C 343629
 c.-46_-9del38insT 343631
 c.-91C>G 343632
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characterised as a ciliopathy disorder, where impaired cilia function is postulated as a 
contributor to the clinical manifestation (Stiff et al., 2016). Appropriate centrosome 
functionality is required for the formation of primary cilia, and ATR-SS cells display 
modest defects in cilia function and formation (described in more detail in section 1.7.4).  
Considering ATM and ATR have significant homology and vastly overlapping 
substrate sets following DNA damage, striking contrast exists between the clinical 
presentations of the congenital disorder of each protein. Currently, the underlying basis 
of this distinction is unknown. Why centrosomal proteins and ATR converge, where 
mutations in either result in the clinical manifestation of SS is also unclear, although 
roles for ATR in the spindle assembly checkpoint and centrosome function are 
postulated (Brown and Costanzo, 2009; Katsura et al., 2009). In the context of impaired 
prenatal neuronal development, SS does share similarities with a variety of other DDR 
syndromes (O’Driscoll and Jeggo, 2003); mutations in genes encoding DNA repair 
pathway proteins often generate disorders characterised by cancer predisposition and 
neurological deficits (Kerzendorfer and O’Driscoll, 2009). It is likely that the underlying 
cause of the neurological deficits observed within ATR-SS and other congenital DDR 
disorders is due to a striking sensitivity of neuronal tissue to unrepaired DNA lesions and 
replicative stress.  
The development of several functionally distinct mouse models of ATR deficiency 
has allowed further investigation into the impacts of reduced ATR function.  
1.10. Mouse models of ATR deficiency  
1.10.1. Atr -/+ mouse 
Brown and Baltimore (2000) demonstrated that Atr-/- mice are embryonic lethal due to 
the requirement of ATR for early embryonic cellular proliferation (Brown and Baltimore, 
2000). In this study, heterozygosity of Atr led to increased tumour incidence. However, 
they were unfortunately unable to confirm if tumours from the Atr -/+ mice had lost 
heterozygosity of Atr.  
1.10.2. Inducible Atr deletion mouse 
A study investigating the conditional deletion of Atr in adult mice confirmed that the 
most marked clinical features of SS originate from reduced Atr expression during 
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embryonic development (Ruzankina et al., 2007). Using the tamoxifen-inducible CRE-
ERT2 promoter system in adult mice to selectively delete Atr, the group circumvented 
the early embryonic lethality related to deficiencies in ATR during development. 
However, successful recombination and deletion of the Atrflox allele was not achieved in 
a significant minority of cells, rendering the cellular phenotype of this transgenic mouse 
closer to a mosaic of Atrflox- and Atr expression. Interestingly, 3 months after inducing 
AtrmKO (Atr mosaic knockout) in adult mice, animals displayed a 70% decrease in their 
subcutaneous adipose layer, leading to a 20% lower body weight compared to control 
mice after 1 year (Fig 1.10.2) (Ruzankina et al., 2007). The group reported this phenotype 
as the result of a depletion of the cycling sub-population of stem progenitors (required 
to sustain and replenish the adipocyte population), due to the inherent toxicity of ATR 
deficiency in cycling cells. However, they did not characterise further whether the sharp 
decrease in subcutaneous fat tissue was due to cell death, or reduced intracellular lipid 
content, hence the potential for a role of ATR in maintaining appropriate lipid 
metabolism remains unchallenged. 
Figure 1.10.2. Abnormalities of subcutaneous fat and accelerated ageing 3 months after induced 
knockdown of Atr in adult mouse. A) Significant reduction in white subcutaneous adipocyte layer of 
AtrmKO mice after 3 months (marked A). B) Accelerated ageing observed in AtrmKO mice. Modified 
from (Ruzankina et al., 2007) 
A 
B 
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Although the group summarised their results with the conclusion that ATR 
activity appeared to be unessential for the homeostasis of non-dividing cells, this 
contradicts their observation that the subcutaneous adipose tissue layer was vastly 
depleted. Very little research into the life-span of rodent adipocytes has been 
undertaken (Lee et al., 2010), however it is roughly estimated the life span of rodent and 
human adipocytes is 3-6 months and 5-10 years respectively (Neese et al., 2002; 
Rigamonti et al., 2011; Spalding et al., 2008). Having an established rate of turnover of 
murine WAT is relevant here to contextualise the disappearance of subcutaneous fat 
layer in the AtrmKO mouse.  
1.10.3. Humanised AtrS/S mouse 
The SS-generating ATR A2101G mutation will not generate SS when mutated in mouse 
Atr, due to significant differences in the layout of introns within each orthologue 
(Ragland et al., 2009). To address this, and generate a mouse model which faithfully 
recapitulated the ATRS/S mutation and almost all the clinical features characteristic of 
SS, Murga et al. introduced a region of human genomic ATR incorporating A2101G and 
adjacent introns into the mouse Atr locus (Murga et al., 2009). Interestingly, AtrS/S mice 
died within 6 months of birth, exhibiting a ‘cachexic’ appearance and an accelerated 
aging phenotype. The authors also noted a supressed IGF-1/growth hormone axis, which 
could have impacted the growth retardation phenotype. Although a dampened 
somatotrophic axis is associated with genotoxic stress and progeria (Bartke, 2005), this 
is a noteworthy phenotype as components of the insulin signalling pathway have been 
identified in several screens as putative ATM/ATR substrates (described further in 
section 1.8) (Cara et al., 2016; Matsuoka et al., 2007; Stokes et al., 2007). Furthermore, 
Figure 1.10.3. Humanised AtrS/S mouse exhibiting severe microcephaly, low birth weight and 
dwarfism, characteristic of ATR-SS. Modified from (Murga et al., 2009) 
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the authors implied a role for ATR in the maintenance of stem cell progenitors due to 
the development of pancytopenia (loss of all blood cell types) in ATRs/s mice.  
1.10.4. p53 -/-/ATRS/S mouse  
Murga et al. observed increased accumulation of p53 and accelerated ageing in ATRS/S 
mouse embryos; mouse models of increased p53 activity often display accelerated aging 
phenotypes (Maier et al., 2004; Tyner et al., 2002). In an attempt to mitigate against the 
aging phenotypes, the group explored the effect of p53 deficiency on ATRS/S mice. 
Surprisingly, ATRS/S/p53-/- double mutant animals were born at sub-mendelian ratios, 
with more dramatic ageing phenotypes than observed in the ATRS/S mice alone. Due to 
this, ATRS/S/p53-/- mice did not survive further than 2 months. Further to this, the group 
characterised the enhanced cytotoxicity of ATRS/S/p53-/- as due to increased replicative 
stress and apoptosis. 
In this manner, Murga et al. proposed that although ATR haploinsufficiency was 
tumorigenic; in striking contrast, near-complete inhibition of ATR function appeared to 
have a cytotoxic effect on p53-/- cells - indicating the therapeutic potential of ATR 
inhibitors in the selective elimination of p53-deficient tumours (Murga et al., 2009). 
Following from this crucial discovery, subsequent investigation has generated 
understanding of the true potential of small molecule kinase inhibition of ATR (ATRis) as 
novel cancer chemotherapeutic agents.  
1.10.5. p53-/-/AtrmKO mouse 
In the same year, Brown and colleagues also characterised the effects of p53-/- on the 
adult conditional Atr deletion mouse model (Ruzankina et al., 2009a). Mosaic deletion 
of Atr in adult p53+/+ and p53-/- mice was induced with tamoxifen as previously described 
(Ruzankina et al., 2007), where adult p53-/-/AtrmKO animals where characterised by cells 
carrying excessive levels of DNA damage, and synthetic lethality. The enhanced toxicity 
of p53-/-/AtrmKO in adult mice further reinforced the concept of synthetic lethality 
between p53-deficient cells and ATR knockdown, evidencing for the first time a specific 
synthetic interaction between ATR and p53 inhibition in adult mammals (Ruzankina et 
al., 2009a). 
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Mouse models have demonstrated that complete inhibition of ATR function 
appears to confer selective synthetic lethality in p53-deficient tissues, making it an 
exciting target for cancer therapy. However, ATR haploinsufficiency also has roles in 
cancer progression, suggesting a narrow therapeutic window for the use of ATRis. In the 
next section, I will discuss the roles of ATR as a putative therapeutic target and also as a 
driver of cancer progression. I will further discuss existing and postulated synthetic 
lethal approaches in cancer therapy, the development of bioavailable ATRis, and their 
current standing in clinical trials.  
1.11. Cancer and the DDR 
DNA damage is inducible from a variety of genotoxic agents. If left unrecognised or 
inappropriately repaired, lesions can result in the stable incorporation of mutations into 
the genome. Deleterious mutations carry the potential to induce aberrant cellular 
behaviour, resulting in malignancies such as cancer (Hoeijmakers 2009). 
The DDR axis inhibits the proliferation of cells lacking genomic integrity, and 
deviations from typical DDR activity are intimately linked with malignant transformation. 
The transformation of pre-malignant cells requires increased rates of mutagenesis, and 
increasing genomic instability generated by compromised DDR function enhances this 
process (Halazonetis et al., 2008). Many hereditary cancer predisposition disorders are 
the result of deleterious germline mutations in DDR proteins or oncogenic effectors, and 
almost all tumours show functional loss or deregulation of DDR proteins (Jeggo et al., 
2016). Most frequently mutated and notable of these DDR proteins are ATM and tumour 
suppressor protein p53 (Cremona and Behrens, 2014; Muller and Vousden, 2013). 
1.11.1. Oncogenes  
The RAS-MAPK pathway is an essential regulator of cell growth, proliferation, 
differentiation and senescence pathways (Aksamitiene et al., 2012). Hence, somatic RAS 
mutations are highly oncogenic, endowing tumorigenic cells the necessary hallmark for 
carcinoma development - self-sufficiency in growth signalling (Pylayeva-Gupta et al., 
2011). Oncogenic activation of RAS through numerous mutations is observed in around 
20% of all cancers (Bos, 1989). Oncogenic RAS isoforms (H-RAS, K-RAS and N-RAS) have 
key roles in malignant transformation, but they also increase the replicative stress 
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burden within the cell due to increased and aberrant gene transcription (Kotsantis et al., 
2016), increasing the cancer cell dependence on ATR. Schoppy et al. and other groups 
have shown ATR inhibition increases cancer cell sensitivity to oncogene-induced 
replication stress, resulting in synthetic lethality (Gilad et al., 2010; Schoppy et al., 2012). 
1.11.2. ATR haploinsufficiency  
Haploinsufficiency of ATR/CHK1 is seen in cancer cells exhibiting high microsatellite 
instability and defective mismatch repair (MMR), most often endometrial, colon and 
stomach cancers (Fang et al., 2004; Lewis et al., 2007; Lewis et al., 2005). Gilad et al. 
demonstrated ATR haploinsufficiency in an oncogenic RAS context could act as a driver 
for oncogenic mutations (Gilad et al., 2010).  
A more recent study has also shown that cancer cell ATR mutations can also 
modulate the tumour microenvironment through altered expression of inflammatory 
genes and increased recruitment of pro-tumorigenic macrophages (Chen et al., 2017). 
The group noted that 7-13% of melanomas appeared to have loss-of-function mutations 
in the ATR signalling pathway (ATR or CHK1). 
Hypomorphic mutations of ATR have been characterised as the underlying 
genetic basis of the disorder ATR-SS. Interestingly, a unique pedigree containing 24 
individuals with defective ATR function has also recently been characterised. The 
affected individuals are heterozygous for germline mutations in ATR, resulting in an 
autosomal-dominant cancer syndrome (Tanaka et al., 2012). The associated condition 
comprised of oropharyngeal cancers, skin telangiectases and mild developmental 
abnormalities of hair, teeth and nails. The authors identified a single mutation 
(c.6431A>G) that occurred within the p53-activating FAT domain of ATR. Cultured 
patient fibroblasts showed a compromised ATR-p53 axis following DNA damage, whilst 
maintaining functional ATR kinase activity. Loss of heterozygosity at the ATR locus was 
noted in the oropharyngeal tumour tissue, suggesting the underlying ATR mutation is 
neomorphic, due to its ability to drive tumour formation (Tanaka et al., 2012). 
The cancer predisposition and telangiectasia aspects of this condition bear 
undeniable similarities to other congenital disorders of the DDR. Mutations resulting in 
the loss of function of ATR homologue ATM underlie neurodegenerative disorder AT, in 
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which ocular, skin and pharyngeal telangiectases are common (Taylor et al., 2015). 
Further, Fanconi anemia, an autosomal-recessive cancer syndrome caused by defects in 
several DDR proteins, many of whom are phosphorylated by ATR, is also associated with 
epithelial cancers (Wang, 2007).  
Further characterisation of this novel mutation in ATR, and the pathological 
consequences of complete homozygosity within an organism is essential. Juxtaposed 
against the ATR-SS mouse, a homozygous mouse model could provide a unique 
opportunity to uncouple the putative, metabolic impacts of reduced ATR function from 
its canonical role in DNA repair. Defects in ATR activity increase genomic instability, 
which can cause either synthetic lethality or enhanced tumorigenesis, dependent on the 
level of ATR activity. They reinforce the importance of genotyping and assessing tumour 
heterogeneity for the effective use of synthetic lethality approaches. Utilising a 
‘personalised’ genetic approach will prove essential in the targeted treatment of cancer 
with ATRis. 
1.11.3. Synthetic lethality  
The DDR carries important implications for the efficacy of cancer therapies. 
Conventional cancer treatments such as chemo- and radiotherapy act as sensitizers - 
targeting proliferating tissues in a relatively non-specific manner by increasing the 
cytotoxic load of DNA damage – cancerous cells are sensitised due to their high 
proliferative activity and genomic instability (Bruce and Jay, 2015). However, the 
relatively non-specific nature of these therapies results in severe side effects, greatly 
limiting their therapeutic window. Cancers can also resist chemo- and radiotherapies 
through the acquisition of further mutations to re-activate various DDR pathways 
(Holohan et al., 2013). Existing DNA damage-based cancer therapies often fail to be 
curative. 
The increased genomic instability seen in cancers, due to defective branches of 
the DDR, has also more recently been widely studied as an exploitable target based on 
synthetic lethal approaches. Synthetic lethality exploits the uniquely exposed 
vulnerabilities in cancer cells that come hand in hand with favourable carcinogenic 
mutations. Defective DDR pathways allow cancers elevated rates of mutagenesis and 
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growth progression, but also drive dependence on the remaining functional DDR 
components to survive the increased burden of genomic instability. Healthy cells carry 
the protective redundancy of multiple, functional DDR pathways. Targeted inhibition of 
the key DDR components that remain in cancer cells results in a highly selective and 
potent toxicity, due to the resulting acquisition of insurmountable DNA damage in the 
absence of an appropriate DDR axis (Beijersbergen et al., 2016; Gilad et al., 2010; 
Iglehart  and Silver 2009). 
The synthetic lethality approach was initially demonstrated in BRCA2- deficient 
cancer cells (Bryant et al., 2005; Farmer et al., 2005). Germline mutations in genes 
BRCA1 and BRCA2 can result in enhanced susceptibility to ovarian, breast and prostate 
cancers. BRCA1/2 are essential for homologous repair (HR) (Powell and Kachnic, 2003) 
– with no functional HR pathway, BRCA2-/- cancer cells show enhanced dependence on 
the repair of DNA SSBs to maintain viability, which can be targeted using small molecule 
inhibitors of PARP1. PARP1 is required for the detection and repair of SSBs via the BER 
pathway, and PARP1 inhibition results in synthetic lethality in BRCA2-/- cancers (Fig 
1.11.3). Cancerous cells enter mitosis with largely incomplete DNA replication and 
experience elevated replicative stress, causing selective cell death (Nghiem et al., 2001). 
The first-in-class PARP inhibitor olaparib was approved for use in BRCA1 or BRCA2 
mutated cancers in 2014, showing milder side effects than conventional therapies 
(Frampton, 2015).  
Figure 1.11.3. Synthetic lethality concept of PARPi on BRCA-defective tumours. Taken from (Iglehart  
and Silver 2009) 
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ATR inhibition has been widely discussed as a potential, novel anti-cancer agent 
due to its selective toxicity profile (Peasland et al., 2011; Reaper et al., 2011). Almost all 
cancer cells have defective G1 checkpoint activity (Ho and Dowdy, 2002). This leads to 
increased dependence on the ATR-dependent intra-S- and G2/M-phase cell cycle 
checkpoints. Whilst G1-proficient cells remain unaffected, impairing ATR function in G1-
defective cells results in premature mitotic entry, mitotic catastrophe and cell death 
(Brown and Baltimore, 2000), hence further enhancing the sensitivity of cancerous cells 
to ATRis.  
ATR appears to be essential for maintaining homeostasis in all proliferating 
tissues (Ruzankina et al., 2007). However, Schoppy et al. found incomplete inhibition of 
ATR (reducing expression to <10%) was sufficient to induce synthetic lethality in RAS-
mutated tumours, without affecting normal proliferative tissues (Schoppy et al., 2012). 
Additionally, Vendetti et al. reported ATRi synergistic killing with cisplatin in K-RAS 
mutant tumours (Vendetti et al., 2015). Jardim et al. also demonstrated that ATR/CHK1-
defective MMR-deficient cells display enhanced sensitivity to 5-fluorouracil, a 
commonly used colorectal chemotherapeutic whose clinical use is limited by drug 
resistance (Jardim et al., 2009). This suggests therapeutic value of using combination 
treatment of 5-fluorouracil and ATR inhibition in MMR-deficient cancers. Collectively, 
this data suggests is a therapeutic window for the use of ATRis in cancer.  
1.11.4. Development of ATR inhibitors (ATRis) and ATRi Clinical trials 
There appears to be remarkable promise for the use of small molecule ATR kinase 
inhibitors (ATRis) in ATM- and p53- defective cancers (Hurley et al., 2006; Ruzankina et 
al., 2009b), as well as effectively enhancing the selective cytotoxicity of other anticancer 
drugs including cisplatin and PARP Inhibitors (Peasland et al., 2011; Reaper et al., 2011).  
 Small molecule kinase inhibitors of ATR have only recently been developed. 
Following from their work in the humanised ATRS/S mouse, Fernandez-Capetillo and 
colleagues developed a cell-based screening approach to identify compounds with ATR 
inhibitory activity (Toledo et al., 2011). Using a retroviral system, in which an inducible 
ATR-stimulating fragment generated enhanced levels of ATR-dependent H2AX 
phosphorylation (H2AX), Toledo et al. investigated the impact of over 600 compounds 
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on ATR activity. Through this technique, the group identified the first compounds with 
selective ATR inhibitory activity, most notably the dual PI3K/mTOR inhibitor NVP-BEZ235 
(Toledo et al., 2011). Within the same year, Peasland et al. characterised ATRi activity of 
the compound NU6027, originally developed as a CDK2 inhibitor (Peasland et al., 2011).  
1.11.4.1. Vertex Pharmaceuticals 
4In 2011 Vertex Pharmaceuticals reported the first highly potent and selective ATRi VE-
821 (Charrier et al., 2011). VE-822 (also known as VX-970 – now acquired by Merck) is a 
VE-821 analogue with improved solubility, potency and selectivity against ATR (Table 
1.11.4.1). Pre-clinical studies utilising these inhibitors have validated ATR as a novel 
therapeutic target in vitro – where treatment sensitized cancer cells to cisplatin, ionising 
Table 1.11.4.1. ATR inhibitor molecular structures. Modified from (Rundle et al., 2017) 
ATR 
kinase 
inhibitor 
II 
12 nM ATM, DNA-PK (IC50 > 8 
µM) 
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radiation, PARP inhibitors and other therapies (Fujisawa et al., 2015; Jossé et al., 2014; 
Prevo et al., 2012; Vávrová et al., 2013). In xenograft models, VE-822 restored cisplatin 
sensitivity to resistant tumours, and both VE-821 and VE-822 synergised with radiation 
and other therapies in pancreatic cancer models (Hall et al., 2014; Reaper et al., 2011).  
1.11.4.2. AstraZeneca 
AstraZeneca also generated potent and highly selective ATRis. AZ20 and its orally 
available analogue AZD6738 (Table 1.11.4.1) were reported in 2013 (Foote et al., 2013). 
AZD6738 is reported to have single agent activity in p53- and ATM- deficient tumours, 
and synergistic anti-tumour activities similar to VE-821 and VE-822 (2015; Vendetti et 
al., 2015). 
1.11.4.3. Clinical Trials 
With proof-of-principle and mechanistic evidence for their therapeutic benefits 
established, VE-822 and AZD6738 are in early phase clinical trials (Table 1.11.4.3). Taken 
intravenously, VE-822 is reported as generally well tolerated as a monotherapy, and in 
combination with carboplatin, with no dose-limiting toxicities. AZD6738 is the first orally 
Table 1.11.4.3 Clinical trials ongoing for ATRis VE-822 and AZD6738 (August 2017). Modified from 
(Rundle et al., 2017) 
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available ATRi to enter clinical trials - recruitment is ongoing for these trials, and there 
are no published preliminary results to date (Rundle et al., 2017). 
1.12. Metabolic consequences of ATR deficiency 
SS patients and mouse models demonstrate that defective ATR seems to affect adipose 
tissue homeostasis (O’Driscoll, 2009), and functions at the mitochondria, in autophagy 
and insulin signalling have been characterised in the literature (Hilton et al., 2015; Li et 
al., 2009; Yi et al., 2017). The presentation of ATR-SS and these novel metabolic 
functions of ATR deliver a potential hurdle for the use of ATR kinase inhibitors as a cancer 
therapeutic, as an invariant feature of cancer is metabolic deregulation (Fearon et al., 
2012).  Consistently in mouse models with reduced ATR and ATR-SS patients, one aspect 
of the presentation is a severe lack of subcutaneous fat, suggesting a failure to maintain 
adipogenic stem cells on an adipogenic program (O’Driscoll, 2009; O’Driscoll et al., 
2004). Currently there is very limited understanding of the underlying mechanisms in 
which a congenital defect in ATR function affects adiposity or metabolism. 
Evidence characterising novel links between the cellular metabolism pathways 
controlled principally by PIKK member mTOR, and DNA repair mechanics primarily 
regulated by ATR and ATM, is mounting (Xu et al., 2012). Although further 
characterisation is required for a mechanistic understanding of the processes that 
associate these PIKK-regulated pathways, what can be elucidated is that the ATR-CHK1 
signalling axis is fundamentally affected by cellular metabolic status. This begs the 
question of whether a feedback mechanism could exist here, where ATR activity is also 
an effector of AKT-mTOR activity and general cell metabolic homeostasis.  
The potential unforeseen metabolic consequences of ATRi therapy are of 
particular concern due to the inherent metabolic deregulation associated with cancer 
progression, which I will continue to discuss in the next section. 
1.12.1. Cancer Cachexia 
Cachexia is a chronic disease concomitant with metabolic dysfunction. A considerable 
comorbidity of cancer, cachexia is defined as the progressive wasting of muscle and 
adipose tissue regardless of adequate nutritional intake (von Haehling and Anker, 2014). 
Widely acknowledged as a marker for poor prognosis and outcome, research into anti-
cachexia therapeutics reflect the complexity of the signalling factors and regulatory 
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pathways involved in nutrient-status recognition, lipolysis and white adipose tissue 
(WAT) ‘browning’. Cachexia is particularly prevalent in advanced cancers – manifesting 
in 50-80% of all cancer patients and accountable for 20% of mortalities (von Haehling 
and Anker, 2014). Cachexia is a multi-faceted disorder, associated with resistance to 
traditional cancer therapies and in itself appears to be refractory to clinical intervention 
(Fearon et al., 2012). The ‘browning’ of WAT has been implicated as one of the 
underlying molecular mechanisms of cancer cachexia (Fig 1.12.1) (Argiles et al., 2014; 
Fearon et al., 2012; Kir et al., 2014; Tsoli et al., 2012). Increased brown adipose tissue 
(BAT) leads to greater resting energy expenditure in cachexic patients, due to the 
inherent thermogenic activity of this tissue type, resulting in muscle and adipose tissue 
wasting (Bing et al., 2000). The underlying mechanism(s) that cancers utilise to induce 
adipose browning is a current topic in cachexia research, and to date remains 
incompletely characterised at the molecular level.  
Figure 1.12.1. Cancer Cachexia. Through multiple mechanisms, cancer cells promote WAT browning, 
resulting in enhance lipid mobilisation and energy expenditure, generating the cachexic presentation 
of severe weight loss. Taken from (Petruzzelli et al.) 
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Successful tumours are capable of inducing mass hydrolysis of triglycerides (TGs) 
stored in WAT for utilisation of free fatty acids (FFAs) and glycerol. This results in the 
release of fatty acids (FAs) into the plasma, that can be utilised by cancerous cells for 
the increasing rates of FA -oxidation required to sustain proliferation. The dependency 
of non-glycolytic cancer cells on FA oxidation is enhanced in hypoxic and low-nutrient 
tumour microenvironments (Kamphorst et al., 2013).  
Further to this, alterations increasing the avidity of lipid synthesis, metabolism 
and LD formation are also gaining recognition as hallmarks of highly proliferative 
cancers, appearing to increase resistance to chemotherapy (de Gonzalo-Calvo et al., 
2015; Qiu et al., 2015; Yue et al., 2014). Changes in cancer cell lipid membrane 
composition, from unsaturated to saturated phospholipids, can fundamentally alter 
membrane fluidity and signal transduction, potentially blocking the uptake of 
chemotherapeutic drugs (Rysman et al., 2010). Bioactive lipids influence many 
tumorigenic cellular processes, including cell growth, migration and metastasis. For 
example, sphingosine-1-phosphate (S1P) induces angiogenesis via S1P receptor binding, 
facilitating growth and metastasis (Kunkel et al., 2013). Hence, changes in the lipidomic 
status of cancer cells are affiliated with tumour progression (Fig 1.12.2).  
Figure 1.12.2. Simplified schematic of lipid-metabolic reprogramming in cancer. Cancer cells signal to 
adipocytes to undergo lipolysis, autophagy and browning to increase the volume of metabolites 
available for growth. Modified from (Hoy et al., 2013) 
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Therapeutic strategies must be considered to carefully target and exploit the 
metabolic reprogramming and dependency on altered lipid utilisation and FA oxidation 
observed in many types of cancer. Furthermore, the metabolic consequences of novel 
therapies such as ATRis must be carefully considered, to avoid deleterious changes that 
could induce metabolic dysfunction. Changes in host metabolism (to increased catabolic 
events) could behave as a driver for tumour progression and cachexia, through the 
enhanced provision of bioactive lipids and metabolites from the dissolving WAT. 
In this thesis, I aimed to investigate the consequence of reduced ATR activity on the 
functionality of post-mitotic white adipocytes, and cycling preadipocytes. I also 
investigated the effects of ATRi treatment as preadipocytes undergo adipogenic 
differentiation. 
In Chapter Three, I investigate the effects of ATRi treatment on differentiating 
preadipocytes, assessing their capacity to successfully undertake adipogenesis. 
In Chapter Four, I assess the consequences of chronic ATRi treatment on the lipid-
metabolic status of mature adipocytes. 
In Chapter Five, I characterise novel defects following reduced ATR function in cycling 
preadipocytes. 
In Chapter Six, I further characterise the phenotypes I have discovered by assessing the 
impact of ATRi on endoplasmic reticulum (ER) function. 
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2. Chapter Two 
Materials and Methods 
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2.1. Cell culture 
Cell lines were thawed from liquid nitrogen in a 37oC waterbath and re-suspended in 
appropriate medium. All cells were maintained in a humidified atmosphere at 37oC in 
5% CO2. To split cultures, adherent cells were washed 1X in PBS and incubated in 0.25% 
trypsin-PBS at 37oC until completely detached. Fresh media was added to the cell 
suspension to neutralise trypsin before centrifugation at 1800g for 2 min. Cell pellets 
were re-suspended in an appropriate volume of fresh culture medium and plated. For 
storage in liquid nitrogen, ~1x107 cells were pelleted, re-suspended in 1ml of medium 
supplemented with 10% DMSO (except from 3T3-L1s – 5% DMSO), and transferred to 
cryotubes. Cryotubes were then cooled slowly to -80oC before being transferred into 
liquid nitrogen storage. 
3T3-L1 preadipocytes were cultured in DMEM supplemented with 10% new born calf 
serum (NBCS), L-Glutamine (2mM), penicillin (500 U/ml) and streptomycin (50mg/ml). 
To reduce adipogenic induction arising from growth arrest, flasks were split before cells 
reached 80% confluence, and passage number would be increased. At passage >20, cells 
were no longer used for adipogenic differentiation. 
HEK-293 cells were cultured in DMEM supplemented with 10% foetal calf serum (FCS), 
L-Glutamine (2mM), penicillin (500 U/ml) and streptomycin (50mg/ml)  
MG63 cells were cultured in MEM supplemented with 10% FCS, L-Glutamine (2mM), 
penicillin (500 U/ml) and streptomycin (50mg/ml)  
C2C-12 cells were cultured in DMEM supplemented with 10% FCS, L-Glutamine (2mM), 
penicillin (500 U/ml) and streptomycin (50mg/ml)  
Cell Line Source/Reference  
3T3-L1 (murine 
preadipocytes) GDSC cell bank 
C2C12 (murine myoblasts) Prof. Simon Morley, School of Life Sciences, University of 
Sussex, UK 
HEK-293  GDSC cell bank 
MG63 (human 
osteosarcoma) American Type Culture Collection (ATCC) 
RPE (retinal pigment 
epithelium)  GDSC cell bank 
Table 2.1. Cell lines utilised in this thesis. 
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RPE cells were cultured in DMEM:F12 supplemented with 10% FCS, L-Glutamine 
(2mM), penicillin (500 U/ml) and streptomycin (50mg/ml)  
2.2. Adipogenic differentiation of 3T3-L1 preadipocytes 
3T3-L1 preadipocytes were cultured as previously described. To induce adipogenic 
differentiation, 3T3-L1 preadipocytes were plated at 90% confluency and allowed up to 
7 days to reach a post-confluent state before addition of adipogenic cocktail. Adipogenic 
cocktail (1 g/ml insulin (I2643), 0.5 mM isobutylmethylxanthine (IBMX – I5879), 1 mM 
dexamethasone (D4902), 2 g/ml Rosiglitazone (R2408) all purchased from Sigma-
Aldrich) was added to a basal medium (DMEM with 10% FCS, penicillin/streptomycin) 
on day 1. Adipogenic cocktail was refreshed after 24 hrs (day 2). On day 3, media was 
supplemented with 5 g/ml insulin. On day 4, media was replaced for fresh basal 
medium supplemented with 1 g/ml insulin. On day 5, media was replaced for basal 
medium only. Mature adipocytes were left for 4-7 days to acquire lipid droplets before 
experiments were initiated. 
2.3. Extract preparation 
2.3.1. Urea-based whole cell extract 
Cells were washed 1X in PBS, pelleted and stored immediately at -20°C. Cell pellets were 
then re-suspended in urea-based lysis buffer (9M urea, 50mM Tris-HCl pH7.5, 10mM β-
mercaptoethanol), and sonicated for 10-15 seconds at 30% amplitude.  
2.3.2. IP extracts 
Freshly pelleted cells were resuspended in 100-300μL IP buffer (50mM Tris.HCl pH7.5, 
150mM NaCl, 2mM EDTA  
50mM NaF, 25mM β-glycerolphosphate, 0.1mM sodium orthovanadate, 0.2% Triton-
X100, 0.3% Igepal, protease inhibitor cocktail (11836170001 Roche)) and incubated on 
ice for 1hr. 
Cell lysates were then centrifuged (3 min, 13,000 rpm, 4°C) and supernatant transferred 
to a pre-cooled eppendorf. Protein concentration of lysates was determined using the 
Bradford Protein Assay reagent (Bio-Rad Laboratories) at a UV absorbance of 595nm. 
Lysates were stored at -20°C or boiled in 5X SDS-loading buffer (5% SDS, 10% Glycerol, 
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10% β-mercaptoethanol, 125mM Tris-HCL pH6.8 and 0.2% bromophenol blue) and 
loaded onto SDS-PAGE gels. 
2.4. Cell fractionations 
 All cell fractionations were prepared on ice using a 4°C centrifuge.  
2.4.1. Endoplasmic Reticulum (ER) fractionation 
ER were fractionated from HEK 293 cells using Endoplasmic Reticulum Isolation Kit 
(ER0100 Sigma). 2x108 PBS-washed cells were re-suspended in hypotonic buffer 
provided (3x volume of cell pellet) and incubated for 20 min at 4°C before being spun at 
600g for 5 mins. Pellets were then re-suspended in isotonic buffer provided (2x volume 
of cell pellet) and homogenised using 10 strokes in a Dounce tissue homogenizer (D9063 
Sigma). 5% of each lysate was collected at this point as the whole cell extract. Samples 
were spun at 1000g for 10 min and supernatant transferred to a clean, cold tube. Pellets 
were collected and stored at -20°C as the crude nuclear fraction. Samples were spun at 
12,000g for 15 mins and 10% of the post-mitochondrial supernatant fraction (PMF) was 
stored at -20°C for further analysis. The remaining PMF was transferred to a suitable 
tube with enough space for the addition of 7.5X sample volume. ER were further 
enriched from this fraction using the CaCl2 precipitation method - with vigorous 
agitation, 8mM CaCl2 (7.5X sample volume) was added to the PMF and incubated for 15 
mins to precipitate ER. Samples were spun at 8,000g for 10 mins with the rough-ER 
microsomes enriched in the final pellet. 
2.4.2. Nuclear/Cytoplasmic fractionation 
8x106 PBS-washed cells were re-suspended in 900mL ice-cold buffer (0.1% NP40-
IGEPAL/PBS, Roche complete EDTA-free protease inhibitor tablet). 300mL of cell lysate 
was transferred to a cold tube, sonicated (15 seconds at 30% amplitude), centrifuged 
(13,000 rpm, 3min) and stored at -20°C as WCE. The remaining 600ml of cell lysate was 
pulse spun for 10 secs and the top 300ml of supernatant removed and transferred to a 
fresh tube (cytoplasmic fraction). The remaining supernatant was discarded and the 
nuclear pellet washed 5X in ice-cold PBS before resuspension in urea buffer and 
sonication as previously described. 
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2.5. siRNA knockdowns 
All siRNA oligonucleotides used were SMARTpool siGENOME siRNA (Dharmacon). 3T3-
L1 cells were transfected using METAFECTENE® PRO (Cambio) and Lipofectamine 
RNAiMAX (13778075 ThermoFisher Scientific) according to manufacturer’s instructions. 
With the exception of siRNA mediated knockdown of Atr in confluent 3T3-L1 
preadipocytes, all siRNA was transfected into a suspension of logarithmically growing 
cells. Following trypsinisation, 3.5x105 cells were re-suspended in 3mL of fresh, warm 
media to which the siRNA:lipid complex mixture was added. Media would be refreshed 
after 6h and cells would be analysed at 24h or 48h post transfection. 
Target Transfection reagent Oligo Ref/NCBI accession number 
Atr Lipofectamine RNAiMAX  M-062167-01-0005; NM_019864.1 
p62/Sqstm1 METAFECTINE® PRO M-047628-01-0005; NM_001290769.1 
Atg12 METAFECTINE® PRO M-050953-01-0005; NM_026217.3 
Atg16L1 METAFECTINE® PRO M-051699-01-0005; NM_001205391.1 
2.6. cDNA overexpression 
2.6.1. METAFECTINE PRO 
T25 flasks were seeded with 3.5x105 3T3-L1 cells and left overnight for cells to adhere. 
DNA was mixed with serum free media (SF) (3.75mg of DNA in 100mL SF) and added to 
the reagent mixture (7.5mL METAFECTINE PRO in 100 SF) and incubated 20 mins at RT. 
The DNA:lipid complex mixture was added to each flask and media refreshed 4 hrs post 
transfection. Samples were harvested for analysis 24h or 48hrs post transfection.  
2.6.2. Calcium Phosphate 
HEK-293 cells were seeded at 40% confluency in 10cm plates and allowed to become 
fully adherent overnight. A DNA mixture (5mg DNA, 61ml 2M CaCl2 and 435uL ddH2O) 
was prepared and added dropwise into 500ml bubbled 2XHBS (50mM HEPES, 280mM 
NaCl, 2.8mM Na2HPO4) for each plate. The final mixture was added dropwise onto each 
10cm plate. After 24hrs, plates were gently washed 1X in PBS and media refreshed. The 
following day, plates were harvested for ER fractionation- or immuniprecipitation-based 
analysis. 
Table 2.5. siRNA oligonucleotides utilised in this thesis 
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2.6.3. Lipofectamine® 3000 Transfection  
 6-well plates were seeded with 2x105 3T3-L1 cells/well and allowed to become 
adherent. A DNA mixture (2 g DNA, 4L P3000 Reagent, 100 L SF) was prepared and 
added to the reagent mixture (2 L Lipofectamine 3000, 100 L SF) and incubated for 
15 mins at RT. The DNA:lipid complex was added directly to each well and media was 
refreshed 4 hrs post transfection. Samples were harvested for analysis 24 or 48 hrs post 
transfection. 
2.7. FLAG-Immunoprecipitation 
Using the Calcium Phosphate method previously described, HEK 293 cells were 
transfected with various cDNA constructs encoding a FLAG-tagged protein of interest. 
Samples were lysed in IP extraction buffer as previously described. To equilibrate before 
immunoprecipitation, ANTI-FLAG® M2 Affinity Gel (Sigma A2220) beads were washed 3X 
in ice-cold IP buffer with centrifugation of 1000 g for 1 min at 4°C. 350-500 g of cell 
lysate was then immunoprecipitated with 25-40 L washed ANTI-FLAG® M2 Affinity Gel 
beads in a final volume of 500 L. The mixture was agitated for 1-2 hrs at 4°C. After 
centrifugation at 1000 g for 1 min at 4°C, unbound/flowthrough supernatant was 
collected and stored at -20°C for further analysis. ANTI-FLAG® M2 Affinity Gel beads and 
bound proteins were washed 2X in ice-cold IP buffer and 1x in ice-cold TBS before bound 
proteins were eluted with 3X FLAG peptide (Sigma F4799) described below.  
2.8. 3X FLAG peptide elution 
FLAG-tagged proteins were eluted from ANTI-FLAG® M2 Affinity Gel beads via 2X serial 
elution steps with 40-80 L of 100 g/ml 3X FLAG peptide in TBS (50 mM Tris-HCl, pH 
7.4, 150 mM NaCl). Each elution lasted 15 mins at 4°C with agitation throughout. 
Plasmid  Source/Reference   
ATR A generous gift from Tony Carr, GDSC 
ATR-CT 
A generous gift from Atsushi Higashitani, Institute of Genetic Ecology, Tohoku 
University 
ATR-D6 
ATR-KD 
Calnexin RC200229 Origene 
RHEB RC200307 Origene 
VPS4b RC208019 Origene 
Table 2.6.3. cDNA constructs utilised in this thesis 
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Samples were then spun (1000 g, 1 min, 4°C), and supernatant removed. Elution steps 
were ‘pooled’ together and boiled for 10 mins at 96°C in an appropriate volume of 5X 
SDS loading buffer. Remaining ANTI-FLAG® M2 Affinity Gel beads were then washed 2X 
in IP buffer, resuspended in ~60 L IP buffer and 15 L 5X SDS loading buffer and boiled. 
All samples were stored at -20°C for further analysis or loaded directly onto SDS-PAGE 
gels. 
2.9. SDS-PAGE/Western blotting 
Protein gels and western blotting were carried out using the Bio-Rad Mini-PROTEAN III 
gel system. Protein extracts (5-50 g) were boiled and denatured in SDS loading buffer 
as previously described, and resolved by SDS-PAGE (Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis) on acrylamide gels (6-15% with 4% stacking gel). 
Gels were resolved at 120-220V in TGS running buffer (25 mM Tris-HCl, 250 mM Glycine, 
0.1% (w/v) SDS), with Precision Plus Protein Prestained Dual Colour Standards (1610374 
Bio-Rad) used as a molecular weight marker. Following adequate resolution, gels were 
transferred onto a PVDF membrane (1620177 Bio-Rad) using Trans-blot SD Semi-Dry 
Transfer Cell (1703940 Bio-Rad) in semi-dry transfer buffer (20% methanol, 30 mM Tris-
HCl, 200 mM Glycine 0.03% SDS) for 1-2 hrs at 100A. Membranes were blocked in 5% 
BSA (unless stated otherwise) in TBS with 0.2% Tween-20 (TBS-T) for 45 minutes. 
Membranes were then probed with primary antibody in 5% BSA/TBS-T overnight at 4°C 
on an orbital shaker. Membranes were washed 3X in TBS-T for 7 min and probed with 
HRP-conjugated secondary antibodies (DAKO) for 45 mins before a further 3X TBS-T 
washes. Proteins were detected on Amersham Hyperfilm (28906836 GE Healthcare Life 
Sciences) using enhanced chemiluminescence (Amersham ECL Prime Reagent RPN2232, 
SLS, or SuperSignal™ West Femto Maximum Sensitivity Substrate 34096, ThermoFisher 
Scientific). 
2.10. Site directed mutagenesis 
Site directed mutagenesis were completed using the QuikChange II Site-Directed 
Mutagenesis Kit (#200524 Agilent). Oligonucleotides were purchased from Eurofins 
Genomics.  
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Following the mutagenic PCR reaction, Dpn1 was added to samples to digest parental 
DNA at 37oC overnight. Following restriction enzyme digest, samples were purified using 
QIAquick PCR Purification Kit (28104 Qiagen) before transformation into E.Coli using the 
heat shock method. Transformed E.Coli were streaked onto agar plates supplemented 
with the appropriate resistance marker and left overnight at 37oC for colonies to 
develop. Single colonies were selected and amplified overnight for sequencing. Plasmid 
DNA was extracted from amplified colonies using QIAprep Spin MiniPrep Kit (27104 
Qiagen) and sent for Sanger sequencing at GATC Biotech. E.Coli samples successfully 
containing the appropriate mutation were then re-amplified overnight and plasmid DNA 
extracted using QIAGEN Plasmid Maxi Kit (12163 Qiagen) ready for transfection into 
mammalian cells. 
2.10.1. Agarose gel electrophoresis 
0.8-1.2% agarose gels were made by dissolving Ultrapure Electrophoresis Grade Agarose 
(Invitrogen) in 1XTAE buffer (0.4 M Tris acetate, 1 mM EDTA, 0.3 g/ml ethidium 
Table 2.10.2. Mutagenic PCR reaction conditions 
 
Table 2.10.1. Mutagenic PCR reaction mix per sample 
Table 2.10.3. Mutagenic PCR primers 
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bromide). Ethidium bromide was added to the cooled mixture after it had been heated 
to dissolve agarose. Samples were prepared in loading buffer (Orange G, O3756 Sigma) 
and resolved in TAE buffer (40 mM Tris, 20 mM Acetate, 1 mM EDTA) alongside a 1kb 
DNA ladder (Invitrogen). DNA was visualised using a UV transilluminator.  
2.11. Triglyceride and Free Fatty Acid Quantification 
2.11.1. Oil Red O 
Lipid content of mature 3T3-L1 adipocytes was quantified using histochemical lipid stain 
Oil Red O (O0625 Sigma). 3T3-L1 adipocytes were differentiated as previously described 
in 6 well plates, fixed in 10% formalin for 1 hr and washed 2X in ddH2O. Samples were 
incubated in 60% isopropanol for 5 minutes and left to dry fully at RT. Working solution 
of Oil Red O was prepared according to manufacturer’s instructions and 1 mL added per 
well for 10 mins. Oil Red O solution was aspirated and plates were gently dipped in 
ddH2O 3-5X to wash excess Oil Red O without disturbing the fragile cell monolayers. At 
this stage microscopy images were acquired for analysis. To elute Oil Red O, plates were 
dried fully at RT before addition of 1 ml 100% isopropanol for 5 mins with gentle 
agitation. The Oil Red O/isopropanol solution was then transferred to a cuvette and 
quantified at a UV absorbance of 500nm. 
2.11.2. Media Triglyceride Quantification 
Media triglyceride was quantified using PicoProbe Triglyceride Quantification Assay Kit 
(Fluorometric) (ab178780 Abcam). T25 flasks of 3T3-L1 preadipocytes were 
differentiated in 6 mL adipogenic media as previously described. Daily throughout cell 
culture treatments, 100 L media (1.7% total volume) was removed from each flask and 
stored at -20°C for further analysis, and 100 L fresh media added back containing the 
appropriate drug concentration. Upon completion of timecourse, media samples were 
thawed and spun at 13,000 g for 2 mins to remove cell debris. Media samples were 
prepared for analysis on a 96 well plate according to manufacturer’s instructions and 
quantified using a fluorescence microplate reader at Ex/Em = 535/587 nm. 
2.11.3. Free Fatty Acid (FFA) Quantification 
Media FFA was quantified using Free Fatty Acid Quantification Kit (ab65341 Abcam). 
Samples were collected as described previously for quantification of media triglycerides. 
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Samples were prepared on a 96 well plate according to manufacturer’s instructions and 
quantified using a fluorescence microplate reader at (Ex/Em = 535/587 nm). 
2.12. Cell Viability Assays 
CellTiter-Blue® Cell Viability Assay (G8080 Promega) and Cell Counting Kit – 8 (96992 
Sigma) were applied directly to samples in a 96 well plate according to manufacturer’s 
instructions and done in duplicate to increase reliability. CellTiter-Blue fluorescence was 
quantified using a fluorescence microplate reader at Ex/Em = 579/584 nm. Cell Counting 
Kit – 8 absorbance was measured at 450 nm using a microplate reader. Samples were 
incubated until readings reached a linear range (1-4 hrs), which was cell-type 
dependent. The linear range of fluorescence/absorbance was established via generation 
of a standard curve from samples of known cell numbers.  
2.13. Immunofluorescence 
Cells mounted on coverslips were washed 2X with PBS and fixed using 3.7% 
paraformaldehyde for 10 mins a RT followed by 2X PBS washes. Samples were 
permeablised by the addition of 100 L of lysis solution (0.2% Triton X-100/PBS) for 
strictly 2 mins following by 2X PBS washes. Cells were blocked by addition of 100 L 5% 
BSA/PBS for 10 mins followed by 1X PBS wash. Cells were treated with 100 L primary 
antibody (dilutions determined in Table 2.15.2) in 5% BSA/PBS for 0.5-2 hrs at RT 
followed by 3X PBS washes. Cells are exposed to a second blocking step (5% BSA/PBS, 
10 mins RT) and washed 1X in PBS before addition of the appropriate fluorescently-
labelled secondary (1:200 in 5%BSA/PBS) for 30 mins. At this stage (if required) DAPI and 
fluorescently-conjugated Phalloidin (dilutions determined in Table 2.15.2) would be 
directly added to the slides without a wash step and incubated for 15 mins at RT. 
Samples would be subjected to 4X PBS washes before mounting with VectaSheild (H-
1000 VECTOR LABORATORIES LTD.), with slides sealed with nail polish.  
Image acquisition was carried out under two microscopes: 
- Zeiss AxioObserver Z1 epifluorescence microscope equipped with ApoTome2 
structured illumination system, 40x/1.3 oil Plan-Apochromat, 63x/1.4 oil Plan-
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Aprochromat and 100x/1.4 oil Plan-Aprochromat objectives and a Hamamatsu ORCA-
Flash4.0 LT camera. 
- Zeiss AxioPlan 2 epifluorescence microscope equipped with 10x/0.3 NA PLAN-
NEOFLUAR, 40x/0.75 NA PLAN-NEOFLUAR and 100x/1.4 NA oil PLAN-APOCHROMAT 
objectives and a Hamamatsu photonics KK CCD camera.  
2.14. Fluorescent Probes  
BODIPY 493/503, MitoTracker Red CMXRos, MitoTracker Green FM, Calcium Green-1 
AM and MitoSox Red were used according to manufacturer’s instructions at stated 
dilutions to selectively stain live cells for analysis by flow cytometry. Cells were stained 
whilst in suspension and filtered through a BD FACs falcon tube to ensure single cell 
suspension. All FACs data was collected on a BD Accuri C6 flow cytometer using BD 
Accuri C6 software. Fluorescent probes stated in table x were used according to 
manufacturer’s instructions at stated the dilutions to selectively probe cells for analysis 
by fluorescence microscopy. 
2.15. Reagents 
Reagent Cat. No. Supplier 
3-Methyladenine M9281 Sigma 
AlbuMax 11021-029 Life Technologies 
ATMi (KU55933) KU-55933 Stratech 
ATR kinase inhibitor II 118510 Merck Chemicals 
Probe Cat No. Supplier Dilution (IF/FC) Function 
BODIPY 493/503 D3922 ThermoFisher Scientific 2 μM IF/FC Neutral lipid stain 
Lysosensor Green DND-
153 L7534 ThermoFisher Scientific 1 μM IF Fluorescence at neutral pH 
Mitotracker Red CMXRos M7512 ThermoFisher Scientific 250nM FC/IF Mitochondrial visulaisation 
Alexa Fluor® 488 
Phalloidin  #8878 Cell Signalling 1:200 IF Cytoskeleton stain 
DyLight™ 554 Phalloidin #13054 Cell Signalling 1:200 IF Cytoskeleton stain 
Acridine Orange A9231 Sigma-Aldrich 1mM IF 
Bright fluorescence in 
acidic compartments 
DAPI D9542 Sigma-Aldrich 20ng/ml IF DNA probe 
MitoTracker Green FM M7514 ThermoFisher Scientific 250nM FC Mitochondrial Mass 
Calcium Green™-1, AM, 
cell permeant C-3012 Life Technologies Ltd 2.5mM FC Calcium indicator 
Table 2.14. Fluorescent probes utilised in this thesis 
 
56 
 
 
 
Bafilomycin A1 B1793 Sigma 
BAPTA A4926 Sigma 
BAPTA-AM A1076 Sigma 
CSA 30024 Sigma 
Cyclodextrin H107 Sigma 
Dexamethasone D4902 Sigma 
HydroxyUrea H8627  Sigma 
IBMX I5879 Sigma 
Insulin 91077C Sigma 
Lovastatin 1530 Tocris 
Obatoclax S1057 Selleckchem 
Rosiglitazone R2408 Sigma 
Thapsigargin T9033 Sigma 
UCN-01 U6508 Sigma 
VE-821 S8007-SEL  Selleckchem 
VE-822 S7102-SEL Selleckchem 
 
 
Antibody Cat No. Supplier Dilution WB/IF 
53BP1 A300-272A Bethyl 1:200 IF 
AKT #4691 Cell Signaling 1:1000 WB 
AMPK  #2532 Cell Signaling 1:1000 WB 
ATF2 sc-6233 Santa Cruz 1:1000 WB 
ATF4 #11815 Cell Signaling 1:1000 WB 
ATF6 #65880 Cell Signaling 1:1000 WB 
ATG12 #2011 Cell Signaling 1:1000 WB 
ATG16L1 #8089 Cell Signaling 1:1000 WB 
ATM #2873 Cell Signaling 1:1000 WB 
ATR sc-1887 Santa Cruz 1:1000 WB 
ATR (IF) GTX116010 GeneTex 1:500 IF 
ATRIP  sc-33790 Santa Cruz 1:1000 WB 
-tubulin ab4074 Abcam 1:10,000 WB 
acetylated tubulin T7451 Sigma 1:1500 IF 
-actin #4967 Cell Signaling 1:1000 WB 
BiP ab21685 Abcam 1:2000 WB 
-tubulin sc-9104 Santa Cruz 1:2000 WB 
C/EBP  #3087 Cell Signaling 1:1000 WB 
CHK1 #2360 Cell Signaling 1:1000 WB 
CREB #4820 Cell Signaling 1:1000 WB 
DRP1 #8570 Cell Signaling 1:1000 WB 
eIF2 #9722 Cell Signaling 1:1000 WB 
FLAG  F3165  SIGMA 1:5000 WB 
H2AX  #9718 Cell Signaling 1:1000 WB 
GFP #2555 Cell Signaling 1:500 WB 
Table 2.15.1. Reagents utilised in this thesis. 
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H2A #2578 Cell Signaling 1:1000 WB 
IRS1 #2382 Cell Signaling 1:1000 WB 
KAP1 A300-274A BETHYL 1:1000 WB 
Lamin B sc-6216 Santa Cruz 1:1000 WB 
LAMP1 ab24170 Abcam 1:1000 WB/ 1:1000 IF 
LC3  #4599 Cell Signaling 1:1000 WB/1:100 IF 
p44/42 MAPK  #9101 Cell Signaling 1:1000 WB 
p62 #5114 Cell Signaling 1:1000 WB 
p-AKT S473  #4060 Cell Signaling 1:1000 WB 
p-AKT T308 #4056 Cell Signaling 1:1000 WB 
p-AMPK T172  #2535 Cell Signaling 1:1000 WB 
p-ATF2 T71 #9221 Cell Signaling 1:1000 WB 
p-ATR T1989 GTX128145 GeneTex 1:1000 WB 
p-CAMKII T286 #12716 Cell Signaling 1:1000 WB 
p-Chk1 S345  #2341 Cell Signaling 1:500 WB 
p-CREB S121  16589  Pierce 1:1000 WB 
p-CREB S133 #9191 Cell Signaling 1:1000 WB 
PDI  ab2792 Abcam 1:1000 WB/1:500 IF 
p-eIF2a S51 #3398 Cell Signaling 1:1000 WB 
PERILIPIN A #9349 Cell Signaling 1:1000 WB/1:100 IF 
PGC1 ab54481 Abcam 1:1000 WB 
p-H3 S10  Sc-8656 Santa Cruz 1:1000 WB 
p-HSL S563 #4139 Cell Signaling 1:1000 WB 
p-IRS1 Y989 sc-17200 Santa Cruz 1:500 WB/1:50 IF 
p-KAP1 S824 A300-767A Bethyl 1:1000 WB 
p-MAPKAP2 T334 #3007 Cell Signaling 1:1000 WB 
p-p38 MAPK TT180/Y182 #4511 Cell Signaling 1:1000 WB 
PPAR #2443 Cell Signaling 1:1000 WB 
Pre-Lamin A/Lamin A sc-6214 Santa Cruz 1:1000 WB/1:100 IF 
p-S6 S240/S244 #5364 Cell Signaling 1:1000 WB 
p-SQ/TQ #2851 Cell Signaling 1:500 WB 
p-SQ/TQ *QG #6966 Cell Signaling 1:500 WB 
RAB7 #9367s Cell Signaling 1:1000 WB/1:100 IF 
RCAS1 #12290 Cell Signaling 1:200 IF 
S6 #2217 Cell Signaling 1:1000 WB 
Syntaxin 6 #2869 Cell Signaling 1:50 IF 
TFEB A303-673A Bethyl 1:1000 WB 
UCP2 sc-6526 Santa Cruz 1:1000 WB 
UCP1 ab23841 Abcam 1:1000 WB 
WIPI1 ab128901 Abcam 1:1000 WB 
XBP-1s #12782 Cell Signaling 1:1000 WB 
 
 
 
Table 2.15.2. Antibodies utilised in this thesis. 
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3. Chapter Three 
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Inhibition of ATR on Adipogenesis 
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3.1. Introduction 
A hypomorphic splicing mutation in ATR was the first identified mutation 
associated with Seckel Syndrome (SS) (O'Driscoll et al., 2003). Growth retardation and 
lipodystrophy are, amongst others, key striking clinical features of this microcephalic 
primordial dwarfism (MPD) disorder (Fig 3.1.A). Further to this, mice generated from 
humanised model of ATR-SS die within 6 months displaying cachexia (Fig 3.1.B) (Murga 
et al., 2009). 
A ‘cell autonomous’ role for ATR in maintaining adiposity has been previously 
described. Ruzankina et al. investigated the effects of Atr deletion on adult mice; 
generating a tamoxifen-inducible Atr knockdown system that could efficiently delete 
ATR both spatially and temporally within the mouse (Ruzankina et al., 2007). Through 
this system, Ruzankina et al. were able to identify new characteristics of ATR deficiency 
not associated with reduced ATR during development. Atr deletion in adult mice ablated 
canonical ATR-CHK1 signalling at the intra-S-phase checkpoint, required for the effective 
maintenance and replication of proliferating stem cell populations. Reduced ATR 
functionality caused the depletion of proliferative stem cell precursors, necessary for 
tissues that require constitutive regeneration e.g. skin, white adipose tissue (WAT), and 
intestinal epithelia, resulting in atrophy of these tissues (Ruzankina et al., 2007). 
However, within the same study, the group further described a striking and 
disproportionate atrophy of non-proliferative, terminally differentiated WAT following 
Figure 3.1. ATR-SS has the clinical feature of lipodystrophy. A) ATRIP-SS patient at 2 years, displaying 
lipodystrophy visible in the face and neck. B) Humanised ATR-SS mouse recapitulated the MPD 
presentation of SS and died at 6 months displaying a cachexic presentation. Images taken from (Ogi 
et al., 2012) and (Murga et al., 2009) 
A B 
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Atr deletion (Fig 3.2.A and B). This is an unusual result, as mature adipocytes are Go and 
do not require the cell cycle checkpoint functions of ATR.  
The cachexic-like appearance observed in SS, and mouse models of ATR 
deficiency, imply reduced ATR function has consequences on the homeostatic regulation 
of metabolism. The aetiology behind these metabolic consequences of ATR deficiency, 
further observed in SS and other models, has not been adequately explored. 
To reinforce the importance of investigating the consequences of impaired ATR 
function on metabolism, one must consider the use of small molecule inhibitors of ATR 
as novel cancer chemotherapeutic agents. An inherent aspect of almost all late-stage 
cancers is metabolic dysregulation and reprogramming (Hsu and Sabatini, 2008). 
Through poorly characterised mechanisms, catabolic processes become uncoupled from 
their regulatory networks, resulting in the net benefit of increased nutrients available to 
the tumour to facilitate further growth. Such drastic metabolic reprogramming results 
Figure 3.2. Atr deletion in adult mice results in disproportionate wasting of adipose tissue. A)  
Tamoxifen-inducible Atr deletion in adult mouse. Top row demonstrates Atr-proficient mice, bottom row 
is Atr deletion mouse following 3 months to 1 year of tamoxifen where accelerated ageing and weight 
loss are apparent. B) Skin sections from Atr-proficient and Atr-deletion mice following tamoxifen. Atr 
deletion results in striking atrophy of subcutaneous adipose tissue (labelled A) Taken from (Ruzankina et 
al., 2007) 
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in a co-morbidity characterised by severe weight loss – cancer cachexia (Argiles et al., 
2014).  
Investigating the aetiology of ATR deficiency-induced lipodystrophy could 
provide novel insight for the outcomes of individuals utilising prolonged and high doses 
of small molecule kinase inhibitors of ATR (ATRis) as a cancer therapeutic. ATRi usage in 
cancer could have unforeseen negative impacts, through the disruption of WAT 
homeostasis, driving a cachexic presentation which is commonly associated with poor 
outcomes and the development of therapeutic resistance. Further to this, a surprising 
number of putative substrates have been identified for ATR and ATM through 
proteomics screens in the last decade, where many have roles in insulin signalling and 
cell metabolism, suggesting uncharacterised roles of ATR in the regulation of metabolic 
pathways (Matsuoka et al., 2007; Stokes et al., 2007). 
I this chapter, I investigate a novel impact of ATR inhibition on the metabolic 
function and homeostasis of differentiating preadipocytes. I briefly summarised the 
physiological role of WAT in chapter one. Here, I first will discuss how mesenchymal 
stem cells commit to the adipogenic lineage, the induction and execution of adipogenic 
differentiation, and the regulatory mechanisms that control the decision to undergo 
adipogenesis, before detailing my experimental findings. 
3.1.1. Overview of Adipogenesis 
Adipocytes are derived from mesenchymal stem cells (MSCs) residing in the 
vascular stroma of adipose tissue. Throughout the entire mammalian lifespan, signalling 
factors trigger the conversion of these pluripotent MSCs into partially committed 
preadipocytes, restricting them to the adipocyte lineage. In healthy adults, 15-20% of 
adipose tissue is comprised of cycling preadipocytes (Tchkonia et al., 2010), poised to 
undergo maturation into terminally differentiated adipocytes in periods of calorific 
excess. Hence, when investigating the metabolic consequences of small molecule ATRi 
treatment in a cancer therapeutic context, it is relevant to study the outcomes of ATRi 
on adipogenic differentiation, as well as on terminally differentiated adipocytes. 
Upon adipogenic induction, preadipocytes undergo multiple rounds of mitosis 
(mitotic clonal expansion) before the transcriptional and metabolic reprogramming 
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required to induce the adipocyte phenotype. Following MCE, essential master 
adipogenic transcription factor Peroxisome Proliferator-Activated Receptor gamma 2 
(PPAR2) is subject to epigenomic activation, inducing the transcription of adipose-
specific genes necessary for the full adipogenic gene profile and hypoplasia of the 
adipose tissue. PPAR2 is required for adipogenic differentiation, and is used widely as 
a marker for successful adipogenic induction (Farmer, 2005). 
3.1.2. Mesenchymal Stem Cell (MSC) Commitment  
Briefly, MSCs are the common progenitor of adipocytes and osteoblasts. A variety of 
external cues dictate the decision of MSCs to commit to adipo- or osteogenic 
differentiation. Reciprocal signalling processes inhibit and promote these opposing fates 
via the expression of differing lineage-specific transcription factors, to ultimately 
maintain the appropriate balance of each cell population (Chen et al., 2016). Among 
others, members of the bone morphogenic protein (BMP) (Tang et al., 2016) and 
wingless-type MMTV integration site (WNT) (Bowers and Lane, 2008) families are key 
mediators of commitment to the adipocyte lineage and play dual roles (Fig 3.1.2) (Chen 
et al., 2016). The composition and concentration of these cytokines in the 
microenvironment surrounding the MSCs dictates on to which lineage they will impinge 
(Chen et al., 2016). Commitment to the adipocyte lineage is also induced by elevated 
Figure 3.1.2. Schematic of mesenchymal stem cell commitment. Multiple external factors dictate when 
and to which lineage MSCs will differentiate. Taken from (Luu et al., 2009) 
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glucose uptake and excessive energy intake (Shepherd et al., 1993), however it remains 
unclear how this metabolic state is signalled to MSCs. 
3.1.3. Terminal Differentiation of Preadipocytes 
A recent surge of interest into adipocyte function has occurred, as obesity and it’s 
concomitant morbidities and mortalities are steadily reaching epidemic levels (Ogden et 
al., 2006). This has led to increased understanding into the complex, temporally 
regulated transcription cascade that regulates the maturation of preadipocytes into 
terminally differentiated adipocytes. Until recently, attention has vastly been focused 
on nuclear ligand Peroxisome proliferator-activated receptor gamma (PPAR) and the 
CCAAT-enhancer-binding protein (C/EBP) family of transcription factors. It is only now 
becoming clear that almost every essential signalling pathway can influence the decision 
to induce terminal adipogenic differentiation. 
Adipogenesis is initiated following a shift between pro- and anti-adipogenic 
extracellular factors including Ca2+ (Jensen et al., 2004), insulin, static strain and many 
other micro-environmental factors (Pope et al.). In vitro, cell confluence induces growth 
Figure 3.1.3. Temporal schematic of adipogenic differentiation in vitro. Multiple cues and checkpoints 
must be successfully passed in a coordinated manner to successfully complete adipogenesis. Taken from 
(Tang and Lane, 2012)  
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arrest and the transient formation of primary cilia. Primary cilia are solitary mechano- 
and chemosensory organelles that emanate from the cell surface, sensitizing 
preadipocytes to incoming adipogenic signals via the recruitment of insulin growth 
factor-1 receptor (IGF1R) and downstream signalling molecules to the cilia basal body 
(Dalbay et al., 2015; Satir et al., 2010). Primary cilia appear essential for adipogenesis in 
vitro – the model adipogenic cell line 3T3-L1, and human mesenchymal stem cells 
(hMSCs), will not differentiate without primary cilia function (Dalbay et al., 2015; Zhu et 
al., 2009).  
Insulin acts at the IGF1R, inducing phosphorylation of insulin receptor substrate 
1 (IRS-1) and initiation of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) 
signalling cascade. The result of which, is pro-adipogenic phosphorylation of cAMP-
response element binding protein (CREB) (p-S133) within 5 minutes, which induces 
expression of C/EBP(Fig 3.1.3) (Zhang et al., 2004a). C/EBPmust further be 
phosphorylated by mitogen-activated protein kinase (MAPK) and Glycogen synthase 
kinase 3 beta (GSK-3), before it can demonstrate the correct conformation required for 
DNA binding (Tang et al., 2005). C/EBP family member C/EBP homologous protein-10 
(CHOP10) also acts as a dominant negative isoform to repress C/EBP family activity, 
dimerising with C/EBP to prevent it from interacting with DNA (Ron and Habener, 
1992). CHOP10 expression decreases several hours after adipogenic induction - this acts 
as a ‘fail safe’ mechanism to ensure cells enter mitotic clonal expansion (MCE) before 
C/EBP can initiate the next stages of the adipogenic cascade. 
When C/EBPis released, it activates DNA transcription via directly binding to the 
promoter of KLF5, encoding zinc-finger transcription factor kruppel-like factor 5 (KLF5), 
and C/EBP. KLF5 and the C/EBP factors function in concert at the PPARG2 promoter 
(encoding PPAR2) to induce expression (Oishi et al., 2005). Induction of C/EBP requires 
glucocorticoids and C/EBP In contrast to its vital role in the differentiation of WAT, it 
appears C/EBPis not required for brown adipose tissue (BAT) development in mice 
(Linhart et al., 2001). The increased transcription and ligand binding of PPAR2 
terminates MCE, central to the further coordinated transcription of genes required for 
the adipocyte phenotype (Fig 3.1.3) (Tang et al., 2003). PPAR and C/EBP continue to 
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cooperatively activate genes, whose final expression produces the mature adipocyte 
phenotype. 
3.1.4. Regulators of PPAR 
PPAR2is highly expressed in WAT and BAT, and is the only factor identified to date that 
is both essential and sufficient for successful adipogenesis (Farmer, 2006). Importantly, 
mutations of the PPARG gene have been associated with infantile onset lipodystrophy 
and insulin resistance in humans (Dyment et al., 2014). Consequently, the transcription 
and expression of PPAR2 is subject to stringent regulation from a variety of factors, 
ensuring stable expression is obtained only when distinct parameters are met.  
PPARG is expressed as two isoforms, PPAR1 and PPAR2. PPAR2 expression is 
restricted almost entirely to adipogenic tissue, whereas PPAR1 is far more ubiquitous 
(Farmer, 2006). Alternate promoter usage results in the generation of PPARG1 and 
PPARG2 mRNA from the same locus, which are identical other than an additional 
sequence encoding for 30 amino acids at the N-terminus of PPAR2 (Tontonoz et al., 
1994). Several studies have demonstrated that within a PPAR2-deficient context, 
PPAR1 is capable of inducing adipogenesis to an equivalent extent, suggesting PPAR1 
can compensate for some of the adipogenic roles of PPAR2 (Mueller et al., 2002; Zhang 
et al., 2004b). However, PPAR2 appears to be essential in the regulation of insulin 
sensitivity. 
Here, I will review the principal contributors involved in inducing and/or 
regulating PPAR2 expression. 
3.1.4.1. Chromatin remodelling 
Eukaryotic genomes are packaged into chromatin through the architectural wrapping of 
each 146 base pairs of DNA onto a single nucleosome (Kornberg and Lorch, 1999). 
Nucleosomes consist of histone octamers of four core histone units (H2A, H2B, H3 and 
H4), and nucleosome occupancy at a gene site correlates inversely with gene 
transcription (Lee et al., 2004). The combination of covalent histone modifications on 
their N-terminal tails affects chromatin structure and subsequent gene expression.  
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A number of epigenetic factors regulate PPAR2 expression. During 
adipogenesis, nucleosomes occupying the PPARG site are subject to both histone 
modification and alteration by chromatin remodelling complexes, to achieve PPARG 
transcription initiation (Lee and Ge, 2014). Di- and tri-methylated H3K9 is widely 
considered a hallmark of condensed chromatin (heterochromatin) – areas of 
transcriptionally silent genes (Sims Iii et al., 2003). Throughout adipogenesis, histones at 
the PPARG2 promoter are subject to hyperacetylation at H3K9 and H3K27 (positive 
inducers of gene transcription) via enhanced recruitment of histone acetyl transferases 
(HATs), and H3K9 demethylation via the downregulation of histone lysine 
methyltransferases (HKMTs) SETDB1 and G9A (EHMT2) (Okamura et al., 2010). 
Together, these processes enable chromatin relaxation at the PPARG2 promoter, 
allowing transcriptional machinery access to the site. Following chromatin relaxation, 
C/EBP factors bind directly to the PPARG2 promoter and initiate the recruitment of RNA 
polymerase Pol II and the SWI/SNF chromatin remodelling complex (Salma et al., 2004). 
SWI/SNF disrupts the core conformation of nucleosomes by altering DNA-histone 
binding at the PPARG2 locus, stabilising the interaction of Pol II, facilitating preinitiation 
complex formation and transcription (Côté et al., 1998).  
Interestingly, HKMT G9A has recently been identified as a putative ATM/ATR 
substrate, with a second paper identifying a novel role for G9A at the replication fork 
(Dungrawala et al., 2015; Matsuoka et al., 2007). However, the latter study concluded 
G9A activity in the context of replication stress was in fact ATR-independent. Although 
this is evidence to argue against a role for ATR in the regulation of G9A HKMT activity, it 
remains an attractive target for further substrate validation due to the dense clusters of 
conserved S/TQ motifs observed in both G9A and its homologue EHMT1 (Stokes et al., 
2007).  
3.1.4.2. Pre-Lamin A 
Laminopathies are a group of rare genetic disorders caused by mutations in genes 
encoding for proteins of the nuclear lamina (Nagano and Arahata, 2000). For example, 
mutations in LMNA (encoding Lamin A) can cause Dunnigan-type familial partial 
lipodystrophy, characterised by insulin resistance, lipodystrophy of the extremities and 
torso and dyslipidaemia (Hegele, 2000). In fact, a common (if not invariant) clinical 
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feature of laminopathies is lipodystrophy and accelerated ageing (Worman and Bonne, 
2007). 
This presentation is generated by amino acid substitutions in Lamin A and Lamin 
C, which have been postulated to alter adipocyte-specific functions of Lamin A (Capanni 
et al., 2005). An underlying mechanism in which defective Lamin A/C processing results 
in metabolic impairments has been characterised – abnormally accumulating pre-Lamin 
A sequesters SREBP1 at the nuclear rim, inhibiting its transcriptional activity at the 
PPARG locus (Capanni et al., 2005). Through this mechanism, Lamin A/C processing has 
input into the control of PPAR2 expression and subsequent adipogenesis. 
Accumulation of pre-Lamin A also appears to increase genomic instability, 
resulting in increased activation of checkpoint kinases ATR and ATM, inducing early 
replicative senescence and the accelerated aging seen in several laminopathies (Liu et 
al., 2006). Fractions of ATR have been reported to localise at perinuclear regions with 
Lamin A in prophase and in response to mechanical stress. ATR inhibition and ATR-Seckel 
cells also display delayed nuclear envelope breakdown and Lamin A disintegration prior 
to metaphase (Kumar et al., 2014). In some laminopathies, ATR fails to appropriately 
localise at DNA repair foci (Manju et al., 2006), suggesting an element of feedback 
between these two proteins. Interestingly, Lamin A and pre-Lamin A also contain several 
S/TQ motifs, including a TQ motif proximal to pre-Lamin A’s C-terminal farnesylation 
site, where farnesylation is an essential precursory step in the Lamin A maturation 
process. Several groups have recognised these S/TQ motifs in putative ATR/ATM 
substrate screens (Matsuoka et al., 2007; Stokes et al., 2007).  
3.1.4.3. NAD+/SIRT1 (Sirtuin 1) 
SIRT1 is a NAD-dependent deacetylase that acts as an intermediary in a wide array of 
cellular processes. SIRT1 appears to play fundamental roles in metabolism, ageing and 
senescence (Brooks and Gu, 2009; Cao et al., 2016; Fang et al., 2014). SIRT1 is uniquely 
dependent on NAD+ for its catalytic activity rendering it sensitive to cellular nutrient 
status, and through the deacetylation of a wide variety of targets it behaves as a crucial 
resistance factor to stress-induced apoptosis. For example, in response to caloric 
restriction, SIRT1 deacetylates KU70 inducing the sequestration and inhibition of pro-
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apoptotic factor BCL-2 associated X protein (BAX) (Cohen et al., 2004). PPAR is also a 
SIRT1 target (Han et al., 2010), where deacetylation and binding to inhibitory factors 
appears to inhibit adipogenesis (Picard et al., 2004), and induce brown remodelling in 
mature adipocytes (Qiang et al., 2012). 
Importantly, SIRT1 is inhibited following induction of the base excision repair 
branch of the DNA damage response (DDR) (Fang et al., 2014). PARP1 (poly (ADP-ribose) 
polymerase) assists the repair of single stranded nicks by transferring chains of poly-
ADP-ribosyl moieties (PAR groups) derived from NAD+ onto itself and other acceptor 
proteins (D'Amours et al., 1999). In this manner, PARP1 activation is concomitant with 
depletion of NAD+ and inactivation of SIRT1. For example, Fang et al. recently 
characterised mitochondrial abnormalities in the nuclear excision repair disorder 
Xeroderma Pigmentosum A (XPA), where defective mitophagy was due to decreased 
activation of the NAD+-SIRT1-PGC1 axis, which in turn was driven by hyperactivation of 
PARP1 (Fang et al., 2014). 
3.1.4.4. Calcineurin/NFAT (nuclear factor of activated T cells) 
Ca2+-dependent serine/threonine phosphatase Calcineurin transduces intracellular Ca2+ 
status to a variety of signalling pathways, including the dephosphorylation and nuclear 
translocation of members of the NFAT transcription factor family (Li et al.). 
Overexpression of mutant, constitutively active NFATc1 transforms 3T3-L1 cells and 
inhibits adipogenesis at the level of PPAR2 induction (Neal and Clipstone, 2003), an 
effect that appears to be mediated by Calcineurin (Neal and Clipstone, 2002), suggesting 
a Ca2+-dependent negative regulatory role for Calcineurin in adipogenesis.  
3.1.4.5. p38 MAPK signalling 
Stress-response kinase p38 MAPK (p38 mitogen-activated protein kinase) appears to 
have opposing roles in adipogenesis, dependent on the temporality and duration of its 
activation. Most studies characterising a role for p38 in adipogenesis were conducted in 
the partially committed 3T3-L1 cell line, with the use of small molecule inhibitors. Early 
reports validated the requirement of p38 MAPK activation in 3T3-L1 adipogenesis, 
observing a decrease in C/EBP phosphorylation when differentiating cells were treated 
with p38 inhibitors (Engelman et al., 1999; Engelman et al., 1998; Takenouchi et al., 
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2004). A role in mesenchymal commitment has also been observed, where BMP2 steers 
C3H10T1/2 MSCs into the adipocyte lineage through p38 activation (Hata et al., 2003). 
However, further reports show p38 activity has an inhibitory role in 
adipogenesis. p38 substrate growth arrest and DNA damage 153 (CHOP/GADD153) 
inhibits adipogenesis due to its dominant-negative regulation of C/EBPs – a function that 
is abolished with the ablation of p38-dependent phospho sites (Wang and Ron, 1996). 
p38 MAPK also appears to negatively regulate adipogenesis, through the 
phosphorylation and cytoplasmic sequestration of PPAR-inducing transcription factor 
NFATc4 (Ho et al., 1998; Yang et al., 2002). 
Activating transcription factor 2 (ATF2) belongs to the ATF/CREB family of 
transcription factors and is primarily activated by stress-response kinases such as p38 
MAPK. ATF2 binds to cAMP-responsive elements (CRE) within a promoter region, 
transducing stress-kinase signalling into the transcription of target genes. ATF2 is 
induced early in the adipogenesis program and is suggested to play a collaborative role 
with C/EBP, in the promotion of adipogenesis-inducing transcription factors including 
PPAR (Lee et al., 2001).  
ATF2 has also been identified as an essential DNA damage response (DDR) protein 
(Bhoumik et al., 2007). Following IR, ATF2 is phosphorylated on its C-terminal domain by 
ATM, inducing it’s co-localisation with DNA repair machinery components -H2AX and 
the MRN complex (Bhoumik et al., 2005). 
3.1.4.6. Free Fatty Acids 
Several fatty acids act as endogenous PPARligands. As PPAR2 is a key modulator of 
lipid-metabolism related genes, this allows adipose and non-adipose tissues alike the 
ability to protect against excessive lipid overload by enhancing lipid storage, transport 
and release pathways (Medina-Gomez et al., 2007). The detrimental effects associated 
with excessive cellular fatty acid uptake are termed ‘lipotoxicity’. PPAR2 expression can 
be induced in WAT in response to changes in the ‘lipidomic’ status of the cell – resulting 
in increased lipid storage, which in turn reduces peripheral lipotoxicity of the muscles 
and liver. Hence, when fatty acid uptake exceeds the oxidative capacity of the cell, 
PPAR2 induction enhances protective lipid droplet formation. 
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3.1.4.7. mTOR (mechanistic target of rapamycin) 
The involvement of mTOR signalling in adipogenesis has been well documented. 
Through pharmacological and genetic manipulation of its regulators and targets, mTOR 
is believed to have critical and complex inputs into adipogenesis (Kim and Chen, 2004; 
Yoon et al., 2013). mTORC1 appears to both positively and negatively influence 
PPARactivity, through the phosphorylation status of ribosomal protein S6 kinase beta-
1 (S6K1), and inhibition of the insulin receptor substrate 1 and protein kinase B (IRS1-
AKT)-PPAR pathway. mTORC1 and mTORC2 have multiple regulatory effects on PI3K-
AKT signalling, which is indispensable for PPAR activation (Yoon et al., 2013). Adipose 
tissue-specific knockout of essential mTORC1 component Raptor (encoding Regulatory-
associated protein of mTOR) results in lean mice with enhanced levels of BAT (Polak et 
al., 2008), and constitutive mTORC1 activity via deletion of Tsc2 (encoding Tuberous 
Sclerosis Complex 2) in MEFs results in enhanced adipogenesis (Zhang et al., 2009). 
Overexpression of DEP domain-containing mTOR-interacting protein (DEPTOR), an 
endogenous inhibitor of mTOR results in obese mice (Laplante et al., 2012), yet mTORC1 
inhibitor rapamycin has an inhibitory effect on adipogenesis (Yeh et al., 1995).  
ADD1/SREBP1 (sterol responsive element binding protein) is a transcription 
factor induced early in the adipogenic program, whose expression specifically increases 
activity of PPAR through the SREBP1-dependent generation of a secreted PPAR ligand 
(Kim et al., 1998; Spiegelman et al., 1997). SREBP1 maturation, activity and nuclear 
accumulation is positively regulated by mTORC1, adding an additional mechanism into 
mTORC1’s regulation of PPAR function (Laplante and Sabatini, 2013). It is believed that 
the positive and negative effects mTORC1 exerts on adipogenesis are delicately 
dependent on differing thresholds of mTORC1 activity, and that this signalling threshold 
dictates the final effect of mTOR on PPAR activity (Yoon et al., 2013). 
3.1.5. 3T3-L1 Adipogenesis 
The 3T3-L1 cell line is the gold standard for modelling adipogenic differentiation in vitro. 
As murine preadipocytes, 3T3-L1 cells can be induced with an adipogenic cocktail to 
undergo adipogenic differentiation into functional adipocytes (Fig 3.1.4.A and B) (Poulos 
et al., 2010). For some in vitro adipogenic models (including the 3T3-L1 cell line), 
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exposure of arrested preadipocytes to adipogenic inducers triggers synchronous, post-
confluence cell cycle re-entry (mitotic clonal expansion - MCE) prior to differentiation. 
Whether MCE is an artefact of in vitro adipogenesis modelling, or a bone fide 
prerequisite to in vivo adipogenesis remains controversial (Qiu et al., 2001; Tang et al., 
2003).  
The highly specific ATR kinase inhibitor II (Calbiochem – referred to hereon as 
ATRi II) was released for commercial use early in this project (2014). Because of this, 
ATRi II has been the inhibitor of choice for many of the following experiments. Following 
from 2014, other ATRis became commercially available, including VE-821 and the 
clinically relevant analogue VE-822. Subsequently, to add clinical significance to results 
acquired with ATRi II, I have validated key experiments with VE-822 or VE-821. Utilising 
Figure 3.1.5. 3T3-L1 adipogenesis overview. A) To induce adipogenesis, post-confluent preadipocytes 
were cultured in adipogenic supplemented media (described in chapter 2) for 48 hrs. Adipogenic cocktail 
was further supplemented with insulin after 48 hrs (day 3) and refreshed on day 4. On day 5, maintenance 
media was applied. B) After 7 days of adipogenic differentiation, mature adipocytes are obtained. Mature 
adipocytes were allowed up to 4 days to acquire lipid droplets, which can be stained and quantified with 
neutral lipid stain Oil Red O. C) PPAR2 expression is induced throughout adipogenesis. PPAR2 is 
identifiable on western blot as the higher migrating form of PPAR. 
 
A 
B 
C 
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a structurally dissimilar ATRi to gain an equivalent result also suggests that this data is 
not due to an off-target effect of the ATRi compound in question.  
I aimed to investigate the impacts of small molecule ATR inhibitors on 
preadipocytes as they undergo adipogenic differentiation, to characterise a relationship 
between ATR functionality and the adipogenic capability of 3T3-L1 preadipocytes. It is 
relevant to investigate the effects of ATR inhibition on cells as they undergo adipogenic 
differentiation, as from development and throughout adulthood, our adipose tissue is 
undergoing constant regeneration, requiring successful adipogenesis. 
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3.2. Results  
3.2.1. Small molecule inhibition of ATR decreases adipogenic 
differentiation of 3T3-L1 preadipocytes 
I assessed successful adipogenic differentiation through histochemical staining with 
triglyceride (TG) stain Oil Red O (ORO) and western blotting of adipogenic proteins. The 
ability to acquire large cytoplasmic lipid droplets (LDs) is a definitive characteristic of 
mature adipocytes, making ORO a reliable marker of successful adipogenesis (Kraus et 
al., 2016). Further, ORO staining can be quantified following extraction, allowing the 
significance of changes in ORO staining to be fully investigated.  
Small molecule kinase inhibitors of ATR (ATRis) induced a drastic reduction in the 
adipogenic capacity of 3T3-L1 preadipocytes. Fig 3.2.1.A shows undifferentiated and 
differentiated 3T3-L1 cultures stained with ORO, where cultures were co-treated with 
or without ATRis and ATMi (KU-55933) throughout differentiation. ORO staining is 
quantified in Fig 3.2.1.B, where treatment with ATRi II throughout differentiation 
induces a ~9 fold decrease in adiposity (p < 0.001) and VE-822 reduces TG content 2.5 
fold (p < 0.01). The decreased TG content induced by ATRi treatment throughout 
adipogenesis is not phenocopied with ATMi treatment, where instead decreased 
viability accounted for the small decrease in ORO staining (data not shown). This result 
indicates that ATRi treatment throughout adipogenic differentiation appears to induce 
a significant reduction in adipogenic capability of 3T3-L1 preadipocytes. 
To investigate the cause of decreased adipogenesis following ATRi treatment, 
expression of adipogenic regulator PPAR2 in differentiating 3T3-L1 preadipocytes 
treated with or without ATRis was assessed (Fig 3.2.1.C & D). PPAR2 expression is 
induced early in unperturbed 3T3-L1 adipogenesis (lanes 2, 4 and 6). Strikingly, co-
treatment with ATRis throughout adipogenesis results in specific and almost complete 
failure to induce PPAR2 protein expression (lanes 3, 5 & 7). This indicates that the 
failure to accumulate LDs characteristic of successful adipogenic differentiation 
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following ATRi treatment (Fig 3.2.1.A and B) is due to a failure to induce PPAR2 
expression, requisite for adipogenesis.  
A 
B 
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Semi-quantitative RT-PCR was utilised to assess if the ATRi-induced reduction in 
PPAR2 expression was due to defects at a transcriptional level. Fig 3.2.1.E shows 
reduced Pparg expression following treatment with ATRi II throughout adipogenesis, 
suggesting reduced production or enhanced degradation of Pparg mRNA. This suggests 
ATR inhibition may affect adipogenesis at stages of the adipogenic cascade that prelude 
induction of PPAR2 transcription. 
PPAR2 expression was induced and maintained appropriately following co-
treatment with ATMi (Fig 3.2.1.F). Checkpoint kinase 1 inhibitor (CHK1i, UCN-01) co-
treatment appeared to modestly affect PPAR2 induction, a defect that was recovered 
at later time points (Fig 3.2.1.G).  
3.2.2. ATRi has limited effects on viability and S-phase kinetics 
of Mitotic clonal expansion (MCE) 
Before induction of PPAR2 protein expression, differentiating preadipocytes must 
successfully advance several junctures (discussed in section 3.1.2) ensuring adipogenesis 
is instigated successfully only where distinct parameters are met. One essential 
prerequisite to the induction of Pparg2 gene transcription is the induction of MCE (Tang 
and Lane, 2012).  
Figure 3.2.1 Adipogenesis of 3T3-L1 cells co-treated with or without small molecule kinase inhibitors of 
ATR. Successful adipogenesis and accumulation of triglycerides can be observed in 3T3-L1 cell cultures 
following 10 days in adipogenic medium as determined by Oil Red O (ORO) staining and western blotting 
of adipogenesis marker PPAR2. A) ORO staining of confluent 3T3-L1 preadipocytes (well 1) and terminally 
differentiated 3T3-L1 adipocytes treated with ATRis and ATMi throughout adipogenesis. ATRi II, VE-822 
and KU-55933 (ATMi) (all 10 M) were added daily with adipogenic cocktail. B) Quantification of ORO 
staining. ORO was eluted from dried, stained samples in 100% isopropanol and quantified at UV 
absorbance of 500 nm. Treatment with ATRi II (***) and VE-822 (**) but not ATMi throughout 
adipogenesis significantly decreases ORO staining indicating reduced triglyceride accumulation and 
reduced adipogenesis. Statistically significant differences compared to DMSO-treated samples; *** p < 
0.001 and ** p < 0.01 two tailed t-test. Error bars represent standard deviation. C) PPAR2 protein 
expression is induced in early adipogenesis. PPAR2 expression is not induced in samples co-treated with 
ATRi II or in D), samples co-treated with VE-821. Lamin B and-tubulin utilised as loading controls. E) 
Semi-quantitative rtPCR was utilised to assess Pparg gene product levels. PCR primers targeted a region 
of Pparg specific to both 1 and 2 isoforms. Pparg mRNA levels are increased ~16hrs and 24hrs post-
adipogenic induction but not in ATRi II-treated samples. F) ATMi does not affect adipogenic PPAR2 
induction. -tubulin utilised as loading control G) CHK1i UCN-01 (50 nM) reduces PPAR2 expression at 
16 hrs post adipogenic induction. Lamin B utilised as loading control. All images representative of results 
obtained in at least three independent experiments. 
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ATRi is toxic to cycling cells, resulting in mitotic catastrophe and cell death, or 
cell cycle arrest (Hitomi et al., 2008). I assessed the effects of ATRi on the viability of 
differentiating cultures to ensure the decreased adipogenic profile was not a result of 
decreased viability, induced by ATRi-enhanced replicative stress. Utilising the WST-8 
viability assay, Fig 3.2.2.A represents viability of ATRi-treated 3T3-L1 cultures 
throughout adipogenesis. At later time points, there appears to be decreased but not 
significant change in the viability of cultures treated with ATRi, and at 24 hrs there is no 
significant change in viability (p = >0.05). Reduced PPAR2 expression is observed as 
early as six hours (Fig 3.2.1.C), suggesting decreased viability at early time points is not 
the cause of the failure to express this adipogenic master regulator. 
Inhibition of ATR throughout S-phase results in replication fork collapse and the 
increased generation of double strand breaks (DSBs), where replication machinery 
arrives at unrepaired single strand breaks (SSBs). DNA-DSBs induce ATM and DNA-PK 
activity as part of the DDR, an early event of which is the phosphorylation of histone 
variant H2AX at S139 (H2AX). Western blotting in Fig 3.2.2.B and C demonstrate 
increased H2AX and ATM-dependent KRAB-associated protein-1 (KAP1) 
phosphorylation following ATRi treatment throughout adipogenesis. Fig 3.2.2.C also 
shows ATR-dependent CHK1 phosphorylation (S345) and activation throughout early 
adipogenesis. This is likely due to canonical ATR-CHK1 signalling at the intra-S-phase 
checkpoint, where the p-CHK1 signal is enhanced by the high synchronicity of these cells 
cultures as they enter S-phase at these time points. Taken together, this data is 
indicative of increased DNA-DSBs and ATM and/or DNA-PK activation throughout 
adipogenesis, in the absence of ATR-CHK1 signalling.  
Due to the inherent role of ATR in modulating the intra-S-phase checkpoint, I 
hypothesised the ATRi-induced failure to express PPAR2 may be due to replication fork 
stalling and cell cycle arrest, resulting in failure to complete MCE. To assess the S-phase 
kinetics of MCE following ATRi I utilised thymidine analogue EdU (5-Ethynyl-2'-
deoxyuridine), which can be incorporated into cells undergoing DNA synthesis and 
labelled to identify S-phase cells. Fig 3.2.2.D shows fluorescence microscopy of EdU-
treated cultures at 24 hrs differentiation, the early stage of MCE. Quantification of EdU-
positive cells in Fig 3.2.2.E shows ~80% cells undergoing adipogenesis without ATRi are 
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undergoing DNA synthesis at 24 hrs post adipogenic induction. ATRi II treatment appears 
to increase synchronicity (90% at 24 hrs) whereas VE-822 treatment reduces S-phase 
synchronicity to <60%. It appears higher volumes of cells are still undergoing DNA 
synthesis at 48 hrs when treated with VE-822. CHK1i (UCN01) and VE-822 treatment 
have similar S-phase induction at 24 hrs, although <10% of cells in CHK1i treated cultures 
are undergoing DNA synthesis at 48 hrs (Fig 3.2.2.E).  
Interestingly, cultures treated with 10 Gy radiation (inducing high levels of DNA 
SSBs and DSBs) at the initiation of adipogenesis appear to traverse MCE comparably to 
untreated cultures, suggesting high burdens of DNA damage are compatible with MCE 
progression. Samples treated with HU fail to undergo any DNA synthesis at all, due to 
the inhibitory activity of HU on ribonucleotide reductase inducing a severe reduction in 
the dNTP pools essential for DNA replication. 
Taken together, the data in Fig 3.2.2.E suggests that although the two ATRis 
tested have differing effects on the S-phase kinetics of MCE, the ATRi-induced block in 
adipogenesis is not due to a failure to traverse MCE, or due to high levels of DNA damage 
or replication stress, induced by loss of canonical ATR signalling in S-phase.  
3.2.3. ATRi does not induce consistent defects in the early 
adipogenic cascade 
As I was observing defects in adipogenesis within the first 24 hrs of induction with ATRis, 
I next assessed the activity of proteins associated with the early adipogenic signalling 
cascade. CREB is phosphorylated at S133 within five minutes of adipogenic induction, 
Figure 3.2.2. Effects of ATRi on viability and S-phase kinetics of mitotic clonal expansion. A) WST-8 
viability assay was utilised to assess toxicity of ATRis throughout adipogenesis with no significant decrease 
at 24 hrs post induction (p > 0.05). B) Western blotting shows increased H2AX expression throughout 
adipogenesis with ATRi II, suggesting presence of ATRis induces DDR activation. Native H2A utilised as 
loading control (lower band). C) p-CHK1 S345 indicates ATR-CHK1 signalling axis is activated throughout 
MCE stage of adipogenesis. ATRi II treatment ablates ATR-dependent p-CHK1 S345 throughout 
adipogenesis. KAP1 is phosphorylate at S824 is in ATRi-treated samples suggesting ATRi-induced ATM 
activation. * indicates positive controls – 3 hrs 500 M hydroxyurea (HU) treatment for p-CHK1 S345 and 
10 Gy for p-KAP1 S824. KAP1 used as a loading control. D) Fluorescence microscopy of EdU-labelled (S-
phase) 3T3-L1 cells undergoing adipogenesis +/- ATRi II at 40x magnification. E) Quantification of EdU-
positive cells treated with DNA-damage inducing agents and DDR inhibitors throughout adipogenesis 
(ATRi II, VE-822, ATMi all 10 M, 300 nM UCN-01, 500 M HU, 10 Gy). Error bars signify SD. All images 
representative of results obtained in at least three independent experiments. 
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rendering it transcriptionally active and able to induce expression of C/EBP. 
Interestingly, ATM also phosphorylates CREB at S121 after DNA damage, which 
decreases the DNA binding affinity of CREB, hence inhibiting its adipogenic activity (Trinh 
et al., 2013). I hypothesised that the ATRi-dependent ATM activation (Fig 3.2.2.B, C) 
observed throughout adipogenesis might enhance ATM-dependent CREB S121 
phosphorylation, inducing an adipogenic block.  
Fig 3.2.3.A shows western blotting of p-CREB S121 with no change observable 
between samples treated with/without ATRi throughout adipogenesis. Fig 3.2.3.B shows 
no significant difference in CREB S133 phosphorylation and C/EBP expression of 
samples treated +/- VE-821, 6-24 hrs post adipogenic induction, where appropriate 
regulation of these proteins is most essential for successful adipogenesis. Considering 
the high levels of DDR activity observed throughout adipogenic differentiation in 
cultures co-treated with ATRis (Fig 3.2.2.B, C), it is surprising not to see a change in the 
A B 
C 
Figure 3.2.3 Assessment of early adipogenic cascade. A) ATM-dependent, inhibitory CREB 
phosphorylation at s121 shows no increase following ATRi treatment suggesting the ATRi-induced ATM 
activation observed in Fig 3.2.2.C is not causing the adipogenic block at the level of CREB activity. CREB 
used as a loading control. B)  C/EBP and p-CREB S133 are induced early in the adipogenic cascade. Both 
appear normal following VE-821 treatment. Samples here were treated with VE-821 up to 2 hrs before 
induction of adipogenesis to ensure complete inhibition of ATR prior to adipogenic induction. Lamin B 
and CREB utilised as loading controls for C/EBP, and p-CREB S133 respectively. C) C/EBP expression 
is decreased following ATRi II treatment, suggesting an adipogenic block at the level of C/EBP here. 
This phenotype was unreproducible with other ATRis, suggesting this may not be the cause of ATRi-
induced reduction of PPAR2 expression. -tubulin utilised as a loading control. All images 
representative of results obtained in at least three independent experiments. 
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phospho-status of this ATM substrate – perhaps this phospho-site may be ATR-
dependent. It is noteworthy that CREB activity is most important within the first minutes 
of adipogenic induction, hence phosphorylation by ATM, induced by DSBs >16 hrs into 
adipogenesis is unlikely to affect the role of CREB in early adipogenesis.  
Fig 3.2.3.C shows decreased protein expression of C/EBPfollowing co-treatment 
with ATRi II. However, this phenotype of reduced C/EBP expression was not 
recapitulated with other ATRis. To ensure differences were not due to differing rates of 
cellular ATRi uptake and incomplete inhibition of ATR kinase activity at adipogenic 
induction, cultures were pre-treated with VE-821 up to 2 hrs before addition of 
adipogenic cocktail (Fig 3.2.3.B), with no effect on C/EBP expression.  
3.2.4. p38 MAPK pathway is activated following ATR inhibition 
throughout adipogenesis 
MAPKs transduce stress signals to downstream effectors, working in concert to generate 
tailored responses to varying types of cell stress (Roux and Blenis, 2004). Small molecule 
kinase inhibition of p38 MAPK has been documented to increase the replicative capacity 
of ATR-Seckel cells, by limiting the p38 MAPK-mediated cellular stress response (Tivey 
et al., 2013). Considering this relationship of increased p38 activity concomitant with 
reduced ATR function and replicative stress, and the complex roles of p38 MAPK in 
adipogenesis, I assessed p38 MAPK activity following ATRi treatment.  
Western blotting in Fig 3.2.4.A shows phospho-p38 MAPK T180/T182 throughout 
6-24 hrs of adipogenesis +/- VE-821. At six hrs post-adipogenic induction, p-p38 MAPK 
appears to decrease, suggesting a reduction in p38 MAPK activity at this time point in 
unperturbed adipogenesis (lane 2). However, p38 MAPK phosphorylation levels remain 
unchanged following induction of adipogenesis in the presence of ATRis (Fig 3.2.4.A, 
lane 3). To assess the functional significance of this sustained p38 MAPK activity in ATRi-
treated cultures undergoing adipogenesis, I investigated the phospho-status of several 
p38 MAPK substrates. MAPKAP2 (Mitogen-Activated Protein Kinase-Activated Protein 
Kinase 2) is directly phosphorylated by p38 MAPK at T334. Fig 3.2.4.A shows increased 
p-MAPKAP2 T334 following ATRi-treatment of differentiating 3T3-L1 cultures. 
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This phosphorylation is not observed in differentiating cells with ATR function, 
or in unperturbed, undifferentiated cells (Fig 3.2.4.A, lane 1) where p38 MAPK phospho-
status is more similar to samples treated with ATRi.   
Cross-talk exists between the endoplasmic reticulum (ER) unfolded protein 
response (UPR) and MAPK pathways, where p38 MAPK is phosphorylated following ER 
stress. Activated p38 MAPK is also capable of phosphorylating ER-stress transcription 
factors activating transcription factor 6 (ATF6) and CHOP (Darling and Cook, 2014). 
Although the physiological relevance of this phosphorylation on CHOP is unclear, CHOP 
C 
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Figure 3.2.4 p38 MAPK is activated throughout adipogenesis following ATR inhibition. A) Western 
blotting demonstrates p38 MAPK is dephosphorylated at T180/182 upon induction of adipogenesis at 6 
hrs through to 24 hrs. p38 MAPK remains phosphorylated following co-treatment with VE-821 
throughout adipogenesis. Increased p38 MAPK T180/182 has functional significance where p38 MAPK 
phospho-substrates MAPKAP2 (T334) and ATF2 (T71) have increased activation throughout adipogenesis 
following ATRi treatment. ATF2 is dephosphorylated at T71 6 hrs post adipogenic induction; however p-
ATF2 is increased at this time following ATRi treatment. Lamin B used as loading control. B) ATMi 
treatment throughout adipogenesis does not increase p38 MAPK-dependent ATF2 phosphorylation at 6 
hrs post-adipogenic induction, suggesting this phenomenon is ATM-independent. ATF2 used as loading 
control. C) ER stress marker p-eIF2 S51 is decreased following ATRi treatment throughout adipogenesis. 
-tubulin used as loading control. D) p-p44/42 MAPK is unchanged following ATRi in adipogenic context. 
PPAR expression is not recovered at later time points throughout adipogenesis following ATRi 
treatment. -tubulin used as a loading control. All images representative of results obtained in at least 
three independent experiments. 
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activity is intimately linked to ER Ca2+ release, which has an inhibitory effect on 
adipogenesis (Graham et al., 2009; Li et al., 2009). Increased ER stress signalling through 
the eIF2Eukaryotic Initiation Factor 2ATF4-CHOP signalling axis results in 
attenuated adipogenic differentiation in mice (Han et al., 2013), leading me to 
hypothesise that increased p38 MAPK activity following ATRi treatment throughout 
adipogenesis could be indicative of ER stress or dysfunction.  
To investigate the functional significance of increased p38 MAPK activity and 
potential ER stress induction throughout adipogenesis, I assessed phosphorylation of ER 
stress marker eIF2. EIF2 is phosphorylated by protein kinase RNA-like ER kinase 
(PERK) at S51 in one branch of the UPR. Interestingly, Fig 3.2.4.C shows decreased p-
eIF2 S51 following ATRi treatment at early time points throughout adipogenesis, 
indicative of reduced ER stress or reduced PERK activity. 
 p44/42 MAPK (also known as extracellular regulated signal-kinase ERK 1/2) is 
phosphorylated transiently and rapidly at T202/Y204 following induction into 
adipogenesis (Prusty et al., 2002). p44/42 MAPK is also activated following DNA damage, 
downstream of ATM and ATR (Wei et al., 2011). Considering the cross-talk between 
these pathways, and the ATRi-induced ATM activation I observed throughout 3T3-L1 
adipogenesis (Fig 3.2.2.B and C), I wanted to investigate p44/42 MAPK activity. Fig 
3.2.4.D shows western blotting of p-p44/42 MAPK throughout adipogenesis – with no 
change apparent following ATRi treatment, suggesting the reduced PPAR2 protein 
expression is not a result of DNA-damage induced impingement on p44/42 MAPK 
adipogenic signalling. Fig 3.2.4.D also shows a longer timecourse of PPAR expression, 
where PPAR2 is ablated as far as 72 hrs into adipogenesis following ATRi treatment, 
suggesting this defect in expression is not recovered at later timepoints. 
3.2.5. ATRi treatment does not block adipogenesis through 
increased Calcineurin activity          
Increased [Ca2+]cyt (cytoplasmic Ca2+ concentration) enhances p38 MAPK activity and is 
an effector and result of ER stress (Kania et al., 2015; Wright et al., 2007). Considering 
the observed increase in p-p38 MAPK T180/T182 following ATRi treatment throughout 
adipogenesis, and decreased eIF2 activity following ATRi (Fig 3.2.4.), I hypothesised 
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that ATRi treatment could be inducing anti-adipogenic increases in [Ca2+]cyt. Increased 
[Ca2+]cyt will activate Ca2+-dependent phosphatase Calcineurin, increasing the anti-
adipogenic effect of NFATc1, summarised in Fig 3.2.5.A.  
Cyclosporin A (CsA) is an immunosuppressant drug that inhibits Calcineurin activity 
through non-competitive inhibition when it is bound to its target Cyclophillin A (Sieber 
and Baumgrass, 2009). To test the hypothesis that the ATRi-induced block in PPAR2 
expression is caused by increased Ca2+-Calcineuin-NFATC1 signalling, I co-treated 
A 
B 
C 
Figure 3.2.5. ATRi does not block adipogenesis in a Calcineurin-dependent manner. A) Hypothesised 
mechanism in which ATRi blocks adipogenesis through increased Ca2+-dependent Calcineurin activity, 
resulting in increased activity of NFATc1, which has an inhibitory effect on adipogenesis. CsA is an 
inhibitor of Calcineurin, resulting in alleviation of the adipogenic block imposed by increased 
Calcineurin activity. B) & C) Western blotting of co-treatment with CsA and VE-821 (B) or ATRi II (C) 
throughout 24 hrs adipogenic differentiation. CsA co-treatment with either ATRi does not rescue 
PPAR2 expression, suggesting ATRi does not block adipogenesis through increased Calcineurin 
activity. CsA appears in fact to inhibit PPAR2 expression in a dose dependent manner in this model 
system.-actin utilised as loading control. All images representative of results obtained in at least 
three independent experiments. 
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differentiating 3T3-L1 cultures with CsA and ATRis throughout adipogenesis (Fig 3.2.5.B 
& C). If this mechanism were relevant in this context, CsA treatment would recover 
PPAR2 expression following ATRi.  
Fig 3.2.5.B and C show western blots of PPAR following treatment with CsA and 
ATRis throughout adipogenesis. Interestingly, CsA treatment alone negatively affected 
adipogenesis in a dose-dependent manner, by reducing PPAR2 expression (last 2 and 3 
lanes, Fig 3.2.5.B and C). Treatment with CsA did not rescue PPAR2 expression when 
co-treated with ATRi II or VE-821 throughout adipogenesis, suggesting that increased 
Calcineurin-dependent NFATC1 activity is not the cause of the ATRi-induced adipogenic 
defects I have observed. 
3.2.6. ATRi does not block adipogenesis through defective pre-
Lamin A processing 
Considering the existing relationship between ATR and Lamin A processing (summarised 
in section 3.1.4.2), there is precedence for a potential, novel role for ATR in Lamin A 
maturation. I hypothesised ATRi throughout adipogenesis might induce defects in the 
Lamin A processing pathway, resulting in sequestration of SREBP1 and the observed 
failure to induce PPAR2 (summarised in Fig 3.2.6.A). 
Lovastatin is a farnesyl transferase inhibitor – application to cell cultures blocks 
pre-Lamin A farnesylation and hence successful maturation into Lamin A, resulting in 
accumulation of pre-Lamin A localised to the nuclear periphery. Utilising lovastatin as a 
positive control, I assessed the effects of ATRis on pre-Lamin A accumulation via indirect 
immunofluorescence (IF). An antibody specific to both pre-Lamin A and Lamin A was 
utilised to detect perinuclear accumulation of pre-Lamin A by IF, associated with 
reduced pre-Lamin A maturation. Fig 3.2.6.B shows distinct perinuclear accumulation of 
pre-Lamin A following treatment with lovastatin. Fig 3.2.6.B also shows that this 
perinuclear accumulation of pre-Lamin A is not observed in samples treated with ATRi 
II. I also assessed protein expression levels of pre-Lamin A and Lamin A by western blot 
(Fig 3.2.6.C).  
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A 
B 
C 
Figure 3.2.6. ATRi does not block adipogenesis through defective Pre-Lamin A processing. A) 
Proposed mechanism of ATRi-induced adipogenic block through. ATRi results in defective processing 
of pre-Lamin A, resulting in accumulation. Increased pre-Lamin A sequesters SREBP1 at the nuclear 
periphery, inhibiting its nuclear adipogenic activity. Farnesyl transferase inhibitor lovastatin is used 
as a positive control due to its activity inhibiting farnesylation-dependent processing of pre-Lamin A. 
[Ca2+]cyt – cytoplasmic Ca2+ concentration B) Immunofluorescence microscopy utilising an antibody 
specific to both Lamin A and pre-Lamin A. Lamin A/pre-Lamin A is enriched at the nuclear periphery 
following lovastatin treatment but not ATRi treatment. 40x. C) Western blotting of 3T3-L1 cells 
treated with ATRis and lovastatin utilising Lamin A/pre-Lamin A antibody. Lovastatin treatment 
increases expression of a lower-migrating band, presumed to be pre-Lamin A. Neither VE-822 nor 
ATRi II induced increases in pre-Lamin A here, further reinforcing that ATRi is not inducing defects in 
pre-Lamin A processing. Upper band (Lamin A) used as loading control. All images representative of 
results obtained in at least three independent experiments. 
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Lovastatin treatment induced a lower migrating form of Lamin A that can be 
identified as pre-Lamin A (Fig 3.2.6.C, lane 2). ATRi treatments did not appear to induce 
an increase in the lower migrating band equivalent to lovastatin, leading me to deduce 
that altered pre-Lamin A processing is not the cause of the ATRi-induced defects in 
adipogenic differentiation. 
3.2.7. ATRi reduces insulin sensitivity in a primary cilia-
independent manner, resulting in reduced mTORC1 activity 
A role for ATR in primary cilia function has recently been established, where impairing 
ATR functionality resulted in impaired cilia-dependent signalling (Stiff et al., 2016). Post-
confluent preadipocytes acquire primary cilia enriched in IGF-1 receptors, which behave 
as adipogenic sensitizers, amplifying incoming differentiative signals (Zhu et al., 2009).  
I assessed the insulin sensitivity of post-confluent and cycling 3T3-L1 
preadipocytes treated with ATRi, and further investigated if such alterations in insulin 
sensitivity were dependent on the presence of primary cilia. The phospho-status of AKT 
and IRS1 can act as markers of insulin sensitivity. Asynchronous, cycling 3T3-L1 
preadipocytes do not express primary cilia, whereas post-confluent 3T3-L1 cultures will 
produce primary cilia as a requisite to adipogenesis (Fig 3.2.7.A) (Zhu et al., 2009). 
Hence, to delineate a role for primary cilia in the ATRi-induced adipogenic defects I have 
observed, I investigated the insulin sensitivity of confluent preadipocytes as well as 
asynchronous samples after treatment with ATRis. If ATR-inhibited cultures could not 
appropriately propagate adipogenic signals due to dysfunctional formation or signalling 
at the primary cilia, insulin sensitivity should remain unaffected in ATRi-treated, non-
ciliated cells.  
I confirmed that confluent 3T3-L1 preadipocytes formed primary cilia using 
immunofluorescence against primary cilia marker acetylated tubulin (Fig 3.2.7.A). Fig 
3.2.7.B shows western blotting of proteins containing insulin-sensitive phospho-sites in 
confluent and asynchronous cells, before and after acute insulin treatments, where 
samples were pre-treated with or without VE-822 for 30 minutes. Five minutes post 
insulin addition, phosphorylation of IRS1 at Y989 and AKT at S473 and T308 is markedly 
increased, suggesting induction of the insulin-PI3K-AKT signalling axis (lane 3). 
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Strikingly, in samples pre-treated with VE-822, both AKT and IRS1 phosphorylations are 
dramatically reduced, suggesting cells without functional ATR are less sensitive to insulin 
(Fig 3.2.7.B, lanes 4 & 6). Reduced p-AKT S473 was also observed following ATRi 
treatment in asynchronous cells, where cells treated with ATRi alone exhibited 
decreased p-AKT S473 compared to their unstimulated counterpart. This suggests ATRi 
induces defects in the PI3K-AKT signalling pathway in the absence of stimulation by 
insulin. The decreased AKT activity in both ATRi-treated confluent and asynchronous 
cells suggests that the ATRi-induced defects in the PI3K-AKT signalling axis I have 
observed are independent of primary cilia presence, and furthermore that ATRi 
treatment is reducing mTORC2 activity. As both PDK- and mTORC2-dependent AKT sites 
are ablated following ATRi treatment, it is possible ATRi may prevent recruitment of AKT 
to the plasma membrane, where these phosphorylation events occur. 
 AKT has downstream activator effects on mTORC1 via inhibitory 
phosphorylations of the TSC1/2 complex (Fig 3.2.7.E). The TSC complex has GTPase 
activity, and functions to maintain mTORC1 activator RHEB-GTP in an inactive RHEB-GDP 
state. Inactivation of the TSC complex by AKT results in active RHEB-GTP, which can 
activate mTORC1. Reduced AKT activity results in decreased mTORC1 activity. To assess 
the downstream effects of compromised insulin signalling following ATRi, I assessed p-
S6 S240/244 as an indirect marker of mTORC1 activity. S6 is a substrate of S6 kinase, 
itself a direct target of mTORC1. Fig 3.2.7.C shows asynchronous 3T3-L1 preadipocytes 
Figure 3.2.7 Acute ATRi treatment and Atr siRNA reduces insulin sensitivity and mTORC1 activity in 3T3-
L1 preadipocytes. A) Immunofluorescence of confluent 3T3-L1 preadipocytes with DAPI (blue) and 
primary cilia marker acetylated tubulin (green) shows transient formation of primary cilia. Images taken 
at 100x. B) Western blotting of insulin-sensitive phospho-proteins AKT and IRS1 following insulin and ATRi 
treatment, in confluent and asynchronous cells. Cell cultures were treated with ATRi for 30 minutes before 
addition of insulin. Insulin induces phosphorylation of AKT and IRS1 within minutes, regardless of 
confluence. When co-treated with ATRi and insulin, samples display impaired AKT and IRS1 
phosphorylation kinetics. In asynchronous samples, decreased p-AKT S473 following ATRi is recovered at 
15 minutes. Increased degradation of native IRS1 in ATRi-treated confluent samples suggests rates of IRS1 
phosphorylation could be equivalent +/- ATRi, but degradation is causing reduced signal as assessed by 
western blotting here. AKT utilised as loading control. C) p-S6 S240/244 is decreased following ATRi 
treatment in cycling cells, indicative of reduced mTORC1 activity. S6 utilised as loading control. D) Atr 
siRNA induces decreased S6 phosphorylation at 48 hrs. 4 hrs of ATRi VE-822 treatment also decreased p-
S6 S240/244. All images representative of results obtained in at least three independent experiments.E) 
Simplified schematic of PI3K-AKT-mTORC1/2 pathway. AKT is phosphorylated on S473 and T308 by 
mTORC2 and PDK1, respectively, in response to insulin. mTORC1 complex activates S6K, resulting in S6 
phosphorylation. Taken from (Yu and Cui, 2016). 
 
89 
 
treated with ATRi II for 1-16 hours. Following addition of ATRi, as early as one hour there 
is decreased phosphorylation of S6, suggesting reduced mTORC1 activity when ATR lacks 
kinase activity. To validate that this was not due to an off-target effect of ATRi II, I utilised 
Atr siRNA to ablate ATR expression in cycling 3T3-L1 preadipocytes. Fig 3.2.7.D shows p-
S6 S240/244 following Atr siRNA and VE-822 treatment. After four hours VE-822 
treatment, and 48 hrs Atr siRNA treatment, S6 phosphorylation is drastically decreased, 
suggesting this is not an off target effect of ATRi treatment. Interestingly, ATR is depleted 
after 24 hrs of Atr siRNA treatment, yet at this time point, S6 phosphorylation remains 
unaffected, hinting at a threshold-based mechanism in which reduced ATR functionality 
may affect mTORC1. 
3.2.8. Atr siRNA induces PPAR2 expression 
To investigate if differentiating 3T3-L1 preadipocytes with reduced (as opposed to 
inhibited) ATR would display the same adipogenic defects as those treated with ATRis 
throughout adipogenesis, I transiently transfected confluent preadipocytes with Atr 
siRNA prior to adipogenic differentiation.  
siRNA knockdown depletes mRNA in a targeted manner to reduce protein 
product, requiring active gene transcription of the protein of interest to deplete 
expression. Hence, transient transfection of siRNA is commonly undertaken in cycling 
cells that have high levels of transcriptional activity. As confluence is a prerequisite to 
adipogenesis, transient genetic ablation of ATR before initiation of adipogenesis 
required transfection of Atr siRNA into confluent cell cultures. However, a benefit of 
utilising growth-arrested cells in this experiment was the circumvention of toxicity 
associated with depleting ATR in a cycling cell population. 
Transient transfection of Atr siRNA required optimisation to ensure ATR protein 
expression was ablated at the initiation of adipogenesis and throughout. It was also 
necessary to assess the consequence of transfection reagents on adipogenic induction. 
Induction of the adipogenic program was evaluated by western blotting of PPAR2. 
Treatment of differentiating cultures with transfection reagent alone did not affect 
PPAR2 expression (Fig 3.2.8, lane 5). Very surprisingly, genetic ablation of Atr induced 
PPAR2 expression in the absence of adipogenic cocktail (lane 3), and appeared to 
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enhance PPAR2 expression following adipogenic induction (lane 6). Considering the 
impaired PPAR2 induction following ATRi treatment throughout adipogenesis (Fig 
3.2.8, lane 7), this interesting result of enhanced PPAR2 expression following Atr siRNA 
alone could provide insight into the multifaceted, threshold-based regulatory  
mechanisms that govern the decision to proceed into terminal adipogenic 
differentiation. This result suggests inhibition of ATR may have a different outcome to 
ATR absence in this context, or perhaps ATRi treatments have off-target impacts. Over 
expression of a dominant-negative, KD-ATR construct could provide insight here and 
address this difference. 
 
 
 
 
 
Figure 3.2.8. Atr siRNA induces PPAR2 expression in the absence of adipogenic inducers. Confluent 
preadipocytes were transfected with multiple hits of Atr siRNA, resulting in almost complete ablation of 
ATR protein expression at the initiation of adipogenesis (Fig 8a, lane 3). Both higher and lower migrating 
bands of ATR have been depleted, suggesting two forms of ATR. Atr siRNA treatment did not reduce 
viability and cells remained confluent throughout transfection. Following successful ATR knockdown, 
samples were induced to differentiate with adipogenic cocktail as previously described. After 24 hrs 
adipogenesis, cultures treated with Atr siRNA consistently appeared to recover small levels ATR 
expression, specifically the higher migrating band (lane 6).Treatment with ATRi II throughout 
adipogenesis appeared to deplete the higher migrating ATR band, whilst some lower migrating ATR 
remained. Depletion of ATR expression through small molecule kinase inhibition is induced by a failure 
of ATR to auto-trans-phosphorylate at T1989, reducing overall protein stability. Representative of 
results obtained in four independent experiments. 
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3.3. Summary  
In summary, I have found that: 
 ATRis decrease adipogenic differentiation in 3T3-L1 cells (section 3.2.1) 
The decreased adipogenic capability of cells treated with ATRis is not due to:  
 Decreased viability or altered S-phase kinetics of MCE (section 3.2.2) 
 Defects in the early adipogenic signalling cascade (section 3.2.3) 
 Increased Calcineurin activity (section 3.2.5) 
 Defective pre-Lamin A processing (section 3.2.6) 
However, I have observed, in response to ATRi treatment: 
 A functionally relevant reduction in insulin sensitivity, in a primary cilia-
independent manner, resulting in reduced mTORC1 activity (section 3.2.7) 
 Increased p38 MAPK activity and increased phosphorylation p38 MAPK 
substrates (section 3.2.4) 
Furthermore: 
 Atr siRNA unexpectedly induces PPAR2 expression in post-confluent 3T3-L1 
preadipocytes, independently of other adipogenic inducers, in marked contrast 
to my findings with ATRi (section 3.2.8) 
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3.4. Discussion 
A significant clinical feature commonly observed in SS is lipodystrophy, suggesting a 
failure to maintain adipogenic stem cells on a differentiative program (O’Driscoll, 2009; 
O’Driscoll et al., 2004). Mice generated from a humanized model of SS recapitulate this 
presentation of diminished WAT, and a common feature of both SS patient cell lines and 
mouse models is suppression of the insulin-somatotrophic axis (Murga et al., 2009). 
Patients and mouse models of SS demonstrate that defective ATR seems to 
disproportionately affect adipose tissue (O’Driscoll, 2009). Currently, there is limited 
understanding of the underlying mechanisms in which this congenital defect in ATR 
function affects adiposity or metabolism. 
In this chapter, I investigated whether the cachexic presentation of ATR-SS is due 
to ‘cell autonomous’ effects of loss of ATR, due to the essential role of ATR in cell 
replication, or whether ATR signalling has an uncharacterised role in the differentiation 
of WAT. I have characterised a novel impact of ATR deficiency on the dynamic process 
of adipogenic differentiation. The negative effect of clinically relevant ATRis on 
adipocyte biology requires further investigation, to ensure the impacts that I have 
observed in vitro will not drive a cachexic presentation in a cancer setting in vivo, 
associated with poor patient outcome and prognosis.  
ATR inhibition with clinically relevant small molecule kinase inhibitors blocks 
adipogenic differentiation in 3T3-L1 preadipocytes, as indicated by failure to increase 
adipogenic marker PPAR2 following induction with an adipogenic cocktail. In this novel 
consequence of ATRi treatment, ATRi-treated differentiating preadipocytes underwent 
MCE successfully, which suggests that although high levels of DSBs and DDR signalling 
were present, differentiation was not blocked due to defects in the ATR-dependent 
intra-S-phase checkpoint. Using western blotting of PPAR2 alone, it was unclear 
whether the novel adipogenic defects observed with ATRis were independent of 
canonical ATR signalling through CHK1, as CHK1i also caused reduced PPAR2 protein 
induction. By assessing MCE kinetics, I demonstrated that CHK1i induces a defect in MCE 
suggesting that, although both CHK1i and ATRi induce defects in adipogenesis, they are 
through differing MCE-dependent and -independent mechanisms respectively.  
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Furthermore, I assessed adipogenesis following ATMi treatment and DNA 
damaging agents – neither ATMi nor ionising radiation-induced DNA damage had an 
effect on adipogenic differentiation, suggesting that the adipogenic defects observed 
with ATRi treatment were not due to cell autonomous effects of loss of ATR, elevated 
replicative stress or DNA damage signalling, and more specifically reduced ATR-CHK1 
signalling. This result is highly indicative that the impacts of ATRi treatment on 
adipogenic differentiation are occurring through a novel mechanism. 
I examined several potential mechanisms that could have contributed to an ATRi-
dependent failure to induce PPAR2. I demonstrated ATR inhibition did not generate 
defects in pre-Lamin A processing, and further did not block adipogenesis through 
Calcineurin-dependent increases in nuclear NFATC1 activity. 
Probably the most striking consequences of ATR inhibition I observed were 
defects in the Insulin-PI3K-AKT-mTORC1 pathway. I observed decreased insulin-
dependent phosphorylation of IRS1 and AKT, and reduced mTORC1 activity with ATRi 
and Atr siRNA, as assessed by S6 phosphorylation. These results appeared cell cycle and 
primary cilia independent, as they were observed in cycling (non-ciliated) and post-
confluent (ciliated) 3T3-L1 preadipocytes. In striking contrast, I saw a remarkable 
induction of PPAR2 when I ablated ATR expression in post-confluent preadipocytes with 
Atr siRNA, in the absence of any adipogenesis-inducing drugs. At face value, these results 
appear contradictory. Many models could be postulated to explain how Atr siRNA could 
induce adipogenesis – for example, perhaps ATR is required to maintain post-mitotic cell 
cycle arrest, where ablation of ATR allows preadipocytes to enter MCE without other 
adipogenic stimulation.  
However, I propose a mechanism that unifies my observations on the regulation 
of adipogenesis following reduced ATR function. mTORC1 has essential inputs into 
adipogenesis at the level of PPAR2 induction, through downstream target S6K and the 
4EBP1-eIF4e axis (Zhang et al., 2009). mTORC1 also has inhibitory effects on 
adipogenesis through the inhibition of the IRS1-AKT-PPAR axis (Fig 3.4.1.A). Complete 
inhibition of mTORC1 through Rapamycin treatment or deletion of essential mTORC1 
subunit RAPTOR causes complete inhibition of S6K activation, resulting in blocked 
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adipogenic differentiation at the level of PPAR2 (Fig 3.4.1.B). Phosphorylation of S6K 
substrate S6 rapidly decreases following ATRi treatment, indicative of mTORC1 
inhibition, and it is through this pathway that I propose ATRi treatment generates an 
adipogenic block at the level of PPAR2 expression. Furthermore, following ATRi 
treatment I observe reduced IRS1 expression, concomitant with reduced IRS1 and AKT 
activation, indicating that this arm of mTOR signalling, required for adipogenesis, is also 
compromised following ATRi treatment. 
To explain the increased adipogenesis following Atr siRNA, I suggest that 
incomplete depletion of ATR results in incomplete depletion of mTORC1 activity, 
alleviating mTORC1-dependent inhibition of IRS1, whilst minimal mTORC1-dependent 
S6K activity remains. Increased IRS1 activity could potentially lead to hyperactivation of 
AKT and enhanced adipogenic differentiation (Fig 3.4.1.C). In Fig 3.4.1.D (also shown in 
Figure 3.4.1. Schematisation of postulated mechanisms of reduced adipogenesis following ATRi, 
and enhanced adipogenesis following Atr siRNA. Grey shading denotes reduced activity. A) mTORC1 
activity maintains adipogenic homeostasis through pro-adipogenic activation of S6K, and anti-
adipogenic downregulation of the IRS1-PI3K-AKT axis. B) Following ATRi, mTORC1 function is fully 
inhibited resulting in attenuation of S6K activation, inhibiting adipogenesis. Also observed following 
mTORC1 inhibitor Rapamycin (Rap) and Raptor knockout. C) Following Atr siRNA, mTORC1 is partially 
inhibited, resulting in minimal S6K activity and reduced inhibition of the IRS1-PI3K-AKT axis, 
enhancing adipogenesis – also observed following Deptor overexpression. Edited from (Yoon et al., 
2013). D) Atr siRNA reduces S6K activity as assessed by S6 phosphorylation (S240/S244), whereas VE-
822 (10 M, 2 hrs) completely ablates S6 phosphorylation, supporting this hypothesis.  
A B 
C D 
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Fig 3.2.7.D), I do observe different impacts on p-S6 S240/244 between ATRi and Atr 
siRNA; the latter treatment has a more modest impact suggesting incomplete mTORC1 
inhibition. Yoon et al. have previously postulated this model, where partial depletion of 
mTOR in 3T3-L1 cells resulted in enhanced adipogenesis (Yoon et al., 2013). 
Furthermore, another group discovered that overexpression of DEPTOR, an endogenous 
mTOR inhibitor, resulted in enhanced adipogenesis against their predictions (Laplante 
et al., 2012). Laplante et al. characterised this phenomenon similarly, as via the 
dampening of mTORC1-mediated feedback inhibition of insulin signalling via IRS1, 
resulting in enhanced activity of the IRS1-AKT-PPAR axis (Fig 3.4.1.C). In the case of ATRi 
and Atr siRNA treatments, this hypothesis would be easily testable through by assessing 
AKT phosphorylation at mTORC2-dependent site S473. Alternatively, assessing the 
effects of overexpression of mTORC1 activators (such as constitutively inactive TSC2) 
following ATRi treatment on PPAR2 expression. 
A failure to maintain preadipocytes within an adipogenic program following 
treatment with ATRis could constitute evidence for a novel role for ATR in metabolism. 
The consequences of ATRi treatment on the adipogenic capability of preadipocytes, that 
I have characterised in this chapter, have potential for the therapeutic use of ATRis in 
cancer as they reveal potentially undesirable metabolic consequences. Further, this data 
may provide a pathomechanistic link between the cachexic presentation of SS and ATR 
deficiency. It is essential to next investigate the effects of chronic ATRi treatment on the 
metabolic homeostasis of mature, terminally differentiated adipocytes. 
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4. Chapter Four 
 Results II:  Impact of Chemical ATR                     
Inhibition on Mature Adipocytes 
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4.1. Introduction 
In Chapter three I found that treating differentiating 3T3-L1 preadipocytes with 
small molecule kinase inhibitors of ATR (ATRis) resulted in failure to successfully 
complete the adipogenic program, a result that carries significance for those who may 
be treated with ATRis as a cancer chemotherapeutic. Cancer patients are at high risk of 
metabolic dysfunction as the tumour tissue encourages the body to increase catabolic 
processes and generate metabolites to facilitate cancer progression {Argiles, 2014 
#858}. The earliest adaptive event tumours undertake is an extensive shift towards 
glycolysis and glucose dependency, known as the Warburg effect (Warburg, 1956). 
Cancer cells undergo distinct metabolic reprogramming to sustain their growth at the 
detriment of the host, generating the cachexic presentation that is so frequently 
observed in late-stage cancers.  
In this chapter, I investigate the effects of chronic ATRi treatment on adipocyte 
metabolism. I will first discuss several aspects of adipocyte biology in further detail, 
before detailing my findings. 
4.1.1. Adipocyte and adipose tissue overview 
Almost all animal species are equipped with a mechanism to promote energy storage 
during periods of calorific excess, and mobilization of this supply when nutrition is scarce 
(Gesta et al., 2007). Adipose tissue is specialized connective tissue, which functions as a 
major energy reserve in the form of stored triglycerides (TGs). In humans, lipid-storing 
white adipocytes (WAT) are the most abundant constituent of adipose tissue, 
encompassed within a stromal-vascular fraction composed of a variety of structure-
forming cells including preadipocytes, fibroblasts and macrophages (Berg and Scherer, 
2005). Cycling preadipocytes provide a constant supply of adipocyte precursors, which 
upon appropriate induction, undergo adipogenic differentiation, allowing this metabolic 
tissue the essential plasticity required to adapt to variable energy output and nutrient 
statuses. Following excess calorific intake, a small reserve of carbohydrates are stored 
within the liver as glycogen. When liver glycogen levels are maximal, hepatocytes and 
adipocytes utilise excess glucose in the de novo fatty acid synthesis pathway for 
assembly of very-low-density lipoproteins (VLDL) and triglycerides (Coleman R. A., 
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2000). VLDLs export triglycerides from the liver to the adipose tissue, where they are 
incorporated into the lipid droplet (Tang and Lane, 2012).  
Adipose tissue is a vastly dynamic organ, with key roles in many pathways 
reaching further than its established role in metabolic homeostasis (Sethi and Vidal-Puig, 
2007). Two functionally distinct types of adipocyte tissue are found in mammals – WAT 
and brown adipose tissue (BAT). BAT is a thermogenic tissue, with high mitochondrial 
content and enhanced fatty acid oxidation, designed to dissipate chemical energy as 
heat via the elevated expression of mitochondrial uncoupling protein UCP1 (Wang et al., 
2015). BAT protects new-born and hibernating mammals from hypothermia, and the 
trans-differentiation of WAT to BAT (known as ‘adipocyte browning’) is inducible 
through several mechanisms, including cold exposure (Wang et al., 2015). 
As well as providing insulation and mechanical support, adipose tissue also has 
endocrine functions – secreting numerous bioactive peptides, known as adipokines, that 
can promote inflammatory responses (Berg and Scherer, 2005), influence food intake 
via the hypothalamus (Halaas et al., 1995) and regulate haemostasis (Blüher and 
Mantzoros, 2015) among other central and peripheral immune-regulatory functions 
(Greenberg and Obin, 2006). Adipose tissue is also innervated by the sympathetic 
nervous system. This renders neurological stimuli an additional regulator of fat 
mobilisation, via neuronal secretion of adrenergic hormones acting directly at the 
adipose tissue (Rodbell, 1966). 
The diversity of adipose tissue function and regulation is reiterated in the variety 
of pathological conditions associated with its dysfunction. Characterising the complex 
mechanisms behind these pathologies may allow us to identify novel therapeutic targets 
against the metabolic diseases and co-morbidities that are rapidly becoming a global 
epidemic. 
4.1.2. The lipid droplet 
Lipid droplets (LDs) are found in almost all cells, and are the intracellular site of neutral 
lipid storage. LDs not only act as a reservoir of energetic substrates, utilised in times of 
inadequate nutrition, but also provide essential membrane components and bioactive 
lipid mediators Welte (2015). One of the defining characteristics of WAT and BAT 
99 
 
differentiation is the accumulation of LDs, which occupy the vast majority of the 
cytoplasm. White adipocytes generally contain one gigantic, nascent LD, whereas brown 
adipocytes contain many multilocular LDs, to increase access of lipolytic machinery to 
the lipid content via the increased surface-to-volume ratio (Fig 4.1.2) (Strzyz, 2016).  
Many proteins function at the LD surface to facilitate the controlled release and 
uptake of TGs. In contrast to almost all other organelles, which contain aqueous content 
within a lipid bilayer, LDs consist of a single phospholipid monolayer (Tauchi-Sato et al., 
2002). LD synthesis and maturation is poorly understood. Widely postulated is the 
model of membrane budding of the cytoplasmic leaflet of the endoplasmic reticulum 
Figure 4.1.2. Sub-types of adipocyte. White adipocytes contain one vast lipid droplet, brown 
adipocytes have high mitochondrial content and many, small lipid droplets. White adipocytes have no 
thermogenic capacity, but can be induced to express thermogenic markers and increased 
mitochondria (beige adipocytes). Brown adipocytes have high thermogenic capacity. Modified from 
(Sepa-Kishi and Ceddia, 2016) and (Contreras et al., 2016) 
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(ER) membrane (Murphy and Vance, 1999; Ploegh, 2007; Zweytick et al., 2000). Lipid 
droplets are known to physically interact with other organelles, including the ER, 
mitochondria and peroxisomes (Walther and Farese, 2012). Association with the 
mitochondria may be important for the direct transfer of FAs (liberated from lipolysis) 
to sites of oxidative phosphorylation (Tarnopolsky et al., 2007).  
4.1.2.1. Lipid Synthesis 
The lipid synthesis pathway involves the conversion of acetyl-CoA into FAs, cholesterol, 
phosphoglycerides and lipids (sphingolipids, DAGs and TGs) – summarised in Fig 4.1.2.1. 
Most acetyl-CoA used for de novo FA/cholesterol synthesis is derived from glucose, via 
the glycolytic tricarboxylic acid (TCA) cycle. Acetyl-CoA is converted to malonyl-CoA by 
acetyl-CoA carboxylase (ACC). These acetyl groups behave as the common precursor of 
almost all lipids, and are repeatedly condensed by fatty acid synthase (FASN) generating 
the saturated FA palmitic acid, which acts as the primary building block for the further 
generation of a diverse spectrum of lipid components (Baenke et al., 2013).  
Figure 4.1.2.1. Schematic of lipid synthesis pathways. Acetyl-CoA is the common intermediate in all 
lipid synthesis. FA – fatty acids; ACC – acetyl-CoA carboxylase; FASN – FA synthase; Glycerol-3-P – 
glycerol-3-phosphate. Modified from (Baenke et al., 2013) 
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Cholesterol is generated from acetyl-CoA via the mevalonate pathway. FAs are 
converted to DAGs/TGs, phosphoinositides and phosphoglycerides via the glycerol 
phosphate pathway – glycerol-3-phosphate is utilised as glycerol backbone to generate 
lipid groups. Phosphoglycerides are required as essential membrane components.  
4.1.2.2. Lipolysis 
Lipolysis is the catabolism of TGs (Zechner et al., 2012). Within adipocytes, lipolysis is 
under hormonal regulation and can be executed in a nutrient-dependent manner 
(Zimmermann et al., 2004). Lipases are recruited to the LD membrane, facilitating the 
controlled release of lipids into the cytoplasm for immediate hydrolysis. At the LD 
membrane, PERILIPIN A (PLIN1) is the main regulatory factor of lipolysis. Upon 
stimulation by -adrenergic receptor agonists or other Protein Kinase A (PKA) activators, 
PERILIPIN A is phosphorylated by PKA, enabling it to facilitate the translocation of 
Hormone-sensitive lipase (HSL) to the LD, and activation of adipocyte TG lipase (ATGL) 
(Subramanian et al., 2004; Sztalryd et al., 2003). Sequentially, ATGL hydrolyses TGs to 
DAGs, HSL hydrolyses DAG to monoacylglycerol, and monoacylglycerol lipase catalyses 
the final hydrolysis into FAs and glycerol (Fig 4.1.2.2) (Lass et al., 2011).  
Figure 4.1.2.2. Schematic of lipolysis. TG – triglyceride; ATGL – adipose triglyceride lipase; CGI -  
comparative gene identification-58; NEFA – non-essential fatty acids (FAs); DAG – diacylglycerol; MAG – 
monoacylglycerol; HSL – hormone-sensitive lipase; MGL – monoacylglycerol lipase. Modified from 
(Baenke et al., 2013; Ojha et al., 2014)  
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Another mechanism has been described for the utilisation of TGs stored within the 
LD – lipophagy. Lipophagy (autophagic degradation of lipid droplets) appears to play a 
critical role in energy metabolism during fasting in non-adipose tissues. Double 
membraned autophagosomes have been observed forming in and around the LD 
surface, pinching off small portions of the LD. Lipids are degraded by lipases contained 
within the lysosome following fusion. Surprisingly, Microtubule-associated protein 
1A/1B-light chain 3 (LC3-II) is constitutive member of the LD membrane proteome, 
suggesting autophagy plays an important role in the regulation of lipid metabolism 
(Singh et al., 2009a).  
4.1.3. Adipocyte browning  
Within WAT, a sub-population of inducible ‘brown-like’ or ‘beige’ adipocytes exists, 
capable of developing thermogenic activity in response to a variety of factors (Fig 4.1.2). 
The activity of BAT and inducible ‘beige’ adipocytes has been demonstrated to suppress 
weight gain and reduce metabolic disease (Kopecky et al., 1995), making the pathways 
involved exciting and novel targets for the treatment of obesity. Initially perceived as 
transdifferentiated white adipocytes, a recent study has suggested beige adipocytes are 
derived from their own distinct progenitor (Wu et al., 2012). However, the induction of 
‘beige’-like adipocytes in 3T3-L1 white adipocyte cultures has been demonstrated in 
multiple studies (Asano et al., 2014; Parray and Yun, 2016), suggesting an element of 
fluidity remains uncharacterised within these functionally distinct varieties of adipocyte. 
Brown adipocytes contain uniquely high levels of uncoupling protein-1 (UCP1)-
expressing mitochondria. UCP1 activity generates thermogenesis through the controlled 
uncoupling of oxidative phosphorylation and ATP synthesis. As a transmembrane 
protein, UCP1 increases the permeability of the inner mitochondrial membrane (IMM), 
allowing protons pumped into the intermembrane space to return to the mitochondrial 
matrix. This results in a net decrease in the proton gradient required for efficient ATP 
production, where protons returning to the mitochondrial matrix dissipate their energy 
as heat (Wang and Seale, 2016).  
UCP1 is generally induced in beige adipocytes via elevated intracellular cAMP-
induced PKA activation and induction of lipolysis (Fig 4.1.3). TGs stored in the LD are 
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hydrolysed to FAs and released, where they activate existing mitochondrial UCP1 and 
their oxidation generates heat. Increased cytoplasmic FFAs can induce white adipocyte 
browning, and furthermore induce PPAR2 activation, to increase expression of 
adipocyte-specific genes (discussed further in section 3.1.3.6). Increased PKA activation 
also leads to increased expression of thermogenic genes, via the activation of p38 MAPK 
and downstream transcription factors activating transcription factor 2 (ATF2) and PPAR 
coactivator 1-alpha (PGC1) (Lo and Sun, 2013; Peirce et al., 2014). ATF2 and PGC1 can  
be induced through the activation of other signalling pathways that result in increased 
Figure 4.1.3. Schematic of adipocyte browning. Nervous innervation of WAT allows -adrenergic 
stimulation, one mechanism of inducing adipocyte browning. Increased p38 MAPK activity is also a 
common mediatory event in browning induction. Edited from (Harms and Seale, 2013) 
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p38 MAPK activation, including increased cyt[Ca2+] (cytoplasmic Ca2+ concentration) via 
Ca2+/calmodulin-dependent protein kinase II (CAMKII)-dependent activation of p38 
MAPK (Fig 4.1.3) (Wright et al., 2007).  
Impaired autophagy in WAT has also been implicated in WAT browning. Recently, 
the return of UCP1-inducible ‘beige’ adipocytes to their nascent, fat-storing WAT status 
has been characterised as dependent on increased mitophagy and TFEB (Transcription 
factor EB)-mediated lysosomal biogenesis (Altshuler-Keylin et al., 2016), where genetic 
and pharmacological inhibition of autophagy retained the subpopulation of beige 
adipocytes. Knockdown of autophagy proteins ATG5, ATG7, or pharmacological 
inhibition of autophagic or lysosomal function inhibits lipid accumulation in 
differentiating 3T3-L1 preadipocytes. Adipocyte-specific knockdown of Atg7 in mice 
results in a lean phenotype, due to an increased beige adipocyte population and BAT, 
suggesting autophagy is one of several determinants in adipocyte differentiation and 
the balance between BAT and WAT (Singh et al., 2009b).   
4.1.3.1. 4E-BP1 
4E-BP1 (or eIF4E-BP1 - eukaryotic translation initiation factor 4E (eIF4E) binding protein 
1) reversibly binds to eukaryotic initiation factor eIF4E, repressing its ability to initiate 
translation in the eIF4F complex. Knockout of 4E-BP1 gene Eif4ebp1 in mice results in 
Figure 4.1.3.1. Mechanism of eIF4E-BP1 (4E-BP1) inactivation-induced browning. In the basal state, 
eIF4E-BP1 binding to eIF4E sequesters eIF4E, inhibiting initiation of cap-dependent translation. 
Inactivation of eIF4E-BP1, through mTORC1-dependent phosphorylation results in dissociation of eIF4E 
from eIF4E-BP1 resulting in in increased translation of PGC1 and expression of thermogenic genes. 
Modified from (Chen and Farese, 2001) 
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increased metabolic rate, decreased WAT and the increased appearance of BAT 
(Tsukiyama-Kohara et al., 2001). It was suggested this effect was due to increased 
PGC1 translation. 4E-BP1 association with eIF4E is regulated by mechanistic target of 
rapamycin (mTOR)-dependent phosphorylation – when mTORC1 is active, 
phosphorylated 4E-BP1 releases eIF4E, allowing the initiation of cap-dependent 
translation. This mechanism appears to allow mTOR activity a role in adipocyte browning 
(Showkat et al., 2014). 
In this chapter, I investigate the effects of ATRi treatment on mature, non-cycling, 
post-mitotic adipocytes, to ascertain the potential impacts of ATRis on WAT 
homeostasis. My results in chapter three indicate that ATRi treatment of differentiating 
preadipocytes has dramatic effects on their capacity to successfully differentiate. 
Investigating the effects of ATRis on WAT could also be relevant in the proposed use of 
ATRi in cancer. Furthermore, to characterise the pathomechanism behind the cachexic-
like presentation of Seckel Syndrome (SS) and ATR deficiency, and the apparent attrition 
of WAT in the conditional adult Atr deletion mouse model (Ruzankina et al., 2007).  
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4.2. Results  
4.2.1. Chronic ATRi treatment does not affect adipocyte 
viability or induce the DDR 
Before investigating a role for ATR in adipocyte metabolism, it was important to assess 
the effects of ATR inhibition on the canonical ATR signalling axis in mature adipocytes. 
As adipocytes are not cycling cells, I hypothesised I would not observe decreased 
viability following ATR inhibition, as these cells have no requirement of the role of ATR 
in cell replication. Utilising the WST-8 viability assay, I assessed viability of 3T3-L1 
adipocytes throughout chronic treatment with ATRis. Fig 4.2.1.A demonstrates no 
significant changes in viability were observed following treatment with ATRis (ATRi II, 
A 
B 
Figure 4.2.1. Chronic ATRi treatment of mature 3T3-L1 adipocytes does not affect viability or induce 
the DNA damage response. A) Viability of 3T3-L1 adipocytes throughout chronic treatment with 
ATRis and ATMi (all 10 M) where no significant change is observed until day 10. B) Western blotting 
of DSB marker H2AX and mitosis initiation marker p-H3 S51 – both showing no change following ATRi 
treatment, suggesting the canonical activity of ATR is non-essential in this system. * indicates positive 
controls, 10 Gy for H2AX and asynchronous preadipocytes of p-H3 S51. -actin utilised as loading 
control for p-H3 S10, native H2a as loading control for H2AX. All images representative of results 
obtained in at least three independent experiments. 
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VE-822, and VE-821) or ATMi (KU-55933). The observed increases in viability are likely 
due to replication of a small pool of preadipocyte-like cells that remain following the 
completion of adipogenesis.  
To further confirm the Go nature of these cells, I assessed phosphorylation of 
histone H3 at S10 – an established marker of chromatin condensation and mitosis. Using 
asynchronous, cycling preadipocytes as a positive control, Fig 4.2.1.B shows H3 appears 
unphosphorylated at S10 in untreated mature adipocytes, and in those chronically 
treated with ATRi, indicative of an absence of mitotic cells. This indicates that the 
essential function of ATR in cell replication may not be required in mature adipocytes.  
In Chapter 3, I demonstrated that ATRi treatment of differentiating 3T3-L1 
preadipocytes induces ATM activation, due to the increased replication stress-induced 
DNA damage acquired in the absence of ATR function, as assessed by increased H2AX. 
I did not observe this in mature adipocytes treated with ATRis, as shown in Fig 4.2.1.B, 
indicating that there is no replication-stress mediated DDR activation following ATRi 
treatment. This further reinforces the reduced requirement of the ATR-DDR signalling 
axis in terminally differentiated 3T3-L1 adipocytes. 
4.2.2. Acute ATRi treatment results in decreased lipid droplet 
(LD) integrity 
Whilst treating mature adipocytes with ATRis to assess the consequences of reduced 
ATR functionality on their viability, I observed interesting morphological changes. 
Cytoplasmic LDs, clearly visible in untreated adipocytes, were far less apparent following 
chronic ATRi II treatment. Fig 4.2.2.1.A shows brightfield microscopy images of 
untreated mature 3T3-L1 adipocytes, and also samples treated with ATRi II for 6 days, 
where large LDs were no longer visible. Having confirmed that chronic ATRi treatment 
was not inducing DNA damage and had no effect on the viability of mature 3T3-L1 
adipocytes, I set out to investigate the effects of chronic ATRi treatment on the adiposity 
(ability to store TGs) of these cells.  
I utilised Oil Red O (ORO – described in chapter 3) to assess the TG content of 
mature 3T3-L1 adipocytes treated with ATRis following successful adipogenic 
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differentiation – hypothesising that ATRi-treated adipocytes would have decreased 
adiposity. Fig 4.2.2.1.B shows TG content (as assessed by ORO quantification) of mature 
adipocytes treated with ATRis and ATMi for 7 days. I observed significant decreases in 
TG content following treatment with ATRis VE-822 (p < 0.01) and ATRi II (p < 0.05), but 
not with ATMi (p > 0.05). The viability of adipocytes treated with ATRis remained 
unaffected at 7 days treatment (Fig 4.2.1.A), hence the observed 30% decrease in 
adiposity observed following ATRi is not due to decreased viability. This striking result is 
indicative of metabolic reprogramming events following chronic ATRi treatment.  
A 
Figure 4.2.2.1 Chronic ATRi treatment reduces TG content of mature 3T3-L1 adipocytes. A) 
Brightfeild microscopy images of mature 3T3-L1 adipocytes treated with or without ATRi II for 6 days. 
Untreated adipocytes have characteristic LDs within cytoplasmic compartment. Following chronic 
ATRi II treatment LDs appear less frequent and largely fragmented. B) Quantification of TG content 
of mature adipocytes treated with ATRis (10 M) daily for 7 days, as assessed by Oil Red O staining. 
ATRi- and ATMi-treated samples were normalised to the DMSO-treated control for quantification. 
ATRi II (*) and VE-822 (**) induce significant decreases in TG content where * p < 0.05 and ** p < 
0.01 – statistically significant changes compared to DMSO treatment (two-tailed T test). No 
significant decrease observed in TG content following ATMi treatment.  
B 
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To further investigate the cause of the decreased TG content of adipocytes 
treated with ATRi, I assessed changes in LD membrane protein PERILIPIN A by western 
blotting and immunofluorescence (IF), utilising fluorescent triglyceride stain BODIPY 
493/503 to visualise LDs.  
Fig 4.2.2.2.A and B shows western blotting of adipocytes chronically treated with 
ATRis to investigate PERILIPIN A expression. Fig 4.2.2.2.A and B demonstrate a drastic 
decrease in PERILIPIN A expression following treatment with ATRis - ATRi II (Fig 4.2.2.2.A) 
and VE-822 (Fig 4.2.2.2.B). This phenotype was not observed with ATMi (Fig 4.2.2.2.C). 
Interestingly, treatment with ATRi II consistently induced a large but transient increase 
in PERILIPIN A expression at days 1 and 2 (Fig 4.2.2.A lanes 2 and 3).  
To further investigate the functional relevance of the decreased PERILIPIN A 
protein expression following ATRi treatment, I assessed LD integrity and PERILIPIN A 
localisation to the LD membrane using IF. Fig 4.2.2.2.D shows IF of mature 3T3-L1 
adipocytes treated with DMSO or ATRi II for 4 days, stained with antibody to PERILIPIN 
A and nuclear stain DAPI. I chose to assess PERILIPIN A by IF after 4 days of ATRi 
treatment, as this was the earliest time PERILIPIN A expression levels were consistently 
depleted. In DMSO-treated samples, PERILIPIN A evenly coats the LD membrane (Fig 
4.2.2.2.D). Drastically and unexpectedly, following 4 days of ATRi II treatment, the even 
LD-coating of PERILIPIN A appears fragmented, where small gaps without PERILIPIN A at 
the LD membrane can be observed. The inconsistent placement of this remaining 
protein implies the fundamental role of PERILIPIN A in the regulation of lipolysis could 
be compromised following ATRi treatment. 
 To further investigate this phenomenon, I co-stained mature adipocytes with 
PERILIPIN A and BODIPY 493/503 to investigate how PERILIPIN A depletion and 
fragmentation could be effecting intracellular TG content. Fig 4.2.2.2.E shows BODIPY 
493/503 (green, neutral lipids) contained within PERILIPIN A-coated LDs in untreated 
adipocytes. Following 4 days ATRi treatment, the cytoplasmic compartment is stained 
with BODIPY 493/503, indicating increased cytoplasmic lipid content, concomitant with 
fragmented PERILIPIN A staining at the LD membrane. This is concerning considering TGs 
do not often remain unprocessed within the cytoplasm, and highly suggestive of a ‘leaky’ 
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Figure 4.2.2.2. Chronic ATRi treatment decreases lipid droplet integrity of 3T3-L1 adipocytes. A) and 
B) Western blotting of mature adipocytes treated with ATRi II (A) and VE-822 (B) (both 10 M, 
refreshed every 48 hrs) for lipid droplet protein PERILIPIN A show dramatic decreases following 
chronic ATRi treatment. PERILIPIN A levels were consistently and transiently increased following ATRi 
II treatment. C) ATMi did not affect adipocyte PERILIPIN A expression in this system. -actin utilised 
as loading control in all WBs here. D) PERILIPIN A immunofluorescence staining of 3T3-L1 adipocytes 
(PERILIPIN A red; DAPI blue) following 4 days treatment with ATRi II or DMSO. Following ATRi II 
treatment, PERILIPIN A has lost consistency around the LD membrane and LDs appear fragmented. 
E) Immunofluorescence staining of mature adipocytes with PERILIPIN A (red) and neutral lipid strain 
BODIPY 493/503 (green). In DMSO treated samples, TGs are contained within the LD, with limited 
cytoplasmic staining. PERILIPIN A evenly coats the LD membrane. Following 4 days ATRi II treatment, 
TGs have leaked into the cytoplasmic compartment and PERILIPIN A appears compromised at the LD 
membrane. Images captured at 100x. All images representative of results obtained in at least three 
independent experiments. 
A 
E 
B 
C 
D 
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LD membrane and TG release that is uncoupled from adequate lipolysis.  
 Mature 3T3-L1 adipocytes treated with ATRis have reduced TG content (Fig 
4.2.2.1.B). TG release from the LD is inherently coupled to lipolytic pathways to ensure 
unhydrolysed TGs do not accumulate in the cytoplasmic compartment. However, TG 
stain BODIPY 493/503 is increased within the cytoplasm following ATRi treatment in Fig 
4.2.2.2.E. I wanted to investigate if the reduced ‘adiposity’ of mature adipocytes 
following ATRi treatment was due to increased lipolysis, or an aberrant release of 
intracellular TGs. To investigate this, I treated mature 3T3-L1 adipocytes chronically with 
ATRi II (10 days) and assessed the FFA and TG content of cell culture media throughout 
treatment. In this experiment, I utilised FACs analysis of BODIPY 493/503 to confirm I 
was observing a decrease in cellular adiposity following ATRi, shown in Fig 4.2.2.3.A, 
where 10 days ATRi II treatment reduces TG content of mature adipocytes by 50%. I 
utilised a plate-reader based enzymatic assay to quantify media TG content of 
adipocytes treated with or without ATRi II for 10 days. Fig 4.2.2.3.B shows that in 
untreated 3T3-L1 adipocytes, media TG content increases slowly over 10 days. In 
A 
B C 
Figure 4.2.2.3. Chronic ATRi treatment induces FFA and TG release. A) FACs quantification of cellular 
TG content of mature 3T3-L1 preadipocytes following 10 days ATRi II treatment (10 M) using BODIPY 
493/503. TG content is decreased by 50% following ATRi. B) Media TG content throughout 10 days 
ATRi II treatment shows a striking increase in TG release when adipocytes are treated with ATRi. C) 
Quantification of media FFA content following 10 days ATRi II treatment shows increased media FFA, 
suggesting enhanced lipolysis. 
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cultures treated with ATRi II, there is a striking increase in media TG content, indicating 
uncontrolled TG release concomitant with the loss of PERILIPIN A expression (Fig 
4.2.2.2A). In Fig 4.2.1.A I demonstrated ATRi treatment of mature adipocytes did not 
induce a significant loss of viability, suggesting this striking increased in media TG 
content is not due to cell death. I also assessed media FFA concentration after 10 days 
ATRi treatment of mature adipocytes, where media FFAs are 3-fold higher in ATRi II-
treated samples, indicative of enhanced lipolysis (Fig 4.2.2.2.C). 
My data thus far is indicative of profound changes in TG release upon chronic 
treatment with ATRis, potentially due to compromised LD integrity, with reduced 
PERILIPIN A expression and enhanced lipolysis.  
4.2.3. ATRi induces adipocyte ‘browning’ 
Upon appropriate stimulation, white adipocytes can undergo the transcriptional 
reprogramming required for thermogenesis, usually a defining characteristic of brown 
adipocytes. This likely reversible transdifferentiation process is termed adipocyte 
‘browning’; where the induced white adipocytes are coined ‘beige’ or ‘brite’ adipocytes. 
Brown and beige adipocytes contain lower protein expression levels of PERILIPIN A than 
white adipocytes, and lower TG content; hence I hypothesised the decreased PERILIPIN 
A following ATRi treatment could perhaps be indicative of adipocyte browning.   
PGC1 is the master regulator of mitochondrial biogenesis – essential for 
mitochondrial gene transcription to express the thermogenic, brown adipocyte 
phenotype. To increase mitochondrial content PGC1 must be expressed, rendering it 
a marker of adipocyte browning. UCP1 expression is also required to achieve the 
mitochondrial uncoupling required for thermogenesis, and is not expressed in WAT, 
making UCP1 another reliable marker of beige/brown adipocytes. Fig 4.2.3.A shows 
western blotting of mature 3T3-L1 adipocytes treated chronically with ATRi II - where 
transient induction of PGC1 and UCP1 following treatment with ATRi II is observed. 
This indicates a mass metabolic reprogramming of white adipocytes treated with ATRi, 
into the programmed catabolism of stored TGs. Fig 4.2.3.A also shows increased PKA-
dependent activating phosphorylation of HSL at S563 – further indicative of increased 
lipolysis, required to generate FFAs which could then be channelled towards uncoupled 
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-oxidation and thermogenesis. These striking metabolic phenotypes following ATRi 
treatment indicate that chronic ATR deficiency has profound impacts on adipocyte 
metabolism – where no reduction of viability or increased replication stress is apparent. 
The dedifferentiation of mature 3T3-L1 adipocytes has been documented (Zoico 
et al., 2016). I questioned, considering the absence of common adipocyte markers such 
as PERILIPIN A in ATRi-treated mature adipocytes, whether these cells were undergoing 
‘dedifferentiation’ following the transient browning phenomenon. PPAR is a reliable 
marker of white adipocytes, hence I used western blotting to investigate PPAR 
expression following chronic ATRi treatments in mature, post-mitotic adipocytes. 
Interestingly, Fig 4.2.3.A shows PPAR1 and 2 are upregulated following the transient 
increase in PGC1. PPARG is a target of transcription factor PGC1, hence the increased 
expression of both PPAR isoforms could be as a result of PGC1 activity. The increased 
generation of FFAs (or their reduced metabolism following return of UCP1 and PGC1 
to basal levels) could also be inducing PPAR expression. Regardless, PPAR induction 
here suggests I am not observing a dedifferentiation of ATRi-treated adipocytes to a 
preadipocyte-like state.  
Increased PGC1 expression induces mitochondrial biogenesis. I utilised flow 
cytometry analysis of mitochondrial probe MitoTracker Green FM to quantify the 
mitochondrial content of 3T3-L1 adipocytes following 10 days of ATRi II treatment. Fig 
4.2.3.B demonstrates that following ATRi treatment, mitochondrial content is 
significantly increased by ~80%. Such an extreme increase in mitochondrial content is 
further evidence to suggest mass metabolic reprogramming and adipocyte browning 
following ATRi treatment. Interestingly, at 6 days ATRi treatment, PGC1 and UCP1 
expression consistently returns to basal levels, although the mitochondrial mass of ATRi-
treated adipocytes remains high. 
I investigated the long-term effects (>7 days) of ATRi treatment on mature 
adipocytes, with the aim of further assessing the metabolic significance of the transient 
browning phenomenon I have observed (Fig 4.2.3.C). After treating mature adipocytes 
with ATRi II for 10 days, I utilised western blotting to probe for deviations in phospho-
status and expression of the following proteins: 
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 LC3-I/II   
LC3-I/II status is a widely recognised marker of autophagic flux. Following ATRi 
treatment, the lower migrating LC3-II band has decreased, suggesting a reduced 
accumulation of autophagosomes/increased autophagic clearance. 
 DRP1 (Dynamin-1-like protein)  
Translocation of DRP1 to the mitochondria is a precursor to mitochondrial  
fission. The modest decrease in expression here following ATRi could be 
indicative of long-term downregulation of this mito-fission protein. 
Figure 4.2.3. ATRi treatment induces markers of adipocyte ‘browning’. A) Western blotting of 
browning markers PGC1a and UCP1, PPAR and p-HSL S563, and -actin as loading control. Transient 
adipocyte browning is observed with increased p-HSL S563, indicative of increased lipolysis. B) 
Quantification of mitochondrial mass of mature 3T3-L1 adipocytes treated with ATRi II for 7 days, 
assessed by flow cytometry using mitochondrial probe MitoTracker Green FM. ATRi was refreshed 
every 48 hours. C) Western blotting of proteins involved in several key pathways that influence 
adipocyte browning following 10 days treatment with or without ATRi. LC3 - Microtubule-associated 
protein 1A/1B-light chain 3; DRP1 - Dynamin-1-like protein; p44/42 MAPK - p44/42 Mitogen-
activated protein kinase; CAMKII - Ca2+/calmodulin-dependent protein kinase II. -actin as loading 
control. D) Western blotting of autophagic flux marker LC3 following ATRi treatment of mature 
adipocytes. Expression of LC3-I and LC3-II is increased at 24 hrs ATRi treatment (lane 2), and further 
at day 2 (lane 3) indicating increased autophagic processing. Day 3 of ATRi treatment onwards LC3 
status slowly decreases back to basal levels. -actin utilised as loading control. All images 
representative of results obtained in at least three independent experiments. 
B A 
C 
D 
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 PGC1  
PGC1 remains stable here, consistent with my previous findings that increased 
PGC1 expression is a transient event. Interestingly, these adipocyte cultures 
appear to have much higher basal levels of PGC1 than those in Fig 4.2.3.B, 
however this may be due to variation between batches of polyclonal PGC1 
antibody.  
 p-p44/42 MAPK T202/Y204 (p44/42 Mitogen-activated protein kinase)  
This activating phosphorylation has implications in browning and BAT 
differentiation, however I observe no change in p44/42 MAPK levels. 
 p-HSL S563 and PERILIPIN A 
p-HSL S563 appears unchanged following ATRi treatment, which is interesting 
considering PERILIPIN A expression remains decreased after 10 days. 
 p-CAMKII T286 (Ca2+/calmodulin-dependent protein kinase II)  
The activating T286 phosphorylation on this Ca2+-sensitive kinase is an early 
event in Ca2+-induced adipocyte browning, via the p38 MAPK-ATF2 signalling 
cascade. After 10 days ATRi treatment, CAMKII activity appears modestly 
decreased. 
I chose to further investigate autophagy protein LC3 following my observations in 
Fig 4.2.3.C – subtle changes in autophagic status of white adipocytes can be sufficient to 
induce browning, and furthermore increased autophagic activity is observed during the 
‘beige’-to-white transition (Altshuler-Keylin et al., 2016). Autophagy is a highly regulated 
process, sensitive to cellular nutrient-status. I hypothesised that, considering the altered 
and aberrant metabolic status of mature adipocytes treated with ATRis, perhaps altered 
autophagic processing could be a driver or consequence of browning.  
Fig 4.2.3.D shows western blotting of LC3-I/II throughout chronic treatment with 
ATRi II – where large increases in LC3-II following ATRi treatment in mature adipocytes 
are observed, indicative of enhanced or blocked autophagy, at the same time points I 
observe the transient browning phenotype. This change in LC3 processing, observed in 
Fig 4.2.3.D following the ATRi treatment of mature adipocytes, indicates that autophagy 
may have a role in the transient browning I have observed. Perhaps, autophagy is 
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upregulated following the aberrant induction into adipocyte browning, in a measure to 
restore these ‘beige’ adipocytes back to their original white adipocyte status. 
4.2.4. ATRi induces Ca2+-p38 MAPK-ATF2 signalling in 
adipocytes 
In Fig 4.2.3.C I also observed decreased activating phosphorylation of CAMKII (T286), 
indicative of changes in the cytoplasmic Ca2+ status within adipocytes treated with ATRis. 
Increases in intracellular Ca2+ comprise one established inducer of browning in WAT 
(Wright et al., 2007). Increased Ca2+ activates CAMKII, which in turn activates p38 MAPK, 
resulting in increased activation of browning transcription factors ATF2 and PGC1. In 
chapter 3 I observed increased p38 MAPK activity and early ATF2 induction following 
ATRi treatment throughout 3T3-L1 adipogenesis (section 3.2.4). Investigating changes in 
CAMKII and p38 MAPK activity in ATRi-treated adipocytes could provide mechanistic 
insight into how ATR inhibition could be inducing transient adipocyte browning. 
I further investigated CAMKII activity throughout chronic ATRi treatment of 
mature adipocytes via western blotting of p-CAMKII T286. Fig 4.2.4 shows p-CAMKII 
T286 transiently increased at the same time points we observe UCP1 and PGC1 
induction. Activation of CAMKII at these time points appears to have functional 
relevance, as downstream of CAMKII, adipocyte browning mediator p38 MAPK also 
Figure 4.2.4. ATRi treatment activates the Ca2+-p38 MAPK-ATF2 signalling axis in mature adipocytes. 
CAMKII is activated following chronic ATRi II treatment in mature adipocytes as assessed by p-CAMKII 
T286 activity. CAMKII appears highly phosphorylated in the first 3 days of ATRi II treatment, however 
it still remains phosphorylated at later time points. p38 MAPK is also activated transiently for three 
days following ATRi treatment. Browning transcription factor and p38 MAPK substrate ATF2 is 
concomitantly phosphorylated at T71, although this activity returns to basal levels after just 2 days of 
ATRi II treatment. -actin used as loading control. 
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appears activated at these time points, as assessed by activating phosphorylations at 
T180/Y182. ATF2, a p38 MAPK substrate and transcription factor responsible for 
adipocyte browning in response to increased CAMKII activity, appears transiently 
activated following ATRi treatment, as assessed by activating p38-dependent 
phosphorylation at T71. The increased and transient activation of this adipocyte 
browning axis, from Ca2+-sensitive signal transducer to transcriptional activator, strongly 
suggests this pathway contributes to the transient browning and metabolic 
reprogramming following ATRi treatment.  
This indicates ATRi treatment may induce adipocyte browning via marked shifts in 
the Ca2+-status of mature adipocytes. Ca2+ is also a fundamental regulator of autophagy, 
hence ATRi-induced deregulation of intracellular Ca2+ status may have also induced the 
increased autophagic processing I observed in Fig 4.2.3.E following ATRi treatment. 
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4.3. Summary 
In this chapter I have shown you: 
 Chronic treatment of 3T3-L1 adipocytes with ATRis does not affect viability or 
induce the DNA damage response (section 4.2.1) 
Chronic ATRi treatment in mature 3T3-L1 adipocytes results in: 
 Profoundly reduced PERILIPIN A expression, ‘leaky’ LDs with decreased TG 
content and enhanced lipolysis (section 4.2.2) 
 Transient expression of markers of adipocyte browning - UCP1, p38 MAPK and 
PGC1 (section 4.2.3) 
 Increased mitochondrial mass (section 4.2.3) 
 Activation of Ca2+-dependent signalling axis related to expression of beige 
adipocyte markers (section 4.2.4) 
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4.4. Discussion 
In this chapter, I have characterised and investigated several novel consequences of 
chronic treatment of mature, white 3T3-L1 adipocytes with small molecule ATRis. The 
net effect of chronic ATRi treatment in this model system I have observed is a 
programmed metabolic shift towards catabolism. This phenomena was not a secondary 
effect of ATRi-induced DNA damage. Instead, a variety of cytoplasmic signalling 
pathways not previously associated with DNA repair and cell cycle checkpoint signalling 
appear to have been affected by kinase inhibition of ATR.  
The metabolic reprogramming that these cells have undertaken is reminiscent of 
the browning of WAT observed in cancer cachexia. I have demonstrated that the 
increased activity of factors that are more commonly associated with beige and brown 
adipocytes, has significant effects on the metabolic status of white adipocytes - 
following chronic ATRi treatment, mitochondrial mass is drastically increased and TG 
content markedly reduced. Although the ATRi-induced expression of browning-
associated proteins was transient, after 7 days of ATRi treatment TG content remained 
significantly decreased. After 10 days of ATRi treatment, mitochondrial content was 
increased by ~80%, suggesting the impact of the browning phenotypes are not transient 
and have long-lasting effects on cellular metabolism. Further characterisation and 
eventual mechanistic evidence is required to fully understand the implications of ATR 
deficiency on adipose biology. 
Following ATRi treatment of at least 24 hrs, increased activation of CAMKII and 
p38 MAPK results in the transient upregulation of transcriptional activators required for 
browning. At the same time points, I also observe increased UCP1 and p-HSL S563, 
indicative of increased lipolysis and uncoupled -oxidation at the mitochondria. Notably, 
HSL has recently been implied in the transdifferentiation of white adipocytes to 
beige/brown, where its activity of inducing lipolysis and supressing lipogenesis supports 
the browning transition (Kim et al., 2016).  
 Furthermore, following ATRi treatment, a striking loss of LD membrane 
protein PERILIPIN A is observed, where what little PERILIPIN A remains appears 
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fragmented across the LD membrane. Concomitantly, I observed cytoplasmic staining 
with TG marker BODIPY 493/503, indicative of uncontrolled TG release into the 
cytoplasm. It is clear that inhibiting the kinase activity of ATR has fundamental 
implications in WAT biology, where ATRis are driving white adipocytes into a beige-like 
metabolic state. It is difficult to discern whether the decreased PERILIPIN A is a cause or 
consequence of the ATRi-induced phenotypes I observe in adipocytes. For example, 
decreased PERILIPIN A could facilitate uncontrolled TG release as I observed, and 
perhaps increased HSL activity is a compensatory mechanism to process released TGs, 
which generates high levels of FAs and induces browning; however, decreased PERILIPIN 
A expression is also one aspect of the beige adipocyte phenotype.  
Although I did not assess mTORC1 activity in mature adipocytes, in chapter 3 I 
demonstrated reduced mTORC1 activation following acute ATRi-treatments in 
Figure 4.3. Schematic of pathways associated with ATRi-induced adipocyte browning. Gold shading denotes 
markers of beige/brown adipocytes. ATRi could induce 3T3-L1 adipocyte ‘browning’ via: 1) Decreasing expression 
of PERILIPIN A, inducing increased FA release; 2) Reduced mTORC1 activation, increasing HSL-dependent lipolysis of 
TGs into FAs; 3) Blocked autophagy, generating increased [Ca2+]cyt or enhanced PKA activity; 4) Through increasing 
[Ca2+]cyt through an unknown mechanism.  
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preadipocytes. Rapamycin is an established immunosuppressant. Inhibition of mTORC1 
with rapamycin has been shown to activate HSL, increasing lipolysis with the clinical 
outcome of hypertriglyceridemia and elevated circulating FFAs (Soliman et al., 2010). 
Considering the reduced activity of mTORC1 following ATRi in preadipocytes and 
increased HSL activity following ATRi in mature adipocytes, perhaps ATRi-induced 
reduction in mTORC1 activity has a central role to play in these adipocyte phenotypes 
following ATRi.  
The putative mechanisms I have discussed here, that may explain the adipocyte 
phenotypes following ATRi, are summarised in Fig 4.3. 
Interestingly, consistent with the end of the transient ‘browning’ event, (day 1-2 
of ATRi treatment) I observed increases in LC3-II, indicative of increased autophagy. As 
autophagy has recently been directly implicated in the beige-to-white transition 
(Altshuler-Keylin et al., 2016), I postulate that perhaps this increased LC3-II signal is the 
precursory event to the loss of browning markers UCP1 and PGC1. At this point, UCP1-
dependent uncoupling of the respiratory chain will become diminished. Perhaps, with 
mitochondrial -oxidation beginning to return to basal levels of efficiency, the 
cytoplasmic FAs that would have previously been metabolised will increase in 
concentration and activate PPAR. I postulate that this is why we see PPAR expression 
increasing only following the loss of UCP1 and PGC1. Further to this, the increased FA 
release induced by ATRi treatment may have concerning physiological implications. Not 
only are increased circulating FAs associated with insulin resistance and cardiovascular 
disease, but more importantly FA mobilisation from WAT is associated with cancer 
progression (Edmonson, 1966; Liu, 2006). 
I have shown in this chapter that chronic ATRi treatment has a fundamental 
effect on adipocyte homeostasis. Here, I have characterised a relationship between ATR 
deficiency and defective white adipocyte metabolism and homeostasis. This work 
provides the first pathomechanistic insight between the cachexic presentation of SS and 
ATR deficiency. Furthermore, for the first time, concerning metabolic consequences of 
ATRi treatment have been uncovered, where ATRi treatment of white adipocytes 
appears to increase lipolysis and FA mobilisation; both of which are considered factors 
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aspects of cancer cachexia and tumour growth and progression. Further work must be 
undertaken to fully understand the pathways responsible for the metabolic 
consequences following ATRi treatment. In addition, a complete understanding of the 
pathways associated with ATRi-induced metabolic dysfunction could allow the 
generation of novel synthetic-lethality co-treatments – where ATRi may be utilised with 
drugs targeting metabolic pathways, for example, mTORC1 inhibitor rapamycin. 
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5. Chapter Five 
       Results III:  Compromised ATR function                          
results in defective autophagy 
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5.1. Introduction 
In Chapter 4, I demonstrated a change in microtubule-associated protein 1A/1B-light 
chain 3 (LC3) processing in mature 3T3-L1 adipocytes following treatment with ATR 
inhibitors (ATRis), indicative of altered autophagic processing. I also showed in Chapter 
3 that mechanistic target of rapamycin complex 1 (mTORC1) activity was attenuated in 
3T3-L1 preadipocytes, following acute ablation of ATR function with ATRis and also 
following transient knockdown of ATR with Atr siRNA. mTORC1 is a fundamental 
regulator of autophagy, and appropriate autophagy is required for effective adipogenic 
differentiation. Hence, I wanted to further characterise the effects of acute ATRi 
treatments on autophagic processing.  
Autophagy is intrinsically a survival-promoting pathway. There are dual roles for 
autophagy in cancer progression, although in most contexts the upregulation of 
autophagic pathways facilitates tumorigenesis. Enhanced autophagy ensures 
maintenance of functional mitochondria, suppression of p53 induction, and allows 
cancerous cells increased ability to survive micro-environmental stresses (White, 2015). 
The relationship between autophagy and cancer is complex however; 40-75% of breast, 
prostate, and ovarian cancers lack essential autophagy gene Beclin 1, indicating that 
autophagy may play a role in the suppression of these tumour types (Qu et al., 2003). 
Pre-clinical data has demonstrated that autophagy inhibitors can restore tumour 
chemo-sensitivity and potentiate existing therapies, establishing autophagy inhibitors 
as a novel therapeutic target (Yang et al., 2011). Early clinical trials report autophagy 
inhibitor hydroxychloroquine is not well tolerated however, and the development of 
lower-toxicity compounds is required to make the autophagy axis a valid target for 
cancer therapy (Rosenfeld et al., 2014). 
Here I will review the key pathways associated with autophagic processing. I will 
give particular focus to the factors I have manipulated and investigated, to reveal novel 
consequences of ATR deficiency on cellular autophagic function. 
The term autophagy was first coined in 1963 by Nobel Prize-winning Belgian 
scientist Christian de Duve (Ohsumi, 2014). Autophagy is now the umbrella term for the 
catabolic processes cells utilise for the recycling and degradation of cytoplasmic 
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constituents. 18 autophagy-essential proteins were initially identified in S.cerevisiae, 
aptly named the autophagy (ATG)-related proteins (Thumm et al., 1994; Tsukada and 
Ohsumi, 1993). Following this initial characterisation in yeast, the molecular basis of 
mammalian autophagy has been subject to extensive research. Almost all constituents 
of the mammalian autophagy machinery are homologues of those observed in yeast. 
The high conservation of this process from yeast to man is evidence to the essential 
nature of the autophagy process. 
Appropriate induction of macroautophagy (hereafter referred to as autophagy) 
ensures salvage of metabolites during periods of nutrient stress, removal of misfolded 
or aggregated proteins, elimination of intracellular pathogens and clearance of damaged 
organelles (Glick et al., 2010). Collectively, autophagy maintains cellular homeostasis, 
facilitating core anabolic processes by enforcing stringent proteomal/organelle quality 
controls, and the recovery of nutrients from deleterious cellular components. 
With many common constituents, the endocytic pathway acts as a companion 
to autophagy, through the systematic uptake of nutrients and macromolecules from the 
extracellular microenvironment (Hyttinen et al., 2013). Where autophagy coordinates 
the degradation intracellular cargoes, endocytosis allows effective reclamation of 
extracellular material, with the two pathways converging at the common end-point of 
lysosomal degradation. 
Mechanistically, autophagy requires the combined activity of several 
cytoplasmic complexes, which can be categorised into sequential steps (Fig 5.1). 
Autophagy is induced from an array of intra- and extra-cellular cues, cargos targeted for 
autophagic degradation are packaged as the phagophore membrane is expanded and 
closed to form mature autophagosomes. Cargo-bound autophagosomes are then 
transported into the proximity of lysosomes via the dynein-microtubule trafficking 
machinery (Fu et al., 2014), and degraded by lysosomal proteases following lysosomal 
fusion.  
Autophagy and the endoplasmic reticulum (ER) stress response are also 
intimately linked. Accumulation of excessive misfolded proteins in the ER leads to the 
activation of a homeostatic signalling network committed to recuperating ER function. 
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Collectively, this is termed the unfolded protein response (UPR), and one aspect of this 
highly orchestrated response is the induction of autophagy. ER stress is a potent inducer 
of autophagy, due to the enhanced requirement of this degradation pathway to clear 
misfolded/aggregated proteins (Rashid et al., 2015). Several transcription factors 
initiated by the UPR directly promote transcription of autophagy-protein containing 
genes (B’chir et al., 2013), a key function of AMP-activated protein kinase (AMPK) is to 
induce autophagy in response to ER-stress mediated toxicity (Lee et al., 2012), and 
further to this, the loss of ER-luminal Ca2+ that often accompanies ER stress is adequate 
to induce autophagy via AMPK-dependent mTORC1 inhibition (Høyer-Hansen et al., 
2007).  
Defective autophagic processing has recently been associated with a variety of 
pathologies, including cancer and neurodegenerative disorders such as Parkinson’s 
disease, Alzheimer’s and amyotrophic lateral sclerosis (Jiang and Mizushima, 2014). The 
underlying mechanisms in which faulty autophagy induces these neurological deficits 
are currently subject to extensive research (Nixon, 2013). What can be ascertained is 
the undoubtable housekeeping role of autophagy in terminally differentiated neurons, 
and that defects at any point in proteasomal management can result in neurological 
disorder (Mizushima and Komatsu, 2011).  
Figure 5.1. Autophagy complexes - initiation to lysosomal fusion. The ULK1 complex mediates PAS 
formation, and the PI3K complex induces nucleation. Then, the ATG5-ATG12-ATG16L1 complex 
conjugates LC3-I into LC3-II (LC3-PE) allowing association of cargos targeted for degradation. Taken from 
(Kaur and Debnath, 2015) 
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5.1.1. Phagophore formation and nucleation 
Following incoming signals to induce autophagy, initiation begins with the formation of 
a phagophore assembly site (PAS) within proximity of the endoplasmic reticulum (ER) 
(Fig 5.1.1.1) (Sanchez-Wandelmer et al., 2015). Different protein complexes interact at 
the PAS to orchestrate the formation of autophagosomes. The ULK1/2 complex consists 
of UNC51-like kinase (ULK), autophagy protein 13 (ATG13), FAK family kinase interaction 
protein of 200 kDa (FIP200) and ATG1. During initiation, the ULK1/2 complex is directed 
to the ER, along with the autophagy-specific class III PI3K complex, which consists 
of vacuolar protein sorting 34 (VPS34) PI3K and regulatory subunits ATG14L, VPS15 and 
Beclin 1 (Fig 5.1.1.1) (Xie and Klionsky, 2007).  
Membrane-bound ATG9 cycles between the PAS and peripheral sites in vesicles, 
delivering membrane for phagophore expansion/elongation (Yamamoto et al., 2012). 
Efficient anterograde delivery of ATG9 vesicles to the PAS requires transport factors 
ATG23 and ATG27 – proteins also believed to have an essential role in ATG9 vesicle 
biogenesis (Yamamoto et al., 2012; Yen et al., 2007). Although ATG9 vesicles provide 
some membrane for the formation of autophagosomes, they do not provide the amount 
of lipid required for a complete autophagosome. The origins of the majority of the lipid 
membrane required for phagophore biogenesis remain controversial, but it is most likely 
Figure 5.1.1.1. Phagophore formation and nucleation complexes. The ULK1/2 and PI3K complexes 
associate with the PAS to instigate phagophore formation. VPS15 is also known as p150.  Taken from  
(Cheong et al., 2012) 
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derived from a Golgi-related secretory pathway, as well as multiple other sources 
(Bernard and Klionsky, 2014).  
Nucleation requires the PI3K complex; double-membraned phagophores are 
compelled into curvature by the deposition of multiple phosphatidylinositol groups (PIs) 
on the ‘cytoplasmic’ membrane face. In close proximity, these lipid groups favour 
positive membrane curvature and allow recruitment of the PI(3)P-binding WD repeat 
domain phosphoinositide-interacting protein (WIPI) family, to facilitate the final steps 
autophagosome formation (Dooley et al., 2014). The exact function of the ATG2-WIPI 
complex in autophagosome formation is not clear, although it appears necessary for and 
dependent on the appropriate distribution of ATG9 vesicles (Reggiori et al., 2004). 
Recruitment of two ubiquitin-like conjugation complexes mediates phagophore 
membrane elongation, on distinct ER domains known as ‘omegasomes’ (Axe et al., 
2008). The localisation of these conjugation complexes to the PAS/omegasome is 
dependent on ATG9 and the PI3K complex. The C-terminus of ATG12 is covalently 
conjugated to a lysine residue at the centre of ATG5 – a process catalysed by the 
ubiquitin-E1-like and ubiquitin-E2-like proteins ATG7 and ATG10, respectively (Fig 
5.1.1.2) (Mizushima et al., 1998). Following conjugation, ATG5 interacts directly with 
ATG16L1 to form the trimeric ATG12-ATG5-ATG16L1 complex. ATG16L1 contains a 
homo-dimerization domain, hence binding of ATG16L1 to ATG12-ATG5 prompts the 
dimerization of ATG12-ATG5-ATG16L1 trimers (Fig 5.1.1.2) (Fujioka et al., 2010). 
Figure 5.1.1.2. ATG12-ATG5-ATG16 complex formation and LC3-I conjugation. ATG7 and ATG12 
conjugate ATG12 to ATG5. ATG12-ATG5 then interacts with ATG16L1, inducing dimerization of ATG12-
ATG5-ATG16L1 trimers. ATG4 primes LC3 (ATG8) for conjugation to PE (LC3-II), a reaction catalysed by 
ATG7, ATG3, and ATG12-ATG5. ATG4 cleaves LC3-II following completion of autophagosomal formation. 
Modified from (Williams et al., 2012) 
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ATG16L1 directly binds to the ULK1 complex subunit FIP200, an interaction required for 
amino-acid starvation-induced autophagy response (ULK1-dependent), although this 
interaction is not required for autophagy induced by glucose deprivation (ULK1-
independent) (Gammoh et al., 2013). ATG16L1 has also been implicated in the utilisation 
of the plasma membrane as a membrane source due to its interaction with clathrin-
coated structures (Ravikumar et al., 2010). 
The ATG12-ATG5 conjugate also functions as the E3-like enzyme required for the 
conjugation of phosphatidylethanolamine (PE) to LC3-I (microtubule-associated protein 
1 light chain 3, mammalian homologue of Atg8) to generate LC3-II (Hanada et al., 2007). 
ATG7 and ATG3 act as the E1- and E2-like enzymes for this conjugation (Fig 5.1.1.2). LC3-
II can stably associate with numerous autophagic components and is used widely as a 
marker within analysis of autophagic processing (Mizushima and Yoshimori, 2007). LC3-
II is required for the expansion of autophagic membranes, as well as cargo recognition, 
closure of the isolation membrane and lysosomal fusion (Kabeya et al., 2000). 
Closure and detachment of mature autophagosomes from the ER is poorly 
understood. When formation is completed, conjugated LC3-II on the outer 
autophagosomal membrane is cleaved from PE by ATG4, releasing LC3 back into the 
cytoplasm (Fig 5.1.1.2) (Kirisako et al., 2000). Detachment and disassembly of the ATG 
complexes appears to be regulated by inactivation of the ULK1 complex and clearance 
of PI(3)P at the autophagosome membrane (Karanasios et al., 2013; Lamb et al., 2013). 
ULK1 is one of the earliest proteins to dissociate from the completed autophagosome, 
and disassembly of the ATG machinery appears to be dependent on ULK1 kinase 
inactivity (Karanasios et al., 2013). The mechanism in which PI(3)P turnover clears ATG 
complexes from mature autophagosomes is likely that the hydrolysis of PI(3)P to PI leads 
to the dissociation of the PI(3)P-binding WIPI family, or that high local concentrations of 
PI(3)P inhibit ATG machinery disassembly (Sanchez-Wandelmer et al., 2015). 
5.1.2. Transport and lysosomal fusion 
To complete autophagy and degrade the contents of the mature autophagosome, 
autophagosomal-lysosomal fusion must occur. LC3-II appears to be required for 
transporting autophagosomes into the vicinity of lysosomes (Nair et al., 2012). Once 
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autophagosomes are formed, they are transported across the microtubule network in a 
dynein-dependent manner, towards the nuclear periphery and residence of late 
endosomes and lysosomes (Fass et al., 2006; Kimura et al., 2008). The role of 
microtubule machinery in autophagosome-lysosome fusion has been secured by 
evidence that autophagosome migration to the perinuclear region is microtubule- and 
dynein-dependent in primary neurons (Cheng et al., 2015), and loss of function of dynein 
leads to accumulation of autophagosomes and failure to clear aggregated proteins in 
cultured cells, Drosophila and mice (Ravikumar et al., 2005).  
Three distinct families, identified from general intracellular membrane 
trafficking pathways, work in concert to orchestrate lysosomal fusion – RAS-related 
proteins in brain (RAB) GTPases, membrane-tethering complexes, and Soluble N-
ethylmaleimide-sensitive factor activating protein receptor  (SNARE) proteins (Bento et 
al., 2016). With roles not restricted to autophagy, the RAB GTPase family act as master 
regulators of vesicle sorting and coordinators of membrane-bound traffic throughout 
the cell (Stenmark, 2009). Specifically referring to autophagy, RAB7 appears to play 
fundamental, multifunctional roles in coordinating the journey of the mature 
phagosome towards the lysosomal fusion process, and is a widely established marker of 
late endosomes/autophagosomes (Bucci et al., 2000).  
Following recruitment to the autophagosomal membrane, dependent on the 
interacting effector, RAB7 can mediate both plus- and minus-end transport across the 
microtubule. Large effector protein FYCO1 (FYVE and coiled-coil domain containing 1) 
interacts via C-terminal domains with RAB7, LC3 and PI(3)P whilst concomitantly 
interacting with the kinesin motor protein via its N-terminal coiled-coil domain to 
mediate movement in the plus direction. Minus-end transport to the perinuclear region 
is mediated via interaction between the dynein-dynactin motor, oxysterol-binding-
protein-related protein 1 (ORP1L), RAB7 and effector protein RAB-interacting lysosomal 
protein (RILP) (Fig 5.1.2) (Wang et al., 2011). 
The homotypic fusion and vacuole protein sorting (HOPS) complex acts as the 
primary membrane-tethering factor to facilitate autophagosome-lysosomal fusion, via 
the capture and bridging of RAB-labelled vesicles, and initiation of fusion in conjunction 
with the SNARE proteins (Bröcker et al., 2010). Amongst the six subunits of HOPS, VPS39 
131 
 
activates RAB7 and VPS16 interacts with the UV Radiation Resistance Associated 
(UVRAG) complex (Bröcker et al., 2010). Active RAB7 appears to displace the fusion-
inhibiting interaction between Rubicon and UVRAG, increasing the availability of the 
UVRAG complex to associate with the VPS16 subunit of HOPS. This further activates 
RAB7 (Sun et al., 2010), propagating a strong feed-forward mechanism to instigate 
membrane fusion. 
SNARE proteins anchored on opposing membranes at the fusion site interact to 
form a trans-SNARE complex inducing membrane fusion. Three Q-SNAREs on the 
acceptor membrane associate with one R-SNARE on the donor membrane (Jahn and 
Scheller, 2006). Autophagosome-bound Q-SNARE Syntaxin 17 has a direct role in fusion 
through its interaction with lysosomal R-SNARE vesicle-associated membrane protein 8 
(VAMP8), although this appears to be dependent on a priming step by essential 
autophagy protein ATG14L1 (Diao et al., 2015).  
SNARE protein function appears to be disrupted in several lysosomal storage 
disorders (LSDs) – rare, inherited metabolic disorders caused by defects in lysosomal 
function (Fraldi et al., 2010). LSDs can arise from a variety of mechanistic defects, 
Figure 5.1.2. RAB7 and FYCO1- or RILP-ORP1L-mediated transport of late autophagosomes across the 
microtubule.  Kinesin drives autophagosomes towards the cell periphery, dynein-dynactin mediates 
transport to the perinuclear region, towards lysosomal fusion. Image modified from (Nakamura and 
Yoshimori, 2017) 
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resulting in compromised degradation of deleterious cytoplasmic components. 
Currently over 50 disorders have been characterised, with widely varying pathological 
presentations including abnormal skeletal and neurological development, blindness, 
deafness and early death (Parenti et al., 2015) (Boustany, 2013). LSDs can be caused by 
elevated cholesterol accumulation in the lysosomal membrane – causing sequestration 
and inactivity of SNAREs within these compartments. Reduced activity of SNARE 
proteins results in gross impairments of membrane sorting and fusion, and lysosomal 
dysfunction (Fraldi et al., 2010).  
Lysosomal biogenesis is also regulated by mTORC1. TFEB (transcription factor EB) 
is the key regulator of lysosomal biogenesis, the transcriptional activator of the 
Coordinated Lysosomal Expression and Regulation (CLEAR) network of >470 lysosome–
associated genes (Palmieri et al., 2011; Settembre et al., 2012). mTORC1-dependent 
phosphorylation of TFEB sequesters it within the cytoplasm in times when lysosomal 
activity is adequate. Following starvation (when enhanced autophagy is paramount) 
mTORC1 activity is decreased, relieving TFEB of inhibitory phosphorylations, resulting in 
TFEB translocation to the nucleus where it stimulates genes required for lysosomal 
biogenesis proteins (Roczniak-Ferguson et al., 2012). 
5.1.3. Starvation-induced autophagy 
The autophagy response to starvation is bulk degradation of cytoplasmic components, 
to recover non-essential macromolecules and substrates for survival. Central to the 
induction of autophagy following nutrient deprivation and other stress conditions is the 
ULK1 complex (Wong et al., 2013). The ULK1 complex is a substrate of mTOR, 60 kDa 
Tat-interactive protein (TIP60) and AMPK, and its phospho- and acetyl- status is 
inherently dependent on the activity of these kinases (Fig 5.1.1.1) (Glick et al., 2010). 
Upon starvation, mTORC1 activity is decreased, resulting in the elimination of inhibitory 
mTOR-dependent phosphorylations on ULK1 and increased acetylation by TIP60. ULK1 
appears to act as a scaffold for the recruitment of downstream ATG proteins, and is 
essential for autophagy in mammals (Hara et al., 2008). However, how the ULK1 complex 
transduces incoming signals from these nutrient status-sensing kinases to the 
downstream autophagic machinery is unknown.  
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Starvation-induced autophagy also requires PI3K complex activity. Beclin 1 is 
required for the interaction between core PI3K complex subunits VPS34 and ATG14L1, 
without which the complex cannot localise to the PAS (Matsunaga et al., 2010). The PI3K 
complex cannot be effectively activated without the liberation of subunit Beclin 1 from 
an inhibitory association with anti-apoptotic BH3 family members B-cell lymphoma 2 
(BCL-2), B-cell lymphoma-extra-large (BCL-XL) or Induced myeloid leukaemia cell 
differentiation protein (MCL-1) (Kang et al., 2011). The Beclin 1-BCL-2 interaction can be 
disrupted through competitive displacement of Beclin 1 by other BCL-2 family members, 
including truncated BH3 interacting-domain death agonist (tBID), BCL-2-associated 
death promoter (BAD) and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
(BNIP3) (Sinha and Levine, 2008). BCL-2/BCL-XL can also be competitively displaced by 
Beclin 1-binding proteins including ATG14L1 and UVRAG (Bento et al., 2016). Further to 
this, posttranslational modification of Beclin 1 and its inhibitory interactants, that induce 
disassociation or enhance association, is a key mechanism of regulating autophagic 
activity of Beclin 1. These include (but are not limited to) Beclin 1 phosphorylation by 
death associated protein kinase (DAPK) (Zalckvar et al., 2009), and phosphorylation of 
BCL-2 by c-Jun N-terminal kinase 1 (JNK1) and extracellular signal-regulated kinase (ERK) 
(Wei et al., 2008). Following association with the PI3K complex, ULK1 additionally 
phosphorylates ATG14L1-Beclin 1 to induce autophagy (Bento et al., 2016).  
5.1.4. Receptor-mediated autophagy 
Receptor-mediated autophagy is the selective targeting of cellular components for 
autophagic degradation. This directed approach requires additional levels of regulation 
above the autophagic machinery utilised for bulk degradation. A variety of target 
cargoes have been characterised including misfolded proteins, organelles and 
pathogens (Stolz et al., 2014). Receptors recognise labelled cargoes, binding them to the 
growing autophagosomal membrane via LC3-interacting regions (LIRs) (Slobodkin and 
Elazar, 2013).  
In mammals, the most common modification targeting a component for 
degradation is ubiquitylation – almost all characterised autophagy receptors harbour 
Ub-binding domains (UBDs) and LIRs (Kirkin et al., 2009). The ubiquitin-proteasome 
system (UPS) of rapid targeted degradation was initially thought to function 
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independently of selective autophagy, but the discovery of such high frequency of UBDs 
in autophagy receptors indicates levels of cross-talk between these degradation 
pathways (Kraft et al., 2010).  
P62/Sequestosome 1 (p62/SQSTM1 – hereon referred to as p62) is one such 
cargo receptor that interacts with ubiquitylated targets, and is an autophagic substrate 
(Seibenhener et al., 2004). Cargo-bound p62 is conveyed to the PAS where it is tethered 
to the developing inner-autophagosomal membrane, via the interaction between p62 
and LC3-II. Degradation of p62 occurs as the p62-cargo-containing autophagosomes fuse 
with lysosomes (Fig 5.1.4) – a block in autophagic processing will induce the 
accumulation of intracellular p62 (Bjørkøy et al., 2005). This renders p62 a useful marker 
of blocked autophagy when analysed with autophagic flux indicator LC3-I/II (Bjørkøy et 
al., 2009). However, p62 protein expression levels can be ambiguous, as it is also subject 
to transcriptional regulation by an array of factors, including oxidative damage-sensor 
nuclear factor erythroid 2–related factor 2 (NRF2) (Jiang et al., 2015), TFEB, and ER 
stress/UPR transcription factor activating transcription factor 4 (ATF4) (Kouroku et al., 
2006). P62 also has the unique activity of upregulating nutrient-status sensor mTORC1 
activity via its Raptor subunit, at the lysosomal membrane – allowing autophagic activity 
further input into the regulation of this master kinase (Duran et al., 2011).  
Interestingly, adipocyte-specific p62-deficient mice are obese and exhibit 
decreased metabolic rates. p62 deficiency in this model resulted in impaired 
mitochondrial function and brown adipose tissue (BAT) thermogenesis, indicating a role 
for p62 in the regulation of adipogenesis or adipocyte homeostasis (Müller et al., 2013). 
Figure 5.1.4. Role of p62 in receptor-mediated autophagy. P62 recognises and binds to ubiquitylated 
targets. Cargo-bound p62 interacts with LC3-II on the inner autophagosomal membrane. Following 
lysosomal fusion, p62 and cargo are degraded. Taken from (Rusten and Stenmark, 2010) 
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5.1.5. Interpreting LC3-I/LC3-II western blotting 
Changes in autophagic flux can be assessed through western blotting of LC3-I/II. Yet, 
both increased autophagic induction and a block in autophagic degradation can alter 
levels of LC3-II (Fig 5.1.5.A). Co-treatment with autophagy inhibitors here will produce 
an additive or epistatic effect on LC3-I/LC3-II status, dependent on which is the cause of 
altered autophagic flux (Fig 5.1.5.C). Assessing LC3 status following co-treatment with 
autophagy inhibitors allows the delineation of changes in autophagic induction or 
degradation.  
Bafilomycin A is an inhibitor of vacuolar H+ ATPase (V-ATPase) which functions 
to inhibit autophagy at the late stage of autophagosome-lysosomal fusion. Treatment 
with Bafilomycin A blocks autophagic degradation, resulting in increased LC3-II as 
autophagosomes accumulate (Fig 5.1.5.B). To test if an observed change in LC3-I/II 
status is due to a block in autophagic degradation, samples can be co-treated with 
Bafilomycin A and the treatment in question (for example, ATRi). One of two outcomes 
can occur following this co-treatment, as shown in Fig 5.1.5.C (lane 3). If you observe an 
additive increase in LC3-II following Bafilomycin A co-treatment, you are observing 
enhanced autophagy induction; however, if you observe a block in autophagic 
degradation, the LC3 status will remain unchanged. Bafilomycin A co-treatment with 
autophagy inducers results in increased LC3-II, due to the additive effect of enhanced 
levels of autophagic induction concomitant with inhibition of autophagic degradation 
generating LC3-II positive autophagosomes. Furthermore, 3-methyladenenine (3-MA), 
Figure 5.1.5. Assessing autophagy with western blotting of LC3. A) and C) See text for narrative. B) 
Western blot of cycling 3T3-L1 preadipocytes treated with or without Bafilomycin A (50 nM, 2 hrs) show 
increased expression of LC3-II, indicative of a block in autophagosomal maturation/fusion. 
A B 
C 
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an inhibitor of PI3K and early autophagosome formation, can be utilised to assess at 
which point an observed block in autophagy is occurring. 
Considering the role of autophagy in cancer progression, therapy and adipogenic 
differentiation, and my data in chapter 4 showing LC3-I/II status is affected by ATRi, it is 
important to investigate the effects of ATRi treatment on the autophagy axis. If ATRi 
treatments were to affect cellular autophagic status, novel combination strategies could 
be explored to capitalise on cancer cell dependency of enhanced autophagy. Conversely, 
there may be unforeseen consequences of chronic ATRi treatment in the treatment of 
cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
5.2. Results  
5.2.1. ATRi results in defective autophagy and p62 accumulation  
I utilised western blotting of LC3 to assess autophagic flux in cycling 3T3-L1 
preadipocytes following acute treatments with ATRis, and Atr siRNA. I chose to study 
the effects of acute treatments with ATRis in 3T3-L1 preadipocytes as these cells require 
canonical ATR function throughout cell replication, rendering longer ATRi treatments 
highly cytotoxic. 
Fig 5.2.1.1.A shows western blotting of LC3 in cycling 3T3-L1 preadipocytes 
treated with ATRi II for 0-16 hrs. Altered LC3 processing is observed following 2 hrs 
treatment with ATRi II, where LC3-II levels (Fig 5.2.1.1.A, lower migrating band) are 
drastically increased from 6-16 hrs of ATRi treatment. To ensure this was not a cell-type 
specific response, I repeated this time course in the murine C2C12 myoblast cell line (Fig 
5.2.1.1.B), where increased LC3-II following ATRi treatment is observed with similar 
kinetics to the 3T3-L1 preadipocytes. Fig 5.2.1.1.C further shows ATRi-induced increases 
in LC3-II are also dose-dependent, where just 10 nM VE-822 is sufficient to induce small 
changes in LC3-I/II ratio. To further investigate the shift in LC3 status following ATRi, I 
visualised cells treated with or without VE-822 using IF microscopy with an anti-LC3 
antibody. Fig 5.2.1.1.D shows cycling 3T3-L1 preadipocytes stained for LC3, AlexaFluor-
conjugated phalloidin (to visualise the actin cytoskeleton) and DAPI. In untreated cells, 
LC3-I/II staining is mainly nuclear. Following ATRi treatment, there appears to be 
increased LC3-I/II within the cytoplasmic compartment, suggesting changes in cellular 
autophagy activity. 
I utilised ATMi to confirm the autophagic phenomenon I was observing was ATRi-
specific, and not due to inhibition of an apical DNA damage response (DDR) PIKK 
(phosphoinositide 3-kinase (PI3K)-related protein kinase) (Fig 5.2.1.1.E). Here, ATMi 
appears to induce increased LC3-II levels after 4 hrs of treatment, although when 
compared to LC3-II induction following 8 hrs ATRi treatment (last lane, Fig 5.2.1.1.E), it 
appears relatively small. Following these experiments, roles for ATM in the regulation of 
pexophagy and autophagy following DNA damage-inducing agents have been 
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characterised, suggesting inhibition of ATM activity would likely affect the autophagic 
processing of LC3-I/II (Chen et al., 2015; Zhang et al., 2015). In one respect, this renders 
ATMi a less effective control in the investigation into the effects of ATR inhibition on 
autophagy; however, established roles for ATM in the autophagy pathway also 
Figure 5.2.1.1. ATRi induces aberrant autophagic processing. A) and B) Western blotting analysis of 
LC3-I/II following 0-16 hrs ATRi II treatment (10 M) in cycling 3T3-L1 preadipocytes (A) and cycling 
C2C-12s (B). With limited effects on LC3-I, ATRi treatment induces drastic increases LC3-II after 2 hrs, 
indicative of enhanced or blocked autophagy. C) ATRi induced changes in LC3-II status are dose-
dependent. In asynchronous 3T3-L1 preadipocytes, 4 hrs treatment with VE-822 at every dose tested 
induces altered LC3 processing. D) IF microscopy of LC3 following ATRi treatment shows increased 
cytoplasmic LC3 expression. Actin stain AlexaFluor-phalloidin (red), LC3-I/II (green), DAPI (blue). 
Images taken at 100x magnification. E) Wester blotting of LC3 following ATMi treatment of cycling 
3T3-L1 preadipocytes, where * is 8 hrs ATRi II treatment. ATMi induces modest changes in LC3-I/II. All 
images representative of results obtained in at least three independent experiments. 
A 
B C 
D 
E 
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demonstrate there is existing crosstalk between a DDR PIKK and the systems controlling 
intracellular degradation.  
LC3 has also been associated with endosomal maturation, endocytosis and the 
processing of other membrane-bound cellular components (Hyttinen et al., 2013). To 
confirm the changes I observed in LC3 were autophagy-dependent and autophagy–
specific, I ablated ATG12 expression using Atg12 siRNA, and assessed LC3 processing 
following ATRi treatment. ATG12 is essential for autophagy, autophagy cannot occur 
without ATG12 expression (Mizushima et al., 2001). Fig 5.2.1.2.A shows successful 
knockdown of ATG12 following Atg12 siRNA transfection (lanes 3&4). Treatment with 
VE-822 when ATG12 expression is unperturbed induces increased LC3-II expression, 
however following ATG12 ablation, the ATRi-dependent increase in LC3-II is lost (lanes 
2&4). This strongly suggests the ATRi-induced increases in LC3-II I have observed are 
dependent on a functional autophagy axis. This indicates that the altered LC3-I/II status 
I observe after ATRi is due to a defect in autophagy-dependent processing of LC3. 
Figure 5.2.1.2. ATRi induces aberrant autophagic-dependent LC3 processing. A) Atg12 siRNA ablates 
ATRi-induced LC3-II increase. Cycling 3T3-L1 preadipocytes were transfected with Atg12 siRNA. 48 hrs 
post transfection ATG12 is successfully knocked down and samples were treated with ATRi II for 6 hrs. 
Following siRNA treatment, VE-822 no longer induces LC3-II increase indicating shifted LC3 status is 
autophagy-dependent. Lamin B used as loading control. B) 50 nM Bafilomycin A treatment has an 
epistatic effect on LC3 status when co-treated with ATRi, indicating ATRi treatment induces an 
autophagic block at the stages of lysosomal fusion. C) 3-MA (10 mM, 4 hrs) has an additive effect on 
LC3-I and –II following ATRi treatment, indicating ATRi treatment is not blocking early autophagy (lanes 
3-5). D) VE-822 treatment induces drastic increases in p62 expression after 1 hr treatment. CDX 
denotes cyclodextrin (16hrs, 10 mM) – an inducer of p62 and positive control. * denotes LC3-II band. 
-actin used as loading control for p62 western blotting. All images representative of results obtained 
in at least three independent experiments. 
A B 
C 
D 
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To further characterise at which stage ATRi was affecting autophagic LC3 
processing, I co-treated ATRi-treated 3T3-L1 preadipocytes with Bafilomycin A and 
assessed LC3 status by western blotting. Bafilomycin A treatment increased LC3-II levels 
equivalent to ATRi treatment (Fig 5.2.1.2.B, lanes 2 and 3). Co-treatment with both 
compounds did not have an additive effect on LC3-II status, suggesting that ATRi is 
inducing an autophagic block at the level of autophagosomal maturation and lysosomal 
fusion. To further confirm that the observed ATRi-induced block in autophagy was not 
occurring at earlier stages of the autophagy process, I assessed the effects of co-
treatment with ATRi II and 3-MA. 3-MA induces increases in LC3-I (Fig 5.2.1.2.C, lane 3), 
due to the inhibition of early autophagosome formation and LC3-I conjugation to LC3-II. 
Co-treatment of ATRi and 3-MA had an additive effect, where both LC3-I and –II were 
increased, indicating the two compounds affect autophagy at differing nodes. 
 P62 is degraded throughout autophagic processing. Hence, a block in autophagic 
degradation will induce increased p62 expression, as p62-containing autophagosomes 
accumulate within the cytoplasm. Fig 5.2.1.2.D shows striking increases in p62 protein 
levels following treatment with VE-822. The significance of the increased p62 levels 
observed with ATRi treatment is reinforced when considering lane 1 of Fig 5.2.1.2.D - 
treatment with cyclodextrin, an inducer of p62 expression that I utilised as a positive 
control. These results suggest that acute treatments with ATRis have a fundamental 
impact on autophagic processing.  
5.2.2. Genetic approaches to compromise ATR phenocopy ATRi-
induced defects in autophagy and p62 accumulation 
I wanted to confirm the autophagy defects I was observing following ATRi treatments 
were not due to a non-specific effect of small molecule kinase inhibitors of ATR. To 
investigate this, I utilised genetic approaches to ablate ATR protein function and assess 
LC3-I/II status.  
ATR-ATRIP exists in a stable homodimer, requiring trans-autophosphorylation to 
become activated and remain stable (Nam et al., 2011). Hence, overexpression of a 
kinase-dead (KD) ATR construct can induce a dominant-negative effect on ATR kinase 
activity, through the dilution of available kinase-active ATR. Wild-type (WT) ATR 
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dimerises with KD-ATR and fails to trans-autophosphorylate and activate. Through the 
overexpression of KD-ATR, it is possible to investigate the effects of reduced ATR kinase 
function without reducing total ATR protein expression. Due to this, KD-ATR 
overexpression is considered more similar to the effects of small molecule kinase 
inhibition than siRNA approaches, which ablate protein expression rather than kinase 
activity specifically.  
I overexpressed a KD-ATR construct in cycling 3T3-L1 preadipocytes to assess the 
effects of ablating ATR kinase activity on LC3-I/II and p62 kinetics. As a control, I also 
overexpressed WT-ATR, which has been previously shown to induce autophagic cell 
death (Mori et al., 2013). Fig 5.2.2.A shows both WT- and KD-ATR transient 
overexpression induces p62 and LC3 phenotypes similar to treatment with ATRi, where 
KD-ATR appears to induce the strongest increase in p62 and LC3-II between the two 
constructs. This suggests that altering either ATR expression or activity has a 
considerable effect on autophagic status. 
I utilised Atr siRNA to deplete total ATR, where 24 and 48 hrs following transient 
siRNA transfection ATR expression is ablated (Fig 5.2.2.B, lanes 2 and 3). After 48 hrs of 
ATR knockdown with Atr siRNA, an increase in LC3-II is observed equivalent to 4 hrs ATRi 
treatment, further suggesting the autophagic block I observed following ATRi is a 
genuine effect of depleting ATR function. Furthermore, I observed increased p62 
A B 
Figure 5.2.2. Over expression of WT and KD-ATR constructs and Atr siRNA results in enhanced p62 
and autophagic block. A) Western blotting of cycling 3T3-L1 preadipocytes transfected with untagged 
WT-ATR and KD-ATR show altered LC3 processing and increased p62 expression compared to 
transfection reagent alone. Lamin B used as loading control B) Atr siRNA induces LC3 and p62 
phenotypes equivalent to ATRi treatment. Interestingly, siRNA treatment induced increased LC3-II and 
p62 expression at separate time points following transfection, indicating that the two phenomenon 
may occur independently of one another. Lamin B used as loading control. All images representative 
of results obtained in at least three independent experiments. 
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expression following 24 hrs Atr siRNA treatment, although this effect was not sustained 
48 hrs post siRNA transfection (Fig 5.2.2.B). Interestingly, increased p62 and LC3-II are 
not observed here at the same time, indicative that ATRi-induced p62 accumulation may 
not be directly linked to the ATRi-induced block in autophagy.  
5.2.3. ATRi-induced p62 accumulation is autophagy- and DDR- 
independent 
In section 5.2.2, I discovered that the kinetics of increased p62 and LC3-II following ATR 
ablation appear to deviate from one another. Because of this, I wanted to investigate 
and confirm if the ATRi-induced p62 accumulation I observe is independent of the ATRi-
induced block in autophagy. To do this, I ablated autophagy-essential protein ATG16L1 
in cycling 3T3-L1 preadipocytes using Atg16L1 siRNA. Following ATRi treatment of 
samples with normal ATG16L1 expression, p62 and LC3-II are increased (Fig 5.2.3.A, lane 
2). Following ATRi treatment and genetic ablation of ATG16L1, LC3-II has not increased 
(lane 4), reinforcing that the ATRi-induced increases in LC3-II are autophagy-dependent. 
However, following ATRi treatment and ATG16L1 knockdown, p62 expression is 
increased equivalent to samples with an intact autophagy axis (lanes 2&4). As cells 
A B 
Figure 5.2.3. Increased p62 expression following ATRi is independent of autophagy and DNA damage 
induction and signalling. A) Atg16l1 siRNA transfection of cycling 3T3-L1 preadipocytes results in 
effective knockdown of ATG16L1. Following ATRi treatment (VE-822, 10 M) LC3-II and p62 expression 
is increased. ATRi treatment following Atg16l1 siRNA does not increase LC3-II levels, but p62 
expression remains enhanced indicating that ATRi-induced increase in p62 protein expression is 
autophagy-independent. Lamin B used as loading control. B) Western blotting of p62 expression 
following 4 hrs CHK1i (UCN01, 300 nM) ATMi (KU55933, 10 M) and ATRi (VE-822, 10 M) and HU 
treatment (500 M). CHK1i appears to modestly reduce p62 expression, indicating that the ATRi-
induced increase in p62 expression is independent of deficits in ATR-CHK1 signalling. HU treatment 
does not affect p62 expression alone or in concert with ATRi, CHK1i or ATMi, indicating that enhanced 
replicative stress is not responsible for the ATRi-induced increase in p62 expression. -tubulin used as 
a loading control. All images representative of results obtained in at least three independent 
experiments. 
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cannot undertake autophagy without ATG16L1, this indicates ATRi-induced p62 
accumulation is autophagy-independent. This suggests that two separate phenomena 
may be occurring within the cell to generate an accumulation of p62 and an autophagic 
block in response to acute ATR kinase inhibition. This result also indicates that the 
increased p62 protein expression observed following ATRi treatment may be due to 
increased transcription of p62, rather than reduced autophagic degradation. 
Following the discovery that the majority of ATRi-induced p62 accumulation was 
autophagy-independent, I wanted to further characterise this phenomenon. I wanted to 
assess if p62 accumulation was independent of ATRi-induced DNA damage, and also of 
the canonical ATR-CHK1 signalling axis. I treated cycling 3T3-L1 preadipocytes with 
CHK1i, ATMi, and hydroxyurea (HU) to assess the effects of these treatments on p62 
expression (Fig 5.2.3.B).  HU induces replication stress through the depletion of dNTP 
pools required for DNA synthesis, rendering it an effective inducer of replication stress 
- an established effect of ATRi treatment. Strikingly, CHK1i UCN01 did not have any 
impact on p62 expression (Fig 5.2.3.B, lane 3). This indicates that the p62 accumulation 
I have observed using two structurally distinct ATRis, Atr siRNA and over expression of 
KD-ATR cannot be recapitulated by inhibiting an established ATR-dependent DDR kinase. 
ATMi treatment appeared to induce a modest increase in p62 expression (Fig 5.2.3.B, 
lane 4), however roles for ATM in pexophagy have been characterised (Zhang et al., 
2015) suggesting p62 accumulation is to be expected following ATMi treatment. Further 
to this, treatment with HU did not augment p62 accumulation alone or following CHK1, 
ATM or ATR kinase inhibition treatment (lanes 5-8), suggesting ATRi-induced p62 
accumulation is independent of DNA damage or replication stress induced by inhibition 
of ATR kinase activity.  
5.2.4. ATRi induces TFEB translocation and lysosomal biogenesis 
P62 is transcriptionally regulated by several factors, including master lysosomal 
biogenesis regulator TFEB (Settembre et al., 2012). TFEB activity is regulated by 
mTORC1-dependent inhibitory phosphorylations at the lysosome. I hypothesised that, 
considering the reduced mTORC1 activity following acute ATRi treatment and Atr siRNA 
I observed in chapter 3, nuclear TFEB activity could be increased following ATRi 
treatments, resulting in enhanced p62 transcription. TFEB activity can be assessed by 
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cellular localisation; sequestration in the cytoplasm by mTORC1 renders it inactive, and 
following activation, it translocates to the nucleus to activate gene targets.  
2-Hydroxypropyl-β-cyclodextrin (hereon cyclodextrin) can be utilised in cell 
culture as an inducer of TFEB activation. Using cyclodextrin as a positive control, I 
treated cycling 3T3-L1 preadipocytes with ATRi and fractionated the nuclear 
compartment to assess TFEB translocation via western blotting. Untreated samples 
contain relatively low nuclear TFEB levels (Fig 5.2.4.A, lane 1). Following addition of 
cyclodextrin, nuclear TFEB content is visibly increased (lane 3). As hypothesised, nuclear 
TFEB levels are also increased following ATRi treatment (lane 2), suggesting that ATRi-
induced reduction in mTORC1 activity has functional significance - increasing TFEB-
mediated lysosomal biogenesis and p62 expression.  
WIPI1 and Lysosomal-associated membrane protein 1 (LAMP1) are also targets 
of TFEB-mediated gene transcription. To further assess the significance of ATRi-induced 
increased TFEB activity, I assessed WIPI1 and LAMP1 expression in 3T3-L1 preadipocytes 
following ATRi treatment by western blotting. Cyclodextrin was used as a positive 
control in this experiment. Treatment with cyclodextrin induces increased LAMP1 
Figure 5.2.4. ATRi induces TFEB translocation and expression of lysosomal markers. A) Western 
blotting of nuclear and whole-cell extracts (WCE) for TFEB following ATRi treatment. Cyclodextrin used 
as positive control (lane 3). Lamin B used as loading control for nuclear extract; -tubulin used as a 
loading control in WCE, and as a marker of cytoplasmic compartment in nuclear extracts. 4 hrs VE-822 
treatment increased nuclear TFEB equivalent to cyclodextrin, indicative of enhanced TFEB-mediated 
lysosomal biogenesis. B) Western blotting of WIPI1 and lysosomal marker LAMP1 (TFEB transcriptional 
targets) following ATRi treatment. * indicates cyclodextrin treatment as positive control (16 hrs, 10 
mM). LAMP1 expression increases following ATRi equivalent to cyclodextrin after 6 hrs, indicative of 
increased TFEB-mediated transcription and expression of LAMP1. -actin used as loading control. All 
images representative of results obtained in at least three independent experiments. 
B A 
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expression when compared to untreated samples (Fig 5.2.4.B, lanes 1 & 2), but WIPI1 
expression remains unaffected. After 6 hrs ATRi treatment, LAMP1 expression is 
increased equivalent to cyclodextrin. At 8 hrs ATRi treatment a small increase can be 
observed in WIPI1 expression (lane 7). This potentially indicates ATRi-induced TFEB 
nuclear translocation is inducing lysosomal biogenesis, as assessed by LAMP1 protein 
expression levels. 
5.2.5. Altering cellular Ca2+ status affects ATRi-induced p62 
accumulation 
In chapter 4, I demonstrated that mature 3T3-L1 adipocytes treated with ATRi II for 24 
hrs had increased Ca2+/calmodulin-dependent protein kinase II (CAMKII) activation as 
assessed by western blotting of p-CAMKII T286, indicative of altered intracellular Ca2+. 
Since fluctuations in cytoplasmic Ca2+ concentration have a fundamental effect on 
autophagy, I wanted to investigate if alterations in Ca2+ flux were inducing the 
autophagic phenotypes following ATRi treatment.  
I examined the relationship of Ca2+ with ATRi-induced increased p62 expression 
and ATRi-induced autophagic block by co-treating cells with ATRi and Krebs-Henseleit 
(KH) medium. KH medium is Ca2+-free, hence I was able to investigate whether 
extracellular Ca2+ was required to induce ATRi-dependent increases in p62 and/or LC3-
II. Cycling 3T3-L1 preadipocytes were treated with ATRi II or VE-822 for 2 hrs in standard 
or Ca2+-free KH medium. In unperturbed samples, VE-822 and ATRi II treatment 
increased p62 expression and enhanced LC3-II (Fig 5.2.5.A, lanes 1, 3 & 5). Samples 
incubated in KH medium (lanes 2, 4 & 6) have decreased p62 expression and enhanced 
LC3-II expression. Interestingly, following ATRi treatments in KH medium, p62 
expression is no longer increased, suggesting a Ca2+-dependent mechanism is 
responsible for the ATRi-induced increases in p62. Culturing 3T3-L1 preadipocytes in KH 
medium appears to induce strong induction of LC3-II (lane 2), where co-treatment with 
ATRis gives no additive effect, indicating a role for Ca2+ in the observed autophagic block.  
Taken together, these results could also suggest Ca2+-free medium is enhancing 
autophagic processing which overrides the effects induced by ATRi treatment. The 
reduced p62 expression following KH medium treatment suggests the concomitant 
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enhanced LC3-II is not the result of a block in autophagy, rather an upregulation. 
Enhanced autophagy will increase the rate of p62 degradation, and furthermore reduce 
the expression of LC3-I as it is conjugated into LC3-II, both phenotypes observed after 
KH medium treatment.  
From Fig 5.2.5.A it is clear that Ca2+ status affects ATRi-induced p62 expression. 
To further investigate a role for Ca2+ homeostasis in the phenotypes I have observed 
following ATR deficiency, I studied the effects of Ca2+ chelators on ATRi-induced changes 
in autophagic flux. Chelating intracellular or extracellular Ca2+ enables the delineation of 
potential pathways that could alter Ca2+ flux. BAPTA (1,2-bis(o-aminophenoxy)ethane-
N,N,N′,N′-tetra-acetic acid) is a cell-impermeable Ca2+ chelator, that should function 
similarly to KH medium incubation. BAPTA is a metabolic product of BAPTA-AM, a cell-
permeable Ca2+ chelator that can control intracellular Ca2+ levels. BAPTA-AM sequesters 
intracellular Ca2+, rendering the cell insensitive to changes in Ca2+ release.  
I utilised BAPTA and BAPTA-AM to investigate the effects of depleting intra- and 
extra-cellular Ca2+ following ATRi treatment in 3T3-L1 preadipocytes (Fig 5.2.5.B). 
Neither BAPTA nor BAPTA-AM affected ATRi-induced increased LC3-II (Fig 5.2.5.B, lanes 
2, 4 and 6), however BAPTA appeared to modestly reduce p62 induction following ATRi 
(lane 4). This supports the observation in Fig 5.2.5.A that KH medium ablates ATRi-
induced p62 induction, suggesting that altering the availability of extracellular Ca2+ may 
have a role in p62 induction. 
Figure 5.2.5. Depleting extracellular Ca2+ inhibits ATRi-induced p62 accumulation. A) Western 
blotting of p62 and LC3. Cycling 3T3-L1 preadipocytes were incubated in Ca2+-free KH medium and 
ATRis for 2 hrs. KH medium prevented ATRi-induced p62 expression. KH medium increased LC3-II in 
untreated cells, which was additive following ATRi treatment indicating ATRi-induced autophagic 
block was not dependent on extracellular Ca2+. -tubulin used as loading control. B) p62 and LC3 
following BAPTA-AM, BAPTA and ATRi treatment. Neither chelator affects ATRi-induced LC3-II, 
however BAPTA reduced p62 similar to KH medium following ATRi. Lamin B used as loading control. 
All images representative of results obtained in at least three independent experiments. 
B A 
147 
 
5.3. Summary 
In this chapter, I have demonstrated that acute ATR inhibition treatment results in: 
 Enhanced autophagy-dependent expression of LC3-II, indicative of a block in 
autophagy at the stages of autophagosomal maturation (section 5.2.1) 
 Autophagic phenotypes of increased LC3-II and p62 accumulation, that are 
mimicked with Atr siRNA and overexpression of KD-ATR construct (section 
5.2.2) 
 p62 accumulation, that appears independent of autophagy blockage, CHK1 
activity and replication stress (section 5.2.3) 
 Increased TFEB nuclear translocation and increased expression of TFEB 
transcriptional targets LAMP1 and p62 (section 5.2.4) 
The ATRi-induced increase in p62 expression appeared dependent on extracellular Ca2+ 
availability. ATRi induced autophagic block as assessed by LC3 status was not affected 
by cell permeable or cell-impermeable calcium chelators (section 5.2.5) 
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5.4. Discussion 
In this chapter, I have demonstrated that small molecule kinase inhibitors of ATR, 
Atr siRNA and overexpression of a KD-ATR construct result in profound defects in 
autophagic processing, as well as autophagy-independent increases in p62.  
In Chapter 4, I demonstrated chronically ATRi-treated mature white adipocytes 
undertook a transdifferentiation process into beige adipocytes. p62 deficiency in mice 
has been shown to reduce metabolic rate, reduce BAT thermogenesis and enhance 
white adipocyte differentiation in an p44/42 MAPK-dependent manner (Müller et al., 
2013; Rodriguez et al., 2006). Perhaps the increased p62 expression levels I observe 
following ATRi treatment of 3T3-L1 preadipocytes has a role in the adipocyte browning 
I observed following ATRi in Chapter 4. The ATRi-induced increase in p62 expression 
appeared independent of CHK1 activity and replication stress, strongly indicating that 
this phenotype was not dependent on reduced ATR-CHK1 DDR signalling.  
Strikingly, normal p62 expression was recovered by extracellular Ca2+ chelation 
and Ca2+-free media, indicating a role of Ca2+ here. Throughout this work, a common 
theme of dysregulated modulation and availability of Ca2+ is becoming apparent in my 
ATRi-dependent phenotypes. ATRi-induced increased p62 expression was independent 
of the ATRi-induced defects in autophagy processing, which in turn appeared insensitive 
to changes in cellular Ca2+ status. This indicates that ATR deficiency may be impinging 
on more than one pathway to generate these autophagic phenotypes. Following from 
these results I considered it important to next investigate the effects of ATR deficiency 
on the two Ca2+-modulating organelles – the mitochondria and the ER. 
In Chapter 3, I showed mTORC1 activity was suppressed following acute ATRi 
treatments in 3T3-L1 preadipocytes. The reduced mTORC1-dependent cytoplasmic 
sequestration of TFEB, resulting in enhanced lysosomal biogenesis, adds further 
functional significance to the reduction in mTORC1 activity following acute ATRi 
treatments. Interestingly, ATRi treatments, a KD-ATR construct and Atr siRNA all induced 
a block in autophagy at the stage of autophagosomal maturation and lysosomal fusion, 
indicating that increased TFEB-mediated lysosomal biogenesis, a pathway commonly 
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associated with enhanced autophagic clearance, was not adequate to recover the ATR-
deficiency induced autophagic block.  
For full activation of mTORC1, p62 must interact with mTORC1 at the lysosome 
(Duran et al., 2011). The reduced mTORC1 activity following ATRi indicates that 
increased p62 expression is not inducing mTORC1 activation, suggesting the defects I 
have observed in mTORC1 signalling following ATRi may exist upstream of the mTORC1 
complex.  
Essential autophagy protein ATG16L1 mediates the conjugation of LC3-I to LC3-
II. Interestingly, ATG16L1 S269 appeared in a putative ATR/ATM substrate screen 
(Stokes et al., 2007). If ATG16L1 were to be an ATR substrate in my system, where ATRi 
induces defects in autophagy, the only considerable effect of ATR on ATG16L1 activity 
in this model would be to repress LC3-I conjugation. ATRi treatment would relieve this 
potential repressive, ATR-dependent phosphorylation at S269, allowing the ATG5-
ATG12-ATG16L1 complex to aberrantly conjugate LC3 increasing levels of membrane 
bound LC3-II, generating the observed ATRi-induced increases in LC3-II. However, the 
epistatic effect of Bafilomycin A and ATRi treatment on LC3-II status disproves this model 
– if ATRi was inducing ATG16L1-dependent increases in LC3-II conjugation, Bafilomycin 
A co-treatment would have produced an additive increase in LC3-II, due to increased 
autophagic induction by the loss of ATR-dependent repressive phosphorylation of 
ATG16L1, and inhibition of degradation by Bafilomycin A. 
This data has positive implications for the proposed use of ATRis in the treatment 
of cancer. Roles for autophagy in almost every stage of tumour metastasis have been 
described (Mowers et al., 2017). Tumour cells capable of increased stress-induced 
autophagy can become chemoresistant, where eventual tumour regrowth and 
progression is frequent (Lu et al., 2008). Furthermore, preclinical models have described 
the recovery of chemosensitivity and enhanced therapy-induced tumour cell death with 
autophagy inhibitor treatments (Amaravadi et al., 2007; Ding et al., 2009).  
I have characterised a novel block in autophagic processing following depletion 
of ATR functionality, with clinically relevant ATRis as well as genetic approaches. If the 
autophagic phenotypes induced by ATRi treatment I have characterised in vitro are 
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recapitulated in vivo, there are additional, as yet unconsidered potential therapeutic 
benefits for the usage of ATRi in cancer therapy. If ATRi treatments in vivo were capable 
of interrupting the enhanced autophagic processing observed frequently in cancers, 
novel synthetic lethality strategies could be developed, for example, co treatment with 
the first-in-class proteasome inhibitor Bortezomib, currently used as a therapeutic in 
cancers such as multiple myeloma (Scott et al., 2016). 
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6. Chapter Six 
Results IV: Characterisation of a                                  
Novel ATRi-induced Vacuolation Phenotype 
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6.1. Introduction 
In chapter 5, I characterised novel impacts of ablating ATR function on autophagic 
processing and lysosomal biogenesis in cycling 3T3-L1 preadipocytes, where some ATRi-
induced phenotypes were rescued by Ca2+ chelation. In chapter 4, I dissected what 
appeared to be Ca2+-dependent metabolic reprogramming of mature 3T3-L1 adipocytes 
following chronic ATRi treatments. The role of Ca2+ dynamics in autophagic induction, 
adipogenesis, and the ‘browning’ of white adipose tissue (WAT) is established in 
literature (Høyer-Hansen et al., 2007; Jensen et al., 2004; Kania et al., 2015; Wright et 
al., 2007). The recovery of some of the observed ATRi-induced phenotypes by 
modulating Ca2+ availability led me to consider a putative role for ATR at the key Ca2+-
sequestering organelles, the mitochondria and the endoplasmic reticulum (ER). Perhaps 
reducing ATR function has an effect on the regulation of these highly dynamic 
organelles, which could be indirectly causing altered Ca2+ sequestration or release, 
resulting in the variety of ATRi-induced phenotypes I have observed throughout my 
studies. 
 In this chapter, I discover a profound impact of ATR deficiency on ER function, 
and striking effects of acute ATRi treatment on mitochondrial dynamics. I conclude that 
acute ATRi treatments have a fundamental effect on the ER in my experimental system, 
with potentially secondary effects on mitochondrial function. Because of this, this 
chapter is focused mostly around the impact of ATRi on ER functionality, hence the 
introduction to these results will be centred on the roles of the ER in maintaining cellular 
homeostasis. 
The endoplasmic reticulum (ER) is a vast, cytoplasmic organelle, consisting of a 
network of planar cisternae and tubular membrane structures. ER tubules stretch 
throughout the cytoplasm and are termed the ‘smooth’ ER due to their diminished 
association with ribosomes. The smooth ER primarily modulates Ca2+ homeostasis, fatty 
acid and phospholipid synthesis and lipid bilayer assembly (Chaudhari et al., 2014). The 
smooth ER also forms abundant membrane contact sites (MSCs) with other organelles. 
The smooth ER forms MSCs with the mitochondria, which is notable as the biogenesis 
of this organelle does not originate from the ER membrane.  
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Perinuclear, ribosome-covered ER sheets make up the rough ER, required for the 
synthesis and processing of secreted, luminal and membrane proteins. Many classes of 
protein require extensive modification, chaperone-mediated folding, membrane 
incorporation and translocation to their appropriate regions in ER-derived vesicles. 
Although the nuclear envelope comprises a diverse proteome typically not enriched in 
the ER, their membranes are continuous (Hetzer, 2010). The ER performs a plethora of 
homeostatic, housekeeping cellular functions, which I will briefly review here.  
 The endomembrane system 
The endomembrane system is the term for the extensive network of lipid membranes 
retained within the cell, consisting collectively of the ER, lysosomes, and Golgi Apparatus 
(GA) (Fig 6.1.1). Coordinated budding and fusion events, mediated by the microtubule 
network and specialised protein complexes at these organelles, generates membrane 
that can be utilised in organelle biosynthesis, vesicular trafficking and autophagy. 
Central to these processes is the ER – providing membrane for autophagosome and 
endosome formation, and receiving retrograde vesicles from the GA (Araki and Nagata, 
2011; Murphy and Vance, 1999; Nakamura and Yoshimori, 2017; Nebenführ, 2002; 
Sanchez-Wandelmer et al., 2015; Scott et al., 2014).  
Figure 6.1.1. The endomembrane system. Lipid membranes are constantly transported throughout 
the cytoplasm to maintain organelle homeostasis. ER – Endoplasmic reticulum; COPI/II – coat protein 
complex I/II; TGN – trans Golgi network; CCV – clathrin-coated vesicles; DV – dense vesicles; PAC – 
precursor accumulating vesicles; LV – lytic vesicle. Taken from (Nebenführ, 2002) 
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Interestingly, ATR has been proposed to potentially have novel roles in the 
endomembrane transport network – proteins enriched with evolutionarily conserved 
ATR/ATM substrate motifs are over-represented in vesicle trafficking and cytoskeletal 
pathways (Cara et al., 2016), and vesicle-associated membrane protein 2 (VAMP2) has 
recently been validated as a novel ATR substrate involved in neurotransmitter release 
(Li et al., 2009). Notable putative ATR susbtrates with roles in membrane transport 
include:  
 Dynein subunits (cytoplasmic dynein 1 intermediate chain 2 - DYNC1I2 p-S95; 
DYNC1 heavy chain 1 - DYNC1H1 multiple sites) – required for minus-end 
transport of all membrane-bound cargos across the microtubule network 
towards the nuclear periphery (Cara et al., 2016; Kimura et al., 2008; Matsuoka 
et al., 2007).  
 Syntaxin 6 (p-S129) – Soluble NSF Attachment Protein Receptor (SNARE) protein, 
associated with the trans-Golgi network (TGN) and early endosomes. Required 
with VAMP2 for insulin-dependent glucose transporter 4 (GLUT4) translocation 
to the plasma membrane in endocrine cells (Jung et al., 2012; Matsuoka et al., 
2007). 
 Vacuolar protein sorting-associated protein 4b (VPS4b p-T317) - An AAA+-ATPase 
(ATPases Associated with diverse cellular Activities) implicated in multi-vesicular 
body (MVB) transport, required for endosomal sorting and trafficking through its 
function in the disassembly and dissociation of the endosomal sorting complexes 
required for transport-III (ESCRT-III) complex from membranes (Obita et al., 
2007) (Matsuoka et al., 2007). 
 Intracellular Ca2+ Homeostasis  
As well as providing membrane for a variety of other organelles within the 
endomembrane system, the ER also functions in concert with the mitochondria to tightly 
govern intracellular Ca2+. Specific temporal and spatial thresholds of [Ca2+]cyt 
(cytoplasmic Ca2+ concentration) activate a variety of Ca2+-dependent kinases, allowing 
signal transduction through multiple cascades resulting in fundamental shifts in 
metabolic and transcriptional programming. Maintenance of low [Ca2+]cyt  (100-300 nM) 
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by the ER and mitochondria, where the luminal concentration of Ca2+ is significantly 
higher (10-100 M), and the availability of Ca2+-dependent kinases of varying sensitivity, 
allows each cell the toolkit to create and respond to diverse temporal and spatial shifts 
in Ca2+ (Berridge et al., 2000). Cells have exploited the versatile nature of this 
intracellular messenger, with Ca2+ efflux controlling diverse intracellular processes 
including proliferation, differentiation, secretion, metabolism, membrane trafficking, 
gene transcription and apoptosis (Berridge et al., 2000). 
6.1.2.1. Ca2+ sequestration 
In skeletal and cardiac muscle, calsequestrin acts as the primary Ca2+-binding protein. In 
almost all other tissues, Ca2+ is sequestered in the ER lumen by Ca2+-dependent 
chaperones binding immunoglobulin protein (BiP), calnexin (CANX) and protein 
disulphide isomerase (PDI), as well as calreticulin (Papp et al., 2003). Ca2+-binding 
proteins such as these also carry other essential functions, including chaperone function 
and influence over ER Ca2+ release and uptake, underscoring the intimate relationship 
between [Ca2+]ER and general ER functionality (Berridge, 2002). 
6.1.2.2. Ca2+ channels/pumps 
Many luminal and transmembrane proteins housed at the ER control Ca2+ movement 
across its membrane. Ca2+ flux through the ER requires extensive regulation under basal 
conditions, as well as in response to external stimuli (Raffaello et al., 2016). ATP-
dependent smooth ER Ca2+ ATPase (SERCA) pumps Ca2+ into the ER lumen, and is 
responsible for maintaining the significant Ca2+ gradient between the ER and cytoplasm. 
SERCA pump activity is increased upon ER Ca2+ release (Periasamy and 
Kalyanasundaram, 2007). Following Ca2+ release and subsequent depletion of [Ca2+]ER, 
store-operated Ca2+ entry (SOCE) works to sustain the enhanced [Ca2+]cyt through 
facilitating refilling of the ER with Ca2+ from the extracellular environment (Smyth et al., 
2010). Protein families coordinate SOCE; ER-membrane bound stromal interaction 
molecule 1 family (STIM) and plasma membrane-bound Ca2+-release-activated Ca2+ 
channel protein 1 (ORAI1). ER Ca2+ depletion induces oligomerisation and translocation 
of STIM1 across the ER membrane to ER-plasma membrane junctions, where it interacts 
with ORAI, inducing Ca2+ influx into the ER (Raffaello et al., 2016). 
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Two subtypes of Ca2+ channel also exist on the ER membrane – the inositol 1, 4, 
5-triphosphate receptor (IP3R) and Ryanodine receptor family (RyRs). Following 
stimulation, these channels act alone or in concert to rapidly release ER Ca2+ into the 
cytoplasm. RyRs form vast homotetramers, whose primary opening trigger is Ca2+ 
binding at multiple sites of differing affinities (Van Petegem, 2012).  
Depletion of ER Ca2+ underlies the pathophysiology of several diseases including 
diabetes mellitus, vascular disease and sensory neuropathy (Mekahli et al., 2011).  
Further to this, compounds that alter ER Ca2+-channel function are clinically 
distinguished in the treatment of hypertension and heart disease, such as IP3R channel 
blocker Verapamil (Zanchetti et al., 1998). Increases in cytoplasmic IP3 stimulate the 
release of Ca2+ from the ER via the IP3R. Increased IP3 pools are generated through the 
activation of phospholipase C (PLC) following ligand-GPCR (G protein-coupled receptor) 
binding, where PLC functions to cleave PI(4, 5)P2 into DAG and I(1, 4, 5)P3 (Raffaello et 
al., 2016). IP3Rs are also opened as part of Ca2+-induced Ca2+ release - a positive feedback 
mechanism also associated with RyRs. Until a specific threshold that is inhibitory, 
increasing [Ca2+]cyt increases IP3R open probability. IP3R activity is modified by a variety 
of factors, including Ca2+-binding protein calmodulin (Hirota et al., 1999) and pro-
survival BH3 family members B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra 
large (BCL-XL) (Distelhorst and Bootman, 2011). Several Ca2+-dependent kinases 
function in the induction of autophagy, such as Ca2+/calmodulin-dependent kinase 
kinase-beta (CAMKK) (Glick et al., 2010; Høyer-Hansen et al., 2007; Kania et al., 2015).  
 The BCL-2 family  
As well as roles in modulating ER and mitochondrial Ca2+ homeostasis, a fundamental 
role of BCL-2 family members is in the control of cell fate. This family of pro- and anti-
apoptotic proteins have dynamic relationships with one another, where their activities 
culminate in a sensitive ‘molecular switch’ between the survival and death pathways 
within the cell – autophagy and apoptosis (Youle and Strasser, 2008). The decision to 
undertake either programmed cell death or enhance autophagic, survival-associated 
pathways is generated by BCL-2 family members through the competitive binding and 
sequestration of one another, inhibitory and activatory phosphorylations from 
upstream regulators and multiple other mechanisms. Three functional groups, with 
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opposing roles, exist within the BCL-2 family, working in concert to decide cell fate (Fig 
6.1.3.1): 
1) Pro-survival ‘multi-region’ members – BCL-2, BCL-XL, Induced myeloid leukaemia cell 
differentiation protein (MCL-1) 
2) Pro-apoptosis ‘BH3-only’ effectors – sub-classified into ‘sensitizers’ (BCL-2-
associated death promoter - BAD) and ‘activators’ (BH3 interacting-domain death 
agonist - BID, BCL-2-like protein 11 - BIM, p53 upregulated modulator of apoptosis - 
PUMA, Phorbol-12-myristate-13-acetate-induced protein 1 - NOXA) 
3) ‘Executioner’ members - BCL-2 homologous antagonist/killer (BAK) and BCL-2-
associated X protein (BAX) 
Activation of the ‘executioner’ proteins BAK/BAX is central to the induction of 
apoptosis. Activation of BAK/BAX induces a conformational change, resulting in their 
oligomerisation, allowing them to form pores in the mitochondrial outer membrane 
(MOM) (Wei et al., 2001). The permeablised MOM releases cytochrome C into the 
cytoplasm, activating apoptotic effector caspases to initiate programmed cell death 
pathways and degradation of cellular components. BAK is constitutively membrane 
Figure 6.1.3.1. Structure of BCL-2 family members. Pro-survival members are multi-region, 
executioners BAK/BAX are also multi-region, pro-apoptosis members are generally BH3-only, with the 
exception of BID. Taken from (Shamas-Din et al., 2013) 
  158 
bound, whereas BAX remains cytoplasmic until activated, and elements of redundancy 
exist between these two BCL-2 members (Westphal et al., 2011).  
In unperturbed cells, the opposing actions of the pro-survival (multi-region) and 
pro-apoptosis (BH3-only) BCL-2 family members on BAX/BAK remains in a stable, pro-
survival state of equilibrium. This is achieved through the mutual sequestration of 
opposing members, posttranslational modifications (PTMs) from upstream effectors, 
and targeted degradation (Shamas-Din et al., 2013). Pro-survival, multi-region members 
(such as BCL-2, BCL-XL, and MCL-1) sequester BH3-only proteins, and bind to and inhibit 
BAK/BAX oligomerisation to prevent apoptosis (Emily et al., 2001; Willis et al., 2005). 
These pro-survival family members prevent the mitochondrial association of BAX and 
sequester BAK, effectively inhibiting apoptosis (Fig 6.1.3.2). Pro-survival BCL-2 also binds 
to and inhibits Beclin 1 from inducing autophagy, where this interaction can be 
interrupted (and autophagy induced) by activated BH3-only proteins that sequester BCL-
2, as well as PTMs of BCL-2 (Kang et al., 2011). Hence, in unperturbed conditions pro-
Figure 6.1.3.2. Simplified schematic of BCL-2 family mechanisms of action. In unperturbed cells, BAK 
and BAX are sequestered by pro-survival members (such as BCL-2). Following activation of pro-
apoptotic members, mutual sequestration of multi-region and BH3-only members occurs, increasing 
likelihood of BAK/BAX oligomerisation.  Taken from (Rautureau et al., 2010) 
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survival BCL-2 family members inhibit autophagy, but their sequestration by BH3-only 
proteins in times of stress effectively induces pro-survival, autophagic activation. 
BAK/BAX oligomerisation is induced by the binding of activated, BH3-only 
effectors coined ‘activators’, such as truncated BID (tBID), BIM and PUMA (Kuwana et 
al., 2005). BH3-only ‘activator’ proteins can bind to BAK/BAX as well as mutually 
sequester other pro-survival multi-region members with varying specificities; 
‘sensitizers’ such as BAD can only sequester pro-survival members, and do not have the 
binding affinity for direct activation of BAX/BAK. ‘Sensitizer’ BH3-only members can also 
displace ‘activator’ BH3-only proteins from their mutual sequestration with pro-survival 
members, allowing them to go forward in activating BAK/BAX (Giam et al., 2008).  
BID/tBID will preferentially bind to pro-survival, multi-region BCL-2 proteins 
(Cheng et al., 2001), however if it is diplaced by another BH3-only protein, it will bind to 
and activate BAK. Using sequence alignments, Hilton et al. (2015) interestingly noted 
that the BH3-like domains of ATR resembled those within the pro-survival, multi-region 
BCL-2 family (such as BCL-2). ATR co-precipitated with tBID at the mitochondria, 
appearing to sequester and inhibit the pro-apoptotic function of tBID, suggesting a 
genuine functional significance of the BH3-like domains of ATR (Hilton et al., 2015). 
Furthermore, BID/tBID is an established ATR substrate following DNA damage (Liu et al., 
2011; Zinkel et al., 2005). 
As well as influencing IP3R activity, ER-associated BCL-2 also increases ER 
membrane Ca2+ permeability, causing Ca2+ to ‘leak’ back into the cytoplasm (Oakes et 
al., 2003). This has the net effect of reducing the impact of agonist-induced ER Ca2+ 
release, reducing the activity of kinases dependent on sharp increases in [Ca2+]cyt for 
activation such as autophagy inducer CAMKK, and reducing Ca2+ transfer from the ER 
to the mitochondria to initiate apoptosis (Høyer-Hansen et al., 2007; Mattson and Chan, 
2003). 
 Protein folding and quality control 
Perhaps the most vital role of the ER is as the quality control centre of newly synthesised 
proteins. Stringent quality control parameters on the production of secreted, large or 
membrane-bound proteins at the ER ensure misfolded proteins or aggregates do not 
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enter the cytoplasm and compromise proteomic homeostasis. Resident ER chaperones 
and enzymes aid protein folding, signal peptide cleavage, and PTMs such as N-linked 
glycosylation and the formation of disulphide bridges (Araki and Nagata, 2011).  
One example of such surveillance of newly synthesised proteins is the 
management of PTMs required to generate glycoproteins. Ca2+-responsive chaperones 
CANX and Calreticulin will recognise proteins carrying untrimmed N-glycan groups – 
binding to them to prevent aggregation or premature export from the ER whilst they are 
optimally folded (Williams, 2006). Following cleavage of a single glucose residue by 
glucosidase II, these glycosylated polypeptides are released from CANX/Calreticulin for 
the next quality control check by UDP-glucose/glycoprotein glucosyl-transferase (UGGT) 
(Gelebart et al., 2005). UGGT assesses the folded conformation of released 
glycoproteins; if they are not appropriately folded they are reglucosylated, sending them 
back to CANX/calreticulin for another chance to reach their correct conformation 
(Hebert et al., 2005). 
Another major chaperone system resident to the ER is mediated by BiP. BiP is a 
key member of the heat shock protein 70 (HSP70) family of chaperones (Kaufman et al., 
2002), and like CANX and Calreticulin, BiP also acts as a Ca2+ buffer, binding the ion with 
1:1 stoichiometry in the ER lumen (Lamb et al., 2006). Further from this, in unperturbed 
conditions BiP binds to and regulates the activities of the three unfolded protein 
response (UPR) inducers - activating transcription factor 6 (ATF6), inositol requiring 
kinase 1 (IRE1) and protein kinase RNA-like ER kinase (PERK) – making it a key 
modulator of the UPR (Bertolotti et al., 2000). Multiple cochaperones mediate the 
activity and stimulation of BiP as well as nucleotide exchange factors (NEFs). ADP-bound 
BiP will bind to substrates with closed hydrophobic regions, preventing aggregation of 
unfolded polypeptides, ensuring they remain soluble (Kampinga and Craig, 2010).  
The ER also facilitates the formation of disulphide bonds – important covalent 
bonds required to ensure the folding, stability and correct quaternary structure of many 
proteins. Oxidoreductases (within the PDI family) facilitate disulphide bridge formation 
at cysteine residues, through their catalytic oxidation and isomerisation activities 
(Ellgaard and Ruddock, 2005).  
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Following successful folding, proteins that require further PTMs exit the ER via 
ER exit sites (ERES), and are shuttled to the GA via specialised vesicles. The GA functions 
as a molecular assembly line, completing complex PTMs before membrane-bound 
proteins can reach full maturation. When the ER is not able to successfully facilitate 
protein folding, terminally aggregated or misfolded proteins are targeted for 
degradation. The ERAD and autophagy pathways work to remove and degrade these 
polypeptides. 
 The ER stress response 
6.1.5.1. ER-Associated Degradation (ERAD) 
ERAD is the series of pathways that removes inoperably misfolded proteins from the ER 
for targeted proteasomal degradation (Grootjans et al., 2016). A substantial fraction of 
proteins entering the ER for processing will never reach their native states. Hence, the 
folding protein population within the ER lumen is under constant surveillance to ensure 
terminally misfolded polypeptides are recognised, dislocated and degraded. Central to 
the ERAD system are ER transmembrane complexes containing E3 ubiquitin ligases 
(Denic et al., 2006). The ERAD E3s work in concert with adaptor proteins (including BiP) 
to survey overlapping but distinct substrates with diverse topologies, which require 
removal (Smith et al., 2011).  
Terminally misfolded proteins are polyubiquitinated and subsequently extracted 
from the ER membrane by AAA+ ATPase valosin-containing protein (VCP/p97 – referred 
to hereon as p97), allowing them to be escorted to the proteasome (Ye et al., 2005). 
Interestingly, p97 is also phosphorylated by ATR (S784) in response to UV-induced DNA 
damage (Livingstone et al., 2005), within a consensus sequence required for localisation 
to specific cellular compartments and nuclear-cytoplasmic shuttling (Song et al., 2015). 
Phospho-p97 S784 is localised to sites of DNA DSBs, and is proposed to be required for 
the removal of ubiquitinated proteins from chromatin (Vaz et al., 2013). Further to this, 
over-expression of dominant negative p97 construct, or p97 siRNA results in ER swelling, 
due to the accumulation of misfolded proteins within the ER with no effective ER 
secretory pathway to remove them for degradation (Mimnaugh et al., 2006).  
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6.1.5.2. The UPR 
Times of increased translation that exceed the ER’s capacity to appropriately fold and 
modify newly synthesised polypeptides, can result in the accumulation of mis- or un-
folded proteins, referred to as ER stress. When the ERAD pathways are no longer 
sufficient to manage degradation of these terminally misfolded proteins, pathways 
collectively termed the UPR are initiated to re-establish normal function of the ER 
(Chakrabarti et al., 2011). If adequate restoration of ER function does not occur, the UPR 
will result in apoptosis via the down-regulation of pro-survival members of the BCL-2 
family (BCL-2, BCL-XL). Here I will briefly review the three branches of the UPR. 
The UPR is regulated by three transmembrane receptors: ATF6, IRE1, and PERK 
(Fig 6.1.5.2).  
 
6.1.5.3. PERK 
The main function of the PERK cascade is to modulate translation. Dissociation of BiP 
from the ER-luminal N-terminus initiates PERK dimerization and C-terminal 
autophosphorylation (Kebache et al., 2004). PERK activation attenuates protein 
Figure 6.1.5.2. The three arms of the UPR. BiP activates IRE1, PERK and ATF6, inducing transcriptional 
cascades that result in the upregulation of ER chaperones and ERAD proteins. Taken from (Grootjans et 
al., 2016).  
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translation via phosphorylation of eukaryotic initiation factor 2 (eIF2) at S51, 
preventing eIF2 dissociation from partner initiation factor eIF2B, inhibiting its critical 
translation initiation activity (Gebauer and Hentze, 2004). Inhibition of translation 
initiation ensures the folding demand on the ER can begin to diminish. Not all translation 
is blocked however – mRNA containing the sequence for an internal ribosome entry site 
(IRES) in the upstream open reading frame (UORF) can bypass the eIF2 block, allowing 
targeted translation (Schröder and Kaufman, 2005). ATF4 is one such gene that evades 
the eIF2 transcriptional block, encoding CCAAT-enhancer-binding protein (C/EBP)-
factor activating transcription factor 4 (ATF4). ATF4 drives many pro-survival functions, 
including ER chaperone expression, oxidative stress resistance and regulation of glucose 
and amino acid metabolism (Chakrabarti et al., 2011; Seo et al., 2009). 
Interestingly, ATF4 has also been implicated in the regulation of adipogenesis 
through the targeted activation of C/EBP and PPARγ (Yu et al., 2014). This is further 
bolstered by the generation of Atf4-/- mice that present with hypoglycaemia and lean fat 
mass (Seo et al., 2009), suggesting further uncharacterised roles for ATF4 in metabolism. 
6.1.5.4. ATF6 
The key role of the ATF6 pathway is to induce a gene expression program that increases 
chaperone activity and enhances degradation of unfolded proteins (Chakrabarti et al., 
2011). ATF6 upregulates BiP, PDI and X box-binding protein 1 (XBP1), a transcription 
factor that requires further mRNA processing by activated IRE1 before translation. Like 
PERK and IRE1, ATF6 activation is induced by BiP dissociation from the luminal N-
terminus of ATF6. Activation is followed by translocation to the GA - the factors 
controlling ATF6 translocation remain relatively unclear, but there appears to be 
requirement for (and redundancy between) two N-terminal Golgi localisation sequences 
(GLS), one of which is the binding site of BiP (Shen et al., 2002).  
ATF6 acquires its transcription activity in a unique manner. Following Golgi 
localisation, ATF6 undergoes regulated intramembrane proteolysis (RIP) by S1P (serine 
protease site-1 protease) and S2P (metalloprotease site-2 protease) – the coordinated 
cleavage of luminal peptides (Wang et al., 2000). This results in a transcriptionally active 
50 kDa fragment of ATF6, which translocates to the nucleus and regulate expression of 
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CRE- and ER-stress response element (ERSE)- promoter genes (Kokame et al., 2001). 
ATF6 activation also induces expression of HSP70-binding DNAJ protein P58IPK, which 
binds to the cytosolic, C-terminal kinase domain of PERK and inhibits its activity (Yan et 
al., 2002). 
6.1.5.5. IRE1 
The IRE1 pathway is the most evolutionarily conserved limb of the UPR and has 
opposing roles. Following BiP dissociation, IRE1 is activated following homo-
oligomerisation and autophosphorylation of its cytosolic C-terminus (Shamu and Walter, 
1996; Welihinda and Kaufman, 1996). IRE1 contains both an endoribonuclease and 
Ser/Thr kinase domain, which can transduce signals simultaneously upon activation, 
triggering two distinct signalling axes. IRE1 endoribonuclease activity cleaves a short 
intron from XBP1 mRNA, generating the transcriptionally active frameshift variant XBP-
1s (Lee et al., 2002). XBP-1s dimerises and potently regulates the expression of multiple 
ER chaperones, as well as PERK-inhibiting P58IPK and ER-associated degradation (ERAD) 
pathway proteins (Yan et al., 2002).  
The cytosolic kinase activity of IRE1 activates adaptor proteins such as tumour 
necrosis factor receptor-associated factor 2 (TRAF2), resulting in signal transduction and 
subsequent activation of the mitogen-activated kinases p38 mitogen activated protein 
kinase (p38 MAPK) and c-Jun N-terminal kinase (JNK) (Urano et al., 2000). IRE1 also 
phosphorylates several other kinases, however their role in the UPR is poorly 
understood (Hu et al., 2006; Nguyên et al., 2004). JNK functions to phosphorylate and 
activate pro-apoptotic BCL-2 family member BIM whilst simultaneously supressing pro-
survival member BCL-2, via inhibitory phosphorylations at several sites (Lei and Davis, 
2003; Wei et al., 2008) which ultimately results in BAX/BAK-dependent apoptosis. 
Activated p38 also phosphorylates BCL-2, further inducing inhibition (De Chiara et al., 
2006). Inhibition of BCL-2 by the IRE1 branch of the UPR results in the liberation of 
autophagy inducer Beclin1 (Wei et al., 2008), resulting in pro-survival upregulation of 
autophagy. Signals initiated from IRE1’s kinase domain are largely pro-apoptotic, and it 
is likely this branch of the UPR is activated after PERK and ATF6. Through these three 
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pathways, the ER works to recover appropriate protein folding and synthesis and initiate 
apoptosis where this is no longer possible.  
In the previous chapters, I have characterised novel impacts of acute ATRi 
treatment on cycling and post-mitotic cells, where it appears reduced ATR functionality 
has profound effects on metabolism. Clinically relevant ATRis appear to induce defects 
in autophagy and adipogenic differentiation, as well as inducing the ‘browning’ of 
mature white adipocytes, phenotypes which could have concerning implications if 
recapitulated in vivo. In this chapter, I investigate the impacts of ATR deficiency on ER 
functionality – with the aim of uncovering putative mechanistic links between the 
defects I have observed previously following ATRi treatments.  
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6.2. Results  
 ATR inhibition and Atr siRNA induce conspicuous 
cytoplasmic vacuolisation 
In chapter 5, I treated cycling 3T3-L1 preadipocytes with Atr siRNA and ATRis to 
investigate the effects of depleting ATR activity on autophagy. Whilst undertaking these 
experiments, I noticed the unusual and striking phenomenon of conspicuous 
cytoplasmic vacuolisation within minutes of treating samples with ATRis. Fig 6.2.1.1 
shows brightfield microscopy of conspicuous cytoplasmic vacuolisation in cycling 3T3-L1 
Figure 6.2.1.1. ATRis and Atr siRNA induce mass cytoplasmic vacuolisation. Brightfield microscopy of 
cycling 3T3-L1 preadipocytes treated with ATRis for 1 hr, and ~18 hrs post Atr siRNA transfection. 
Treatment with ATRis induced vacuoles after >10 minutes treatment in 3T3-L1 preadipocytes, which 
increased in size and number in a time- and dose-dependent manner. Atr siRNA transiently and 
inconsistently induced vacuolisation, suggesting almost complete ablation of ATR function may be 
necessary to induce vacuolisation. All images representative of results obtained in at least three 
independent experiments. 
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preadipocytes, treated with ATRis and Atr siRNA. That I also observed cellular 
vacuolisation following genetic ablation of ATR suggests this phenotype was not due to 
off-target effects of small molecule ATRis. Interestingly, vacuolisation following Atr 
siRNA was a transient event, and cytoplasmic vacuolisation was not observed 
consistently following Atr siRNA treatments. This suggests that the vacuolisation event 
observed following depletion of ATR function might be dependent on a temporal 
threshold of ATR activity, expressed only when kinase function of ATR is ablated acutely 
and entirely. Atr siRNA consistently induced increased p62 expression and blocked 
autophagy (as assessed by LC3-I/II), suggesting that the cytoplasmic vacuolisation may 
be independent of the autophagy block following depletion of ATR function. 
Additionally, Atg12 and Atg16L1 siRNA treatments to ablate the autophagy axis did not 
affect ATRi-induced vacuolisation (data not shown). This striking phenotype was 
observed in every cell type treated with all ATRis tested – summarised in Table 6.2.1. 
ATRi-induced cytoplasmic vacuolisation did not appear cell-cycle dependent, and 
appeared almost within minutes following ATRi treatment, suggesting it is independent 
of replication stress-induced DNA damage. Vacuolisation did not appear to carry 
inherent toxicity, as confluent cells treated with ATRis did not lose viability.  
 
 
 
 
Incidentally, on closer inspection of existing mouse models of ATR deficiency, 
vacuolar phenotypes are strikingly apparent. Ruzankina et al. (2007) described dramatic 
testicular atrophy after conditional deletion of Atr in adult mice - in the supporting 
images, vacuolisation can be observed (Ruzankina et al., 2007) (Fig 6.2.1.2.A). The 
authors failed to comment on this phenotype. Additionally, in the supplementary 
material of a paper characterising a mouse model of ATR-Seckel Syndrome, Murga et al. 
Cell line Origin 
MG63 human osteosarcoma 
3T3-L1 mouse preadipocytes 
C2C12 mouse myoblasts 
1BR3 human fibroblast 
HEK293 human embryonic kidney cells 
RPE human retinal pigment epithelium 
Table 6.2.1. Cell types where ATRi treatment induced conspicuous cytoplasmic vacuolisation. 
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(2009) also comment briefly on the presence of vacuoles within the primary follicles of 
newborn Atrs/s ovaries, shown in Fig 6.2.1.2.B (Murga et al., 2009). 
 I have shown here that an array of approaches inducing reduced ATR function 
result in a cytoplasmic vacuolisation phenotype. Existing literature, and my data utilising 
ATRis and Atr siRNA, suggest that this is a veritable and previously uncharacterised effect 
of ATR deficiency. It is plausible that such a profound cytoplasmic remodelling event 
could be the cause or consequence of dramatic alterations in cellular homeostasis. 
 Contents of ATRi-induced vacuoles are pH neutral  
Considering the cytoplasmic vacuolisation I observed following ATRi treatment was so 
prominent, I wanted to investigate the origins of this phenotype. Such a vast 
A 
B 
Figure 6.2.1.2. ATR deficiency-induced vacuolisation phenotypes exist in literature. A) Inducible 
knockdown of Atr in adult mouse testicular tissue induces mass cytoplasmic vacuolisation at 3 months 
and 1 year post-knockdown. Image taken from (Ruzankina et al., 2007). B) Cytoplasmic vacuoles are 
observed in the ovarian follicles of a humanised mouse model of ATR-SS, 1 day after birth (red arrows). 
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reorganisation of the cytoplasm likely influenced the defective adipogenesis (chapter 3) 
and autophagy (chapter 5) I observed previously following ATRi treatments.  
 Considering the block in autophagy I observed in chapter 4, I hypothesised that 
the ATRi-induced vacuoles could have arisen from blocked autophagic processing. 
Perhaps the accumulation of autophagosomes (as assessed by LC3-I/II status after 
Bafilomycin A and ATRi treatment) was generating aberrant, swollen autophagosomes 
or lysosomes. Swollen autophagosomes generated by a block in autophagic degradation 
have been described in literature (Mleczak et al., 2013). Lysosomes are acidic in content 
whereas autophagosomes are pH neutral. Assessing the pH of vacuoles induced by ATRis 
would provide insight into their origin.  
 To investigate the pH of ATRi-induced vacuoles, I utilised Acridine Orange (A.O.), 
a pH-sensitive fluorescent probe commonly used to label acidic compartments within 
the cell. Fig 6.2.2.A shows A.O.-stained cycling 3T3-L1 preadipocytes treated with ATRi 
II. A.O. exhibits bright orange fluorescence in acidic compartments, which can be 
observed in untreated samples. Following ATRi treatment, vacuoles did not stain orange, 
suggesting that they are not acidic in nature.  
 To confirm that the vacuoles observed following ATRi treatments were pH 
neutral, I utilised pH-neutral fluorescent probe Lysosensor Green DND-153. Lysosensor 
Green DND-153 can be used for microscopic analysis of cellular vacuolisation events, 
selectively staining neutral cellular compartments red. Following 3 hrs of ATRi 
treatment, vacuoles have up taken Lysosensor Green DND-153, indicative of pH neutral 
content (Fig 6.2.2.B). This indicates that the vacuoles cannot be functional, acidic 
lysosomes.  
 
 
Figure 6.2.2. (Overleaf) ATRi-induced vacuoles are pH neutral. A) Acridine Orange (A.O.) staining of 
cycling 3T3-L1 preadipocytes and C2C12 myoblasts treated with ATRi II for 2 hrs. ATRi-induced 
vacuoles are clearly visible as dark holes in the cytoplasm. A.O. was not uptaken by ATRi-induced 
vacuoles, indicating they are not acidic. Images taken at 100x. B) Cycling 3T3-L1 preadipocytes were 
stained with 2 M Lysosensor Green DND-153 throughout 3 hrs of ATRi II treatment. Uptake of 
Lysosensor Green DND-153 into ATRi-induced vacuoles indicates they are pH neutral. Images captured 
at 100x. All images representative of results obtained in at least three independent experiments. 
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 ATRi induces mitochondrial fission 
I hypothesised that the cytoplasmic vacuoles observed following ATRi treatments could 
derive from swollen mitochondria. Considering the metabolic and autophagy defects I 
have characterised in the previous chapters, I wanted to investigate the effect of ATRi 
treatment on mitochondrial dynamics. The mitochondrial network is highly dynamic, 
where fusion and fission events, biogenesis and mitophagy (mitochondrial autophagy) 
can occur within minutes of appropriate stimulation (Westermann, 2012). Generally, 
mitochondria exist in extensive branched structures that undergo constant remodelling, 
undertaking fission following changes in nutritional status or to prepare for cell division.  
MitoTracker Red is a fluorescent probe that labels live mitochondria dependent 
on membrane potential, allowing visualisation of mitochondrial events via fluorescence 
microscopy. Cycling 3T3-L1 preadipocytes were treated with ATRis for 2 hours and 
stained with MitoTracker Red (Fig 6.2.3.A). ATRi II and VE-822 treatments appear to have 
induced mitochondrial fission apparent by the fractured appearance of mitochondria 
following treatment. It is also clear that MitoTracker Red staining is not localised to the 
vacuolar structures induced by ATRi treatment, suggesting vacuoles are not swollen 
mitochondria. To further assess the consequences of ATRi treatment on mitochondrial 
dynamics, I utilised MitoTracker Green (described in section 4.2.3.) to assess 
mitochondrial mass by flow cytometry (FACS).  
Fig 6.2.3.B. shows FACS analysis of 3T3-L1 preadipocytes treated with or without 
ATRi II for 2 hrs. Strikingly, mitochondrial mass is increased over 5-fold following ATRi 
treatment. This is reminiscent of the 80% increase in mitochondrial mass observed in 
mature adipocytes following chronic treatment with ATRi II (Fig 4.2.3.B). In Chapter 4, I 
observed that 24 hr treatment of mature 3T3-L1 adipocytes with ATRi induced increased 
PGC-1 expression and mitochondrial mass. To investigate if the increased 
mitochondrial mass in preadipocytes after acute ATRi treatment was a result of 
increased mito-biogenesis, I assessed PGC-1 expression via western blotting. Fig 
6.2.3.C shows no change in PGC-1 expression following ATRi treatments, suggesting 
that increased mito-biogenesis is not responsible for the increased mitochondrial 
content observed after ATRi treatment. The massive increase in mitochondrial content 
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following ATRi treatments could be explained by considering the highly dynamic nature 
of the mitochondrial network – perhaps the autophagic block induced by ATRi treatment 
(characterised in chapter 5) could be preventing effective mitophagy, resulting in an 
accumulation of defective mitochondria.  
Figure 6.2.3. ATRi treatment induces profound changes in mitochondrial dynamics. A) MitoTracker 
Red staining of cycling 3T3-L1 preadipocytes treated with ATRis for 2 hrs. AlexaFluor-conjugated 
Phalloidin (green), MitoTracker Red and DAPI (blue). Following treatment with VE-822 or ATRi II (10 
M), mitochondria appear to have lost perinuclear localisation and are fragmented throughout the 
cytoplasm, indicative of mitochondrial fission. B) Flow cytometry analysis of mitochondrial mass utilising 
MitoTracker Green AM-1. Following 2 hrs treatment with ATRi II, mitochondrial mass has increased 5-
fold. Results normalised to  the corresponding untreated sample. C) Western blotting of mito-biogenesis 
marker PGC-1 in cycling 3T3-L1 preadipocytes shows no change following acute ATRi II treatments, 
suggesting increased mitochondrial content following ATRi is not due to increased biogenesis. Lamin B 
used as loading control. All images representative of results obtained in at least three independent 
experiments. 
A 
B C 
  173 
 ATRi-induced vacuoles are swollen ER 
Continuing my investigation into the origins of the ATRi-induced cytoplasmic vacuoles, I 
utilised immunofluorescence microscopy (IF) of ER and Golgi apparatus (GA) markers 
following ATRi treatments of 3T3-L1 preadipocytes. RCAS1 (receptor binding cancer 
antigen expressed on SiSo cells) is a GA-associated protein, commonly utilised as a 
marker of the GA. Fig 6.2.4.1.A shows IF of RCAS1, where in untreated 3T3-L1 
Figure 6.2.4.1. ATRi-induced vacuoles are not swollen Golgi Apparatus (GA). A) IF of cycling 3T3-L1 
preadipocytes treated with VE-822 for 2 hrs. In untreated and VE-822-treated cells RCAS1 staining 
remains perinuclear and unchanged indicating ATRi treatment may not be remodelling the GA. B) IF 
of putative ATR substrate and membrane fusion protein Syntaxin 6 before and after VE-822 
treatment. Following ATRi treatment, Syntaxin 6 loses perinuclear localisation and appears to 
localised to ATRi-induced vacuoles, indicating vacuoles could be associated with a defect in membrane 
fusion or vesicle trafficking. AlexaFluor-conjugated Phalloidin (red), Syntaxin 6 or RCAS1 (green) and 
DAPI (blue). All images representative of results obtained in at least three independent experiments. 
A 
B 
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preadipocytes RCAS1 staining appears completely perinuclear. Following 2 hrs of VE-822 
treatment, RCAS1 localisation appears unchanged, and no localisation to ATRi-induced 
vacuoles is apparent, suggesting they have not arisen from swollen GA.  
Syntaxin 6 is a vesicle- and GA-associated protein, a mediator of membrane 
fusion required for several vesicle-transport associated pathways (Bock et al., 1997). 
Interestingly, Syntaxin 6 has been recognised as a putative ATR/ATM substrate (S129) 
after DNA damage (Cara et al., 2016; Matsuoka et al., 2007). Considering its significance 
as a putative ATR/ATM substrate and membrane-associated protein, I chose to further 
investigate the effect of ATRi treatment on Syntaxin 6 localisation. Fig 6.2.4.1.B shows 
in untreated 3T3-L1 preadipocytes, Syntaxin 6 is localised to the perinuclear region 
similarly to RCAS1 (Fig 6.2.4.1.A). Following 2 hrs VE-822 treatment, Syntaxin 6 has lost 
its perinuclear localisation and also appears to localise to ATRi-induced vacuoles (Fig 
6.2.4.1.B, magnified section). This indicates the ATRi-induced cytoplasmic vacuolisation 
may be originating from aberrant processing of vesicular membranes. Organelles 
undergo constant remodelling as part of cellular homeostasis, and for this to occur, the 
appropriate provision of lipid membranes shuttled from the endomembrane system is 
required. Defects in vesicular transport at any stage can fundamentally shift the dynamic 
equilibrium required to maintain cellular homeostasis.  
I hypothesised that ATRi could be causing a defect in the activity of putative 
substrate VPS4b (discussed in section 6.1.1), inducing the vacuolar phenotype. VPS4b is 
of particular interest because mutations generating defects in the ATPase activity of 
VPS4b result in a cytoplasmic vacuolisation phenotype (Bishop and Woodman, 2000; 
Scott et al., 2005). Furthermore, the putative ATR/ATM phospho-site is proximal to the 
ATPase domain of VPS4b, suggesting potential functional relevance of this SQ motif.  
To test this hypothesis, I used a site directed mutagenesis approach to generate 
a FLAG-tagged ATPase-defective VPS4b mutant construct (E235Q) (Bishop and 
Woodman, 2000) and also a phospho-mutant construct where the putative ATR 
phospho-site was ablated (T317A). If this site was a bona fide ATR target, responsible for 
the ATRi-induced vacuolisation, transient over-expression of the phospho-mutant 
would generate similar consequences to ATRi treatment.  
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Fig 6.2.4.2.A shows western blotting of 3T3-L1 preadipocytes transiently over-
expressing FLAG-tagged VPS4b constructs, treated with or without VE-822 for 2 hrs. Fig 
6.2.4.2.B shows representative brightfield microscopy images of samples over-
expressing each construct, treated with VE-822 for 2 hrs. Strikingly, both WT-VPS4b and 
T317A-VPS4b appear to rescue the ATRi-induced vacuolar phenotype, whereas ATPase-
Figure 6.2.4.2. VPS4b overexpression attenuates ATRi-induced vacuolisation. A) Western blotting of 
3T3-L1 preadipocytes transiently over-expressing FLAG-tagged VPS4b constructs treated with VE-822 
(10 M, 2 hrs). -tubulin used as loading control. B) Brightfield microscopy of VE-822-treated 
preadipocytes over-expressing VPS4b constructs. WT- and T317A-VPS4b rescue the ATRi-induced 
vacuolisation, whereas E235Q-VPS4b modestly alleviates this phenotype. All images representative of 
results obtained in at least three independent experiments. 
A 
B 
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defective mutant E235Q-VPS4b only partially diminishes this phenomenon. This 
suggests that shifting the dynamics of MVB transport, by saturating the cell with 
membrane fusion-associated protein VPS4b, has alleviated the potential block in 
membrane transport generated by ATRi. That both WT and phospho-mutant VPS4b 
constructs attenuate ATRi-induced vacuolisation suggests this putative ATR phospho-
site has limited relevance in this phenotype, and perhaps furthermore, on VPS4b 
functionality in general.  
Syntaxin 6 and VPS4b are also associated with GA-ER transport {Bock, 1997 
#1305}{Obita, 2007 #1368}. Considering the limited effects of ATRi on GA-marker RCAS1, 
I considered that perhaps I was observing ER swelling following ATRi treatment. ER 
swelling has been documented in literature in response to a variety of agents, although 
the mechanism behind this phenomenon is poorly characterised. Further, there is wide 
variety in the nature of the vacuoles induced by ER swelling, which appears dependent 
on the inducing agent (Shubin et al., 2016). It appears the process of intracellular 
membrane organisation can be affected at multiple stages to induce a vacuolisation 
phenotype. 
I used antibodies against ER membrane protein PDI to investigate if ATRi-induced 
vacuoles were of ER origin using IF microscopy. Fig 6.2.4.3.A shows cycling 3T3-L1 
preadipocytes have punctae of PDI staining throughout the cytoplasm. Following 2 hrs 
VE-822 treatment, PDI is associated with the ATRi-induced vacuoles, evenly coating the 
membrane (Fig 6.2.4.3.A, lower panel, magnified section). This is highly indicative that 
ATRi treatment is inducing aberrant ER swelling. To further characterise this 
phenomenon I utilised antibodies against late autophagosome and endosomal protein 
RAB7 for IF microscopy. RAB7-positive endosomes are tightly associated with the ER 
(Hyttinen et al., 2013; Wang et al., 2011). Fig 6.2.4.3.B (magnified section) demonstrates 
that following VE-822 treatment, RAB7 punctae have associated with ATRi-induced 
vacuoles, reinforcing the hypothesis that ATRi treatment is inducing ER swelling.  
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 ATRi-induced vacuolisation is attenuated by Ca2+-free 
media 
In chapter 4, I characterised the upregulation of the Ca2+-dependent CAMKII-p38 MAPK-
ATF2 axis following 24 hrs ATRi treatment. In Chapter 5, I demonstrated that ATRi-
induced increased p62 expression was dependent on extracellular Ca2+ by utilising Ca2+-
free Krebs-Henseleit (KH) medium. To further characterise the ATRi-induced cytoplasmic 
vacuolisation, I wanted to investigate the effects of depleting extracellular Ca2+. The ER 
Figure 6.2.4.3. ATRi-induced vacuoles arise from swollen ER. A) IF of ER-marker PDI in cycling 3T3-L1 
preadipocytes before and after treatment with VE-822 (10 M). Following ATRi treatment for 2 hrs, 
vacuoles are evenly coated in PDI staining, indicating they are swollen ER. AlexaFluor-conjugated 
Phalloidin (red), PDI (green) DAPI (blue). B) IF of late endosomal marker RAB7 (red) before and after ATRi 
treatment, where punctae of RAB7 localise to ATRi-induced vacuoles, reminiscent of late endosomes 
bound to the ER. Phalloidin (green) and DAPI (blue). All images representative of results obtained in at 
least three independent experiments. 
A 
B 
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is a Ca2+-sequestering organelle – perhaps the ER remodelling I have observed following 
ATRi could be effected by modulating the availability of extracellular Ca2+. 
Fig 6.2.5 shows brightfeild microscopy of cycling 3T3-L1 preadipocytes pre-
cultured in DMEM or KH medium for 2 hrs, treated with or without ATRis for 15 minutes. 
These images correspond to the data I discussed in Fig 5.2.5, where samples were 
harvested after 2 hrs ATRi treatment and KH medium prevented ATRi-induced increases 
in p62 expression, but not ATRi-induced changes in LC3-I/II status. Culturing cells in KH 
medium appears to modestly reduce the volume and size of ATRi-induced vacuoles, 
suggesting this vacuolation process is not dependent entirely on extracellular Ca2+, but 
can be reduced when the equilibrium of Ca2+ is altered.  
 ATRi treatment induces ER stress 
Considering such striking remodelling of the ER following ATRi treatment, I wanted to 
investigate the effects of ATRi on the ER stress response. Fig 6.2.6 shows western 
blotting of ER stress and UPR markers eIF2, ATF6 and XBP1s. In Fig 6.2.6.A, cycling 3T3-
L1 preadipocytes treated with VE-822 show a small increase in BiP expression, and 
increased expression of the active, 50 kDa isoform of ATF6, indicating ATRi treatment is 
inducing increased activation and processing of ER stress protein ATF6. Fig 6.2.6.B shows 
Figure 6.2.5. Treatment with Ca2+-free medium reduces the appearance of ATRi-induces vacuoles. 
Brightfeild microscopy of cycling 3T3-L1 preadipocytes treated with or without ATRis (VE-822 and ATRi 
II, both 10 M) whilst cultured in DMEM (regular) or KH (Ca2+-free) medium. It is worth noting KH 
medium was exceptionally toxic to both samples treated with and without ATRis. 
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eIF2 phosphorylation (S51) is increased following 4 hrs ATRi treatment, indicative of 
increased PERK activation. 
IRE1-dependent splicing of XBP1 mRNA to generate active XBP1s also has roles 
in mediating specific checkpoints within the cell-cycle (Thorpe and Schwarze, 2010), so 
I chose to investigate potential ATRi-induced changes in XBP1s splicing in confluent 3T3-
L1 preadipocytes. Using an antibody targeted to specifically the active, cleaved form of 
XBP1 (XBP1s), Fig 6.2.6.C shows western blotting of XBP1s following 4 hrs treatment 
with VE-822 or ATMi, where VE-822 treatment appears to drastically reduce XPB1s 
expression, indicative of IRE1 inhibition or dysfunction following ATRi. ATMi appears 
to have no effect on XBP1s expression levels.  
Interestingly, XBP1s has well documented roles in adipogenic differentiation – 
IRE1 activity and post-transcriptional splicing of XBP1 is required for successful 
adipogenesis in differentiating 3T3-L1 cultures (Sha et al., 2009). I hypothesised that the 
profound defect in XBP1 splicing following ATRi (Fig 6.2.6.C) could perhaps cause the 
ATRi-induced adipogenic block I characterised in chapter 3. To investigate this, I 
Figure 6.2.6. Acute ATRi treatment affects markers of ER stress. A) Western blotting of BiP and ATF6 in 
cycling 3T3-L1 preadipocytes treated with VE-822 (10 M). After 4 hrs of ATRi treatment, ATF6 
expression is increased suggesting increased ER stress and UPR activation. eIF2 used as loading control. 
B) Western blotting for XBP1s of confluent 3T3-L1 preadipocytes treated with VE-822 or ATMi for 4 hrs 
(both 10 M). ATMi does not affect XBP1s whereas VE-822 drastically decreases protein expression 
levels. Lamin B used as loading control. C) Western blotting of cycling RPE cells treated with VE-822 (10 
M, 4 hrs). p-eIF2 S51 is increased following ATRi treatment, indicative of ER stress. All images 
representative of results obtained in at least three independent experiments. 
A B C 
D 
  180 
differentiated post-confluent 3T3-L1 preadipocytes with or without VE-822, and used 
western blotting to assess XBP1s expression. I chose to harvest differentiating cultures 
after 6 hours as literature states it is at this time that XBP1s is most required for 
adipogenesis (Cho et al., 2014). Fig 6.2.6.D shows that at 6 hours post induction into 
adipogenic differentiation, XBP1s expression has massively decreased in both untreated 
and VE-822-treated cultures, where VE-822 does not appear to impact XBP1s 
expression. This indicates that reduced IRE1-dependent splicing of XBP1 to XBP1s is 
not the cause of the ATRi-induced adipogenic block. 
 ATR is localised to the ER 
ER-associated protein Calnexin (CANX) has been identified in several putative ATR/ATM 
substrate screens, although the physiological relevance of this has never been reported 
(Matsuoka et al., 2007; Stokes et al., 2007). Considering the marked remodelling of the 
ER I have observed following ATRi treatment, and the precedence of ATR interactants at 
the ER membrane, I hypothesised that ATR could have a potential role in maintaining ER 
functionality. To investigate this hypothesis, initially I confirmed the existence of 
abundant cytoplasmic ATR and ATRIP within the 3T3-L1 preadipocyte cell line, through 
sub-cell fractionation and western blotting approaches (Fig 6.2.7.A).  
Having confirmed cytoplasmic ATR and ATRIP, I investigated if cytoplasmic ATR 
was localised to the ER. To do this, I used western blotting of enriched ER extracts, 
fractionated from HEK293 cells. I chose not to use 3T3-L1 preadipocytes as the ER 
fractionation process requires >1 mg of cell pellet per sample to generate an ER-
enriched protein lysate adequate for western blotting. 3T3-L1 preadipocytes must be 
cultured with careful consideration of their passage number, and hence cannot be 
grown effectively to such large volumes. HEK-293 cells however, can be continuously 
cultured, allowing the generation of the large cell quantities required for the ER 
fractionation process. 
 Fig 6.2.7.B shows western blotting of the ER, ‘nuclear’ and whole-cell lysates 
(WCE) generated from the ER fractionation process, where ATR appears within the 
enriched ER fraction at expression levels equivalent to that observed in the nuclear 
fraction. Interestingly, ATR localisation to the ER fraction appears unchanged following 
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VE-822 treatment, indicating that this localisation may be independent of ATR kinase 
activity. Enrichment of the ER can be gauged via the examination of several markers of 
cellular compartments; the absence of Lamin B in this lysate indicates there is no 
contamination with nuclear components; it contains luminal ER protein BiP; also the ER 
fraction does not appear enriched for cytoplasmic marker -tubulin, indicating limited 
contamination with cytoplasmic components. The ‘nuclear’ fraction here however is 
relatively impure, as the fractionation process I utilised to enrich for the ER does not 
allow for equally clean enrichment of the nuclear compartment.  
To further investigate the activity of ER-localised ATR, I assessed the localisation 
of ATRIP to the ER, and also the phospho-status of the activating ATR trans-
autophosphorylation site T1989. Canonical activation of ATR requires ATRIP and 
phosphorylation of T1989. Fig 6.2.7.C shows that ATRIP localises to the ER fraction, 
suggesting that ATR at the ER is capable of kinase activity. Further, assessing p-ATR 
T1989 status indicates that ATR is activated at the ER. Together, this data is indicative of 
a novel localisation of kinase-active ATR-ATRIP to the ER.  
Interestingly, ATM also localised to the ER fraction (Fig 6.2.7.C). The presence of 
ATM in my enriched ER fraction could indicate several possibilities which could be 
delineated with further experiments: 
1) The ER fraction I am assessing could also contain lysosomes or other 
membrane-bound compartments; where a role for ATM has been 
characterised. Using western blotting to probe for lysosomal marker LAMP1, 
I could investigate if the enriched ER fraction also contains lysosomal matter, 
or use ATM/ATR IF to confirm ER localisation; 
2) ATM and ATR localisation could be due the newly synthesised and folded 
ATM/ATR within the ER, not due to a novel role here. Using protein synthesis 
inhibitors I could investigate if ER ATR/ATM localisation is maintained whilst 
protein synthesis is blocked; 
3) Both ATM and ATR could in fact be localised to the ER. To reinforce this 
hypothesis it would be necessary to rule out the 2 hypotheses above. 
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Figure 6.2.7. ATR is active at the ER. A) Western blotting of nuclear-cytoplasmic sub-cellular 
fractionation of cycling 3T3-L1 preadipocytes reveals that ATR and ATRIP are abundant within the 
cytoplasm. Lamin B used as control for nuclear fraction, -tubulin used as control for cytoplasmic 
fraction. B) Western blotting of ER fractionation of HEK-293 cells before and after ATRi treatment 
(VE-822, 10M, 2hrs) reveals cytoplasmic ATR is enriched at the ER, independently of ATRi 
treatment. BiP used as ER enrichment control, Lamin B as nuclear fraction control, -tubulin as 
cytoplasmic fraction control. C) Western blotting of ER fractionation of HEK-293 cells for ATR, p-ATR 
T1989, ATRIP and ATM shows ATRIP is also localised to the ER and ATR appears activated. ATM 
appears localised to the ER also. Lamin B used as nuclear faction control, -tubulin as cytoplasmic 
control. D) Western blotting of ER fractionation of HEK-293 cells overexpressing a GFP-tagged KD-
ATR construct. Probing for GFP reveals limited KD-ATR is localised within the ER fraction. E) IF of RPE 
cells before and after ATRi treatment. ER marker PDI (red) and ATR (green) staining demonstrates 
that following ATRi treatment cytoplasmic ATR appears within the ATRi-induced vacuoles. All images 
representative of results obtained in at least three independent experiments. 
A B 
C D 
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I considered that the ATR and ATM signal I observe in my ER fraction could be 
newly synthesised protein, undergoing folding as part of canonical ER function. ATR and 
ATM are large PIKKs (>270 kDa) that require chaperone-mediated folding to reach their 
correct conformation and tertiary structure (Hurov et al., 2010; Takai et al., 2007). For 
this reason, newly synthesised ATR/ATM may appear within the ER for extended periods 
of time, unlike smaller nuclear protein Lamin B (67 kDa), which does not appear within 
the ER fraction at all (Fig 6.2.7.C). However, my data indicates this is not the case, as 
ATRIP is also abundant within my ER–enriched fraction, and like ATR, it appears at 
expression levels equivalent to those observed within the nuclear compartment. ATRIP 
is far more similar in size to Lamin B (ATRIP is ~90 kDa), suggesting that like Lamin B, it 
should either not require ER-mediated folding to reach it’s correct conformation, or, if 
newly synthesised ATRIP was within the ER, it would be at expression levels far lower 
than observed in Fig 6.2.7.C. The presence of ATRIP at the ER is perhaps indicative of a 
supporting role in the function of ATR at this organelle. 
I next investigated if the localisation of ATR at the ER was kinase-activity 
independent, by overexpressing an eGFP-tagged KD-ATR construct and assessing ER 
localisation. Fig 6.2.7.D shows western blotting of HEK-293 cells overexpressing eGFP-
tagged KD-ATR, where GFP is indicative of KD-ATR expression. Two isoforms of KD-ATR 
are visible, similar to the double band I observe in western blots of endogenous ATR in 
3T3-L1 samples. This indicates that the difference responsible for generating two 
separate bands of ATR, observed via western blotting, are not dependent on the kinase 
activity of ATR. Fig 6.2.7.D also shows relatively low levels of GFP appear within the ER 
fraction, indicating KD-ATR may not be able to effectively localise to the ER. Taken with 
the limited effect of VE-822 of the ER localisation of endogenous ATR (Fig 6.2.7.B), this 
suggests that perhaps the initial ER localisation of ATR is kinase activity-dependent, but 
maintaining ATR at the ER is kinase-independent.  
 To further validate that ATR was localised to the ER, I co-stained cycling RPE cells 
with antibodies directed to ATR and ER-marker PDI. I utilised IF microscopy to assess the 
co-localisation of ATR and PDI before and after ATRi treatment. Fig 6.2.7.E shows that in 
untreated RPE cells, ATR does not co-localise with PDI, indicative that cytoplasmic ATR 
may in fact be more enriched at another organelle, for example the GA. The staining of 
  184 
cytoplasmic ATR within these cells is far more reminiscent of IF of the GA marker RCAS1 
(Fig 6.2.4.1.A). Following ATRi treatment, a fraction of cytoplasmic ATR appears within 
the ATRi-induced vacuoles.  
 ATR kinase-dependently immunoprecipitates with CANX 
To further investigate a novel localisation of ATR at the ER, I chose to interrogate a 
physiological relationship between ATR and putative ATM/ATR substrate CANX. CANX is 
an ER-membrane protein that functions to sequester Ca2+ within the ER – the majority 
of CANX protein exists within the ER lumen, with a short tail protruding into the 
cytoplasm. The cytoplasmic tail of CANX is subject to modification and cleavage by 
several proteins, allowing CANX to transduce apoptotic signals from the cytoplasm into 
the ER lumen (Takizawa et al., 2004). This cytoplasmic tail of CANX contains the S/TQ 
motifs identified in ATM/ATR substrate screens. I hypothesised that ER-localised ATR 
could have a role in modulating CANX function via its cytoplasmic C-terminus tail. To 
investigate this, I transiently overexpressed and immunoprecipitated (IP) a FLAG-tagged 
CANX construct in HEK-293 cells. Following IP, I used western blotting to investigate the 
phospho-status of CANX S/TQ motifs before and after ATRi treatment, and further I 
probed for ATR within the IP extracts to investigate a potential interaction between 
CANX and ATR.  
Fig 6.2.8 shows western blotting of CANX IP and input lysates, where FLAG 
indicates the expression of FLAG-CANX within total cell lysates and following IP. Anti-p-
SQ/TQ antibody indicates that FLAG-CANX is phosphorylated at one or several S/TQ 
motifs, independently of ATRi treatment (2 hrs), suggesting the phospho-status of CANX 
S/TQ motifs is independent of ATR activity. Most strikingly, Fig 6.2.8 indicates that ATR 
can be co-precipitated with CANX, dependent on ATR kinase function. Taken together, 
this data suggests that there may not be a direct interaction where ATR is 
phosphorylating CANX, but perhaps ATR may be immunoprecipitating as part of another 
complex associated with ER membrane that is immunoprecipitated with CANX. This 
novel co-precipitation further reinforces the likelihood that ATR is localised to the ER, 
where no role for ATR has been characterised previously. 
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 ATRi-induced vacuolisation is rescued by Obatoclax 
Altering the activities of BCL-2 family members can have multiple effects on cellular 
homeostasis - pro-survival BCL-2 proteins have recently been investigated as novel 
cancer therapy targets, due to their frequent dysregulation in cancers (Adams and Cory, 
2007; Schimmer et al., 2008). Upregulation of pro-suvival members increases 
sequestration of pro-apoptotic members, allowing cancerous cells the ability to evade 
apoptosis (Adams and Cory, 2007). Obatoclax (GX15-070) is a compound that acts as a 
BH3-mimetic, inhibiting autophagy and promoting pro-apoptotic pathways through the 
selective inhibition of pro-survival BH3 proteins such as BCL-2 (Adams and Cory, 2007). 
Obatoclax selectively kills cancerous cells dependent on pro-survival BH3 proteins for 
growth and survival (Konopleva et al., 2008). Obatoclax is in clinical trials as a novel 
cancer therapeutic agent, although data suggests the pro-survival pathways associated 
with cancer progression are more complex than initially considered, where cellular 
levels of other anti-apoptotic proteins must be accounted for (Harazono et al., 2014). 
Interestingly, altering the BCL-2 family members BAK and BCL-XL has also been 
shown to induce mass cytoplasmic vacuolisation caused by ER swelling, similar to that 
observed following ATRis (Klee and Pimentel-Muiños, 2005). Co-overexpression of BCL-
XL and BAK resulted in ER swelling, through increased interaction with specifically one 
BH3 domain within BAK (Zong et al., 2003). BCL-XL is an antagonist of pro-apotptotic 
BAK, hence increased interaction with BAK results in pro-survival outcomes. For ER 
Figure 6.2.8. ATR co-precipitates with CANX. Western blotting of HEK-293 overexpressing FLAG-CANX 
were immunoprecipitated before and after ATRi treatment (VE-822, 4 hrs, 10 M) and elutured with 3X 
FLAG peptide. CANX IP lysates were probed for ATR, p-SQ/TQ motifs and FLAG. FLAG used as control for 
transfection efficiency (input) and IP efficiency (CANX IP) and as loading control. p-SQ/TQ status of CANX 
appears independent of VE-822 treatment, indicating these phospho-sites are ATR-independent. ATR co-
precipitates with CANX in a kinase-dependent manner. Representative of results obtained in at least three 
independent experiments. 
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swelling to occur following the increased BAK-BCL-XL interaction, unbound BID was 
required to induce a conformational change in ER-localised BAK. This mechanism is 
summarised in Fig 6.2.9.A. BAX appeared to be irrelevant in the vacuolisation 
phenotypes uncovered in this study, generating a novel functional divergence between 
the two pro-apoptotic proteins. Like almost all other published literature investigating 
cytoplasmic vacuolisation, the mechanism responsible for the generation of vacuoles 
following BAK-BCL-XL overexpression remained elusive. 
I postulated that considering the existing literature characterising BID as a novel 
ATR interactant, perhaps BID/tBID may be associated with ATR, and ATRi was releasing 
BID from this association, allowing increased BID-dependent conformational change of 
BAK, increasing BAK-BCL-XL association, generating ATRi-induced vacuolisation (Fig 
6.2.9.A). Overexpression of ATR and specifically ATR-HEAT repeats, which contain BH3-
like domains, induces cytoplasmic vacuolisation (Mori et al., 2013). The literature also 
indicates that a potential role of ATR in the modulation of BCL-2 family members is 
possible. Considering the role of BCL-2 proteins in cancer progression, and their 
localisation to the ER, I wanted to investigate the impact of BCL-2 inhibitor Obatoclax on 
my ATRi-induced phenotype of mass cytoplasmic vacuolisation. I considered that due to 
the membrane-bound nature of CANX, ATR may be co-precipitating in a dynamic 
manner, through association with a different ER membrane-bound complex or BCL-2 
family member, via its BH3-like domains. Perhaps ATR could also be interacting with a 
BCL-2 member at the ER, where ATRi was affecting this interaction generating ER 
swelling. If BCL-2 family members had a role in the ER swelling observed following ATRi 
treatment, inhibition of pro-survival BH3 proteins (BCL-2, MCL-1 and BCL-XL) with acute 
Obatoclax treatment could have an impact on this phenotype (Fig 6.2.9.A).  
Fig 6.2.9.B shows microscopy images of cycling 3T3-L1 preadipocytes treated 
with VE-822 and Obatoclax for 2 hrs. Co-treatment with VE-822 and Obatoclax results in 
complete rescue of the ATRi-induced vacuolar phenotype. Interestingly, Obatoclax co-
treatment also rescued the ATRi-induced increase in p-eIF2 S51 (Fig 6.2.9.C), 
suggesting ATRi-induced ER swelling may generate the ER stress I have observed in Fig 
6.2.6. This striking result further indicates a relationship between impaired ATR function 
and the modulation of BCL-2 family members.  
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Figure 6.2.9. Obatoclax rescues ATRi-induced vacuolisation. A) Schematic of one proposed 
mechanism in which ATRi induces ER swelling via liberation of tBID from ATR, allowing induction of 
conformational change in BAK resulting in enhanced ER swelling-inducing BAK-BCL-XL interaction, 
which could be blocked by Obatoclax treatment. B) Microscopy of cycling 3T3-L1 preadipocytes - co-
treatment with 10 M VE-822 and 50nM Obatoclax (both 2 hrs) prevents ATRi-induced vacuolisation. 
C) Western blotting of ER stress marker p-eIF2 in cycling RPE cells, treated with ATRi VE-822 (10 M) 
and Obatoclax (50 nM) for 4 hrs. VE-822 treatment increased p-eIF2a S51, a phenotype rescued by co-
treatment with Obatoclax. Images representative of results obtained in at least three independent 
experiments. 
A 
B 
C 
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6.3. Summary 
I have shown in this chapter: 
 Acute ATRi treatments and Atr siRNA induce conspicuous cytoplasmic 
vacuolisation, which appears to derive from swollen ER, where the GA does not 
appear to have undergone remodelling (sections 6.2.1, 6.2.2 and 6.2.4) 
 ATRi treatment induces mitochondrial fission and increased mitochondrial mass 
(section 6.2.3)  
 ATRi-induced vacuolisation can be modestly attenuated by co-culturing ATRi-
treated samples in Ca2+-free medium (section 6.2.5) 
 At later timepoints (+4 hrs) ATRi treatment invokes the UPR (section 6.2.6) 
 ATR is both cytoplasmic and nuclear, and is localised to the ER (section 6.2.7) 
 ATRi-induced vacuolisation can be rescued through co-treatment with Obatoclax 
(section 6.2.9) 
I have also investigated two putative ATR substrates associated with ER and cytoplasmic 
vacuolisation; CANX and VPS4b, where: 
 ATR co-precipitates with ER protein CANX, an interaction that can be disrupted 
with ATRi (section 6.2.8) 
 Overexpression of VPS4b ablates ATRi-induced vacuoles independently of its 
putative ATR-dependent phosphorylation at T317 (section 6.2.4) 
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6.4. Discussion 
In this chapter, I have characterised a conspicuous cytoplasmic remodelling event 
following ATR inhibition. Using multiple approaches, I have demonstrated a fraction of 
ATR appears to localise to the ER, and ablating ATR function causes mass ER swelling and 
ER stress. Mitochondrial phenotypes of increased mito-fission and increased 
mitochondrial mass are concomitant with these ER phenotypes. In chapter 5, I observed 
blocked autophagy and enhanced lysosomal biogenesis after acute treatments with 
ATRis and Atr siRNA. Unaltered PGC1 levels following ATRi suggest that the increased 
mitochondrial mass may be due to a block in mitophagy. Together, this data is indicative 
of fundamental changes in the structure and function of several cytoplasmic organelles 
following ATR deficiency, with detrimental effects on cellular homeostasis.  
 When considering these results in the context of the usage of ATRis in cancer 
treatment, there are potential functional significances. Tumours with increased 
mitochondrial dysfunction often exhibit a more aggressive phenotype (Simonnet et al., 
2002) and it is conceivable that the mitochondrial dysfunction seen following 
impairment of the ATR signalling axis could assist cancerous cells in their metabolic shift. 
The defects observed in the mitochondria of ATRi-treated cells are remarkably similar 
to those observed in the mitochondria of cancer cells (Simonnet et al., 2002). This 
mitochondrial phenotype is caused by a metabolic shift to high rates of aerobic glycolysis 
called the ‘Warburg effect’(Hsu and Sabatini, 2008). It occurs hand-in-hand with the 
autophagy of local cells, converting the surrounding stroma into a ‘factory’ for the local 
production of recycled nutrients (Hsu and Sabatini, 2008). The cancerous tissue 
capitalises on high energy nutrients and essential substrates (such as L-Lactate) to 
support its increase in proliferative activity (Hsu and Sabatini, 2008). The significance of 
the ATRi-induced mitochondrial dysfunction warrant further investigation - if ATRi 
therapy did not destroy all cancerous tissue in vivo, it may possibly fuel a more 
aggressive, secondary cancer. Furthermore, decreased IRE1activity and XBP1s splicing 
(which I observe following acute ATRi treatment) has recently been identified as a driver 
in the development of multiple myeloma (Bujisic et al., 2017). 
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ER stress and induction of the UPR were observed following acute ATRi 
treatment, although these phenotypes did not occur alongside the cytoplasmic 
vacuolisation. Instead, the UPR was induced after several hours of ATRi treatment. Both 
increased PERK-dependent phosphorylation of eIF2 at S51 (a marker of UPR induction) 
and ER swelling following ATRi treatment were prevented by co-treatment with 
Obatoclax, indicating a relationship between ER stress/UPR induction and ER swelling 
following ATRi treatment, and a role for pro-survival BCL-2 family members in these 
ATRi-induced ER phenotypes. 
I would like to present a putative hypothesis that unifies my findings regarding 
reduced ATR activity and ER functionality. One mechanism to induce the UPR is through 
dysfunction of the ERAD system. If ERAD function is compromised, the burden of 
unfolded proteins within the ER increases, and after some time this results in the 
induction of the UPR as ER stress increases (Oslowski and Urano, 2011). An ATRi-induced 
deficit in the ERAD pathway would explain the instant ER swelling and slightly delayed 
UPR induction (>4 hrs ATRi).  
It is here that I would like to re-introduce the ATR substrate, DNA damage 
response protein and ERAD complex subunit VCP/p97. Disease-causing mutations in p97 
cause inclusion body myopathy (IBM) – associated with muscle atrophy, dementia and 
amyotrophic lateral sclerosis (Ching et al., 2013). Ching et al. (2013) investigated the 
pathomechanistic and molecular basis of these disease-causing VCP/p97 mutations in 
vitro, revealing strikingly similar phenotypes to those that I have discovered following 
ATRi or Atr siRNA treatments of 3T3-L1 cells. Mutations in VCP/p97 induced ER swelling, 
UPR induction, as well as autophagic phenotypes of increased p62 and LC3-II, and 
reduced mTORC1 activity (Ching et al., 2013). Defects in VCP/p97 function prevent 
effective ERAD, resulting in UPR induction (Wójcik et al., 2006). It has been postulated 
that defects in VCP/p97-dependent ERAD induce ER swelling due to the build-up of 
aggregated and unfolded proteins within the ER lumen that cannot be effectively 
removed for proteasomal degradation (Mimnaugh et al., 2006).  
I postulate that ATRi and Atr siRNA may induce cytoplasmic vacuolisation/ER 
swelling due to the lack of ATR-dependent phosphorylation of VCP/p97, resulting in 
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reduced VCP/p97 activity, reducing ERAD functionality generating ER swelling and 
eventual induction of the UPR. Alternatively, through an unknown mechanism, 
depleting ATR activity could be increasing the proteotoxic burden on ERAD. VCP/p97 has 
also been characterised as a substrate of AKT; I observe striking a reduction in AKT 
activation following acute ATRi treatments which could provide an alternative route to 
reduce VCP functionality (Klein et al., 2005; Vandermoere et al., 2006). Furthermore, 
functional VCP/p97 has also been characterised as a requisite of effective mTOR 
activation (Ching et al., 2013) – I also observe defects in mTORC1 activity after treatment 
with ATRis and Atr siRNA. 
Mimnaugh et al. (2006) discovered that co-treatment with proteotoxic-stress 
inducing drugs that increased the requirement for ERAD induced an ER 
swelling/vacuolisation phenotype, which could be attenuated with VCP/p97 
overexpression (Mimnaugh et al., 2006). This information is relevant when considering 
a paper investigating the structural similarities between VPS4b and VCP/p97 (Scott et 
al., 2005). Scott et al. revealed the crystal structure of VPS4b, in which the VPS4b AAA 
ATPase cassette closely resembled the analogous domains in VCP/p97 (Fig 6.4.1).  
Figure 6.4.1. Structural similarities between VPS4b and p97/VCP. A) Overlay of VPS4b (rainbow) and 
p97 (beige) AAA ATPase cassettes reveals near-identical structural homology. B) Structure of VPS4b 
123-444 ring oligomer. Taken from (Scott et al., 2005) 
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In section 6.2.4, I reported that overexpression of WT- and phospho-mutant- 
VPS4b prevented ATRi-induced cytoplasmic vacuolisation in 3T3-L1 preadipocytes. I 
investigated VPS4b as putative ATR substrate(Matsuoka et al., 2007), concluding that 
the putative ATR phospho-residue on VPS4b (T317) had no functional significance in the 
defects I observed following ATRi. Considering the striking structural homology of VPS4b 
and VCP/p97 and their similar roles in the removal of protein complexes from 
membranes, I postulate that VPS4b overexpression might alleviate the ATRi-induced 
proteotoxic stress by facilitating ERAD in the absence of optimally functional VCP/p97.  
How Obatoclax could prevent ATRi-induced defects in ERAD and ER swelling 
remains unclear. However, relationships between the BCL-2 family and ERAD pathways 
do exist; for example, expression of constitutively active pro-apoptotic effector BOK 
(BCL-2 ovarian killer) is maintained at low levels by the ERAD system; when ERAD is 
compromised, BOK expression increases resulting in induction of apoptosis (Llambi et 
al., 2016). However, BOK has been characterised as insensitive to the antagonistic 
effects of canonical pro-survival BCL-2 family members, suggesting Obatoclax treatment 
would not affect BOK activity (Llambi et al., 2016). The significance of this relationship 
between one BCL-2 family member and the ERAD pathway remains unclear. These 
putative mechanisms are summarised in Fig 6.4.2. 
Furthermore, BCL-2 family member Beclin-1 has a role in early autophagy in the 
formation and enlongation of autophagosomes, and is inhibited by pro-apoptosis 
members of the BCL-2 family (discussed in section 5.1.3). As the ATRi-induced 
autophagic block appears at the later stages of autophagy, it is possible that alterations 
in Beclin-1 activity were not responsible for this effect. 
As discussed in section 6.2.9 and 1.9.2, ATR can interact with BID/tBID in context 
dependent manners through phosphorylation or via ATRs ‘BH3-like’ domains. Free tBID 
is required to induce ER swelling that is generated by co-over-expression of BAK and 
BCL-XL (Klee and Pimentel-Muiños, 2005). Another hypothesis that could explain ATRi-
induced vacuolisation, is that tBID may be bound to ATR, and ATRi is liberating tBID from 
this interaction, allowing increased tBID-mediated conformational change of BAK, 
required for BCL-XL binding to induce vacuolisation. Although the mechanism behind 
the ATRi-induced vacuolisation is unclear, what can be ascertained is that ATRi appears 
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to alter the equilibrium of the BCL-2 family members, where co-treatment with a BH3 
mimetic restores some level of ER functionality following ATRi treatment. At face value 
this appears contradictory, as ATRi treatment should liberate constitutively active, pro-
apoptosis multi-region protein tBID, and Obatoclax is a pro-apoptotic, BH3-only 
mimetic. These putative mechanisms are also summarised in Fig 6.4.2. 
A further way to dissect the mechanism of ATRi-induced cytoplasmic 
vacuolisation is to consider the roles of BCL-2 family members in the regulation of ER 
Ca2+ stores. Ca2+-free KH medium attenuated the ATRi-induced cytoplasmic 
vacuolisation phenotype. The complex relationship between [Ca2+]ER and apoptosis, and 
how this is modulated by multiple BCL-2 family members has been subject to extensive 
research, where it appears that normal [Ca2+]ER is required for the initiation of apoptosis 
at the mitochondria by BAX/BAK. Additionally, pro-survival BCL-2 can function to limit 
[Ca2+]ER by increasing the ‘leakiness’ of the ER membrane and through inhibition of IP3Rs, 
to reduce the availability of Ca2+ required to initiate apoptosis (Monaco et al., 2012; 
Figure 6.4.2. Schematic of putative mechanisms of ATRi-induced ER swelling. ATRi could block 
putative interaction with VCP/p97, compromising ERAD function, which could be rescued by 
overexpression of structurally homologous VPS4b. ATRi could also be liberating tBID from an ATR-
tBID interaction, increasing tBID-mediated conformational changes in BAK, resulting in enhance BCL-
XL-BAK interactions inducing ER swelling, similar to co-over-expression of BAK and BCL-XL. Obatoclax 
rescues ATRi induced ER swelling by blocking interaction between BAK and BCL-XL. 
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Pinton et al., 2000). Small molecule inhibitors of BCL-2 and BCL-XL have also been shown 
to deplete [Ca2+]ER, suggesting multifaceted roles of pro-survival BCL-2 members in 
[Ca2+]ER modulation (Gerasimenko et al., 2010). Furthermore, BCL-2 has also been 
implicated in the regulation of cellular Ca2+ extrusion, where knockout of BCL-2 
enhanced Ca2+ extrusion after a period of enhanced Ca2+ entry (Ferdek et al., 2012). This 
suggests that following inhibition of BCL-2 activity with Obatoclax, intracellular Ca2+ may 
be depleted, in a similar manner to treating cells with Ca2+-free medium, linking these 
two treatments that attenuate ATRi-induced ER swelling. 
Further understanding of the mechanism/s underlying the ATRi- and Atr siRNA- 
induced ER swelling and ER stress could have therapeutic benefits and facilitate the 
discovery of novel synthetic lethality approaches in the use of ATRis in cancer therapy. 
Existing, approved medical compounds could be utilised alongside ATRi treatments to 
enhance or protect against these novel ER stress- or autophagy- associated defects, 
selectively sensitising cancerous cells whilst reducing the therapy burden of ATRi 
treatment. For example, Geldanamycin interrupts HSP90 chaperone activity, increasing 
cell dependency on VCP/p97-mediated ERAD to clear mis-folded HSP90 clients. 
Geldanamycin analogues (17-DMAG) and other HSP90 inhibitors are being extensively 
researched as novel anti-cancer therapies. As well as investigating clinically relevant 
autophagy inhibitors such as hydroxychloroquine, or proteasome inhibitors such as 
Bortezomib, investigating the effect of ATRis and HSP90is represents a logical step in 
looking for novel ATRi-based synthetic lethalities centred on ATRi-induced proteotoxic 
stress. Conversely, combination therapies must also be considered for the potentially 
detrimental effects on the patient – for example, although Obatoclax selectively kills 
cells dependent on pro-survival BCL-2 proteins, it also appears to have a cytoprotective 
effect on cells treated with ATRis, reducing ER swelling and ER stress. 
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7.1 Summary 
In this thesis, I aimed to characterise novel impacts of small molecule kinase inhibitors 
of ATR (ATRis) on the adipogenic differentiation of preadipocytes, as well as the impact 
of chronic ATRi treatment on mature, post-mitotic white adipocytes. My intended aim 
was to characterise a pathomechanistic link between reduced ATR function and the 
lipodystrophy commonly observed in mouse models of ATR deficiency and ATR-Seckel 
Syndrome patients. These findings potentially have significant relevance, due to the 
postulated use of ATRis as a novel cancer therapy, and the lipodystrophy known as 
cachexia observed frequently in cancers. Here I will briefly summarise my findings, 
before my final discussion. 
7.1.1 Chapter Three 
In this chapter, I investigated the effects of kinase inhibition of ATR on 3T3-L1 adipogenic 
differentiation. ATRi treatments throughout adipogenesis resulted in a failure to 
successfully differentiate, due impaired induction and expression of the master 
adipogenic regulator peroxisome proliferator-activated receptor 2 (PPAR2). By 
assessing the S-phase kinetics of differentiating cultures treated with ATRis, I 
demonstrated that ATRi treatment did not impair the mitotic clonal expansion (MCE) 
step of adipogenic differentiation as initially hypothesised. Failure to successfully 
undergo adipogenesis following ATRi was concomitant with reduced mammalian target 
of rapamycin complex 1 (mTORC1) activity. mTORC1 is known to have dual roles in 
adipogenesis, where its activity either facilitates or inhibits adipogenesis, dependent on 
thresholds of mTORC1 activation (Yoon et al., 2013; Zhang et al., 2009). Furthermore, 
mTORC2-dependent phosphorylation of Protein Kinase B (AKT) was decreased following 
ATRi, indicating that both mTORC1 and mTORC2 activity was compromised. 
Interestingly, transient transfection of Atr siRNA induced adipogenesis in post-confluent 
3T3-L1 preadipocytes. Reduced ATR functionality negatively impacted on mTORC1 
activity, leading me to postulate that the reduced or enhanced adipogenesis observed 
after ATRi and Atr siRNA was due to the threshold-dependent effect of reduced mTORC1 
activity on adipogenesis. 
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7.1.2 Chapter Four 
In this chapter, I investigated the effects of chronic ATRi treatment on mature, post-
mitotic 3T3-L1 adipocytes. I observed profoundly decreased cellular triglyceride (TG) 
content, concomitant with loss of PERILIPIN A expression and markers of lipolysis and 
free fatty acid release (FFA). Collectively, this data is indicative of a profound loss of lipid 
droplet integrity. At the same time, I observed markers of white adipocyte ‘browning’ 
(UCP1, PGC1) and increased mitochondrial mass, indicating ATRi treatment is inducing 
a drastic metabolic reprogramming of white adipocytes towards energy catabolism. 
These results were not due to ATRi-induced enhanced replication stress, or cell cycle re-
entry. The shift in lipid metabolism of mature white adipocytes following ATRi is 
reminiscent of that observed in cancer cachexia. 
7.1.3 Chapter Five 
I investigated the effects of acute ATRi treatment on the autophagy axis of 3T3-L1 
preadipocytes. Acute ATRi, Atr siRNA and overexpression of a kinase dead (KD)-ATR 
construct induced a block in autophagosomal maturation, and an autophagy 
independent increase in sequestosome-1 (p62) expression. This result was not observed 
following Checkpoint kinase 1 inhibition, indicating the effects of ATRi here were not 
due to inhibition of the ATR-CHK1 signalling axis. Following ATRi, I also observed an 
increase in nuclear translocation of lysosomal biogenesis regulator transcription factor 
EB (TFEB). TFEB is sequestered in the cytoplasm by mTORC1-dependent 
phosphorylation. Following reduced mTORC1 activity, TFEB undergoes nuclear 
translocation to activate the lysosomal CLEAR response. This adds further functional 
significance to the ATRi-induced defects in mTORC1 signalling I observed in chapter 
three. Quite surprisingly, the impact of VE-821 treatment on p62 expression has recently 
been documented within the literature (Muralidharan et al., 2017). 
7.1.4 Chapter Six  
Here I characterised a novel conspicuous vacuolisation event in multiple cell lines, 
induced with several structurally dissimilar ATRis, as well as following Atr siRNA. Through 
extensive analysis, I found that ATRi-induced vacuoles were derived from the 
endoplasmic reticulum (ER). I characterised the ATRi-induced cytoplasmic vacuolisation 
198 
 
phenotype further by preventing it, utilising BH3 mimetic Obatoclax, and also with 
transient overexpression of vacuolar protein sorting-associated protein 4b (VPS4b). 
Utilising ER fractionation, immunofluorescence and over-expression of tagged ATR 
constructs, I characterised a novel localisation of ATR-interacting protein (ATRIP)-ATR to 
the ER. I also observed ER stress, and increased mitochondrial mass in 3T3-L1 
preadipocytes following acute ATRi treatments, the latter being indicative of blocked 
mitophagy.  
7.2 Discussion 
Further mechanistic insight into the ATRi-induced adipogenic block can be gained 
through the cross-examination of results within each chapter, which I will discuss here.  
7.2.1 ER stress and adipogenesis 
ER stress activation through the protein kinase RNA-like endoplasmic reticulum kinase-
eukaryotic initiation factor 2 (PERK-eIF2) arm of the unfolded protein response (UPR) 
is also recognised as an inhibitor of adipogenesis - eIF2-dependent increased 
translation of activating transcription factor 4 (ATF4) results in increased transcription 
of adipogenesis-inhibitor CCAAT-enhancer-binding protein (C/EBP)-homologous protein 
(CHOP) (Batchvarova et al., 1995). On the other hand, X-box binding protein-1s (XBP1s), 
induced by the inositol-requiring enzyme 1 (IRE1) arm of the UPR, is required for 
successful adipogenesis, due to its role in the upregulation of C/EBP family members 
(Sha et al., 2009). 
In chapter six, I characterised activation of the UPR (increased p-eIF2 S51 and 
ATF6), and decreased XBP1s following ATRi in 3T3-L1 preadipocytes. Considering the 
relationship between ER stress and adipogenesis, it was interesting to discover the UPR 
was not similarly induced following ATRi throughout 3T3-L1 adipogenesis – XBP1s 
expression remained equivalent in ATRi- and untreated cultures throughout (section 
6.2.6).  I discovered that following ATRi treatment, eIF2 activity is also reduced 
throughout adipogenesis (section 3.2.4). Due to this, the relevance of the ER in the ATRi-
induced adipogenic block remains unclear.  
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7.2.2 ER stress, autophagy and lipid metabolism 
ER stress is also an established inducer of lipolysis in adipocytes (Bogdanovic et al., 2015; 
Deng et al., 2012), where the activation of ER stress pathways underlies the 
pathogenesis several of metabolic syndromes (Zha and Zhou, 2012). However, it appears 
maintaining a balanced ER stress response is also necessary, as complete ablation of Atf4 
enhances lipogenesis and thermogenesis, resulting in lean mice (Wang et al., 2010). 
Investigating markers of the UPR in adipocytes could provide mechanistic insight into 
the metabolic phenotypes observed following chronic ATRi treatment.  
In chapter five I showed that following acute ATRi treatment, lysosomal 
biogenesis regulator TFEB had translocated to the nucleus, indicative of increased 
activity and enhanced lysosomal biogenesis (section 5.2.4). In chapter four, I 
characterised a striking decrease in PERILIPIN A expression, and enhanced TG release 
and lipolysis in mature adipocytes following ATRi treatments (section 4.2.2). 
Interestingly, several studies have reported similar striking and rapid reduction of 
adipocyte PERILIPIN A expression, concomitant with enhanced lipolysis and FFA release 
following the enhancement of lysosome-assisted degradation pathways (Choi et al., 
2016; Kaushik and Cuervo, 2015; Kovsan et al., 2007). The groups reported that 
PERILIPIN A appeared to be selectively degraded through autophagic rather than 
proteasomal degradation - lysosomal protease inhibitors such as leupeptin prevented 
PERILIPIN A degradation and attenuated the concomitant increase in lipolysis. 
Investigating TFEB activity or lysosomal markers in 3T3-L1 adipocytes could provide 
insight into why PERILIPIN A expression decreases so rapidly following ATRi. 
Furthermore, hydroxychloroquine (HC) is a lysosomal protease inhibitor currently in 
clinical trials as a novel chemotherapeutic agent. Investigating the impact of this 
clinically relevant lysosomal inhibitor on the ATRi-induced adipocyte phenotypes of 
PERILIPIN A loss and increased lipolysis could prove beneficial. Combination therapies 
with ATRi and HC could potently target cancer cells exhibiting enhanced dependency on 
autophagic processing, through inducing an autophagic blockage at multiple nodes, 
whilst potentially carrying cytoprotective effects for host adipocyte metabolism, 
through the conservation of PERILIPIN A expression through ATRi therapy. 
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7.2.3 Lysosomal transport, mTOR signalling and autophagy 
3T3-L1 preadipocytes failed to successfully differentiate into mature adipocytes when 
treated with ATRis, perhaps due to reduced activity of the mTORC1-signalling axis, 
required for adipogenesis. However, it was unclear how reduced ATR function had such 
a striking effect on the mTORC1 signalling pathway. Multiple members of the AKT-mTOR 
signalling axis have recently been identified as putative ATR/ATM substrates following 
DNA damage, including Tuberous Sclerosis Complex 1 (TSC1-S1102), Protein Kinase B 
(AKT3-S123) and Insulin Receptor substrate 2 (IRS2-S336) (Fig 7.2.3.1). In 3T3-L1 
preadipocytes, following ATRi treatment I observed defects in both mTORC1 and 
mTORC2 activation, as assessed by AKT (mTORC2) and S6 (mTORC1) phosphorylation. 
The complex feedback mechanisms in place within mTOR-associated pathways, and the 
impact of ATRi on both mTORC1/2 signalling axes, renders the functional significance of 
these putative ATR/ATM-dependent phosphorylations difficult to predict. Furthermore, 
Figure 7.2.3.1. Network of putative ATR/ATM substrates involved in cell metabolism. Red colour 
denotes putative ATR/ATM substrates. Taken from (Matsuoka et al., 2007) 
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their functional relevance in the ATRi-induced phenotypes of blocked autophagy and ER 
stress is uncertain.  
Considering the volume of putative ATR/ATM substrates that have been 
identified within proteomic screens, it is highly likely that ATR has multiple 
uncharacterised targets within the cytoplasm. Reduced ATR activity may in fact impinge 
on several aspects of cellular function - where the phenotypes I observe following ATRi 
and Atr siRNA could be the net result of compromising multiple signalling pathways. 
With this in mind, I suggest a putative mechanism to coalesce several of my findings.  
A requirement for mTORC1 activity is its localisation to the lysosome. For full 
activation of mTORC1, p62 must interact with mTORC1 at the lysosome (Duran et al., 
2011). The reduced mTORC1 activity and increased p62 expression following ATRi 
indicates that p62 may not be effectively inducing mTORC1 activation. Additionally, 
mTORC1 activity is partially dependent on the dynein-driven localisation of lysosomes 
to the nuclear periphery – when dynein is depleted or inhibited, mTORC1 does not 
effectively phosphorylate S6K (Clippinger and Alwine, 2012). Maintaining the correct 
cellular location of organelles is an active process, requiring stable function and kinetics 
of both dynein and kinesin motors. Dynein function is also required to facilitate efficient 
and appropriate autophagy, through its control over lysosome and autophagosome 
localisation (Kimura et al., 2008). Disrupting dynein function results in a failure to 
undergo autophagosome-lysosome fusion, resulting in a block in autophagy. Following 
ATRi, I observed a block in autophagy at the stages of lysosomal fusion/autophagosome 
maturation (chapter 5), and a failure to undergo successful adipogenesis, which could 
be dependent on compromised mTORC1 activity (chapter 3). Compromising dynein 
activity can also result in these phenotypes, due to its essential role in the minus-end 
transport of lysosomes to the nuclear periphery.  
An interaction between dynein and ATR has already be characterised within the 
literature (Fig 7.2.3.2), and dynein subunits have been identified previously as putative 
ATR/ATM substrates including DYNC1I2 T95 (Matsuoka et al., 2007; Poruchynsky et al., 
2015). Interestingly, p62 has recently been reported to directly interact with DYNC1I2 
(Calderilla-Barbosa et al., 2014). Dynein intermediate chain subunits are essential to 
dynein function, playing a key role in assembly, cargo recognition and interactions with 
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regulatory proteins including the dynactin complex. DYNC1I2 also contributes to dynein 
complex localisation to the kinetochore (Raaijmakers et al., 2013), and moreover, dynein 
has been implicated in silencing the spindle assembly checkpoint, where a role for ATR 
is established (Howell et al., 2001; Kim and Burke, 2008; Lawrence et al., 2015). 
I hypothesised that perhaps the ATRi-induced phenotypes of blocked autophagy 
and reduced mTORC1 activity could be linked through compromised dynein function, 
preventing the appropriate cellular localisation of lysosomes. Fig 7.2.3.3 shows 
immunofluorescence (IF) microscopy of asynchronous RPE cells stained for mTOR, 
before and after ATRi treatments. To characterise the loss of dynein-dependent mTOR 
localisation to the nuclear periphery, I utilised dynein inhibitor Ciliobrevin as a positive 
control. In untreated cells, mTOR appears mostly localised to the nuclear periphery. 
Following Ciliobrevin treatment, mTOR has lost its perinuclear localisation. Following 
Figure 7.2.3.2 ATR coprecipitates with dynein. Modified from (Poruchynsky et al., 2015) 
Figure 7.2.3.3. mTOR localisation is affected by ATRi. Cycling RPE cells were treated with Ciliobrevin 
(20 M, 2 hrs) or ATRi II (10 M, 1 hr) before analysis. mTOR is generally localised to the nuclear 
periphery in untreated cells. Following Ciliobrevin, this localisation is lost. Following ATRi treatment, 
mTOR localisation to the perinuclear region appears decreased. Images taken at 100x. 
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ATRi treatment, mTOR localisation at the nuclear periphery is less apparent than in 
untreated cells. Although this does not provide concrete evidence that ATRi-induced 
reduced mTOR activity is due to mislocalisation of mTOR, it justifies further 
investigation.  
Whilst investigating the impact of ATRi treatments on post-mitotic 3T3-L1 
adipocytes (chapter 4), I cultured MG63 human osteosarcoma cells with serum enriched 
with fatty acids (AlbuMax), forcing them to acquire lipid droplets (LDs). Following this 
process characterised in literature (Ruiz-Vela et al., 2011), I aimed to investigate the LD-
forming capability of ATRi-treated cultures. No quantifiable difference was observed 
between ATRi-treated and untreated MG63 cultures in their capacity to form LDs 
following AlbuMax treatment (Fig 7.2.3.4.A), although IF of BODIPY 493/503-stained 
MG63s showed quite strikingly that LDs were localised to the cell periphery following 
ATRi treatments, regardless of AlbuMax treatment (Fig 7.2.3.4.B). Dynein has been 
postulated as a mediator of LD formation and functionality, controlling LD size, fusion, 
fragmentation and dispersion (Boulant et al., 2008; Zehmer et al., 2009).  
Additionally, the dynein complex has an essential role in primary cilia formation 
– where a role for ATR has been characterised within the literature (Stiff et al., 2016). 
Ciliopathies are a clinically heterogeneous spectrum of developmental disorders, 
associated with mutations in genes encoding for members of the ciliary proteome. 
Subsets of ciliopathies are characterised by lipodystrophy and/or obesity (Waters and 
Beales, 2011), and more recently, it has been postulated that the clinical manifestations 
of ATR-SS could be due to disorders of cilia function (Stiff et al., 2016). Further to this, 
Seckel Syndrome-associated genes encoding Ninein and Pericentrin (PCNT) have roles 
in modulating dynein functionality (Purohit et al., 1999; Redwine et al., 2017). 
These experiments, and precedence within the literature, provide preliminary 
evidence that could potentially support the putative hypothesis that ATRi is 
compromising dynein function via a direct or indirect mechanism. Reduced functionality 
of dynein following ATRi treatments could result in reduced activity of mTORC1, causing 
the failure to undergo adipogenic differentiation in the present of ATRis. Further work 
is required to validate this putative hypothesis. 
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7.3 Concluding remarks 
I have utilised clinically relevant ATRis in a model adipogenic cell culture system, to 
investigate a pathomechanistic link between ATR dysfunction and lipodystrophy. 
Lipodystrophy and/or cachexia are presentations commonly observed in congenital 
disorders and mouse models of ATR deficiency, presenting a potential hurdle in the 
therapeutic use of ATRis in cancer. The metabolic consequences of ATRi treatment could 
have implications for their use in cancer therapy; the browning of ATRi-treated white 
Figure 7.2.3.4. Lipid droplets re-localise to cell periphery following ATRi treatment. A) FACs 
quantification of TG content of MG63 cells treated with or without ATRi II (10 M. 16 hrs) and AlbuMax 
(1.6%, 16 hrs) shows ATRi does not affect LD formation in MG63 cells. B) IF microscopy corresponding 
to FACs analysis shows in ATRi-treated MG63 cultures, LD are localised to the cell periphery.  
A 
B 
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adipocytes with enhanced FFA release is not dissimilar to that observed in cancer 
cachexia. The systemic reprogramming and browning of white adipose tissue stores is 
one pathomechanism behind the severe atrophy experienced by cachexic cancer 
patients.  
On the other hand, there may also be as yet unconsidered therapeutic benefits 
to ATRi therapy. Investigating novel combination therapies with pre-existing medicines 
such as mTORC1 inhibitor rapamycin, or lysosomal protease inhibitor 
hydroxychloroquine, may show positive synergistic anti-cancer effects, thereby 
providing scope to develop novel treatment strategies whilst reducing therapy burden 
on the patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
206 
 
References 
 
Adams, J., and Cory, S. (2007). The Bcl-2 apoptotic switch in cancer development and therapy. 
Oncogene 26, 1324-1337. 
Aksamitiene, E., Kiyatkin, A., and Kholodenko, Boris N. (2012). Cross-talk between mitogenic 
Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochemical Society Transactions 40, 139-
146. 
Alcantara, D., and O'Driscoll, M. (2014). Congenital microcephaly. American Journal of Medical 
Genetics Part C: Seminars in Medical Genetics 166, 124-139. 
Alderton, G.K., Joenje, H., Varon, R., Børglum, A.D., Jeggo, P.A., and O'Driscoll, M. (2004). Seckel 
syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Human 
Molecular Genetics 13, 3127-3138. 
Altshuler-Keylin, S., Shinoda, K., Hasegawa, Y., Ikeda, K., Hong, H., Kang, Q., Yang, Y., Perera, 
Rushika M., Debnath, J., and Kajimura, S. (2016). Beige Adipocyte Maintenance Is Regulated by 
Autophagy-Induced Mitochondrial Clearance. Cell Metabolism 24, 402-419. 
Amaravadi, R.K., Yu, D., Lum, J.J., Bui, T., Christophorou, M.A., Evan, G.I., Thomas-Tikhonenko, A., 
and Thompson, C.B. (2007). Autophagy inhibition enhances therapy-induced apoptosis in a Myc-
induced model of lymphoma. Journal of Clinical Investigation 117, 326-336. 
Anacker, D.C., Aloor, H.L., Shepard, C.N., Lenzi, G.M., Johnson, B.A., Kim, B., and Moody, C.A. (2016). 
HPV31 utilizes the ATR-Chk1 pathway to maintain elevated RRM2 levels and a replication-competent 
environment in differentiating Keratinocytes. Virology 499, 383-396. 
Araki, K., and Nagata, K. (2011). Protein Folding and Quality Control in the ER. Cold Spring Harbor 
Perspectives in Biology 3, a007526. 
Argiles, J.M., Busquets, S., Stemmler, B., and Lopez-Soriano, F.J. (2014). Cancer cachexia: 
understanding the molecular basis. Nat Rev Cancer 14, 754-762. 
Asano, H., Kanamori, Y., Higurashi, S., Nara, T., Kato, K., Matsui, T., and Funaba, M. (2014). Induction 
of Beige-Like Adipocytes in 3T3-L1 Cells. The Journal of Veterinary Medical Science 76, 57-64. 
207 
 
Axe, E.L., Walker, S.A., Manifava, M., Chandra, P., Roderick, H.L., Habermann, A., Griffiths, G., and 
Ktistakis, N.T. (2008). Autophagosome formation from membrane compartments enriched in 
phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. The 
Journal of Cell Biology 182, 685-701. 
B’chir, W., Maurin, A.-C., Carraro, V., Averous, J., Jousse, C., Muranishi, Y., Parry, L., Stepien, G., 
Fafournoux, P., and Bruhat, A. (2013). The eIF2α/ATF4 pathway is essential for stress-induced 
autophagy gene expression. Nucleic Acids Research 41, 7683-7699. 
Baenke, F., Peck, B., Miess, H., and Schulze, A. (2013). Hooked on fat: the role of lipid synthesis in 
cancer metabolism and tumour development. Disease Models & Mechanisms 6, 1353-1363. 
Bakkenist, C.J., and Kastan, M.B. (2003). DNA damage activates ATM through intermolecular 
autophosphorylation and dimer dissociation. Nature 421, 499-506. 
Ball, H.L., Myers, J.S., and Cortez, D. (2005). ATRIP Binding to Replication Protein A-Single-stranded 
DNA Promotes ATR–ATRIP Localization but Is Dispensable for Chk1 Phosphorylation. Molecular 
Biology of the Cell 16, 2372-2381. 
Bao, S., Tibbetts, R.S., Brumbaugh, K.M., Fang, Y., Richardson, D.A., Ali, A., Chen, S.M., Abraham, 
R.T., and Wang, X.-F. (2001). ATR/ATM-mediated phosphorylation of human Rad17 is required for 
genotoxic stress responses. Nature 411, 969-974. 
Barlow, C., Ribaut-Barassin, C., Zwingman, T.A., Pope, A.J., Brown, K.D., Owens, J.W., Larson, D., 
Harrington, E.A., Haeberle, A.-M., Mariani, J., et al. (2000). ATM is a cytoplasmic protein in mouse 
brain required to prevent lysosomal accumulation. Proceedings of the National Academy of Sciences 
of the United States of America 97, 871-876. 
Bartke, A. (2005). Minireview: Role of the Growth Hormone/Insulin-Like Growth Factor System in 
Mammalian Aging. Endocrinology 146, 3718-3723. 
Batchvarova, N., Wang, X.Z., and Ron, D. (1995). Inhibition of adipogenesis by the stress-induced 
protein CHOP (Gadd153). EMBO Journal 14, 4654-4661. 
Beijersbergen, R.L., Wessels, L.F., and Bernards, R. (2016). Synthetic Lethality in Cancer Therapeutics. 
Annual Review of Cancer Biology. 
208 
 
Bento, C.F., Renna, M., Ghislat, G., Puri, C., Ashkenazi, A., Vicinanza, M., Menzies, F.M., and 
Rubinsztein, D.C. (2016). Mammalian autophagy: How does it work? Annual review of biochemistry 
85, 685-713. 
Berg, A.H., and Scherer, P.E. (2005). Adipose Tissue, Inflammation, and Cardiovascular Disease. 
Circulation Research 96, 939-949. 
Bernard, A., and Klionsky, D.J. (2014). Defining the membrane precursor supporting the nucleation of 
the phagophore. Autophagy 10, 1-2. 
Berridge, M.J. (2002). The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 
32, 235-249. 
Berridge, M.J., Lipp, P., and Bootman, M.D. (2000). The versatility and universality of calcium 
signalling. Nat Rev Mol Cell Biol 1, 11-21. 
Berti, M., and Vindigni, A. (2016). Replication stress: getting back on track. Nat Struct Mol Biol 23, 
103-109. 
Bertolotti, A., Zhang, Y., Hendershot, L.M., Harding, H.P., and Ron, D. (2000). Dynamic interaction of 
BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2, 326-332. 
Bhoumik, A., Bergami, P.L., and Ronai, Z.e. (2007). ATF2 on the Double – Activating Transcription 
Factor and DNA Damage Response Protein. Pigment cell research / sponsored by the European 
Society for Pigment Cell Research and the International Pigment Cell Society 20, 498-506. 
Bhoumik, A., Takahashi, S., Breitweiser, W., Shiloh, Y., Jones, N., and Ronai, Z.e. (2005). ATM-
Dependent Phosphorylation of ATF2 Is Required for the DNA Damage Response. Molecular cell 18, 
577-587. 
Bing, C., Brown, M., King, P., Collins, P., Tisdale, M.J., and Williams, G. (2000). Increased Gene 
Expression of Brown Fat Uncoupling Protein (UCP)1 and Skeletal Muscle UCP2 and UCP3 in MAC16-
induced Cancer Cachexia. Cancer Research 60, 2405-2410. 
Bishop, N., and Woodman, P. (2000). ATPase-defective Mammalian VPS4 Localizes to Aberrant 
Endosomes and Impairs Cholesterol Trafficking. Molecular Biology of the Cell 11, 227-239. 
209 
 
Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Øvervatn, A., Stenmark, H., and 
Johansen, T. (2005). p62/SQSTM1 forms protein aggregates degraded by autophagy and has a 
protective effect on huntingtin-induced cell death. The Journal of Cell Biology 171, 603-614. 
Bjørkøy, G., Lamark, T., Pankiv, S., Øvervatn, A., Brech, A., and Johansen, T. (2009). Chapter 12 
Monitoring Autophagic Degradation of p62/SQSTM1. In Methods in Enzymology (Academic Press), 
pp. 181-197. 
Blüher, M., and Mantzoros, C.S. (2015). From leptin to other adipokines in health and disease: Facts 
and expectations at the beginning of the 21st century. Metabolism 64, 131-145. 
Bock, J.B., Klumperman, J., Davanger, S., and Scheller, R.H. (1997). Syntaxin 6 functions in trans-Golgi 
network vesicle trafficking. Molecular Biology of the Cell 8, 1261-1271. 
Boder, E., and Sedgwick, R. (1987). Ataxia–telangiectasia. In Neurocutaneous diseases: a practical 
approach (Butterworth-Heinemann), pp. 95-117. 
Bogdanovic, E., Kraus, N., Patsouris, D., Diao, L., Wang, V., Abdullahi, A., and Jeschke, M.G. (2015). 
Endoplasmic reticulum stress in adipose tissue augments lipolysis. Journal of Cellular and Molecular 
Medicine 19, 82-91. 
Bos, J.L. (1989). <em>ras</em> Oncogenes in Human Cancer: A Review. Cancer Research 49, 4682-
4689. 
Boulant, S., Douglas, M.W., Moody, L., Budkowska, A., Targett-Adams, P., and McLauchlan, J. (2008). 
Hepatitis C Virus Core Protein Induces Lipid Droplet Redistribution in a Microtubule- and Dynein-
Dependent Manner. Traffic 9, 1268-1282. 
Boustany, R.-M.N. (2013). Lysosomal storage diseases[mdash]the horizon expands. Nat Rev Neurol 
9, 583-598. 
Bowers, R.R., and Lane, M.D. (2008). Wnt signaling and adipocyte lineage commitment. Cell Cycle 7, 
1191-1196. 
Bredemeyer, A.L., Sharma, G.G., Huang, C.-Y., Helmink, B.A., Walker, L.M., Khor, K.C., Nuskey, B., 
Sullivan, K.E., Pandita, T.K., Bassing, C.H., et al. (2006). ATM stabilizes DNA double-strand-break 
complexes during V(D)J recombination. Nature 442, 466-470. 
210 
 
Bröcker, C., Engelbrecht-Vandré, S., and Ungermann, C. (2010). Multisubunit Tethering Complexes 
and Their Role in Membrane Fusion. Current Biology 20, R943-R952. 
Brooks, C.L., and Gu, W. (2009). How does SIRT1 affect metabolism, senescence and cancer? Nat Rev 
Cancer 9, 123-128. 
Brown, E.J., and Baltimore, D. (2000). ATR disruption leads to chromosomal fragmentation and early 
embryonic lethality. Genes & Development 14, 397-402. 
Brown, N., and Costanzo, V. (2009). An ATM and ATR dependent pathway targeting centrosome 
dependent spindle assembly. Cell Cycle 8, 1997-2001. 
Bruce, A.C., and Jay, L. (2015). Cancer chemotherapy and radiation therapy.  (Oxford, UK, 'Oxford 
University Press'). 
Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, 
N.J., and Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-
ribose) polymerase. Nature 434, 913-917. 
Bucci, C., Thomsen, P., Nicoziani, P., McCarthy, J., and van Deurs, B. (2000). Rab7: A Key to Lysosome 
Biogenesis. Molecular Biology of the Cell 11, 467-480. 
Bujisic, B., De Gassart, A., Tallant, R., Demaria, O., Zaffalon, L., Chelbi, S., Gilliet, M., Bertoni, F., and 
Martinon, F. (2017). Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB 
DLBCL and contributes to tumor growth. Blood 129, 2420-2428. 
Calderilla-Barbosa, L., Seibenhener, M.L., Du, Y., Diaz-Meco, M.-T., Moscat, J., Yan, J., Wooten, M.W., 
and Wooten, M.C. (2014). Interaction of SQSTM1 with the motor protein dynein – SQSTM1 is 
required for normal dynein function and trafficking. Journal of Cell Science 127, 4052-4063. 
Cao, Y., Jiang, X., Ma, H., Wang, Y., Xue, P., and Liu, Y. (2016). SIRT1 and insulin resistance. Journal of 
Diabetes and its Complications 30, 178-183. 
Capanni, C., Mattioli, E., Columbaro, M., Lucarelli, E., Parnaik, V.K., Novelli, G., Wehnert, M., Cenni, 
V., Maraldi, N.M., Squarzoni, S., et al. (2005). Altered pre-lamin A processing is a common 
mechanism leading to lipodystrophy. Human Molecular Genetics 14, 1489-1502. 
211 
 
Cara, L., Baitemirova, M., Follis, J., Larios-Sanz, M., and Ribes-Zamora, A. (2016). The ATM- and ATR-
related SCD domain is over-represented in proteins involved in nervous system development. 
Scientific Reports 6, 19050. 
Casper, A.M., Nghiem, P., Arlt, M.F., and Glover, T.W. (2002). ATR Regulates Fragile Site Stability. Cell 
111, 779-789. 
Chakrabarti, A., Chen, A.W., and Varner, J.D. (2011). A Review of the Mammalian Unfolded Protein 
Response. Biotechnology and bioengineering 108, 2777-2793. 
Charrier, J.-D., Durrant, S.J., Golec, J.M.C., Kay, D.P., Knegtel, R.M.A., MacCormick, S., Mortimore, M., 
O'Donnell, M.E., Pinder, J.L., Reaper, P.M., et al. (2011). Discovery of Potent and Selective Inhibitors 
of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer 
Agents. Journal of Medicinal Chemistry 54, 2320-2330. 
Chaudhari, N., Talwar, P., Parimisetty, A., Lefebvre d’Hellencourt, C., and Ravanan, P. (2014). A 
Molecular Web: Endoplasmic Reticulum Stress, Inflammation, and Oxidative Stress. Frontiers in 
Cellular Neuroscience 8, 213. 
Chen, C.-F., Ruiz-Vega, R., Vasudeva, P., Espitia, F., Krasieva, T.B., de Feraudy, S., Tromberg, B.J., 
Huang, S., Garner, C.P., Wu, J., et al. (2017). ATR Mutations Promote the Growth of Melanoma 
Tumors by Modulating the Immune Microenvironment. Cell Reports 18, 2331-2342. 
Chen, C.-Y., Olayioye, M.A., Lindeman, G.J., and Tang, T.K. (2006). CPAP interacts with 14-3-3 in a cell 
cycle-dependent manner. Biochemical and Biophysical Research Communications 342, 1203-1210. 
Chen, H.C., and Farese, R.V. (2001). Turning WAT into BAT gets rid of fat. Nature medicine 7, 1102-
1103. 
Chen, J.-H., Zhang, P., Chen, W.-D., Li, D.-D., Wu, X.-Q., Deng, R., Jiao, L., Li, X., Ji, J., Feng, G.-K., et al. 
(2015). ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy 
in response to DNA-damaging agents in cancer cells. Autophagy 11, 239-252. 
Chen, Q., Shou, P., Zheng, C., Jiang, M., Cao, G., Yang, Q., Cao, J., Xie, N., Velletri, T., Zhang, X., et al. 
(2016). Fate decision of mesenchymal stem cells: adipocytes or osteoblasts[quest]. Cell Death Differ 
23, 1128-1139. 
212 
 
Cheng, E.H.Y.A., Wei, M.C., Weiler, S., Flavell, R.A., Mak, T.W., Lindsten, T., and Korsmeyer, S.J. 
(2001). BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated 
Mitochondrial Apoptosis. Molecular Cell 8, 705-711. 
Cheng, X.-T., Zhou, B., Lin, M.-Y., Cai, Q., and Sheng, Z.-H. (2015). Axonal autophagosomes recruit 
dynein for retrograde transport through fusion with late endosomes. The Journal of Cell Biology 209, 
377-386. 
Cheong, H., Lu, C., Lindsten, T., and Thompson, C.B. (2012). Therapeutic targets in cancer cell 
metabolism and autophagy. Nat Biotech 30, 671-678. 
Ching, J.K., Elizabeth, S.V., Ju, J.-S., Lusk, C., Pittman, S.K., and Weihl, C.C. (2013). mTOR dysfunction 
contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion 
body myopathy. Human Molecular Genetics 22, 1167-1179. 
Cho, Y.M., Kwak, S.-N., Joo, N.-S., Kim, D.H., Lee, A.-H., Kim, K.-S., Seo, J.B., Jeong, S.-W., and Kwon, 
O.-J. (2014). X-box binding protein 1 is a novel key regulator of peroxisome proliferator-activated 
receptor γ2. FEBS Journal 281, 5132-5146. 
Choi, J.-H., Lindsey-Boltz, L.A., and Sancar, A. (2009). Cooperative activation of the ATR checkpoint 
kinase by TopBP1 and damaged DNA. Nucleic Acids Research 37, 1501-1509. 
Choi, M.S., Kim, H.-J., Ham, M., Choi, D.-H., Lee, T.R., and Shin, D.W. (2016). Amber Light (590 nm) 
Induces the Breakdown of Lipid Droplets through Autophagy-Related Lysosomal Degradation in 
Differentiated Adipocytes. Scientific Reports 6, 28476. 
Cimprich, K.A., and Cortez, D. (2008). ATR: an essential regulator of genome integrity. Nat Rev Mol 
Cell Biol 9, 616-627. 
Clippinger, A.J., and Alwine, J.C. (2012). Dynein mediates the localization and activation of mTOR in 
normal and human cytomegalovirus-infected cells. Genes & Development 26, 2015-2026. 
Cohen, H.Y., Miller, C., Bitterman, K.J., Wall, N.R., Hekking, B., Kessler, B., Howitz, K.T., Gorospe, M., 
de Cabo, R., and Sinclair, D.A. (2004). Calorie Restriction Promotes Mammalian Cell Survival by 
Inducing the SIRT1 Deacetylase. Science 305, 390-392. 
Coleman R. A., L.T.M., Muoio D. M. ( 2000). PHYSIOLOGICAL AND NUTRITIONAL REGULATION OF 
ENZYMES OF TRIACYLGLYCEROL SYNTHESIS. Annual Review of Nutrition 20, 77-103. 
213 
 
Contreras, C., Nogueiras, R., Diéguez, C., Medina-Gómez, G., and López, M. (2016). Hypothalamus 
and thermogenesis: Heating the BAT, browning the WAT. Molecular and Cellular Endocrinology 438, 
107-115. 
Cortez, D., Guntuku, S., Qin, J., and Elledge, S.J. (2001). ATR and ATRIP: Partners in Checkpoint 
Signaling. Science 294, 1713-1716. 
Côté, J., Peterson, C.L., and Workman, J.L. (1998). Perturbation of nucleosome core structure by the 
SWI/SNF complex persists after its detachment, enhancing subsequent transcription factor binding. 
Proceedings of the National Academy of Sciences of the United States of America 95, 4947-4952. 
Cotta-Ramusino, C., McDonald, E.R., Hurov, K., Sowa, M.E., Harper, J.W., and Elledge, S.J. (2011). A 
DNA Damage Response Screen Identifies RHINO: a 9-1-1 and TopBP1 interacting protein required for 
ATR signaling. Science (New York, N.Y.) 332, 1313-1317. 
Cremona, C.A., and Behrens, A. (2014). ATM signalling and cancer. Oncogene 33, 3351-3360. 
Cuadrado, M., Martinez-Pastor, B., Murga, M., Toledo, L.I., Gutierrez-Martinez, P., Lopez, E., and 
Fernandez-Capetillo, O. (2006). ATM regulates ATR chromatin loading in response to DNA double-
strand breaks. The Journal of Experimental Medicine 203, 297-303. 
D'Amours, D., Desnoyers, S., D'Silva, I., and Poirier, G.G. (1999). Poly(ADP-ribosyl)ation reactions in 
the regulation of nuclear functions. Biochemical Journal 342, 249-268. 
D'Angiolella, V., Donato, V., Forrester, Frances M., Jeong, Y.-T., Pellacani, C., Kudo, Y., Saraf, A., 
Florens, L., Washburn, Michael P., and Pagano, M. Cyclin F-Mediated Degradation 
of&#xa0;Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair. Cell 149, 1023-
1034. 
Dalbay, M.T., Thorpe, S.D., Connelly, J.T., Chapple, J.P., and Knight, M.M. (2015). Adipogenic 
Differentiation of hMSCs is Mediated by Recruitment of IGF‐1r Onto the Primary Cilium Associated 
With Cilia Elongation. Stem Cells (Dayton, Ohio) 33, 1952-1961. 
Darling, N.J., and Cook, S.J. (2014). The role of MAPK signalling pathways in the response to 
endoplasmic reticulum stress. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1843, 
2150-2163. 
Dauber, A., LaFranchi, S.H., Maliga, Z., Lui, J.C., Moon, J.E., McDeed, C., Henke, K., Zonana, J., 
Kingman, G.A., Pers, T.H., et al. (2012). Novel Microcephalic Primordial Dwarfism Disorder 
214 
 
Associated with Variants in the Centrosomal Protein Ninein. The Journal of Clinical Endocrinology 
and Metabolism 97, E2140-E2151. 
De Chiara, G., Marcocci, M.E., Torcia, M., Lucibello, M., Rosini, P., Bonini, P., Higashimoto, Y., 
Damonte, G., Armirotti, A., Amodei, S., et al. (2006). Bcl-2 Phosphorylation by p38 MAPK: 
IDENTIFICATION OF TARGET SITES AND BIOLOGIC CONSEQUENCES. Journal of Biological Chemistry 
281, 21353-21361. 
de Gonzalo-Calvo, D., López-Vilaró, L., Nasarre, L., Perez-Olabarria, M., Vázquez, T., Escuin, D., 
Badimon, L., Barnadas, A., Lerma, E., and Llorente-Cortés, V. (2015). Intratumor cholesteryl ester 
accumulation is associated with human breast cancer proliferation and aggressive potential: a 
molecular and clinicopathological study. BMC Cancer 15, 460. 
de Laat, W.L., Appeldoorn, E., Sugasawa, K., Weterings, E., Jaspers, N.G.J., and Hoeijmakers, J.H.J. 
(1998). DNA-binding polarity of human replication protein A positions nucleases in nucleotide 
excision repair. Genes & Development 12, 2598-2609. 
Del Gobbo, A., Peverelli, E., Treppiedi, D., Lania, A., Mantovani, G., and Ferrero, S. (2016). Expression 
of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic 
review. Experimental Cell Research 346, 85-90. 
Delacroix, S., Wagner, J.M., Kobayashi, M., Yamamoto, K.-i., and Karnitz, L.M. (2007). The Rad9–
Hus1–Rad1 (9–1–1) clamp activates checkpoint signaling via TopBP1. Genes & Development 21, 
1472-1477. 
Deng, J., Liu, S., Zou, L., Xu, C., Bin, G., and Xu, G. (2012). Lipolysis response to endoplasmic reticulum 
stress in adipose cells. Journal of Biological Chemistry. 
Denic, V., Quan, E.M., and Weissman, J.S. (2006). A Luminal Surveillance Complex that Selects 
Misfolded Glycoproteins for ER-Associated Degradation. Cell 126, 349-359. 
Diao, J., Liu, R., Rong, Y., Zhao, M., Zhang, J., Lai, Y., Zhou, Q., Wilz, L.M., Li, J., Vivona, S., et al. 
(2015). ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes. 
Nature 520, 563-566. 
Ding, W.-X., Ni, H.-M., Gao, W., Chen, X., Kang, J.H., Stolz, D.B., Liu, J., and Yin, X.-M. (2009). 
Oncogenic transformation confers a selective susceptibility to the combined suppression of the 
proteasome and autophagy. Molecular Cancer Therapeutics 8, 2036-2045. 
215 
 
Distelhorst, C.W., and Bootman, M.D. (2011). Bcl-2 interaction with the inositol 1,4,5-trisphosphate 
receptor: role in Ca(2+) signaling and disease. Cell calcium 50, 234-241. 
Dooley, Hannah C., Razi, M., Polson, Hannah E.J., Girardin, Stephen E., Wilson, Michael I., and Tooze, 
Sharon A. (2014). WIPI2 Links LC3 Conjugation with PI3P, Autophagosome Formation, and Pathogen 
Clearance by Recruiting Atg12–5-16L1. Molecular Cell 55, 238-252. 
Dungrawala, H., Rose, Kristie L., Bhat, Kamakoti P., Mohni, Kareem N., Glick, Gloria G., Couch, 
Frank B., and Cortez, D. (2015). The Replication Checkpoint Prevents Two Types of Fork Collapse 
without Regulating Replisome Stability. Molecular Cell 59, 998-1010. 
Duran, A., Amanchy, R., Linares, Juan F., Joshi, J., Abu-Baker, S., Porollo, A., Hansen, M., Moscat, J., 
and Diaz-Meco, Maria T. (2011). p62 Is a Key Regulator of Nutrient Sensing in the mTORC1 Pathway. 
Molecular Cell 44, 134-146. 
Duursma, A.M., Driscoll, R., Elias, J.E., and Cimprich, K.A. (2013). A role for the MRN complex in ATR 
activation through TOPBP1 recruitment. Molecular cell 50, 116-122. 
Dyment, D.A., Gibson, W.T., Huang, L., Bassyouni, H., Hegele, R.A., and Innes, A.M. (2014). Biallelic 
mutations at PPARG cause a congenital, generalized lipodystrophy similar to the Berardinelli–Seip 
syndrome. European Journal of Medical Genetics 57, 524-526. 
Edmonson, J.H. (1966). Fatty acid mobilization and glucose metabolism in patients with cancer. 
Cancer 19, 277-280. 
Ellgaard, L., and Ruddock, L.W. (2005). The human protein disulphide isomerase family: substrate 
interactions and functional properties. EMBO Reports 6, 28-32. 
Ellison, V., and Stillman, B. (2003). Biochemical Characterization of DNA Damage Checkpoint 
Complexes: Clamp Loader and Clamp Complexes with Specificity for 5′ Recessed DNA. PLOS Biology 
1, e33. 
Emily, H.-Y.C., Wei, M.C., Weiler, S., Flavell, R.A., Mak, T.W., Lindsten, T., and Korsmeyer, S.J. (2001). 
BCL-2, BCL-X L sequester BH3 domain-only molecules preventing BAX-and BAK-mediated 
mitochondrial apoptosis. Molecular cell 8, 705-711. 
Engelman, J.A., Berg, A.H., Lewis, R.Y., Lin, A., Lisanti, M.P., and Scherer, P.E. (1999). Constitutively 
Active Mitogen-activated Protein Kinase Kinase 6 (MKK6) or Salicylate Induces Spontaneous 3T3-L1 
Adipogenesis. Journal of Biological Chemistry 274, 35630-35638. 
216 
 
Engelman, J.A., Lisanti, M.P., and Scherer, P.E. (1998). Specific Inhibitors of p38 Mitogen-activated 
Protein Kinase Block 3T3-L1 Adipogenesis. Journal of Biological Chemistry 273, 32111-32120. 
Errol, C.F., Graham, C.W., Wolfram, S., Richard, D.W., Roger, A.S., and Tom, E. (2006). DNA Repair 
and Mutagenesis, Second Edition (American Society of Microbiology). 
Falck, J., Mailand, N., Syljuasen, R.G., Bartek, J., and Lukas, J. (2001). The ATM-Chk2-Cdc25A 
checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847. 
Fang, Evandro F., Scheibye-Knudsen, M., Brace, Lear E., Kassahun, H., SenGupta, T., Nilsen, H., 
Mitchell, James R., Croteau, Deborah L., and Bohr, Vilhelm A. (2014). Defective Mitophagy in XPA via 
PARP-1 Hyperactivation and NAD+/SIRT1 Reduction. Cell 157, 882-896. 
Fang, Y., Tsao, C.-C., Goodman, B.K., Furumai, R., Tirado, C.A., Abraham, R.T., and Wang, X.-F. (2004). 
ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient 
background. The EMBO Journal 23, 3164-3174. 
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N.J., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, 
K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a 
therapeutic strategy. Nature 434, 917-921. 
Farmer, S.R. (2005). Regulation of PPAR[gamma] activity during adipogenesis. Int J Obes Relat Metab 
Disord 29, S13-S16. 
Farmer, S.R. (2006). Transcriptional control of adipocyte formation. Cell Metabolism 4, 263-273. 
Fass, E., Shvets, E., Degani, I., Hirschberg, K., and Elazar, Z. (2006). Microtubules Support Production 
of Starvation-induced Autophagosomes but Not Their Targeting and Fusion with Lysosomes. Journal 
of Biological Chemistry 281, 36303-36316. 
Fearon, Kenneth C.H., Glass, David J., and Guttridge, Denis C. (2012). Cancer Cachexia: Mediators, 
Signaling, and Metabolic Pathways. Cell Metabolism 16, 153-166. 
Ferdek, Pawel E., Gerasimenko, Julia V., Peng, S., Tepikin, Alexei V., Petersen, Ole H., and 
Gerasimenko, Oleg V. (2012). A Novel Role for Bcl-2 in Regulation of Cellular Calcium Extrusion. 
Current Biology 22, 1241-1246. 
Fernandez-Capetillo, O., Lee, A., Nussenzweig, M., and Nussenzweig, A. (2004). H2AX: the histone 
guardian of the genome. DNA Repair 3, 959-967. 
217 
 
Foote, K. (2015). Drugging ATR: progress in the development of specific inhibitors for the treatment 
of cancer. Future Medicinal Chemistry 7, 873-891. 
Foote, K.M., Blades, K., Cronin, A., Fillery, S., Guichard, S.S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, 
P.J., McGuire, T.M., et al. (2013). Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-
(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR 
Protein Kinase with Monotherapy in Vivo Antitumor Activity. Journal of Medicinal Chemistry 56, 
2125-2138. 
Fraldi, A., Annunziata, F., Lombardi, A., Kaiser, H.J., Medina, D.L., Spampanato, C., Fedele, A.O., 
Polishchuk, R., Sorrentino, N.C., Simons, K., et al. (2010). Lysosomal fusion and SNARE function are 
impaired by cholesterol accumulation in lysosomal storage disorders. The EMBO Journal 29, 3607-
3620. 
Frampton, J.E. (2015). Olaparib: A Review of Its Use as Maintenance Therapy in Patients with 
Ovarian Cancer. BioDrugs 29, 143-150. 
Fu, M.-m., Nirschl, Jeffrey J., and Holzbaur, Erika L.F. (2014). LC3 Binding to the Scaffolding Protein 
JIP1 Regulates Processive Dynein-Driven Transport of Autophagosomes. Developmental Cell 29, 577-
590. 
Fujioka, Y., Noda, N.N., Nakatogawa, H., Ohsumi, Y., and Inagaki, F. (2010). Dimeric Coiled-coil 
Structure of Saccharomyces cerevisiae Atg16 and Its Functional Significance in Autophagy. Journal of 
Biological Chemistry 285, 1508-1515. 
Fujisawa, H., Nakajima, N.I., Sunada, S., Lee, Y., Hirakawa, H., Yajima, H., Fujimori, A., Uesaka, M., 
and Okayasu, R. (2015). VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells 
irradiated with high LET radiation. Radiation Oncology (London, England) 10, 175. 
Furnari, B., Rhind, N., and Russell, P. (1997). Cdc25 Mitotic Inducer Targeted by Chk1 DNA Damage 
Checkpoint Kinase. Science 277, 1495-1497. 
Gammoh, N., Florey, O., Overholtzer, M., and Jiang, X. (2013). Interaction between FIP200 and 
ATG16L1 distinguishes ULK1 complex–dependent and –independent autophagy. Nat Struct Mol Biol 
20, 144-149. 
Ge, X.Q., and Blow, J.J. (2010). Chk1 inhibits replication factory activation but allows dormant origin 
firing in existing factories. The Journal of Cell Biology 191, 1285-1297. 
218 
 
Gebauer, F., and Hentze, M.W. (2004). Molecular mechanisms of translational control. Nat Rev Mol 
Cell Biol 5, 827-835. 
Gelebart, P., Opas, M., and Michalak, M. (2005). Calreticulin, a Ca2+-binding chaperone of the 
endoplasmic reticulum. The International Journal of Biochemistry & Cell Biology 37, 260-266. 
Gerasimenko, J., Ferdek, P., Fischer, L., Gukovskaya, A.S., and Pandol, S.J. (2010). Inhibitors of Bcl-2 
protein family deplete ER Ca(2+) stores in pancreatic acinar cells. Pflugers Archiv 460, 891-900. 
Gesta, S., Tseng, Y.-H., and Kahn, C.R. (2007). Developmental Origin of Fat: Tracking Obesity to Its 
Source. Cell 131, 242-256. 
Giam, M., Huang, D., and Bouillet, P. (2008). BH3-only proteins and their roles in programmed cell 
death. Oncogene 27, S128. 
Gilad, O., Nabet, B.Y., Ragland, R.L., Schoppy, D.W., Smith, K.D., Durham, A.C., and Brown, E.J. 
(2010). Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, 
Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner. Cancer Research 70, 
9693-9702. 
Glick, D., Barth, S., and Macleod, K.F. (2010). Autophagy: cellular and molecular mechanisms. The 
Journal of pathology 221, 3-12. 
Glover, T.W., Berger, C., Coyle, J., and Echo, B. (1984). DNA polymerase α inhibition by aphidicolin 
induces gaps and breaks at common fragile sites in human chromosomes. Human Genetics 67, 136-
142. 
González Besteiro, M.A., and Gottifredi, V. (2015). The fork and the kinase: A DNA replication tale 
from a CHK1 perspective. Mutation Research/Reviews in Mutation Research 763, 168-180. 
Graham, S.J.L., Black, M.J., Soboloff, J., Gill, D.L., Dziadek, M.A., and Johnstone, L.S. (2009). Stim1, an 
endoplasmic reticulum Ca(2+) sensor, negatively regulates 3T3-L1 pre-adipocyte differentiation. 
Differentiation; research in biological diversity 77, 239-247. 
Greenberg, A.S., and Obin, M.S. (2006). Obesity and the role of adipose tissue in inflammation and 
metabolism. The American Journal of Clinical Nutrition 83, 461S-465S. 
Grootjans, J., Kaser, A., Kaufman, R.J., and Blumberg, R.S. (2016). The unfolded protein response in 
immunity and inflammation. Nat Rev Immunol 16, 469-484. 
219 
 
Guernsey, D.L., Jiang, H., Hussin, J., Arnold, M., Bouyakdan, K., Perry, S., Babineau-Sturk, T., Beis, J., 
Dumas, N., Evans, S.C., et al. (2010). Mutations in Centrosomal Protein CEP152 in Primary 
Microcephaly Families Linked to MCPH4. American Journal of Human Genetics 87, 40-51. 
Guintini, L., Charton, R., Peyresaubes, F., Thoma, F., and Conconi, A. (2015). Nucleosome positioning, 
nucleotide excision repair and photoreactivation in Saccharomyces cerevisiae. DNA Repair 36, 98-
104. 
Guo, C., Kumagai, A., Schlacher, K., Shevchenko, A., Shevchenko, A., and Dunphy, William G. (2015). 
Interaction of Chk1 with Treslin Negatively Regulates the Initiation of Chromosomal DNA Replication. 
Molecular Cell 57, 492-505. 
Halaas, J., Gajiwala, K., Maffei, M., Cohen, S., Chait, B., Rabinowitz, D., Lallone, R., Burley, S., and 
Friedman, J. (1995). Weight-reducing effects of the plasma protein encoded by the obese gene. 
Science 269, 543-546. 
Halaby, M.-J., Hibma, J.C., He, J., and Yang, D.-Q. (2008). ATM protein kinase mediates full activation 
of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cellular Signalling 
20, 1555-1563. 
Halazonetis, T.D., Gorgoulis, V.G., and Bartek, J. (2008). An Oncogene-Induced DNA Damage Model 
for Cancer Development. Science 319, 1352-1355. 
Hall, A.B., Newsome, D., Wang, Y., Boucher, D.M., Eustace, B., Gu, Y., Hare, B., Johnson, M.A., Milton, 
S., Murphy, C.E., et al. (2014). Potentiation of tumor responses to DNA damaging therapy by the 
selective ATR inhibitor VX-970. Oncotarget 5, 5674-5685. 
Han, J., Murthy, R., Wood, B., Song, B., Wang, S., Sun, B., Malhi, H., and Kaufman, R.J. (2013). ER 
stress signalling through eIF2α and CHOP, but not IRE1α, attenuates adipogenesis in mice. 
Diabetologia 56, 911-924. 
Han, L., Zhou, R., Niu, J., McNutt, M.A., Wang, P., and Tong, T. (2010). SIRT1 is regulated by a PPARγ–
SIRT1 negative feedback loop associated with senescence. Nucleic Acids Research 38, 7458-7471. 
Hanada, T., Noda, N.N., Satomi, Y., Ichimura, Y., Fujioka, Y., Takao, T., Inagaki, F., and Ohsumi, Y. 
(2007). The Atg12-Atg5 Conjugate Has a Novel E3-like Activity for Protein Lipidation in Autophagy. 
Journal of Biological Chemistry 282, 37298-37302. 
220 
 
Hara, T., Takamura, A., Kishi, C., Iemura, S.-i., Natsume, T., Guan, J.-L., and Mizushima, N. (2008). 
FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. The 
Journal of Cell Biology 181, 497-510. 
Harazono, Y., Nakajima, K., and Raz, A. (2014). Why anti-Bcl-2 clinical trials fail: a solution. Cancer 
metastasis reviews 33, 285-294. 
Harms, M., and Seale, P. (2013). Brown and beige fat: development, function and therapeutic 
potential. Nat Med 19, 1252-1263. 
Hata, K., Nishimura, R., Ikeda, F., Yamashita, K., Matsubara, T., Nokubi, T., and Yoneda, T. (2003). 
Differential Roles of Smad1 and p38 Kinase in Regulation of Peroxisome Proliferator-activating 
Receptor γ during Bone Morphogenetic Protein 2-induced Adipogenesis. Molecular Biology of the 
Cell 14, 545-555. 
Hebert, D.N., Garman, S.C., and Molinari, M. (2005). The glycan code of the endoplasmic reticulum: 
asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends in Cell 
Biology 15, 364-370. 
Heffernan, T.P., Ünsal-Kaçmaz, K., Heinloth, A.N., Simpson, D.A., Paules, R.S., Sancar, A., Cordeiro-
Stone, M., and Kaufmann, W.K. (2007). Cdc7-Dbf4 and the Human S Checkpoint Response to UVC. 
Journal of Biological Chemistry 282, 9458-9468. 
Hegele, R.A. (2000). Familial Partial Lipodystrophy: A Monogenic Form of the Insulin Resistance 
Syndrome. Molecular Genetics and Metabolism 71, 539-544. 
Hetzer, M.W. (2010). The Nuclear Envelope. Cold Spring Harbor Perspectives in Biology 2, a000539. 
Hilton, B.A., Li, Z., Musich, P.R., Wang, H., Cartwright, B.M., Serrano, M., Zhou, X.Z., Lu, K.P., and Zou, 
Y. (2015). ATR Plays a Direct Antiapoptotic Role at Mitochondria Which Is Regulated by Prolyl 
Isomerase Pin1. Molecular cell 60, 35-46. 
Hirota, J., Michikawa, T., Natsume, T., Furuichi, T., and Mikoshiba, K. (1999). Calmodulin inhibits 
inositol 1,4,5-trisphosphate-induced calcium release through the purified and reconstituted inositol 
1,4,5-trisphosphate receptor type 1. FEBS Letters 456, 322-326. 
Hitomi, M., Yang, K., Stacey, A.W., and Stacey, D.W. (2008). Phosphorylation of Cyclin D1 Regulated 
by ATM or ATR Controls Cell Cycle Progression. Molecular and Cellular Biology 28, 5478-5493. 
221 
 
Ho, A., and Dowdy, S.F. (2002). Regulation of G1 cell-cycle progression by oncogenes and tumor 
suppressor genes. Current Opinion in Genetics & Development 12, 47-52. 
Ho, I.C., Kim, J.H.J., Rooney, J.W., Spiegelman, B.M., and Glimcher, L.H. (1998). A potential role for 
the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. 
Proceedings of the National Academy of Sciences of the United States of America 95, 15537-15541. 
Hoeijmakers , J.H.J. (2009). DNA Damage, Aging, and Cancer. New England Journal of Medicine 361, 
1475-1485. 
Holohan, C., Van Schaeybroeck, S., Longley, D.B., and Johnston, P.G. (2013). Cancer drug resistance: 
an evolving paradigm. Nat Rev Cancer 13, 714-726. 
Hořejší, Z., Takai, H., Adelman, C.A., Collis, S.J., Flynn, H., Maslen, S., Skehel, J.M., de Lange, T., and 
Boulton, S.J. (2010). CK2 Phospho-Dependent Binding of R2TP Complex to TEL2 Is Essential for mTOR 
and SMG1 Stability. Molecular Cell 39, 839-850. 
Howell, B.J., McEwen, B.F., Canman, J.C., Hoffman, D.B., Farrar, E.M., Rieder, C.L., and Salmon, E.D. 
(2001). Cytoplasmic dynein/dynactin drives kinetochore protein transport to the spindle poles and 
has a role in mitotic spindle checkpoint inactivation. The Journal of Cell Biology 155, 1159-1172. 
Hoy, A.J., Balaban, S., and Saunders, D.N. (2013). Adipocyte-Tumor Cell Metabolic Crosstalk in Breast 
Cancer. Trends in Molecular Medicine 23, 381-392. 
Høyer-Hansen, M., Bastholm, L., Szyniarowski, P., Campanella, M., Szabadkai, G., Farkas, T., Bianchi, 
K., Fehrenbacher, N., Elling, F., Rizzuto, R., et al. (2007). Control of Macroautophagy by Calcium, 
Calmodulin-Dependent Kinase Kinase-β, and Bcl-2. Molecular Cell 25, 193-205. 
Hsu, P.P., and Sabatini, D.M. (2008). Cancer Cell Metabolism: Warburg and Beyond. Cell 134, 703-
707. 
Hu, P., Han, Z., Couvillon, A.D., Kaufman, R.J., and Exton, J.H. (2006). Autocrine Tumor Necrosis 
Factor Alpha Links Endoplasmic Reticulum Stress to the Membrane Death Receptor Pathway through 
IRE1α-Mediated NF-κB Activation and Down-Regulation of TRAF2 Expression. Molecular and Cellular 
Biology 26, 3071-3084. 
Huang, M., Kim, J.M., Shiotani, B., Yang, K., Zou, L., and D’Andrea, A.D. (2010). The FANCM/FAAP24 
Complex is Required for the DNA Inter-strand Crosslink-Induced Checkpoint Response. Molecular cell 
39, 259-268. 
222 
 
Hurley, P.J., Wilsker, D., and Bunz, F. (2006). Human cancer cells require ATR for cell cycle 
progression following exposure to ionizing radiation. Oncogene 26, 2535-2542. 
Hurov, K.E., Cotta-Ramusino, C., and Elledge, S.J. (2010). A genetic screen identifies the Triple T 
complex required for DNA damage signaling and ATM and ATR stability. Genes & Development 24, 
1939-1950. 
Hyttinen, J.M.T., Niittykoski, M., Salminen, A., and Kaarniranta, K. (2013). Maturation of 
autophagosomes and endosomes: A key role for Rab7. Biochimica et Biophysica Acta (BBA) - 
Molecular Cell Research 1833, 503-510. 
Iglehart , J.D., and Silver , D.P. (2009). Synthetic Lethality — A New Direction in Cancer-Drug 
Development. New England Journal of Medicine 361, 189-191. 
Jahn, R., and Scheller, R.H. (2006). SNAREs [mdash] engines for membrane fusion. Nat Rev Mol Cell 
Biol 7, 631-643. 
Jardim, M.J., Wang, Q., Furumai, R., Wakeman, T., Goodman, B.K., and Wang, X.-F. (2009). Reduced 
ATR or Chk1 Expression Leads to Chromosome Instability and Chemosensitization of Mismatch 
Repair–deficient Colorectal Cancer Cells. Molecular Biology of the Cell 20, 3801-3809. 
Jarrett, S.G., Wolf Horrell, E.M., Christian, P.A., Vanover, J.C., Boulanger, M.C., Zou, Y., and D’Orazio, 
J.A. (2014). PKA-mediated Phosphorylation of ATR Promotes Recruitment of XPA to UV-induced DNA 
Damage. Molecular cell 54, 999-1011. 
Jarrett, S.G., Wolf Horrell, E.M., and D'Orazio, J.A. (2016). AKAP12 mediates PKA-induced 
phosphorylation of ATR to enhance nucleotide excision repair. Nucleic Acids Research 44, 10711-
10726. 
Jeggo, P.A., Pearl, L.H., and Carr, A.M. (2016). DNA repair, genome stability and cancer: a historical 
perspective. Nat Rev Cancer 16, 35-42. 
Jensen, B., Farach-Carson, M.C., Kenaley, E., and Akanbi, K.A. (2004). High extracellular calcium 
attenuates adipogenesis in 3T3-L1 preadipocytes. Experimental Cell Research 301, 280-292. 
Jiang, P., and Mizushima, N. (2014). Autophagy and human diseases. Cell Res 24, 69-79. 
Jiang, T., Harder, B., Rojo de la Vega, M., Wong, P.K., Chapman, E., and Zhang, D.D. (2015). p62 links 
autophagy and Nrf2 signaling. Free Radical Biology and Medicine 88, Part B, 199-204. 
223 
 
Jiang, X., Sun, Y., Chen, S., Roy, K., and Price, B.D. (2006). The FATC Domains of PIKK Proteins Are 
Functionally Equivalent and Participate in the Tip60-dependent Activation of DNA-PKcs and ATM. 
Journal of Biological Chemistry 281, 15741-15746. 
Jossé, R., Martin, S.E., Guha, R., Ormanoglu, P., Pfister, T.D., Reaper, P.M., Barnes, C.S., Jones, J., 
Charlton, P., Pollard, J.R., et al. (2014). ATR inhibitors VE-821 and VX-970 sensitize cancer cells to 
topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses. 
Cancer research 74, 6968-6979. 
Jung, J.-J., Inamdar, Shivangi M., Tiwari, A., and Choudhury, A. (2012). Regulation of intracellular 
membrane trafficking and cell dynamics by syntaxin-6. Bioscience Reports 32, 383-391. 
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., 
and Yoshimori, T. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in 
autophagosome membranes after processing, Vol 19. 
Kakarougkas, A., and Jeggo, P.A. (2014). DNA DSB repair pathway choice: an orchestrated handover 
mechanism. The British Journal of Radiology 87, 20130685. 
Kamphorst, J.J., Cross, J.R., Fan, J., de Stanchina, E., Mathew, R., White, E.P., Thompson, C.B., and 
Rabinowitz, J.D. (2013). Hypoxic and Ras-transformed cells support growth by scavenging 
unsaturated fatty acids from lysophospholipids. Proceedings of the National Academy of Sciences 
110, 8882-8887. 
Kampinga, H.H., and Craig, E.A. (2010). The Hsp70 chaperone machinery: J-proteins as drivers of 
functional specificity. Nature reviews. Molecular cell biology 11, 579-592. 
Kang, R., Zeh, H.J., Lotze, M.T., and Tang, D. (2011). The Beclin 1 network regulates autophagy and 
apoptosis. Cell Death Differ 18, 571-580. 
Kania, E., Pająk, B., and Orzechowski, A. (2015). Calcium Homeostasis and ER Stress in Control of 
Autophagy in Cancer Cells. BioMed Research International 2015, 352794. 
Karanasios, E., Stapleton, E., Manifava, M., Kaizuka, T., Mizushima, N., Walker, S.A., and Ktistakis, 
N.T. (2013). Dynamic association of the ULK1 complex with omegasomes during autophagy 
induction. Journal of Cell Science 126, 5224-5238. 
224 
 
Katsura, M., Tsuruga, T., Date, O., Yoshihara, T., Ishida, M., Tomoda, Y., Okajima, M., Takaku, M., 
Kurumizaka, H., Kinomura, A., et al. (2009). The ATR-Chk1 pathway plays a role in the generation of 
centrosome aberrations induced by Rad51C dysfunction. Nucleic Acids Research 37, 3959-3968. 
Kaufman, R.J., Scheuner, D., Schroder, M., Shen, X., Lee, K., Liu, C.Y., and Arnold, S.M. (2002). The 
unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 3, 411-421. 
Kaur, J., and Debnath, J. (2015). Autophagy at the crossroads of catabolism and anabolism. Nat Rev 
Mol Cell Biol 16, 461-472. 
Kaushik, S., and Cuervo, A.M. (2015). Degradation of lipid droplet-associated proteins by chaperone-
mediated autophagy facilitates lipolysis. Nature cell biology 17, 759-770. 
Kebache, S., Cardin, E., Nguyên, D.T., Chevet, E., and Larose, L. (2004). Nck-1 Antagonizes the 
Endoplasmic Reticulum Stress-induced Inhibition of Translation. Journal of Biological Chemistry 279, 
9662-9671. 
Kemp, M., Spandau, D., and Travers, J. (2017a). Impact of Age and Insulin-Like Growth Factor-1 on 
DNA Damage Responses in UV-Irradiated Human Skin. Molecules 22, 356. 
Kemp, M.G., Akan, Z., Yilmaz, S., Grillo, M., Smith-Roe, S.L., Kang, T.-H., Cordeiro-Stone, M., 
Kaufmann, W.K., Abraham, R.T., Sancar, A., et al. (2010). Tipin-RPA interaction mediates Chk1 
phosphorylation by ATR in response to genotoxic stress. Journal of Biological Chemistry. 
Kemp, M.G., Spandau, D.F., Simman, R., and Travers, J.B. (2017b). Insulin-like Growth Factor 1 
Receptor Signaling Is Required for Optimal ATR-CHK1 Kinase Signaling in Ultraviolet B (UVB)-
irradiated Human Keratinocytes. Journal of Biological Chemistry 292, 1231-1239. 
Kerzendorfer, C., and O’Driscoll, M. (2009). Human DNA damage response and repair deficiency 
syndromes: Linking genomic instability and cell cycle checkpoint proficiency. DNA Repair 8, 1139-
1152. 
Kim, E.M., and Burke, D.J. (2008). DNA Damage Activates the SAC in an ATM/ATR-Dependent 
Manner, Independently of the Kinetochore. PLoS Genetics 4, e1000015. 
Kim, J.B., Wright, H.M., Wright, M., and Spiegelman, B.M. (1998). ADD1/SREBP1 activates PPARγ 
through the production of endogenous ligand. Proceedings of the National Academy of Sciences of 
the United States of America 95, 4333-4337. 
225 
 
Kim, J.E., and Chen, J. (2004). Regulation of Peroxisome Proliferator–Activated Receptor-γ Activity by 
Mammalian Target of Rapamycin and Amino Acids in Adipogenesis. Diabetes 53, 2748-2756. 
Kim, S.W., Choi, J.H., Mukherjee, R., Hwang, K.-C., and Yun, J.W. (2016). Proteomic identification of 
fat-browning markers in cultured white adipocytes treated with curcumin. Molecular and Cellular 
Biochemistry 415, 51-66. 
Kimura, S., Noda, T., and Yoshimori, T. (2008). Dynein-dependent Movement of Autophagosomes 
Mediates Efficient Encounters with Lysosomes. Cell Structure and Function 33, 109-122. 
Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., and Spiegelman, B.M. (2014). 
Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 
513, 100-104. 
Kirisako, T., Ichimura, Y., Okada, H., Kabeya, Y., Mizushima, N., Yoshimori, T., Ohsumi, M., Takao, T., 
Noda, T., and Ohsumi, Y. (2000). The Reversible Modification Regulates the Membrane-Binding State 
of Apg8/Aut7 Essential for Autophagy and the Cytoplasm to Vacuole Targeting Pathway. The Journal 
of Cell Biology 151, 263-276. 
Kirkin, V., McEwan, D.G., Novak, I., and Dikic, I. (2009). A Role for Ubiquitin in Selective Autophagy. 
Molecular Cell 34, 259-269. 
Klee, M., and Pimentel-Muiños, F.X. (2005). Bcl-X(L) specifically activates Bak to induce swelling and 
restructuring of the endoplasmic reticulum. The Journal of Cell Biology 168, 723-734. 
Klein, J.B., Barati, M.T., Wu, R., Gozal, D., Sachleben, L.R., Kausar, H., Trent, J.O., Gozal, E., and Rane, 
M.J. (2005). Akt-mediated Valosin-containing Protein 97 Phosphorylation Regulates Its Association 
with Ubiquitinated Proteins. Journal of Biological Chemistry 280, 31870-31881. 
Kobayashi, M., Hayashi, N., Takata, M., and Yamamoto, K.-i. (2013). NBS1 directly activates ATR 
independently of MRE11 and TOPBP1. Genes to Cells 18, 238-246. 
Kokame, K., Kato, H., and Miyata, T. (2001). Identification of ERSE-II, a New cis-Acting Element 
Responsible for the ATF6-dependent Mammalian Unfolded Protein Response. Journal of Biological 
Chemistry 276, 9199-9205. 
Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., 
Viallet, J., and Samudio, I. (2008). Mechanisms of antileukemic activity of the novel Bcl-2 homology 
domain-3 mimetic GX15-070 (obatoclax). Cancer research 68, 3413-3420. 
226 
 
Kopecky, J., Clarke, G., Enerb, xE, ck, S., Spiegelman, B., and Kozak, L.P. (1995). Expression of the 
mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. The 
Journal of Clinical Investigation 96, 2914-2923. 
Kornberg, R.D., and Lorch, Y. (1999). Twenty-Five Years of the Nucleosome, Fundamental Particle of 
the Eukaryote Chromosome. Cell 98, 285-294. 
Kotsantis, P., Silva, L.M., Irmscher, S., Jones, R.M., Folkes, L., Gromak, N., and Petermann, E. (2016). 
Increased global transcription activity as a mechanism of replication stress in cancer. Nature 
Communications 7, 13087. 
Kouroku, Y., Fujita, E., Tanida, I., Ueno, T., Isoai, A., Kumagai, H., Ogawa, S., Kaufman, R.J., Kominami, 
E., and Momoi, T. (2006). ER stress (PERK//eIF2[alpha] phosphorylation) mediates the 
polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ 
14, 230-239. 
Kovsan, J., Ben-Romano, R., Souza, S.C., Greenberg, A.S., and Rudich, A. (2007). Regulation of 
Adipocyte Lipolysis by Degradation of the Perilipin Protein: NELFINAVIR ENHANCES LYSOSOME-
MEDIATED PERILIPIN PROTEOLYSIS. Journal of Biological Chemistry 282, 21704-21711. 
Kraft, C., Peter, M., and Hofmann, K. (2010). Selective autophagy: ubiquitin-mediated recognition 
and beyond. Nat Cell Biol 12, 836-841. 
Kraus, N.A., Ehebauer, F., Zapp, B., Rudolphi, B., Kraus, B.J., and Kraus, D. (2016). Quantitative 
assessment of adipocyte differentiation in cell culture. Adipocyte 5, 351-358. 
Krejci, L., Altmannova, V., Spirek, M., and Zhao, X. (2012). Homologous recombination and its 
regulation. Nucleic Acids Research 40, 5795-5818. 
Kuljis, R.O., Xu, Y., Aguila, M.C., and Baltimore, D. (1997). Degeneration of neurons, synapses, and 
neuropil and glial activation in a murine Atm knockout model of ataxia–telangiectasia. Proceedings 
of the National Academy of Sciences 94, 12688-12693. 
Kumagai, A., and Dunphy, W.G. (2000). Claspin, a Novel Protein Required for the Activation of Chk1 
during a DNA Replication Checkpoint Response in Xenopus Egg Extracts. Molecular Cell 6, 839-849. 
Kumagai, A., Lee, J., Yoo, H.Y., and Dunphy, W.G. (2006). TopBP1 Activates the ATR-ATRIP Complex. 
Cell 124, 943-955. 
227 
 
Kumar, A., Mazzanti, M., Mistrik, M., Kosar, M., Beznoussenko, Galina V., Mironov, Alexandre A., 
Garrè, M., Parazzoli, D., Shivashankar, G.V., Scita, G., et al. (2014). ATR Mediates a Checkpoint at the 
Nuclear Envelope in Response to Mechanical Stress. Cell 158, 633-646. 
Kunkel, G.T., Maceyka, M., Milstien, S., and Spiegel, S. (2013). Targeting the sphingosine-1-
phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 12, 688-702. 
Kuwana, T., Bouchier-Hayes, L., Chipuk, J.E., Bonzon, C., Sullivan, B.A., Green, D.R., and Newmeyer, 
D.D. (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial 
membrane permeabilization both directly and indirectly. Molecular cell 17, 525-535. 
Lamb, C.A., Yoshimori, T., and Tooze, S.A. (2013). The autophagosome: origins unknown, biogenesis 
complex. Nat Rev Mol Cell Biol 14, 759-774. 
Lamb, H.K., Mee, C., Xu, W., Liu, L., Blond, S., Cooper, A., Charles, I.G., and Hawkins, A.R. (2006). The 
Affinity of a Major Ca2+ Binding Site on GRP78 Is Differentially Enhanced by ADP and ATP. Journal of 
Biological Chemistry 281, 8796-8805. 
Laplante, M., Horvat, S., Festuccia, W.T., Birsoy, K., Prevorsek, Z., Efeyan, A., and Sabatini, D.M. 
(2012). DEPTOR cell-autonomously promotes adipogenesis and its expression is associated with 
obesity. Cell metabolism 16, 202-212. 
Laplante, M., and Sabatini, D.M. (2012). mTOR signaling in growth control and disease. Cell 149, 274-
293. 
Laplante, M., and Sabatini, D.M. (2013). Regulation of mTORC1 and its impact on gene expression at 
a glance. Journal of Cell Science 126, 1713-1719. 
Lass, A., Zimmermann, R., Oberer, M., and Zechner, R. (2011). Lipolysis – A highly regulated multi-
enzyme complex mediates the catabolism of cellular fat stores. Progress in Lipid Research 50, 14-27. 
Lavin, M.F. (2008). Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and 
cancer. Nat Rev Mol Cell Biol 9, 759-769. 
Lavin, M.F., and Shiloh, Y. (1997). The genetic defect in ataxia-telangiectasia. Annual review of 
immunology 15, 177-202. 
228 
 
Lawrence, K.S., Chau, T., and Engebrecht, J. (2015). DNA Damage Response and Spindle Assembly 
Checkpoint Function throughout the Cell Cycle to Ensure Genomic Integrity. PLOS Genetics 11, 
e1005150. 
Lee, C.-K., Shibata, Y., Rao, B., Strahl, B.D., and Lieb, J.D. (2004). Evidence for nucleosome depletion 
at active regulatory regions genome-wide. Nat Genet 36, 900-905. 
Lee, E.K., Jeong, J.U., Chang, J.W., Yang, W.S., Kim, S.B., Park, S.K., Park, J.S., and Lee, S.K. (2012). 
Activation of AMP-Activated Protein Kinase Inhibits Albumin-Induced Endoplasmic Reticulum Stress 
and Apoptosis through Inhibition of Reactive Oxygen Species. Nephron Experimental Nephrology 
121, e38-e48. 
Lee, J.-E., and Ge, K. (2014). Transcriptional and epigenetic regulation of PPARγ expression during 
adipogenesis. Cell & Bioscience 4, 29. 
Lee, K., Tirasophon, W., Shen, X., Michalak, M., Prywes, R., Okada, T., Yoshida, H., Mori, K., and 
Kaufman, R.J. (2002). IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 
cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes & Development 
16, 452-466. 
Lee, M.-J., Wu, Y., and Fried, S.K. (2010). Adipose tissue remodeling in pathophysiology of obesity. 
Current opinion in clinical nutrition and metabolic care 13, 371-376. 
Lee, M.Y., Kong, H.J., and Cheong, J. (2001). Regulation of Activating Transcription Factor-2 in Early 
Stage of the Adipocyte Differentiation Program. Biochemical and Biophysical Research 
Communications 281, 1241-1247. 
Lei, K., and Davis, R.J. (2003). JNK phosphorylation of Bim-related members of the Bcl2 family 
induces Bax-dependent apoptosis. Proceedings of the National Academy of Sciences of the United 
States of America 100, 2432-2437. 
Lempiäinen, H., and Halazonetis, T.D. (2009). Emerging common themes in regulation of PIKKs and 
PI3Ks. The EMBO Journal 28, 3067-3073. 
Lewis, K.A., Bakkum-Gamez, J., Loewen, R., French, A.J., Thibodeau, S.N., and Cliby, W.A. (2007). 
Mutations in the ataxia telangiectasia and rad3-related–checkpoint kinase 1 DNA damage response 
axis in colon cancers. Genes, Chromosomes and Cancer 46, 1061-1068. 
229 
 
Lewis, K.A., Mullany, S., Thomas, B., Chien, J., Loewen, R., Shridhar, V., and Cliby, W.A. (2005). 
Heterozygous ATR Mutations in Mismatch Repair–Deficient Cancer Cells Have Functional 
Significance. Cancer Research 65, 7091-7095. 
Li, G., Mongillo, M., Chin, K.-T., Harding, H., Ron, D., Marks, A.R., and Tabas, I. (2009a). Role of ERO1-
α–mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum 
stress–induced apoptosis. The Journal of Cell Biology 186, 783-792. 
Li, H., Rao, A., and Hogan, P.G. Interaction of calcineurin with substrates and targeting proteins. 
Trends in Cell Biology 21, 91-103. 
Li, J., Han, Y.R., Plummer, M.R., and Herrup, K. (2009b). Cytoplasmic ATM in Neurons Modulates 
Synaptic Function. Current Biology 19, 2091-2096. 
Lim, D.-S., Kirsch, D.G., Canman, C.E., Ahn, J.-H., Ziv, Y., Newman, L.S., Darnell, R.B., Shiloh, Y., and 
Kastan, M.B. (1998). ATM binds to β-adaptin in cytoplasmic vesicles. Proceedings of the National 
Academy of Sciences of the United States of America 95, 10146-10151. 
Linhart, H.G., Ishimura-Oka, K., DeMayo, F., Kibe, T., Repka, D., Poindexter, B., Bick, R.J., and 
Darlington, G.J. (2001). C/EBPα is required for differentiation of white, but not brown, adipose 
tissue. Proceedings of the National Academy of Sciences 98, 12532-12537. 
Liu, H., Cheng, E.H.-Y., and Hsieh, J.J.-D. (2007). Bimodal degradation of MLL by SCFSkp2 and 
APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. 
Genes & Development 21, 2385-2398. 
Liu, K., Paik, J.C., Wang, B., Lin, F.-T., and Lin, W.-C. (2006a). Regulation of TopBP1 oligomerization by 
Akt/PKB for cell survival. The EMBO Journal 25, 4795-4807. 
Liu, Y. (2006). Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate 
Cancer Prostatic Dis 9. 
Liu, Y., Bertram, C.C., Shi, Q., and Zinkel, S.S. (2011). Proapoptotic Bid mediates the Atr-directed DNA 
damage response to replicative stress. Cell Death and Differentiation 18, 841-852. 
Liu, Y., Rusinol, A., Sinensky, M., Wang, Y., and Zou, Y. (2006b). DNA damage responses in progeroid 
syndromes arise from defective maturation of prelamin A. Journal of Cell Science 119, 4644-4649. 
230 
 
Livingstone, M., Ruan, H., Weiner, J., Clauser, K.R., Strack, P., Jin, S., Williams, A., Greulich, H., 
Gardner, J., Venere, M., et al. (2005). Valosin-Containing Protein Phosphorylation at 
Ser<sup>784</sup> in Response to DNA Damage. Cancer Research 65, 7533-7540. 
Llambi, F., Wang, Y.-M., Victor, B., Yang, M., Schneider, D.M., Gingras, S., Parsons, M.J., Zheng, J.H., 
Brown, S.A., Pelletier, S., et al. (2016). BOK Is a Non-Canonical BCL-2 Family Effector of Apoptosis 
Regulated by ER-Associated Degradation. Cell 165, 421-433. 
Lo, Kinyui A., and Sun, L. (2013). Turning WAT into BAT: a review on regulators controlling the 
browning of white adipocytes. Bioscience Reports 33, e00065. 
Lovejoy, C.A., Xu, X., Bansbach, C.E., Glick, G.G., Zhao, R., Ye, F., Sirbu, B.M., Titus, L.C., Shyr, Y., and 
Cortez, D. (2009). Functional genomic screens identify CINP as a genome maintenance protein. 
Proceedings of the National Academy of Sciences of the United States of America 106, 19304-19309. 
Lu, Z., Luo, R.Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., Kondo, S., Kondo, Y., Yu, Y., Mills, G.B., et al. 
(2008). The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human 
ovarian cancer cells. The Journal of Clinical Investigation 118, 3917-3929. 
Lumsden, J.M., McCarty, T., Petiniot, L.K., Shen, R., Barlow, C., Wynn, T.A., Morse, H.C., Gearhart, 
P.J., Wynshaw-Boris, A., Max, E.E., et al. (2004). Immunoglobulin Class Switch Recombination Is 
Impaired in <em>Atm</em>-deficient Mice. The Journal of Experimental Medicine 200, 1111-1121. 
Luu, Y.K., Pessin, J.E., Judex, S., Rubin, J., and Rubin, C.T. (2009). Mechanical signals as a non-invasive 
means to influence mesenchymal stem cell fate, promoting bone and suppressing the fat phenotype. 
IBMS BoneKEy 6, 132-149. 
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., 
and Scrable, H. (2004). Modulation of mammalian life span by the short isoform of p53. Genes & 
Development 18, 306-319. 
Majewski, F., Goecke, T., and Opitz, J.M. (1982). Studies of microcephalic primordial dwarfism I: 
Approach to a delineation of the seckel syndrome. American Journal of Medical Genetics 12, 7-21. 
Manju, K., Muralikrishna, B., and Parnaik, V.K. (2006). Expression of disease-causing lamin A mutants 
impairs the formation of DNA repair foci. Journal of Cell Science 119, 2704-2714. 
Maréchal, A., and Zou, L. (2013). DNA Damage Sensing by the ATM and ATR Kinases. Cold Spring 
Harbor Perspectives in Biology 5, a012716. 
231 
 
Matsunaga, K., Morita, E., Saitoh, T., Akira, S., Ktistakis, N.T., Izumi, T., Noda, T., and Yoshimori, T. 
(2010). Autophagy requires endoplasmic reticulum targeting of the PI3-kinase complex via Atg14L. 
The Journal of Cell Biology 190, 511-521. 
Matsuoka, S., Ballif, B.A., Smogorzewska, A., McDonald, E.R., Hurov, K.E., Luo, J., Bakalarski, C.E., 
Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007). ATM and ATR Substrate Analysis Reveals Extensive 
Protein Networks Responsive to DNA Damage. Science 316, 1160-1166. 
Mattson, M.P., and Chan, S.L. (2003). Calcium orchestrates apoptosis. Nat Cell Biol 5, 1041-1043. 
Medina-Gomez, G., Gray, S.L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., Curtis, R.K., 
Jimenez-Linan, M., Blount, M., Yeo, G.S.H., et al. (2007). PPAR gamma 2 Prevents Lipotoxicity by 
Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism. PLOS Genetics 3, e64. 
Mekahli, D., Bultynck, G., Parys, J.B., De Smedt, H., and Missiaen, L. (2011). Endoplasmic-Reticulum 
Calcium Depletion and Disease. Cold Spring Harbor Perspectives in Biology 3, a004317. 
Mimnaugh, E.G., Xu, W., Vos, M., Yuan, X., and Neckers, L. (2006). Endoplasmic Reticulum 
Vacuolization and Valosin-Containing Protein Relocalization Result from Simultaneous Hsp90 
Inhibition by Geldanamycin and Proteasome Inhibition by Velcade. Molecular Cancer Research 4, 
667-681. 
Mizushima, N., and Komatsu, M. (2011). Autophagy: Renovation of Cells and Tissues. Cell 147, 728-
741. 
Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M.D., Klionsky, D.J., Ohsumi, M., 
and Ohsumi, Y. (1998). A protein conjugation system essential for autophagy. Nature 395, 395-398. 
Mizushima, N., Yamamoto, A., Hatano, M., Kobayashi, Y., Kabeya, Y., Suzuki, K., Tokuhisa, T., Ohsumi, 
Y., and Yoshimori, T. (2001). Dissection of Autophagosome Formation Using Apg5-Deficient Mouse 
Embryonic Stem Cells. The Journal of Cell Biology 152, 657-668. 
Mizushima, N., and Yoshimori, T. (2007). How to Interpret LC3 Immunoblotting. Autophagy 3, 542-
545. 
Mleczak, A., Millar, S., Tooze, S.A., Olson, M.F., and Chan, E.Y.W. (2013). Regulation of 
autophagosome formation by Rho kinase. Cellular Signalling 25, 1-11. 
232 
 
Mokrani-Benhelli, H., Gaillard, L., Biasutto, P., Le Guen, T., Touzot, F., Vasquez, N., Komatsu, J., 
Conseiller, E., Pïcard, C., Gluckman, E., et al. (2013). Primary Microcephaly, Impaired DNA 
Replication, and Genomic Instability Caused by Compound Heterozygous ATR Mutations. Human 
Mutation 34, 374-384. 
Monaco, G., Decrock, E., Akl, H., Ponsaerts, R., Vervliet, T., Luyten, T., De Maeyer, M., Missiaen, L., 
Distelhorst, C.W., De Smedt, H., et al. (2012). Selective regulation of IP(3)-receptor-mediated Ca(2+) 
signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. Cell Death and Differentiation 19, 
295-309. 
Mordes, D.A., and Cortez, D. (2008). Activation of ATR and related PIKKs. Cell cycle (Georgetown, 
Tex.) 7, 2809-2812. 
Mordes, D.A., Glick, G.G., Zhao, R., and Cortez, D. (2008). TopBP1 activates ATR through ATRIP and a 
PIKK regulatory domain. Genes & Development 22, 1478-1489. 
Mori, C., Yamaguchi, Y., Teranishi, M., Takanami, T., Nagase, T., Kanno, S., Yasui, A., and Higashitani, 
A. (2013). Over‐expression of ATR causes autophagic cell death. Genes to Cells 18, 278-287. 
Moss, B. (2013). Poxvirus DNA Replication. Cold Spring Harbor Perspectives in Biology 5. 
Moss, J., Tinline-Purvis, H., Walker, C.A., Folkes, L.K., Stratford, M.R., Hayles, J., Hoe, K.-L., Kim, D.-U., 
Park, H.-O., Kearsey, S.E., et al. (2010). Break-induced ATR and Ddb1–Cul4(Cdt2) ubiquitin ligase-
dependent nucleotide synthesis promotes homologous recombination repair in fission yeast. Genes 
& Development 24, 2705-2716. 
Mowers, E.E., Sharifi, M.N., and Macleod, K.F. (2017). Autophagy in cancer metastasis. Oncogene 36, 
1619-1630. 
Mueller, E., Drori, S., Aiyer, A., Yie, J., Sarraf, P., Chen, H., Hauser, S., Rosen, E.D., Ge, K., Roeder, 
R.G., et al. (2002). Genetic Analysis of Adipogenesis through Peroxisome Proliferator-activated 
Receptor γ Isoforms. Journal of Biological Chemistry 277, 41925-41930. 
Muller, P.A.J., and Vousden, K.H. (2013). p53 mutations in cancer. Nat Cell Biol 15, 2-8. 
Müller, T.D., Lee, S.J., Jastroch, M., Kabra, D., Stemmer, K., Aichler, M., Abplanalp, B., 
Ananthakrishnan, G., Bhardwaj, N., Collins, S., et al. (2013). p62 Links β-adrenergic input to 
mitochondrial function and thermogenesis. The Journal of Clinical Investigation 123, 469-478. 
233 
 
Murga, M., Bunting, S., Montana, M.F., Soria, R., Mulero, F., Canamero, M., Lee, Y., McKinnon, P.J., 
Nussenzweig, A., and Fernandez-Capetillo, O. (2009). A mouse model of ATR-Seckel shows 
embryonic replicative stress and accelerated aging. Nat Genet 41, 891-898. 
Murphy, D.J., and Vance, J. (1999). Mechanisms of lipid-body formation. Trends in Biochemical 
Sciences 24, 109-115. 
Nagano, A., and Arahata, K. (2000). Nuclear envelope proteins and associated diseases. Current 
Opinion in Neurology 13, 533-539. 
Nair, U., Yen, W.-L., Mari, M., Cao, Y., Xie, Z., Baba, M., Reggiori, F., and Klionsky, D.J. (2012). A role 
for Atg8–PE deconjugation in autophagosome biogenesis. Autophagy 8, 780-793. 
Nakamura, S., and Yoshimori, T. (2017). New insights into autophagosome–lysosome fusion. Journal 
of Cell Science 130, 1209-1216. 
Nam, E.A., and Cortez, D. (2011). ATR signalling: more than meeting at the fork. Biochemical Journal 
436, 527-536. 
Nam, E.A., Zhao, R., Glick, G.G., Bansbach, C.E., Friedman, D.B., and Cortez, D. (2011). Thr-1989 
Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase. 
The Journal of Biological Chemistry 286, 28707-28714. 
Neal, J.W., and Clipstone, N.A. (2002). Calcineurin Mediates the Calcium-dependent Inhibition of 
Adipocyte Differentiation in 3T3-L1 Cells. Journal of Biological Chemistry 277, 49776-49781. 
Neal, J.W., and Clipstone, N.A. (2003). A Constitutively Active NFATc1 Mutant Induces a Transformed 
Phenotype in 3T3-L1 Fibroblasts. Journal of Biological Chemistry 278, 17246-17254. 
Nebenführ, A. (2002). Vesicle traffic in the endomembrane system: a tale of COPs, Rabs and SNAREs. 
Current Opinion in Plant Biology 5, 507-512. 
Neese, R.A., Misell, L.M., Turner, S., Chu, A., Kim, J., Cesar, D., Hoh, R., Antelo, F., Strawford, A., 
McCune, J.M., et al. (2002). Measurement in vivo of proliferation rates of slow turnover cells by 
(2)H(2)O labeling of the deoxyribose moiety of DNA. Proceedings of the National Academy of 
Sciences of the United States of America 99, 15345-15350. 
234 
 
Nghiem, P., Park, P.K., Kim, Y.-s., Vaziri, C., and Schreiber, S.L. (2001). ATR inhibition selectively 
sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proceedings of 
the National Academy of Sciences 98, 9092-9097. 
Nguyên, D.T., Kebache, S., Fazel, A., Wong, H.N., Jenna, S., Emadali, A., Lee, E.-h., Bergeron, J.J.M., 
Kaufman, R.J., Larose, L., et al. (2004). Nck-dependent Activation of Extracellular Signal-regulated 
Kinase-1 and Regulation of Cell Survival during Endoplasmic Reticulum Stress. Molecular Biology of 
the Cell 15, 4248-4260. 
Niida, H., Katsuno, Y., Banerjee, B., Hande, M.P., and Nakanishi, M. (2007). Specific Role of Chk1 
Phosphorylations in Cell Survival and Checkpoint Activation. Molecular and Cellular Biology 27, 2572-
2581. 
Nixon, R.A. (2013). The role of autophagy in neurodegenerative disease. Nat Med 19, 983-997. 
O'Driscoll, M., Ruiz-Perez, V.L., Woods, C.G., Jeggo, P.A., and Goodship, J.A. (2003). A splicing 
mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in 
Seckel syndrome. Nat Genet 33, 497-501. 
O’Driscoll, M. (2009). Mouse models for ATR deficiency. DNA Repair 8, 1333-1337. 
O’Driscoll, M., Gennery, A.R., Seidel, J., Concannon, P., and Jeggo, P.A. (2004). An overview of three 
new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. 
DNA Repair 3, 1227-1235. 
O’Driscoll, M., and Jeggo, P.A. (2003). Clinical Impact of ATR Checkpoint Signalling Failure in Humans. 
Cell Cycle 2, 193-194. 
Oakes, S.A., Opferman, J.T., Pozzan, T., Korsmeyer, S.J., and Scorrano, L. (2003). Regulation of 
endoplasmic reticulum Ca2+ dynamics by proapoptotic BCL-2 family members. Biochemical 
Pharmacology 66, 1335-1340. 
Obita, T., Saksena, S., Ghazi-Tabatabai, S., Gill, D.J., Perisic, O., Emr, S.D., and Williams, R.L. (2007). 
Structural basis for selective recognition of ESCRT-III by the AAA ATPase Vps4. Nature 449, 735-739. 
Ogden, C.L., Carroll, M.D., Curtin, L.R., McDowell, M.A., Tabak, C.J., and Flegal, K.M. (2006). 
Prevalence of overweight and obesity in the united states, 1999-2004. JAMA 295, 1549-1555. 
235 
 
Ogi, T., Walker, S., Stiff, T., Hobson, E., Limsirichaikul, S., Carpenter, G., Prescott, K., Suri, M., Byrd, 
P.J., Matsuse, M., et al. (2012). Identification of the First ATRIP–Deficient Patient and Novel 
Mutations in ATR Define a Clinical Spectrum for ATR–ATRIP Seckel Syndrome. PLoS Genetics 8, 
e1002945. 
Ohsumi, Y. (2014). Historical landmarks of autophagy research. Cell Res 24, 9-23. 
Oishi, Y., Manabe, I., Tobe, K., Tsushima, K., Shindo, T., Fujiu, K., Nishimura, G., Maemura, K., 
Yamauchi, T., Kubota, N., et al. (2005). Krüppel-like transcription factor KLF5 is a key regulator of 
adipocyte differentiation. Cell Metabolism 1, 27-39. 
Ojha, S., Budge, H., and Symonds, M.E. (2014). Adipocytes in Normal Tissue Biology A2 - McManus, 
Linda M. In Pathobiology of Human Disease, R.N. Mitchell, ed. (San Diego: Academic Press), pp. 
2003-2013. 
Okamoto, K. (2011). Mitochondria breathe for autophagy. The EMBO Journal 30, 2095-2096. 
Okamura, M., Inagaki, T., Tanaka, T., and Sakai, J. (2010). Role of histone methylation and 
demethylation in adipogenesis and obesity. Organogenesis 6, 24-32. 
Oslowski, C.M., and Urano, F. (2011). Measuring ER stress and the unfolded protein response using 
mammalian tissue culture system. Methods in enzymology 490, 71-92. 
Palmieri, M., Impey, S., Kang, H., di Ronza, A., Pelz, C., Sardiello, M., and Ballabio, A. (2011). 
Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. 
Human Molecular Genetics 20, 3852-3866. 
Papp, S., Dziak, E., Michalak, M., and Opas, M. (2003). Is all of the endoplasmic reticulum created 
equal? The effects of the heterogeneous distribution of endoplasmic reticulum Ca(2+)-handling 
proteins. The Journal of Cell Biology 160, 475-479. 
Parenti, G., Andria, G., and Ballabio, A. (2015). Lysosomal storage diseases: from pathophysiology to 
therapy. Annual review of medicine 66, 471-486. 
Parray, H.A., and Yun, J.W. (2016). Cannabidiol promotes browning in 3T3-L1 adipocytes. Molecular 
and Cellular Biochemistry 416, 131-139. 
236 
 
Patrick, S.M., Oakley, G.G., Dixon, K., and Turchi, J.J. (2005). DNA Damage Induced 
Hyperphosphorylation of Replication Protein A. 2. Characterization of DNA Binding Activity, Protein 
Interactions, and Activity in DNA Replication and Repair(). Biochemistry 44, 8438-8448. 
Peasland, A., Wang, L.Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W.A., Sarkaria, J., Beale, G., 
Edmondson, R.J., et al. (2011). Identification and evaluation of a potent novel ATR inhibitor, NU6027, 
in breast and ovarian cancer cell lines. Br J Cancer 105, 372-381. 
Peirce, V., Carobbio, S., and Vidal-Puig, A. (2014). The different shades of fat. Nature 510, 76-83. 
Periasamy, M., and Kalyanasundaram, A. (2007). SERCA pump isoforms: Their role in calcium 
transport and disease. Muscle & Nerve 35, 430-442. 
Perry, J., and Kleckner, N. (2003). The ATRs, ATMs, and TORs Are Giant HEAT Repeat Proteins. Cell 
112, 151-155. 
Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J., Swarbrick, M., 
Rose-John, S., Rincon, M., Robertson, G., et al. A Switch from White to Brown Fat Increases Energy 
Expenditure in Cancer-Associated Cachexia. Cell Metabolism 20, 433-447. 
Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado de Oliveira, R., Leid, M., 
McBurney, M.W., and Guarente, L. (2004). Sirt1 promotes fat mobilization in white adipocytes by 
repressing PPAR-[gamma]. Nature 429, 771-776. 
Pinton, P., Ferrari, D., Magalhães, P., Schulze-Osthoff, K., Di Virgilio, F., Pozzan, T., and Rizzuto, R. 
(2000). Reduced Loading of Intracellular Ca<sup>2+</sup> Stores and Downregulation of 
Capacitative Ca<sup>2+</sup>Influx in Bcl-2–Overexpressing Cells. The Journal of Cell Biology 148, 
857-862. 
Ploegh, H.L. (2007). A lipid-based model for the creation of an escape hatch from the endoplasmic 
reticulum. Nature 448, 435-438. 
Polak, P., Cybulski, N., Feige, J.N., Auwerx, J., Rüegg, M.A., and Hall, M.N. (2008). Adipose-Specific 
Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration. Cell Metabolism 
8, 399-410. 
Pope, B.D., Warren, C.R., Parker, K.K., and Cowan, C.A. Microenvironmental Control of Adipocyte 
Fate and Function. Trends in Cell Biology 26, 745-755. 
237 
 
Poruchynsky, M.S., Komlodi-Pasztor, E., Trostel, S., Wilkerson, J., Regairaz, M., Pommier, Y., Zhang, 
X., Kumar Maity, T., Robey, R., Burotto, M., et al. (2015). Microtubule-targeting agents augment the 
toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. 
Proceedings of the National Academy of Sciences of the United States of America 112, 1571-1576. 
Postigo, A., Ramsden, A.E., Howell, M., and Way, M. (2017). Cytoplasmic ATR Activation Promotes 
Vaccinia Virus Genome Replication. Cell Reports 19, 1022-1032. 
Poulos, S.P., Dodson, M.V., and Hausman, G.J. (2010). Cell line models for differentiation: 
preadipocytes and adipocytes. Experimental Biology and Medicine 235, 1185-1193. 
Powell, S.N., and Kachnic, L.A. (2003). Roles of BRCA1 and BRCA2 in homologous recombination, 
DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22, 5784-5791. 
Prevo, R., Fokas, E., Reaper, P.M., Charlton, P.A., Pollard, J.R., McKenna, W.G., Muschel, R.J., and 
Brunner, T.B. (2012). The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells 
to radiation and chemotherapy. Cancer Biology & Therapy 13, 1072-1081. 
Prusty, D., Park, B.-H., Davis, K.E., and Farmer, S.R. (2002). Activation of MEK/ERK Signaling Promotes 
Adipogenesis by Enhancing Peroxisome Proliferator-activated Receptor γ (PPARγ) and C/EBPα Gene 
Expression during the Differentiation of 3T3-L1 Preadipocytes. Journal of Biological Chemistry 277, 
46226-46232. 
Purohit, A., Tynan, S.H., Vallee, R., and Doxsey, S.J. (1999). Direct Interaction of Pericentrin with 
Cytoplasmic Dynein Light Intermediate Chain Contributes to Mitotic Spindle Organization. The 
Journal of Cell Biology 147, 481-492. 
Pylayeva-Gupta, Y., Grabocka, E., and Bar-Sagi, D. (2011). RAS oncogenes: weaving a tumorigenic 
web. Nat Rev Cancer 11, 761-774. 
Qiang, L., Wang, L., Kon, N., Zhao, W., Lee, S., Zhang, Y., Rosenbaum, M., Zhao, Y., Gu, W., Farmer, 
Stephen R., et al. (2012). Brown Remodeling of White Adipose Tissue by SirT1-Dependent 
Deacetylation of Pparγ. Cell 150, 620-632. 
Qiu, B., Ackerman, D., Sanchez, D.J., Li, B., Ochocki, J.D., Grazioli, A., Bobrovnikova-Marjon, E., Diehl, 
J.A., Keith, B., and Simon, M.C. (2015). HIF2α-Dependent Lipid Storage Promotes Endoplasmic 
Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma. Cancer Discovery 5, 652-667. 
238 
 
Qiu, Z., Wei, Y., Chen, N., Jiang, M., Wu, J., and Liao, K. (2001). DNA Synthesis and Mitotic Clonal 
Expansion Is Not a Required Step for 3T3-L1 Preadipocyte Differentiation into Adipocytes. Journal of 
Biological Chemistry 276, 11988-11995. 
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E.-L., Mizushima, 
N., Ohsumi, Y., et al. (2003). Promotion of tumorigenesis by heterozygous disruption of the beclin 1 
autophagy gene. Journal of Clinical Investigation 112, 1809-1820. 
Qvist, P., Huertas, P., Jimeno, S., Nyegaard, M., Hassan, M.J., Jackson, S.P., and Børglum, A.D. (2011). 
CtIP Mutations Cause Seckel and Jawad Syndromes. PLOS Genetics 7, e1002310. 
Raaijmakers, J.A., Tanenbaum, M.E., and Medema, R.H. (2013). Systematic dissection of dynein 
regulators in mitosis. The Journal of Cell Biology 201, 201-215. 
Raffaello, A., Mammucari, C., Gherardi, G., and Rizzuto, R. (2016). Calcium at the Center of Cell 
Signaling: Interplay between Endoplasmic Reticulum, Mitochondria, and Lysosomes. Trends in 
Biochemical Sciences 41, 1035-1049. 
Ragland, R.L., Arlt, M.F., Hughes, E.D., Saunders, T.L., and Glover, T.W. (2009). Mice hypomorphic for 
Atr have increased DNA damage and abnormal checkpoint response. Mammalian Genome 20, 375-
385. 
Rahman, K. (2007). Studies on free radicals, antioxidants, and co-factors. Clinical Interventions in 
Aging 2, 219-236. 
Ramm, G., Slot, J.W., James, D.E., and Stoorvogel, W. (2000). Insulin Recruits GLUT4 from Specialized 
VAMP2-carrying Vesicles as well as from the Dynamic Endosomal/Trans-Golgi Network in Rat 
Adipocytes. Molecular Biology of the Cell 11, 4079-4091. 
Rashid, H.-O., Yadav, R.K., Kim, H.-R., and Chae, H.-J. (2015). ER stress: Autophagy induction, 
inhibition and selection. Autophagy 11, 1956-1977. 
Rautureau, G.J.P., Day, C.L., and Hinds, M.G. (2010). Intrinsically Disordered Proteins in Bcl-2 
Regulated Apoptosis. International Journal of Molecular Sciences 11, 1808-1824. 
Ravikumar, B., Acevedo-Arozena, A., Imarisio, S., Berger, Z., Vacher, C., O'Kane, C.J., Brown, S.D.M., 
and Rubinsztein, D.C. (2005). Dynein mutations impair autophagic clearance of aggregate-prone 
proteins. Nat Genet 37, 771-776. 
239 
 
Ravikumar, B., Moreau, K., Jahreiss, L., Puri, C., and Rubinsztein, D.C. (2010). Plasma membrane 
contributes to the formation of pre-autophagosomal structures. Nat Cell Biol 12, 747-757. 
Reaper, P.M., Griffiths, M.R., Long, J.M., Charrier, J.-D., MacCormick, S., Charlton, P.A., Golec, J.M.C., 
and Pollard, J.R. (2011). Selective killing of ATM- or p53-deficient cancer cells through inhibition of 
ATR. Nat Chem Biol 7, 428-430. 
Redwine, W.B., DeSantis, M.E., Hollyer, I., Htet, Z.M., Tran, P.T., Swanson, S.K., Florens, L., 
Washburn, M.P., and Reck-Peterson, S.L. (2017). The Human Cytoplasmic Dynein Interactome 
Reveals Novel Activators Of Motility. bioRxiv. 
Reggiori, F., Tucker, K.A., Stromhaug, P.E., and Klionsky, D.J. (2004). The Atg1-Atg13 Complex 
Regulates Atg9 and Atg23 Retrieval Transport from the Pre-Autophagosomal Structure. 
Developmental Cell 6, 79-90. 
Rigamonti, A., Brennand, K., Lau, F., and Cowan, C.A. (2011). Rapid Cellular Turnover in Adipose 
Tissue. PLoS ONE 6, e17637. 
Rivera-Calzada, A., López-Perrote, A., Melero, R., Boskovic, J., Muñoz-Hernández, H., Martino, F., and 
Llorca, O. (2015). Structure and Assembly of the PI3K-like Protein Kinases (PIKKs) Revealed by 
Electron Microscopy. AIMS Biophysics 2, 36-57. 
Robak, T. (2015). Bortezomib in the treatment of mantle cell lymphoma. Future Oncology 11, 2807-
2818. 
Roczniak-Ferguson, A., Petit, C.S., Froehlich, F., Qian, S., Ky, J., Angarola, B., Walther, T.C., and 
Ferguson, S.M. (2012). The Transcription Factor TFEB Links mTORC1 Signaling to Transcriptional 
Control of Lysosome Homeostasis. Science Signaling 5, ra42-ra42. 
Rodbell, M. (1966). The Metabolism of Isolated Fat Cells: IV. REGULATION OF RELEASE OF PROTEIN 
BY LIPOLYTIC HORMONES AND INSULIN. Journal of Biological Chemistry 241, 3909-3917. 
Rodriguez, A., Durán, A., Selloum, M., Champy, M.-F., Diez-Guerra, F.J., Flores, J.M., Serrano, M., 
Auwerx, J., Diaz-Meco, M.T., and Moscat, J. (2006). Mature-onset obesity and insulin resistance in 
mice deficient in the signaling adapter p62. Cell Metabolism 3, 211-222. 
Ron, D., and Habener, J.F. (1992). CHOP, a novel developmentally regulated nuclear protein that 
dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of 
gene transcription. Genes & Development 6, 439-453. 
240 
 
Rosenfeld, M.R., Ye, X., Supko, J.G., Desideri, S., Grossman, S.A., Brem, S., Mikkelson, T., Wang, D., 
Chang, Y.C., Hu, J., et al. (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation 
therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma 
multiforme. Autophagy 10, 1359-1368. 
Roux, P.P., and Blenis, J. (2004). ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein 
Kinases with Diverse Biological Functions. Microbiology and Molecular Biology Reviews 68, 320-344. 
Rubinson, E.H., Metz, A.H., O'Quin, J., and Eichman, B.F. (2008). A New Protein Architecture for 
Processing Alkylation Damaged DNA: The Crystal Structure of DNA Glycosylase AlkD. Journal of 
molecular biology 381, 13-23. 
Ruiz-Vela, A., Aguilar-Gallardo, C., Martínez-Arroyo, A.M., Soriano-Navarro, M., Ruiz, V., and Simón, 
C. (2011). Specific Unsaturated Fatty Acids Enforce the Transdifferentiation of Human Cancer Cells 
toward Adipocyte-like Cells. Stem Cell Reviews and Reports 7, 898-909. 
Rundle, S., Bradbury, A., Drew, Y., and Curtin, N. (2017). Targeting the ATR-CHK1 Axis in Cancer 
Therapy. Cancers 9, 41. 
Rusten, T.E., and Stenmark, H. (2010). p62, an autophagy hero or culprit? Nat Cell Biol 12, 207-209. 
Ruzankina, Y., Pinzon-Guzman, C., Asare, A., Ong, T., Pontano, L., Cotsarelis, G., Zediak, V.P., Velez, 
M., Bhandoola, A., and Brown, E.J. (2007). Deletion of the Developmentally Essential Gene ATR in 
Adult Mice Leads to Age-Related Phenotypes and Stem Cell Loss. Cell Stem Cell 1, 113-126. 
Ruzankina, Y., Schoppy, D.W., Asare, A., Clark, C.E., Vonderheide, R.H., and Brown, E.J. (2009a). 
Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and 
Trp53. Nat Genet 41, 1144-1149. 
Ruzankina, Y., Schoppy, D.W., Asare, A., Clark, C.E., Vonderheide, R.H., and Brown, E.J. (2009b). 
Tissue regenerative delays and synthetic lethality in adult mice upon combined deletion of ATR and 
p53. Nature genetics 41, 1144-1149. 
Rysman, E., Brusselmans, K., Scheys, K., Timmermans, L., Derua, R., Munck, S., Van Veldhoven, P.P., 
Waltregny, D., Daniëls, V.W., Machiels, J., et al. (2010). <em>De novo</em> Lipogenesis Protects 
Cancer Cells from Free Radicals and Chemotherapeutics by Promoting Membrane Lipid Saturation. 
Cancer Research 70, 8117-8126. 
241 
 
Salma, N., Xiao, H., Mueller, E., and Imbalzano, A.N. (2004). Temporal recruitment of transcription 
factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome 
proliferator-activated receptor gamma nuclear hormone receptor. Mol Cell Biol 24. 
Sanchez-Wandelmer, J., Ktistakis, N.T., and Reggiori, F. (2015). ERES: sites for autophagosome 
biogenesis and maturation? Journal of Cell Science 128, 185-192. 
Satir, P., Pedersen, L.B., and Christensen, S.T. (2010). The primary cilium at a glance. Journal of Cell 
Science 123, 499-503. 
Schimmer, A.D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B.D., Minden, M.D., Yee, K., 
Ravandi, F., Giles, F., and Schuh, A. (2008). A phase I study of the pan bcl-2 family inhibitor obatoclax 
mesylate in patients with advanced hematologic malignancies. Clinical Cancer Research 14, 8295-
8301. 
Schmidt, T.I., Kleylein-Sohn, J., Westendorf, J., Le Clech, M., Lavoie, S.B., Stierhof, Y.-D., and Nigg, 
E.A. (2009). Control of Centriole Length by CPAP and CP110. Current Biology 19, 1005-1011. 
Schoppy, D.W., Ragland, R.L., Gilad, O., Shastri, N., Peters, A.A., Murga, M., Fernandez-Capetillo, O., 
Diehl, J.A., and Brown, E.J. (2012). Oncogenic stress sensitizes murine cancers to hypomorphic 
suppression of ATR. The Journal of Clinical Investigation 122, 241-252. 
Schröder, M., and Kaufman, R.J. (2005). The mammalian unfolded protein response. Annu. Rev. 
Biochem. 74, 739-789. 
Scott, A., Chung, H.-Y., Gonciarz-Swiatek, M., Hill, G.C., Whitby, F.G., Gaspar, J., Holton, J.M., 
Viswanathan, R., Ghaffarian, S., Hill, C.P., et al. (2005). Structural and mechanistic studies of VPS4 
proteins. The EMBO Journal 24, 3658-3669. 
Scott, C.C., Vacca, F., and Gruenberg, J. (2014). Endosome maturation, transport and functions. 
Seminars in Cell & Developmental Biology 31, 2-10. 
Scott, K., Hayden, P.J., Will, A., Wheatley, K., and Coyne, I. (2016). Bortezomib for the treatment of 
multiple myeloma. Cochrane Database of Systematic Reviews. 
Seibenhener, M.L., Babu, J.R., Geetha, T., Wong, H.C., Krishna, N.R., and Wooten, M.W. (2004). 
Sequestosome 1/p62 Is a Polyubiquitin Chain Binding Protein Involved in Ubiquitin Proteasome 
Degradation. Molecular and Cellular Biology 24, 8055-8068. 
242 
 
Sekulić, A., Hudson, C.C., Homme, J.L., Yin, P., Otterness, D.M., Karnitz, L.M., and Abraham, R.T. 
(2000). A Direct Linkage between the Phosphoinositide 3-Kinase-AKT Signaling Pathway and the 
Mammalian Target of Rapamycin in Mitogen-stimulated and Transformed Cells. Cancer Research 60, 
3504-3513. 
Seo, J., Fortuno, E.S., Suh, J.M., Stenesen, D., Tang, W., Parks, E.J., Adams, C.M., Townes, T., and 
Graff, J.M. (2009). Atf4 Regulates Obesity, Glucose Homeostasis, and Energy Expenditure. Diabetes 
58, 2565-2573. 
Sepa-Kishi, D.M., and Ceddia, R.B. (2016). Exercise-mediated effects on white and brown adipose 
tissue plasticity and metabolism. Exercise and sport sciences reviews 44, 37-44. 
Sethi, J.K., and Vidal-Puig, A.J. (2007). Thematic review series: Adipocyte Biology. Adipose tissue 
function and plasticity orchestrate nutritional adaptation. Journal of Lipid Research 48, 1253-1262. 
Settembre, C., Zoncu, R., Medina, D.L., Vetrini, F., Erdin, S., Erdin, S., Huynh, T., Ferron, M., Karsenty, 
G., Vellard, M.C., et al. (2012). A lysosome‐to‐nucleus signalling mechanism senses and regulates the 
lysosome via mTOR and TFEB. The EMBO Journal 31, 1095-1108. 
Sha, H., He, Y., Chen, H., Wang, C., Zenno, A., Shi, H., Yang, X., Zhang, X., and Qi, L. (2009). The IRE1α-
XBP1 Pathway of the Unfolded Protein Response is Required for Adipogenesis. Cell metabolism 9, 
556-564. 
Shamas-Din, A., Kale, J., Leber, B., and Andrews, D.W. (2013). Mechanisms of Action of Bcl-2 Family 
Proteins. Cold Spring Harbor Perspectives in Biology 5, a008714. 
Shamu, C.E., and Walter, P. (1996). Oligomerization and phosphorylation of the Ire1p kinase during 
intracellular signaling from the endoplasmic reticulum to the nucleus. The EMBO Journal 15, 3028-
3039. 
Shen, J., Chen, X., Hendershot, L., and Prywes, R. (2002). ER Stress Regulation of ATF6 Localization by 
Dissociation of BiP/GRP78 Binding and Unmasking of Golgi Localization Signals. Developmental Cell 
3, 99-111. 
Shepherd, P.R., Gnudi, L., Tozzo, E., Yang, H., Leach, F., and Kahn, B.B. (1993). Adipose cell 
hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in 
adipose tissue. Journal of Biological Chemistry 268, 22243-22246. 
243 
 
Showkat, M., Beigh, M.A., and Andrabi, K.I. (2014). mTOR Signaling in Protein Translation Regulation: 
Implications in Cancer Genesis and Therapeutic Interventions. Molecular Biology International 2014, 
14. 
Shubin, A.V., Demidyuk, I.V., Komissarov, A.A., Rafieva, L.M., and Kostrov, S.V. (2016). Cytoplasmic 
vacuolization in cell death and survival. Oncotarget 7, 55863-55889. 
Sibanda, B.L., Chirgadze, D.Y., and Blundell, T.L. (2010). Crystal Structure of DNA-PKcs Reveals a 
Large Open-Ring Cradle Comprised of HEAT Repeats. Nature 463, 118-121. 
Sieber, M., and Baumgrass, R. (2009). Novel inhibitors of the calcineurin/NFATc hub - alternatives to 
CsA and FK506? Cell Communication and Signaling : CCS 7, 25-25. 
Simonnet, H., Alazard, N., Pfeiffer, K., Gallou, C., Béroud, C., Demont, J., Bouvier, R., Schägger, H., 
and Godinot, C. (2002). Low mitochondrial respiratory chain content correlates with tumor 
aggressiveness in renal cell carcinoma. Carcinogenesis 23, 759-768. 
Sims Iii, R.J., Nishioka, K., and Reinberg, D. (2003). Histone lysine methylation: a signature for 
chromatin function. Trends in Genetics 19, 629-639. 
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A.M., and Czaja, 
M.J. (2009a). Autophagy regulates lipid metabolism. Nature 458, 1131-1135. 
Singh, R., Xiang, Y., Wang, Y., Baikati, K., Cuervo, A.M., Luu, Y.K., Tang, Y., Pessin, J.E., Schwartz, G.J., 
and Czaja, M.J. (2009b). Autophagy regulates adipose mass and differentiation in mice. The Journal 
of Clinical Investigation 119, 3329-3339. 
Sinha, S., and Levine, B. (2008). The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene 
27, S137-S148. 
Sirbu, B.M., and Cortez, D. (2013). DNA Damage Response: Three Levels of DNA Repair Regulation. 
Cold Spring Harbor Perspectives in Biology 5. 
Sivasubramaniam, S., Sun, X., Pan, Y.-R., Wang, S., and Lee, E.Y.H.P. (2008). Cep164 is a mediator 
protein required for the maintenance of genomic stability through modulation of MDC1, RPA, and 
CHK1. Genes & Development 22, 587-600. 
Slobodkin, M.R., and Elazar, Z. (2013). The Atg8 family: multifunctional ubiquitin-like key regulators 
of autophagy. Essays In Biochemistry 55, 51-64. 
244 
 
Smith, M.H., Ploegh, H.L., and Weissman, J.S. (2011). Road to Ruin: Targeting Proteins for 
Degradation in the Endoplasmic Reticulum. Science 334, 1086-1090. 
Smyth, J.T., Hwang, S.-Y., Tomita, T., DeHaven, W.I., Mercer, J.C., and Putney, J.W. (2010). Activation 
and regulation of store-operated calcium entry. Journal of Cellular and Molecular Medicine 14, 2337-
2349. 
Soliman, G.A., Acosta-Jaquez, H.A., and Fingar, D.C. (2010). mTORC1 Inhibition via Rapamycin 
Promotes Triacylglycerol Lipolysis and Release of Free Fatty Acids in 3T3-L1 Adipocytes. Lipids 45, 
1089-1100. 
Song, C., Wang, Q., Song, C., Lockett, S.J., Colburn, N.H., Li, C.-C.H., Wang, J.M., and Rogers, T.J. 
(2015). Nucleocytoplasmic Shuttling of Valosin-Containing Protein (VCP/p97) Regulated by Its N 
domain and C-terminal Region. Biochimica et biophysica acta 1853, 222-232. 
Spalding, K.L., Arner, E., Westermark, P.O., Bernard, S., Buchholz, B.A., Bergmann, O., Blomqvist, L., 
Hoffstedt, J., Naslund, E., Britton, T., et al. (2008). Dynamics of fat cell turnover in humans. Nature 
453, 783-787. 
Spiegelman, B.M., Hu, E., Kim, J.B., and Brun, R. (1997). PPARγ and the control of adipogenesis. 
Biochimie 79, 111-112. 
Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10, 513-
525. 
Stiff, T., Casar Tena, T., O'Driscoll, M., Jeggo, P.A., and Philipp, M. (2016). ATR promotes cilia 
signalling: links to developmental impacts. Human Molecular Genetics 25, 1574-1587. 
Stiff, T., Reis, C., Alderton, G.K., Woodbine, L., O'Driscoll, M., and Jeggo, P.A. (2005). Nbs1 is required 
for ATR‐dependent phosphorylation events. The EMBO Journal 24, 199-208. 
Stokes, M.P., Rush, J., MacNeill, J., Ren, J.M., Sprott, K., Nardone, J., Yang, V., Beausoleil, S.A., Gygi, 
S.P., Livingstone, M., et al. (2007). Profiling of UV-induced ATM/ATR signaling pathways. Proceedings 
of the National Academy of Sciences 104, 19855-19860. 
Stolz, A., Ernst, A., and Dikic, I. (2014). Cargo recognition and trafficking in selective autophagy. Nat 
Cell Biol 16, 495-501. 
Strzyz, P. (2016). Lipid metabolism: Lipid droplet growth in brown fat. Nat Rev Mol Cell Biol 17, 3-3. 
245 
 
Subramanian, V., Rothenberg, A., Gomez, C., Cohen, A.W., Garcia, A., Bhattacharyya, S., Shapiro, L., 
Dolios, G., Wang, R., Lisanti, M.P., et al. (2004). Perilipin A Mediates the Reversible Binding of CGI-58 
to Lipid Droplets in 3T3-L1 Adipocytes. Journal of Biological Chemistry 279, 42062-42071. 
Sulli, G., Di Micco, R., and di Fagagna, F.d.A. (2012). Crosstalk between chromatin state and DNA 
damage response in cellular senescence and cancer. Nat Rev Cancer 12, 709-720. 
Sun, Q., Westphal, W., Wong, K.N., Tan, I., and Zhong, Q. (2010). Rubicon controls endosome 
maturation as a Rab7 effector. Proceedings of the National Academy of Sciences 107, 19338-19343. 
Sun, Y., Xu, Y., Roy, K., and Price, B.D. (2007). DNA Damage-Induced Acetylation of Lysine 3016 of 
ATM Activates ATM Kinase Activity. Molecular and Cellular Biology 27, 8502-8509. 
Sztalryd, C., Xu, G., Dorward, H., Tansey, J.T., Contreras, J.A., Kimmel, A.R., and Londos, C. (2003). 
Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. 
The Journal of Cell Biology 161, 1093-1103. 
Taccioli, G.E., Amatucci, A.G., Beamish, H.J., Gell, D., Xiang, X.H., Arzayus, M.I.T., Priestley, A., 
Jackson, S.P., Rothstein, A.M., Jeggo, P.A., et al. (1998). Targeted Disruption of the Catalytic Subunit 
of the DNA-PK Gene in Mice Confers Severe Combined Immunodeficiency and Radiosensitivity. 
Immunity 9, 355-366. 
Takai, H., Wang, R.C., Takai, K.K., Yang, H., and de Lange, T. (2007). Tel2 Regulates the Stability of 
PI3K-Related Protein Kinases. Cell 131, 1248-1259. 
Takenouchi, T., Takayama, Y., and Takezawa, T. (2004). Co-treatment with dexamethasone and 
octanoate induces adipogenesis in 3T3-L1 cells. Cell Biology International 28, 209-216. 
Takizawa, T., Tatematsu, C., Watanabe, K., Kato, K., and Nakanishi, Y. (2004). Cleavage of Calnexin 
Caused by Apoptotic Stimuli: Implication for the Regulation of Apoptosis. The Journal of 
Biochemistry 136, 399-405. 
Tanaka, A., Weinel, S., Nagy, N., O'Driscoll, M., Lai-Cheong, Joey E., Kulp-Shorten, Carol L., Knable, A., 
Carpenter, G., Fisher, Sheila A., Hiragun, M., et al. (2012). Germline Mutation in ATR in Autosomal- 
Dominant Oropharyngeal Cancer Syndrome. American Journal of Human Genetics 90, 511-517. 
Tang, Q.-Q., Grønborg, M., Huang, H., Kim, J.-W., Otto, T.C., Pandey, A., and Lane, M.D. (2005). 
Sequential phosphorylation of CCAAT enhancer-binding protein β by MAPK and glycogen synthase 
246 
 
kinase 3β is required for adipogenesis. Proceedings of the National Academy of Sciences of the 
United States of America 102, 9766-9771. 
Tang, Q.-Q., Otto, T.C., and Lane, M.D. (2003). Mitotic clonal expansion: A synchronous process 
required for adipogenesis. Proceedings of the National Academy of Sciences 100, 44-49. 
Tang, Q.Q., and Lane, M.D. (2012). Adipogenesis: From Stem Cell to Adipocyte. Annual Review of 
Biochemistry 81, 715-736. 
Tang, Y., Qian, S.-W., Wu, M.-Y., Wang, J., Lu, P., Li, X., Huang, H.-Y., Guo, L., Sun, X., Xu, C.-J., et al. 
(2016). BMP4 mediates the interplay between adipogenesis and angiogenesis during expansion of 
subcutaneous white adipose tissue. Journal of Molecular Cell Biology 8, 302-312. 
Tarnopolsky, M.A., Rennie, C.D., Robertshaw, H.A., Fedak-Tarnopolsky, S.N., Devries, M.C., and 
Hamadeh, M.J. (2007). Influence of endurance exercise training and sex on intramyocellular lipid and 
mitochondrial ultrastructure, substrate use, and mitochondrial enzyme activity. American Journal of 
Physiology - Regulatory, Integrative and Comparative Physiology 292, R1271-R1278. 
Tauchi-Sato, K., Ozeki, S., Houjou, T., Taguchi, R., and Fujimoto, T. (2002). The Surface of Lipid 
Droplets Is a Phospholipid Monolayer with a Unique Fatty Acid Composition. Journal of Biological 
Chemistry 277, 44507-44512. 
Taylor, A.M.R., Groom, A., and Byrd, P.J. (2004). Ataxia-telangiectasia-like disorder (ATLD)—its 
clinical presentation and molecular basis. DNA Repair 3, 1219-1225. 
Taylor, A.M.R., Lam, Z., Last, J.I., and Byrd, P.J. (2015). Ataxia telangiectasia: more variation at clinical 
and cellular levels. Clinical Genetics 87, 199-208. 
Tchkonia, T., Morbeck, D.E., Von Zglinicki, T., Van Deursen, J., Lustgarten, J., Scrable, H., Khosla, S., 
Jensen, M.D., and Kirkland, J.L. (2010). Fat tissue, aging, and cellular senescence. Aging Cell 9, 667-
684. 
Thorpe, J.A., and Schwarze, S.R. (2010). IRE1α controls cyclin A1 expression and promotes cell 
proliferation through XBP-1. Cell Stress & Chaperones 15, 497-508. 
Thumm, M., Egner, R., Koch, B., Schlumpberger, M., Straub, M., Veenhuis, M., and Wolf, D.H. (1994). 
Isolation of autophagocytosis mutants of Saccharomyces cerevisiae. FEBS Letters 349, 275-280. 
247 
 
Tivey, H.S.E., Rokicki, M.J., Barnacle, J.R., Rogers, M.J., Bagley, M.C., Kipling, D., and Davis, T. (2013). 
Small Molecule Inhibition of p38 MAP Kinase Extends the Replicative Life Span of Human ATR-Seckel 
Syndrome Fibroblasts. The Journals of Gerontology Series A: Biological Sciences and Medical 
Sciences 68, 1001-1009. 
Toledo, L.I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, 
J.R., and Fernandez-Capetillo, O. (2011). A cell-based screen identifies ATR inhibitors with synthetic 
lethal properties for cancer-associated mutations. Nat Struct Mol Biol 18, 721-727. 
Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M. (1994). mPPAR gamma 2: 
tissue-specific regulator of an adipocyte enhancer. Genes & Development 8, 1224-1234. 
Trenz, K., Errico, A., and Costanzo, V. (2008). Plx1 is required for chromosomal DNA replication under 
stressful conditions. The EMBO journal 27, 876-885. 
Trinh, A.T., Kim, S.H., Chang, H.-y., Mastrocola, A.S., and Tibbetts, R.S. (2013). Cyclin-dependent 
Kinase 1-dependent Phosphorylation of cAMP Response Element-binding Protein Decreases 
Chromatin Occupancy. Journal of Biological Chemistry 288, 23765-23775. 
Tsoli, M., Moore, M., Burg, D., Painter, A., Taylor, R., Lockie, S.H., Turner, N., Warren, A., Cooney, G., 
Oldfield, B., et al. (2012). Activation of Thermogenesis in Brown Adipose Tissue and Dysregulated 
Lipid Metabolism Associated with Cancer Cachexia in Mice. Cancer Research 72, 4372-4382. 
Tsukada, M., and Ohsumi, Y. (1993). Isolation and characterization of autophagy-defective mutants 
of Saccharomyces cerevisiae. FEBS Letters 333, 169-174. 
Tsukiyama-Kohara, K., Poulin, F., Kohara, M., DeMaria, C.T., Cheng, A., Wu, Z., Gingras, A.-C., 
Katsume, A., Elchebly, M., Spiegelman, B.M., et al. (2001). Adipose tissue reduction in mice lacking 
the translational inhibitor 4E-BP1. Nat Med 7, 1128-1132. 
Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., 
Cooper, B., Brayton, C., et al. (2002). p53 mutant mice that display early ageing-associated 
phenotypes. Nature 415, 45-53. 
Ünsal-Kaçmaz, K., Makhov, A.M., Griffith, J.D., and Sancar, A. (2002). Preferential binding of ATR 
protein to UV-damaged DNA. Proceedings of the National Academy of Sciences of the United States 
of America 99, 6673-6678. 
248 
 
Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H.P., and Ron, D. (2000). Coupling of 
Stress in the ER to Activation of JNK Protein Kinases by Transmembrane Protein Kinase IRE1. Science 
287, 664-666. 
Vail, G., Cheng, A., Han, Y.R., Zhao, T., Du, S., Loy, M.M.T., Herrup, K., and Plummer, M.R. (2016). 
ATM protein is located on presynaptic vesicles and its deficit leads to failures in synaptic plasticity. 
Journal of Neurophysiology 116, 201-209. 
Valdés-Sánchez, L., De la Cerda, B., Diaz-Corrales, F.J., Massalini, S., Chakarova, C.F., Wright, A.F., and 
Bhattacharya, S.S. (2013). ATR localizes to the photoreceptor connecting cilium and deficiency leads 
to severe photoreceptor degeneration in mice. Human Molecular Genetics 22, 1507-1515. 
Van Petegem, F. (2012). Ryanodine Receptors: Structure and Function. Journal of Biological 
Chemistry 287, 31624-31632. 
Vandermoere, F., El Yazidi-Belkoura, I., Slomianny, C., Demont, Y., Bidaux, G., Adriaenssens, E., 
Lemoine, J., and Hondermarck, H. (2006). The Valosin-containing Protein (VCP) Is a Target of Akt 
Signaling Required for Cell Survival. Journal of Biological Chemistry 281, 14307-14313. 
Vávrová, J., Zárybnická, L., Lukášová, E., Řezáčová, M., Novotná, E., Šinkorová, Z., Tichý, A., Pejchal, 
J., and Ďurišová, K. (2013). Inhibition of ATR kinase with the selective inhibitor VE-821 results in 
radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiation and Environmental 
Biophysics 52, 471-479. 
Vaz, B., Halder, S., and Ramadan, K. (2013). Role of p97/VCP (Cdc48) in genome stability. Frontiers in 
Genetics 4, 60. 
Vendetti, F.P., Lau, A., Schamus, S., Conrads, T.P., O'Connor, M.J., and Bakkenist, C.J. (2015). The 
orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of 
cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 6, 44289-44305. 
Vignard, J., Mirey, G., and Salles, B. (2013). Ionizing-radiation induced DNA double-strand breaks: A 
direct and indirect lighting up. Radiotherapy and Oncology 108, 362-369. 
von Haehling, S., and Anker, S.D. (2014). Prevalence, incidence and clinical impact of cachexia: facts 
and numbers—update 2014. Journal of Cachexia, Sarcopenia and Muscle 5, 261-263. 
Walker, J.R., Corpina, R.A., and Goldberg, J. (2001). Structure of the Ku heterodimer bound to DNA 
and its implications for double-strand break repair. Nature 412, 607-614. 
249 
 
Walther, T.C., and Farese, R.V. (2012). Lipid Droplets And Cellular Lipid Metabolism. Annual review 
of biochemistry 81, 687-714. 
Wang, C., Huang, Z., Du, Y., Cheng, Y., Chen, S., and Guo, F. (2010). ATF4 regulates lipid metabolism 
and thermogenesis. Cell Res 20, 174-184. 
Wang, G.-X., Zhao, X.-Y., and Lin, J.D. (2015). The brown fat secretome: metabolic functions beyond 
thermogenesis. Trends in Endocrinology & Metabolism 26, 231-237. 
Wang, T., Ming, Z., Xiaochun, W., and Hong, W. (2011). Rab7: Role of its protein interaction cascades 
in endo-lysosomal traffic. Cellular Signalling 23, 516-521. 
Wang, W. (2007). Emergence of a DNA-damage response network consisting of Fanconi anaemia and 
BRCA proteins. Nat Rev Genet 8, 735-748. 
Wang, W., and Seale, P. (2016). Control of brown and beige fat development. Nat Rev Mol Cell Biol 
17, 691-702. 
Wang, X., and Ron, D. (1996). Stress-induced phosphorylation and activation of the transcription 
factor CHOP (GADD153) by p38 MAP kinase. Science 272, 1347-1349. 
Wang, X., Zou, L., Lu, T., Bao, S., Hurov, K.E., Hittelman, W.N., Elledge, S.J., and Li, L. (2006). Rad17 
Phosphorylation Is Required for Claspin Recruitment and Chk1 Activation in Response to Replication 
Stress. Molecular Cell 23, 331-341. 
Wang, Y., Shen, J., Arenzana, N., Tirasophon, W., Kaufman, R.J., and Prywes, R. (2000). Activation of 
ATF6 and an ATF6 DNA binding site by the ER stress response. Journal of Biological Chemistry. 
Warburg, O. (1956). On the Origin of Cancer Cells. Science 123, 309-314. 
Waters, A.M., and Beales, P.L. (2011). Ciliopathies: an expanding disease spectrum. Pediatric 
Nephrology (Berlin, Germany) 26, 1039-1056. 
Wei, F., Yan, J., and Tang, D. (2011). Extracellular Signal-Regulated Kinases Modulate DNA Damage 
Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy. Current Medicinal 
Chemistry 18, 5476-5482. 
250 
 
Wei, M.C., Zong, W.-X., Cheng, E.H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A.J., Roth, K.A., 
MacGregor, G.R., Thompson, C.B., and Korsmeyer, S.J. (2001). Proapoptotic BAX and BAK: a requisite 
gateway to mitochondrial dysfunction and death. Science 292, 727-730. 
Wei, Y., Pattingre, S., Sinha, S., Bassik, M., and Levine, B. (2008). JNK1-Mediated Phosphorylation of 
Bcl-2 Regulates Starvation-Induced Autophagy. Molecular Cell 30, 678-688. 
Welihinda, A.A., and Kaufman, R.J. (1996). The Unfolded Protein Response Pathway in 
Saccharomyces cerevisiae: OLIGOMERIZATION AND TRANS-PHOSPHORYLATION OF Ire1p (Ern1p) 
ARE REQUIRED FOR KINASE ACTIVATION. Journal of Biological Chemistry 271, 18181-18187. 
Welte, Michael A. (2015). Expanding Roles for Lipid Droplets. Current Biology 25, R470-R481. 
Westermann, B. (2012). Bioenergetic role of mitochondrial fusion and fission. Biochimica et 
Biophysica Acta (BBA) - Bioenergetics 1817, 1833-1838. 
Westphal, D., Dewson, G., Czabotar, P.E., and Kluck, R.M. (2011). Molecular biology of Bax and Bak 
activation and action. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1813, 521-531. 
White, E. (2015). The role for autophagy in cancer. The Journal of Clinical Investigation 125, 42-46. 
Williams, D.B. (2006). Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic 
reticulum. Journal of Cell Science 119, 615-623. 
Williams, R.A.M., Smith, T.K., Cull, B., Mottram, J.C., and Coombs, G.H. (2012). ATG5 Is Essential for 
ATG8-Dependent Autophagy and Mitochondrial Homeostasis in Leishmania major. PLoS Pathogens 
8, e1002695. 
Willis, S.N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J.I., Adams, J.M., and Huang, D.C. (2005). 
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only 
proteins. Genes & development 19, 1294-1305. 
Wójcik, C., Rowicka, M., Kudlicki, A., Nowis, D., McConnell, E., Kujawa, M., and DeMartino, G.N. 
(2006). Valosin-containing Protein (p97) Is a Regulator of Endoplasmic Reticulum Stress and of the 
Degradation of N-End Rule and Ubiquitin-Fusion Degradation Pathway Substrates in Mammalian 
Cells. Molecular Biology of the Cell 17, 4606-4618. 
Wold, M.S. (1997). Replication protein A: a heterotrimeric, single-stranded DNA-binding protein 
required for eukaryotic DNA metabolism. Annual review of biochemistry 66, 61-92. 
251 
 
Wong, P.-M., Puente, C., Ganley, I.G., and Jiang, X. (2013). The ULK1 complex. Autophagy 9, 124-137. 
Worman, H.J., and Bonne, G. (2007). “Laminopathies:” a wide spectrum of human diseases. 
Experimental cell research 313, 2121-2133. 
Wright, D.C., Geiger, P.C., Han, D.-H., Jones, T.E., and Holloszy, J.O. (2007). Calcium Induces Increases 
in Peroxisome Proliferator-activated Receptor γ Coactivator-1α and Mitochondrial Biogenesis by a 
Pathway Leading to p38 Mitogen-activated Protein Kinase Activation. Journal of Biological Chemistry 
282, 18793-18799. 
Wu, J., Boström, P., Sparks, Lauren M., Ye, L., Choi, Jang H., Giang, A.-H., Khandekar, M., Virtanen, 
Kirsi A., Nuutila, P., Schaart, G., et al. (2012). Beige Adipocytes Are a Distinct Type of Thermogenic 
Fat Cell in Mouse and Human. Cell 150, 366-376. 
Xie, Z., and Klionsky, D.J. (2007). Autophagosome formation: core machinery and adaptations. Nat 
Cell Biol 9, 1102-1109. 
Xu, N., Hegarat, N., Black, E.J., Scott, M.T., Hochegger, H., and Gillespie, D.A. (2010). Akt/PKB 
suppresses DNA damage processing and checkpoint activation in late G2. The Journal of Cell Biology 
190, 297-305. 
Xu, N., Lao, Y., Zhang, Y., and Gillespie, D.A. (2012). Akt: A Double-Edged Sword in Cell Proliferation 
and Genome Stability. Journal of Oncology 2012, 951724. 
Yamamoto, H., Kakuta, S., Watanabe, T.M., Kitamura, A., Sekito, T., Kondo-Kakuta, C., Ichikawa, R., 
Kinjo, M., and Ohsumi, Y. (2012). Atg9 vesicles are an important membrane source during early steps 
of autophagosome formation. The Journal of Cell Biology 198, 219-233. 
Yan, W., Frank, C.L., Korth, M.J., Sopher, B.L., Novoa, I., Ron, D., and Katze, M.G. (2002). Control of 
PERK eIF2α kinase activity by the endoplasmic reticulum stress-induced molecular chaperone 
P58(IPK). Proceedings of the National Academy of Sciences of the United States of America 99, 
15920-15925. 
Yang, D.-Q., Halaby, M.-J., Li, Y., Hibma, J.C., and Burn, P. (2011a). Cytoplasmic ATM protein kinase: 
an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discovery 
Today 16, 332-338. 
Yang, D.-Q., and Kastan, M.B. (2000a). Participation of ATM in insulin signalling through 
phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2, 893-898. 
252 
 
Yang, D.Q., and Kastan, M.B. (2000b). Participation of ATM in insulin signalling through 
phosphorylation of elF-4E-binding protein 1. Nature Cell Biology 2, 893-898. 
Yang, T.T.C., Xiong, Q., Enslen, H., Davis, R.J., and Chow, C.W. (2002). Phosphorylation of NFATc4 by 
p38 mitogen-activated protein kinases. Molecular and Cellular Biology 22, 3892-3904. 
Yang, Z.J., Chee, C.E., Huang, S., and Sinicrope, F.A. (2011b). The Role of Autophagy in Cancer: 
Therapeutic Implications. Molecular cancer therapeutics 10, 1533-1541. 
Ye, Y., Shibata, Y., Kikkert, M., van Voorden, S., Wiertz, E., and Rapoport, T.A. (2005). Recruitment of 
the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum 
membrane. Proceedings of the National Academy of Sciences of the United States of America 102, 
14132-14138. 
Yeh, W.C., Bierer, B.E., and McKnight, S.L. (1995). Rapamycin inhibits clonal expansion and 
adipogenic differentiation of 3T3-L1 cells. Proceedings of the National Academy of Sciences of the 
United States of America 92, 11086-11090. 
Yen, W.-L., Legakis, J.E., Nair, U., and Klionsky, D.J. (2007). Atg27 Is Required for Autophagy-
dependent Cycling of Atg9. Molecular Biology of the Cell 18, 581-593. 
Yi, C., Tong, J., Lu, P., Wang, Y., Zhang, J., Sun, C., Yuan, K., Xue, R., Zou, B., Li, N., et al. (2017). 
Formation of a Snf1-Mec1-Atg1 Module on Mitochondria Governs Energy Deprivation-Induced 
Autophagy by Regulating Mitochondrial Respiration. Developmental Cell 41, 59-71.e54. 
Yoo, H.Y., Kumagai, A., Shevchenko, A., Shevchenko, A., and Dunphy, W.G. (2007). Ataxia-
telangiectasia Mutated (ATM)-dependent Activation of ATR Occurs through Phosphorylation of 
TopBP1 by ATM. Journal of Biological Chemistry 282, 17501-17506. 
Yoo, H.Y., Shevchenko, A., Shevchenko, A., and Dunphy, W.G. (2004). Mcm2 is a direct substrate of 
ATM and ATR during DNA damage and DNA replication checkpoint responses. Journal of Biological 
Chemistry 279, 53353-53364. 
Yoon, M.-S., Zhang, C., Sun, Y., Schoenherr, C.J., and Chen, J. (2013a). Mechanistic target of 
rapamycin controls homeostasis of adipogenesis. Journal of Lipid Research 54, 2166-2173. 
Yoon, M.S., Zhang, C., Sun, Y., Schoenherr, C.J., and Chen, J. (2013b). Mechanistic target of 
rapamycin controls homeostasis of adipogenesis. Journal of Lipid Research 54, 2166-2173. 
253 
 
Yoshimura, S.H., and Hirano, T. (2016). HEAT repeats – versatile arrays of amphiphilic helices 
working in crowded environments? Journal of Cell Science 129, 3963-3970. 
You, Z., Chahwan, C., Bailis, J., Hunter, T., and Russell, P. (2005). ATM Activation and Its Recruitment 
to Damaged DNA Require Binding to the C Terminus of Nbs1. Molecular and Cellular Biology 25, 
5363-5379. 
Youle, R.J., and Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate cell 
death. Nature reviews Molecular cell biology 9, 47-59. 
Yu, J.S.L., and Cui, W. (2016). Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR 
signalling in pluripotency and cell fate determination. Development 143, 3050-3060. 
Yu, K., Mo, D., Wu, M., Chen, H., Chen, L., Li, M., and Chen, Y. (2014). Activating transcription factor 4 
regulates adipocyte differentiation via altering the coordinate expression of CCATT/enhancer 
binding protein β and peroxisome proliferator-activated receptor γ. FEBS Journal 281, 2399-2409. 
Yue, S., Li, J., Lee, S.-Y., Lee, Hyeon J., Shao, T., Song, B., Cheng, L., Masterson, Timothy A., Liu, X., 
Ratliff, Timothy L., et al. (2014). Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT 
Activation Underlies Human Prostate Cancer Aggressiveness. Cell Metabolism 19, 393-406. 
Zalckvar, E., Berissi, H., Mizrachy, L., Idelchuk, Y., Koren, I., Eisenstein, M., Sabanay, H., Pinkas‐
Kramarski, R., and Kimchi, A. (2009). DAP‐kinase‐mediated phosphorylation on the BH3 domain of 
beclin 1 promotes dissociation of beclin 1 from Bcl‐X<sub>L</sub> and induction of autophagy. 
EMBO reports 10, 285-292. 
Zanchetti, A., Rosei, E.A., Dal Palù, C., Leonetti, G., Magnani, B., and Pessina, A. (1998). The 
Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized 
treatment with either verapamil or chlorthalidone on carotid intima‐media thickness. Journal of 
hypertension 16, 1667-1676. 
Zechner, R., Zimmermann, R., Eichmann, Thomas O., Kohlwein, Sepp D., Haemmerle, G., Lass, A., and 
Madeo, F. (2012). FAT SIGNALS - Lipases and Lipolysis in Lipid Metabolism and Signaling. Cell 
Metabolism 15, 279-291. 
Zehmer, J.K., Huang, Y., Peng, G., Pu, J., Anderson, R.G.W., and Liu, P. (2009). A role for lipid droplets 
in inter-membrane lipid traffic. Proteomics 9, 914-921. 
254 
 
Zha, B.S., and Zhou, H. (2012). ER Stress and Lipid Metabolism in Adipocytes. Biochemistry Research 
International 2012, 9. 
Zhang, H.H., Huang, J., Düvel, K., Boback, B., Wu, S., Squillace, R.M., Wu, C.-L., and Manning, B.D. 
(2009a). Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway. PLoS ONE 4, 
e6189. 
Zhang, J.-W., Klemm, D.J., Vinson, C., and Lane, M.D. (2004a). Role of CREB in Transcriptional 
Regulation of CCAAT/Enhancer-binding Protein β Gene during Adipogenesis. Journal of Biological 
Chemistry 279, 4471-4478. 
Zhang, J., Fu, M., Cui, T., Xiong, C., Xu, K., Zhong, W., Xiao, Y., Floyd, D., Liang, J., Li, E., et al. (2004b). 
Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity. 
Proceedings of the National Academy of Sciences of the United States of America 101, 10703-10708. 
Zhang, J., Tripathi, D.N., Jing, J., Alexander, A., Kim, J., Powell, R.T., Dere, R., Tait-Mulder, J., Lee, J.-
H., Paull, T.T., et al. (2015). ATM functions at the peroxisome to induce pexophagy in response to 
ROS. Nat Cell Biol 17, 1259-1269. 
Zhang, Y.-W., Jones, T.L., Martin, S.E., Caplen, N.J., and Pommier, Y. (2009b). Implication of 
Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage 
Response. The Journal of Biological Chemistry 284, 18085-18095. 
Zhu, D., Shi, S., Wang, H., and Liao, K. (2009). Growth arrest induces primary-cilium formation and 
sensitizes IGF-1-receptor signaling during differentiation induction of 3T3-L1 preadipocytes. Journal 
of Cell Science 122, 2760-2768. 
Zimmermann, R., Strauss, J.G., Haemmerle, G., Schoiswohl, G., Birner-Gruenberger, R., Riederer, M., 
Lass, A., Neuberger, G., Eisenhaber, F., Hermetter, A., et al. (2004). Fat Mobilization in Adipose 
Tissue Is Promoted by Adipose Triglyceride Lipase. Science 306, 1383-1386. 
Zinkel, S.S., Hurov, K.E., Ong, C., Abtahi, F.M., Gross, A., and Korsmeyer, S.J. (2005). A Role for 
Proapoptotic BID in the DNA-Damage Response. Cell 122, 579-591. 
Zoico, E., Darra, E., Rizzatti, V., Budui, S., Franceschetti, G., Mazzali, G., Rossi, A.P., Fantin, F., 
Menegazzi, M., Cinti, S., et al. (2016). Adipocytes WNT5a mediated dedifferentiation: a possible 
target in pancreatic cancer microenvironment. Oncotarget 7, 20223-20235. 
255 
 
Zong, W.-X., Li, C., Hatzivassiliou, G., Lindsten, T., Yu, Q.-C., Yuan, J., and Thompson, C.B. (2003). Bax 
and Bak can localize to the endoplasmic reticulum to initiate apoptosis. The Journal of Cell Biology 
162, 59-69. 
Zou, L., and Elledge, S.J. (2003). Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA 
Complexes. Science 300, 1542-1548. 
Zou, Y., Liu, Y., Wu, X., and Shell, S.M. (2006). Functions of Human Replication Protein A (RPA): From 
DNA Replication to DNA Damage and Stress Responses. Journal of cellular physiology 208, 267-273. 
Zweytick, D., Athenstaedt, K., and Daum, G. (2000). Intracellular lipid particles of eukaryotic cells. 
Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes 1469, 101-120. 
 
